

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International BureauAtty. Docket: PF-0678 US
Ser. No. to be assigned
Reference # 10

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :C12N 15/12, C07K 14/47, 16/18, C12Q
1/68

A2

(11) International Publication Number:

WO 99/40189

(43) International Publication Date:

12 August 1999 (12.08.99)

(21) International Application Number: PCT/IB99/00282

(22) International Filing Date: 9 February 1999 (09.02.99)

(30) Priority Data:

60/074,121	9 February 1998 (09.02.98)	US
60/081,563	13 April 1998 (13.04.98)	US
60/096,116	10 August 1998 (10.08.98)	US
60/099,273	4 September 1998 (04.09.98)	US

(71) Applicant (for all designated States except US): GENSET
[FR/FR]; 24, rue Royale, F-75008 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BOUGUELERET, Ly-
die [FR/FR]; 108, avenue Victor Hugo, F-92170 Vanves
(FR). DUCLERT, Aymeric [FR/FR]; 6 Ter, rue Victorine,
F-94100 Saint-Maur (FR). DUMAS MILNE EDWARDS,
Jean-Baptiste [FR/FR]; 8, rue Grégoire de Tours, F-75006
Paris (FR).(74) Agents: MARTIN, Jean-Jacques et al.; Cabinet Regimbeau,
26, avenue Kléber, F-75116 Paris (FR).(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,
KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU,
ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG,
ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI,
FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE,
SN, TD, TG).

Published

Without international search report and to be republished
upon receipt of that report.

(54) Title: CDNAS ENCODING SECRETED PROTEINS

(57) Abstract

The sequences of extended cDNAs encoding secreted proteins are disclosed. The extended cDNAs can be used to express secreted proteins or portions thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The extended cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The extended cDNAs may also be used to design expression vectors and secretion vectors.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CDNAS ENCODING SECRETED PROTEINS

The extended cDNAs of the present invention were described in several U.S. Provisional Patent applications. Table I lists the SEQ ID Nos. of the extended cDNAs in the present application, the SEQ ID Nos. of the extended cDNAs in the provisional applications, and the identities of the provisional applications in which the extended cDNAs were disclosed.

Background of the Invention

The estimated 50,000-100,000 genes scattered along the human chromosomes offer tremendous promise for the understanding, diagnosis, and treatment of human diseases. In addition, probes capable of specifically hybridizing to loci distributed throughout the human genome find applications in the construction of high resolution chromosome maps and in the identification of individuals.

In the past, the characterization of even a single human gene was a painstaking process, requiring years of effort. Recent developments in the areas of cloning vectors, DNA sequencing, and computer technology have merged to greatly accelerate the rate at which human genes can be isolated, sequenced, mapped, and characterized. Cloning vectors such as yeast artificial chromosomes (YACs) and bacterial artificial chromosomes (BACs) are able to accept DNA inserts ranging from 300 to 1000 kilobases (kb) or 100-400 kb in length respectively, thereby facilitating the manipulation and ordering of DNA sequences distributed over great distances on the human chromosomes. Automated DNA sequencing machines permit the rapid sequencing of human genes. Bioinformatics software enables the comparison of nucleic acid and protein sequences, thereby assisting in the characterization of human gene products.

Currently, two different approaches are being pursued for identifying and characterizing the genes distributed along the human genome. In one approach, large fragments of genomic DNA are isolated, cloned, and sequenced. Potential open reading frames in these genomic sequences are identified using bio-informatics software. However, this approach entails sequencing large stretches of human DNA which do not encode proteins in order to find the protein encoding sequences scattered throughout the genome. In addition to requiring extensive sequencing, the bio-informatics software may mischaracterize the genomic sequences obtained. Thus, the software may produce false positives in which non-coding DNA is mischaracterized as coding DNA or false negatives in which coding DNA is mislabeled as non-coding DNA.

An alternative approach takes a more direct route to identifying and characterizing human genes. In this approach, complementary DNAs (cDNAs) are synthesized from isolated messenger RNAs (mRNAs) which encode human proteins. Using this approach, sequencing is only performed on DNA which is derived from protein coding portions of the genome. Often, only short stretches of the cDNAs are sequenced to obtain sequences called expressed sequence tags (ESTs). The ESTs may then be used to isolate or purify extended cDNAs which include sequences adjacent to the EST sequences. The extended cDNAs may contain all of the sequence of the EST which was used to obtain them or only a portion of the sequence of the EST which was used to obtain them. In addition, the extended cDNAs may contain the full coding sequence of the gene from which the EST was derived or, alternatively, the extended cDNAs may include portions of the coding sequence of the gene from which the EST

was derived. It will be appreciated that there may be several extended cDNAs which include the EST sequence as a result of alternate splicing or the activity of alternative promoters.

In the past, the short EST sequences which could be used to isolate or purify extended cDNAs were often obtained from oligo-dT primed cDNA libraries. Accordingly, they mainly corresponded to the 3' untranslated region of the mRNA. In part, the prevalence of EST sequences derived from the 3' end of the mRNA is a result of the fact that typical techniques for obtaining cDNAs, are not well suited for isolating cDNA sequences derived from the 5' ends of mRNAs. (Adams et al., *Nature* 377:174, 1996, Hillier et al., *Genome Res.* 6:807-828, 1996).

In addition, in those reported instances where longer cDNA sequences have been obtained, the reported sequences typically correspond to coding sequences and do not include the full 5' untranslated region of the mRNA from which the cDNA is derived. Such incomplete sequences may not include the first exon of the mRNA, particularly in situations where the first exon is short. Furthermore, they may not include some exons, often short ones, which are located upstream of splicing sites. Thus, there is a need to obtain sequences derived from the 5' ends of mRNAs which can be used to obtain extended cDNAs which may include the 5' sequences contained in the 5' ESTs.

While many sequences derived from human chromosomes have practical applications, approaches based on the identification and characterization of those chromosomal sequences which encode a protein product are particularly relevant to diagnostic and therapeutic uses. Of the 50,000-100,000 protein coding genes, those genes encoding proteins which are secreted from the cell in which they are synthesized, as well as the secreted proteins themselves, are particularly valuable as potential therapeutic agents. Such proteins are often involved in cell to cell communication and may be responsible for producing a clinically relevant response in their target cells.

In fact, several secretory proteins, including tissue plasminogen activator, G-CSF, GM-CSF, erythropoietin, human growth hormone, insulin, interferon- α , interferon- β , interferon- γ , and interleukin-2, are currently in clinical use. These proteins are used to treat a wide range of conditions, including acute myocardial infarction, acute ischemic stroke, anemia, diabetes, growth hormone deficiency, hepatitis, kidney carcinoma, chemotherapy induced neutropenia and multiple sclerosis. For these reasons, extended cDNAs encoding secreted proteins or portions thereof represent a particularly valuable source of therapeutic agents. Thus, there is a need for the identification and characterization of secreted proteins and the nucleic acids encoding them.

In addition to being therapeutically useful themselves, secretory proteins include short peptides, called signal peptides, at their amino termini which direct their secretion. These signal peptides are encoded by the signal sequences located at the 5' ends of the coding sequences of genes encoding secreted proteins. Because these signal peptides will direct the extracellular secretion of any protein to which they are operably linked, the signal sequences may be exploited to direct the efficient secretion of any protein by operably linking the signal sequences to a gene encoding the protein for which secretion is desired. This may prove beneficial in gene therapy strategies in which it is desired to deliver a particular gene product to cells other than the cell in which it is produced. Signal sequences encoding signal peptides also find application in simplifying protein purification techniques. In such

applications, the extracellular secretion of the desired protein greatly facilitates purification by reducing the number of undesired proteins from which the desired protein must be selected. Thus, there exists a need to identify and characterize the 5' portions of the genes for secretory proteins which encode signal peptides.

Public information on the number of human genes for which the promoters and upstream regulatory regions have been identified and characterized is quite limited. In part, this may be due to the difficulty of isolating such regulatory sequences. Upstream regulatory sequences such as transcription factor binding sites are typically too short to be utilized as probes for isolating promoters from human genomic libraries. Recently, some approaches have been developed to isolate human promoters. One of them consists of making a CpG island library (Cross, S.H. et al., Purification of CpG Islands using a Methylated DNA Binding Column, *Nature Genetics* 6: 236-244 (1994)). The second consists of isolating human genomic DNA sequences containing *SpeI* binding sites by the use of *SpeI* binding protein. (Mortlock et al., *Genome Res.* 6:327-335, 1996). Both of these approaches have their limits due to a lack of specificity or of comprehensiveness.

5' ESTs and extended cDNAs obtainable therefrom may be used to efficiently identify and isolate upstream regulatory regions which control the location, developmental stage, rate, and quantity of protein synthesis, as well as the stability of the mRNA. (Theil et al., *BioFactors* 4:87-93, (1993). Once identified and characterized, these regulatory regions may be utilized in gene therapy or protein purification schemes to obtain the desired amount and locations of protein synthesis or to inhibit, reduce, or prevent the synthesis of undesirable gene products.

In addition, ESTs containing the 5' ends of secretory protein genes or extended cDNAs which include sequences adjacent to the sequences of the ESTs may include sequences useful as probes for chromosome mapping and the identification of individuals. Thus, there is a need to identify and characterize the sequences upstream of the 5' coding sequences of genes encoding secretory proteins.

Summary of the Invention

The present invention relates to purified, isolated, or recombinant extended cDNAs which encode secreted proteins or fragments thereof. Preferably, the purified, isolated or recombinant cDNAs contain the entire open reading frame of their corresponding mRNAs, including a start codon and a stop codon. For example, the extended cDNAs may include nucleic acids encoding the signal peptide as well as the mature protein. Alternatively, the extended cDNAs may contain a fragment of the open reading frame. In some embodiments, the fragment may encode only the sequence of the mature protein. Alternatively, the fragment may encode only a portion of the mature protein. A further aspect of the present invention is a nucleic acid which encodes the signal peptide of a secreted protein.

The present extended cDNAs were obtained using ESTs which include sequences derived from the authentic 5' ends of their corresponding mRNAs. As used herein the terms "EST" or "5' EST" refer to the short cDNAs which were used to obtain the extended cDNAs of the present invention. As used herein, the term "extended cDNA" refers to the cDNAs which include sequences adjacent to the 5' EST used to obtain them. The extended cDNAs may contain all or a portion of the sequence of the EST which was used to obtain them. The

term "corresponding mRNA" refers to the mRNA which was the template for the cDNA synthesis which produced the 5' EST. As used herein, the term "purified" does not require absolute purity; rather, it is intended as a relative definition. Individual extended cDNA clones isolated from a cDNA library have been conventionally purified to electrophoretic homogeneity. The sequences obtained from these clones could not be obtained directly either from the library or from total human DNA. The extended cDNA clones are not naturally occurring as such, but rather are obtained via manipulation of a partially purified naturally occurring substance (messenger RNA). The conversion of mRNA into a cDNA library involves the creation of a synthetic substance (cDNA) and pure individual cDNA clones can be isolated from the synthetic library by clonal selection. Thus, creating a cDNA library from messenger RNA and subsequently isolating individual clones from that library results in an approximately 10^4 - 10^6 fold purification of the native message. Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated.

As used herein, the term "isolated" requires that the material be removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide present in a living animal is not isolated, but the same polynucleotide, separated from some or all of the coexisting materials in the natural system, is isolated.

As used herein, the term "recombinant" means that the extended cDNA is adjacent to "backbone" nucleic acid to which it is not adjacent in its natural environment. Additionally, to be "enriched" the extended cDNAs will represent 5% or more of the number of nucleic acid inserts in a population of nucleic acid backbone molecules. Backbone molecules according to the present invention include nucleic acids such as expression vectors, self-replicating nucleic acids, viruses, integrating nucleic acids, and other vectors or nucleic acids used to maintain or manipulate a nucleic acid insert of interest. Preferably, the enriched extended cDNAs represent 15% or more of the number of nucleic acid inserts in the population of recombinant backbone molecules. More preferably, the enriched extended cDNAs represent 50% or more of the number of nucleic acid inserts in the population of recombinant backbone molecules. In a highly preferred embodiment, the enriched extended cDNAs represent 90% or more of the number of nucleic acid inserts in the population of recombinant backbone molecules. "Stringent", "moderate," and "low" hybridization conditions are as defined in Example 29.

Unless otherwise indicated, a "complementary" sequence is fully complementary. Thus, extended cDNAs encoding secreted polypeptides or fragments thereof which are present in cDNA libraries in which one or more extended cDNAs encoding secreted polypeptides or fragments thereof make up 5% or more of the number of nucleic acid inserts in the backbone molecules are "enriched recombinant extended cDNAs" as defined herein. Likewise, extended cDNAs encoding secreted polypeptides or fragments thereof which are in a population of plasmids in which one or more extended cDNAs of the present invention have been inserted such that they represent 5% or more of the number of inserts in the plasmid backbone are "enriched recombinant extended cDNAs" as defined herein. However, extended cDNAs encoding secreted polypeptides or fragments thereof which are in cDNA libraries in which the extended cDNAs encoding secreted polypeptides or fragments thereof constitute less than 5% of the number of nucleic acid inserts in the population of backbone molecules, such as libraries in

which backbone molecules having a cDNA insert encoding a secreted polypeptide are extremely rare, are not "enriched recombinant extended cDNAs."

In particular, the present invention relates to extended cDNAs which were derived from genes encoding secreted proteins. As used herein, a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal peptides in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g. soluble proteins), or partially (e.g. receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.

Extended cDNAs encoding secreted proteins may include nucleic acid sequences, called signal sequences, which encode signal peptides which direct the extracellular secretion of the proteins encoded by the extended cDNAs. Generally, the signal peptides are located at the amino termini of secreted proteins.

Secreted proteins are translated by ribosomes associated with the "rough" endoplasmic reticulum. Generally, secreted proteins are co-translationally transferred to the membrane of the endoplasmic reticulum. Association of the ribosome with the endoplasmic reticulum during translation of secreted proteins is mediated by the signal peptide. The signal peptide is typically cleaved following its co-translational entry into the endoplasmic reticulum. After delivery to the endoplasmic reticulum, secreted proteins may proceed through the Golgi apparatus. In the Golgi apparatus, the proteins may undergo post-translational modification before entering secretory vesicles which transport them across the cell membrane.

The extended cDNAs of the present invention have several important applications. For example, they may be used to express the entire secreted protein which they encode. Alternatively, they may be used to express portions of the secreted protein. The portions may comprise the signal peptides encoded by the extended cDNAs or the mature proteins encoded by the extended cDNAs (i.e. the proteins generated when the signal peptide is cleaved off). The portions may also comprise polypeptides having at least 10 consecutive amino acids encoded by the extended cDNAs. Alternatively, the portions may comprise at least 15 consecutive amino acids encoded by the extended cDNAs. In some embodiments, the portions may comprise at least 25 consecutive amino acids encoded by the extended cDNAs. In other embodiments, the portions may comprise at least 40 amino acids encoded by the extended cDNAs.

Antibodies which specifically recognize the entire secreted proteins encoded by the extended cDNAs or fragments thereof having at least 10 consecutive amino acids, at least 15 consecutive amino acids, at least 25 consecutive amino acids, or at least 40 consecutive amino acids may also be obtained as described below. Antibodies which specifically recognize the mature protein generated when the signal peptide is cleaved may also be obtained as described below. Similarly, antibodies which specifically recognize the signal peptides encoded by the extended cDNAs may also be obtained.

In some embodiments, the extended cDNAs include the signal sequence. In other embodiments, the extended cDNAs may include the full coding sequence for the mature protein (i.e. the protein generated when the signal polypeptide is cleaved off). In addition, the extended cDNAs may include regulatory regions upstream of the

translation start site or downstream of the stop codon which control the amount, location, or developmental stage of gene expression. As discussed above, secreted proteins are therapeutically important. Thus, the proteins expressed from the cDNAs may be useful in treating or controlling a variety of human conditions. The extended cDNAs may also be used to obtain the corresponding genomic DNA. The term "corresponding genomic DNA" refers to the genomic DNA which encodes mRNA which includes the sequence of one of the strands of the extended cDNA in which thymidine residues in the sequence of the extended cDNA are replaced by uracil residues in the mRNA.

The extended cDNAs or genomic DNAs obtained therefrom may be used in forensic procedures to identify individuals or in diagnostic procedures to identify individuals having genetic diseases resulting from abnormal expression of the genes corresponding to the extended cDNAs. In addition, the present invention is useful for constructing a high resolution map of the human chromosomes.

The present invention also relates to secretion vectors capable of directing the secretion of a protein of interest. Such vectors may be used in gene therapy strategies in which it is desired to produce a gene product in one cell which is to be delivered to another location in the body. Secretion vectors may also facilitate the purification of desired proteins.

The present invention also relates to expression vectors capable of directing the expression of an inserted gene in a desired spatial or temporal manner or at a desired level. Such vectors may include sequences upstream of the extended cDNAs such as promoters or upstream regulatory sequences.

In addition, the present invention may also be used for gene therapy to control or treat genetic diseases. Signal peptides may also be fused to heterologous proteins to direct their extracellular secretion.

One embodiment of the present invention is a purified or isolated nucleic acid comprising the sequence of one of SEQ ID NOs: 40-84 and 130-154 or a sequence complementary thereto. In one aspect of this embodiment, the nucleic acid is recombinant.

Another embodiment of the present invention is a purified or isolated nucleic acid comprising at least 10 consecutive bases of the sequence of one of SEQ ID NOs: 40-84 and 130-154 or one of the sequences complementary thereto. In one aspect of this embodiment, the nucleic acid comprises at least 15, 25, 30, 40, 50, 75, or 100 consecutive bases of one of the sequences of SEQ ID NOs: 40-84 and 130-154 or one of the sequences complementary thereto. The nucleic acid may be a recombinant nucleic acid.

Another embodiment of the present invention is a purified or isolated nucleic acid of at least 15 bases capable of hybridizing under stringent conditions to the sequence of one of SEQ ID NOs: 40-84 and 130-154 or a sequence complementary to one of the sequences of SEQ ID NOs: 40-84 and 130-154. In one aspect of this embodiment, the nucleic acid is recombinant.

Another embodiment of the present invention is a purified or isolated nucleic acid comprising the full coding sequences of one of SEQ ID Nos: 40-84 and 130-154 wherein the full coding sequence optionally comprises the sequence encoding signal peptide as well as the sequence encoding mature protein. In a preferred embodiment, the isolated or purified nucleic acid comprises the full coding sequence of one of SEQ ID Nos. 40-59,

61-73, 75, 77-82, and 130-154 wherein the full coding sequence comprises the sequence encoding signal peptide and the sequence encoding mature protein. In one aspect of this embodiment, the nucleic acid is recombinant.

5 A further embodiment of the present invention is a purified or isolated nucleic acid comprising the nucleotides of one of SEQ ID NOs: 40-84 and 130-154 which encode a mature protein. In a preferred embodiment, the purified or isolated nucleic acid comprises the nucleotides of one of SEQ ID NOs: 40-59, 61-75, 77-82, and 130-154 which encode a mature protein. In one aspect of this embodiment, the nucleic acid is recombinant.

10 Yet another embodiment of the present invention is a purified or isolated nucleic acid comprising the nucleotides of one of SEQ ID NOs: 40-84 and 130-154 which encode the signal peptide. In a preferred embodiment, the purified or isolated nucleic acid comprises the nucleotides of SEQ ID NOs: 40-59, 61-73, 75-82, 84, and 130-154 which encode the signal peptide. In one aspect of this embodiment, the nucleic acid is recombinant.

15 Another embodiment of the present invention is a purified or isolated nucleic acid encoding a polypeptide having the sequence of one of the sequences of SEQ ID NOs: 85-129 and 155-179.

Another embodiment of the present invention is a purified or isolated nucleic acid encoding a polypeptide having the sequence of a mature protein included in one of the sequences of SEQ ID NOs: 85-129 and 155-179. In a preferred embodiment, the purified or isolated nucleic acid encodes a polypeptide having the sequence of a mature protein included in one of the sequences of SEQ ID NOs: 85-104, 106-120, 122-127, and 155-179.

20 Another embodiment of the present invention is a purified or isolated nucleic acid encoding a polypeptide having the sequence of a signal peptide included in one of the sequences of SEQ ID NOs: 85-129 and 155-179. In a preferred embodiment, the purified or isolated nucleic acid encodes a polypeptide having the sequence of a signal peptide included in one of the sequences of SEQ ID NOs: 85-104, 106-118, 120-127, 129, and 155-179.

25 Yet another embodiment of the present invention is a purified or isolated protein comprising the sequence of one of SEQ ID NOs: 85-129 and 155-179.

Another embodiment of the present invention is a purified or isolated polypeptide comprising at least 10 consecutive amino acids of one of the sequences of SEQ ID NOs: 85-129 and 155-179. In one aspect of this embodiment, the purified or isolated polypeptide comprises at least 15, 20, 25, 35, 50, 75, 100, 150 or 200 consecutive amino acids of one of the sequences of SEQ ID NOs: 85-129 and 155-179. In still another aspect, 30 the purified or isolated polypeptide comprises at least 25 consecutive amino acids of one of the sequences of SEQ ID NOs: 85-129 and 155-179.

Another embodiment of the present invention is an isolated or purified polypeptide comprising a signal peptide of one of the polypeptides of SEQ ID NOs: 85-129 and 155-179. In a preferred embodiment, the isolated or purified polypeptide comprises a signal peptide of one of the polypeptides of SEQ ID NOs: 85-104, 106-118, 35 120-127, 129, and 155-179.

Yet another embodiment of the present invention is an isolated or purified polypeptide comprising a mature protein of one of the polypeptides of SEQ ID NOs: 85-129 and 155-179. In a preferred embodiment, the isolated or purified polypeptide comprises a mature protein of one of the polypeptides of SEQ ID NOs: 85-104, 106-120, 122-127, and 155-179. In a preferred embodiment, the purified or isolated nucleic acid encodes a polypeptide having the sequence of a mature protein included in one of the sequences of SEQ ID NOs: 85-104, 106-120, 122-127, and 155-179.

A further embodiment of the present invention is a method of making a protein comprising one of the sequences of SEQ ID NO: 85-129 and 155-179, comprising the steps of obtaining a cDNA comprising one of the sequences of sequence of SEQ ID NO: 40-84 and 130-154, inserting the cDNA in an expression vector such that the cDNA is operably linked to a promoter, and introducing the expression vector into a host cell whereby the host cell produces the protein encoded by said cDNA. In one aspect of this embodiment, the method further comprises the step of isolating the protein.

Another embodiment of the present invention is a protein obtainable by the method described in the preceding paragraph.

In a preferred embodiment, the above method comprises a method of making a protein comprising the amino acid sequence of the mature protein contained in one of the sequences of SEQ ID NOs. 85-104, 106-120, 122-127 and 155-179, comprising the steps of obtaining a cDNA comprising one of the nucleotide sequences of SEQ ID Nos. 40-59, 61-75, 77-82 and 130-154 which encode for the mature protein, inserting the cDNA in an expression vector such that the cDNA is operably linked to a promoter, and introducing the expression vector into a host cell whereby the host cell produces the mature protein encoded by the cDNA. In one aspect of this embodiment, the method further comprises the step of isolating the protein.

Another embodiment of the present invention is a method of making a protein comprising the amino acid sequence of the mature protein contained in one of the sequences of SEQ ID NOs: 85-104, 106-120, 122-127, and 155-179 comprising the steps of obtaining a cDNA comprising one of the nucleotides sequence of sequence of SEQ ID NOs: 40-59, 61-75, 77-82, and 130-154 which encode for the mature protein, inserting the cDNA in an expression vector such that the cDNA is operably linked to a promoter, and introducing the expression vector into a host cell whereby the host cell produces the mature protein encoded by the cDNA. In one aspect of this embodiment, the method further comprises the step of isolating the protein.

Another embodiment of the present invention is a mature protein obtainable by the method described in the preceding paragraph.

Another embodiment of the present invention is a host cell containing the purified or isolated nucleic acids comprising the sequence of one of SEQ ID NOs: 40-84 and 130-154 or a sequence complementary thereto described herein.

Another embodiment of the present invention is a host cell containing the purified or isolated nucleic acids comprising the full coding sequences of one of SEQ ID NOs: 40-59, 61-73, 75, 77-82, and 130-154, wherein the

full coding sequence comprises the sequence encoding signal peptide and the sequence encoding mature protein described herein.

Another embodiment of the present invention is a host cell containing the purified or isolated nucleic acids comprising the nucleotides of one of SEQ ID NOs: 40-84 and 130-154 which encode a mature protein which are described herein. Preferably, the host cell contains the purified or isolated nucleic acids comprising the nucleotides of one of SEQ ID NOs: 40-59, 61-75, 77-82, and 130-154 which encode a mature protein.

Another embodiment of the present invention is a host cell containing the purified or isolated nucleic acids comprising the nucleotides of one of SEQ ID NOs: 40-84 and 130-154 which encode the signal peptide which are described herein. Preferably, the host cell contains the purified or isolated nucleic acids comprising the nucleotides of one of SEQ ID Nos.: 40-59, 61-73, 75-82, 84, and 130-154 which encode the signal peptide.

Another embodiment of the present invention is a purified or isolated antibody capable of specifically binding to a protein having the sequence of one of SEQ ID NOs: 85-129 and 155-179. In one aspect of this embodiment, the antibody is capable of binding to a polypeptide comprising at least 10 consecutive amino acids of the sequence of one of SEQ ID NOs: 85-129 and 155-179.

Another embodiment of the present invention is an array of cDNAs or fragments thereof of at least 15 nucleotides in length which includes at least one of the sequences of SEQ ID NOs: 40-84 and 130-154, or one of the sequences complementary to the sequences of SEQ ID NOs: 40-84 and 130-154, or a fragment thereof of at least 15 consecutive nucleotides. In one aspect of this embodiment, the array includes at least two of the sequences of SEQ ID NOs: 40-84 and 130-154, the sequences complementary to the sequences of SEQ ID NOs: 40-84 and 130-154, or fragments thereof of at least 15 consecutive nucleotides. In another aspect of this embodiment, the array includes at least five of the sequences of SEQ ID NOs: 40-84 and 130-154, the sequences complementary to the sequences of SEQ ID NOs: 40-84 and 130-154, or fragments thereof of at least 15 consecutive nucleotides.

A further embodiment of the invention encompasses purified polynucleotides comprising an insert from a clone deposited in a deposit having an accession number selected from the group consisting of the accession numbers listed in Table VI or a fragment thereof comprising a contiguous span of at least 8, 10, 12, 15, 20, 25, 40, 60, 100, or 200 nucleotides of said insert. An additional embodiment of the invention encompasses purified polypeptides which comprise, consist of, or consist essentially of an amino acid sequence encoded by the insert from a clone deposited in a deposit having an accession number selected from the group consisting of the accession numbers listed in Table VI, as well as polypeptides which comprise a fragment of said amino acid sequence consisting of a signal peptide, a mature protein, or a contiguous span of at least 5, 8, 10, 12, 15, 20, 25, 40, 60, 100, or 200 amino acids encoded by said insert.

An additional embodiment of the invention encompasses purified polypeptides which comprise a contiguous span of at least 5, 8, 10, 12, 15, 20, 25, 40, 60, 100, or 200 amino acids of SEQ ID NOs: 85-129 and 155-179, wherein said contiguous span comprises at least one of the amino acid positions which was not shown to

be identical to a public sequence in any of Figures 10 to 12. Also encompassed by the invention are purified polynucleotides encoding said polypeptides.

Another embodiment of the present invention is a computer readable medium having stored thereon a sequence selected from the group consisting of a cDNA code of SEQID NOs. 40-84 and 130-154 and a polypeptide code of SEQ ID NOs. 85-129 and 155-179.

Another embodiment of the present invention is a computer system comprising a processor and a data storage device wherein the data storage device has stored thereon a sequence selected from the group consisting of a cDNA code of SEQID NOs. 40-84 and 130-154 and a polypeptide code of SEQ ID NOs. 85-129 and 155-179. In some embodiments the computer system further comprises a sequence comparer and a data storage device having reference sequences stored thereon. For example, the sequence comparer may comprise a computer program which indicates polymorphisms. In other aspects of the computer system, the system further comprises an identifier which identifies features in said sequence.

Another embodiment of the present invention is a method for comparing a first sequence to a reference sequence wherein the first sequence is selected from the group consisting of a cDNA code of SEQID NOs. 40-84 and 130-154 and a polypeptide code of SEQ ID NOs. 85-129 and 155-179 comprising the steps of reading the first sequence and the reference sequence through use of a computer program which compares sequences and determining differences between the first sequence and the reference sequence with the computer program. In some embodiments of the method, the step of determining differences between the first sequence and the reference sequence comprises identifying polymorphisms.

Another embodiment of the present invention is a method for identifying a feature in a sequence selected from the group consisting of a cDNA code of SEQID NOs. 40-84 and 130-154 and a polypeptide code of SEQ ID NOs. 85-129 and 155-179 comprising the steps of reading the sequence through the use of a computer program which identifies features in sequences and identifying features in the sequence with said computer program.

Brief Description of the Drawings

Figure 1 is a summary of a procedure for obtaining cDNAs which have been selected to include the 5' ends of the mRNAs from which they are derived.

Figure 2 is an analysis of the 43 amino terminal amino acids of all human SwissProt proteins to determine the frequency of false positives and false negatives using the techniques for signal peptide identification described herein.

Figure 3 shows the distribution of von Heijne scores for 5' ESTs in each of the categories described herein and the probability that these 5' ESTs encode a signal peptide.

Figure 4 shows the distribution of 5' ESTs in each category and the number of 5' ESTs in each category having a given minimum von Heijne's score.

Figure 5 shows the tissues from which the mRNAs corresponding to the 5' ESTs in each of the categories described herein were obtained.

Figure 6 illustrates a method for obtaining extended cDNAs.

Figure 7 is a map of pED6dpc2. PED6dpc2 is derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning. SST cDNAs are cloned between EcoRI and NotI. PED vectors are described in Kaufman et al. (1991), NAR 19:4485-4490.

Figure 8 provides a schematic description of the promoters isolated and the way they are assembled with the corresponding 5' tags.

Figure 9 describes the transcription factor binding sites present in each of these promoters.

Figure 10 is an alignment of the proteins of SEQ ID NOs: 120 and 180 wherein the signal peptide is in italics, the predicted transmembrane segment is underlined, the experimentally determined transmembrane segment is double-underlined, and the ATP1G/PLMN/MAT8 signature is in bold.

Figure 11 is an alignment of the proteins of SEQ ID NOs: 121 and 181 wherein the predicted transmembrane segment is underlined.

Figure 12 is an alignment of the proteins of SEQ ID NOs: 128 and 182 wherein the PPPPY motif is in bold.

Detailed Description of the Preferred Embodiment

I. Obtaining 5' ESTs

The present extended cDNAs were obtained using 5' ESTs which were isolated as described below.

A. Chemical Methods for Obtaining mRNAs having Intact 5' Ends

In order to obtain the 5' ESTs used to obtain the extended cDNAs of the present invention, mRNAs having intact 5' ends must be obtained. Currently, there are two approaches for obtaining such mRNAs. One of these approaches is a chemical modification method involving derivatization of the 5' ends of the mRNAs and selection of the derivatized mRNAs. The 5' ends of eucaryotic mRNAs possess a structure referred to as a "cap" which comprises a guanosine methylated at the 7 position. The cap is joined to the first transcribed base of the mRNA by a 5', 5'-triphosphate bond. In some instances, the 5' guanosine is methylated in both the 2 and 7 positions. Rarely, the 5' guanosine is trimethylated at the 2, 7 and 7 positions. In the chemical method for obtaining mRNAs having intact 5' ends, the 5' cap is specifically derivatized and coupled to a reactive group on an immobilizing substrate. This specific derivatization is based on the fact that only the ribose linked to the methylated guanosine at the 5' end of the mRNA and the ribose linked to the base at the 3' terminus of the mRNA, possess 2', 3'-cis diols. Optionally, where the 3' terminal ribose has a 2', 3'-cis diol, the 2', 3'-cis diol at the 3' end may be chemically modified, substituted, converted, or eliminated, leaving only the ribose linked to the methylated guanosine at the 5' end of the mRNA with a 2', 3'-cis diol. A variety of techniques are available for eliminating the 2', 3'-cis diol on the 3' terminal ribose. For example, controlled alkaline hydrolysis may be used to generate mRNA fragments in which the 3' terminal ribose is a 3'-phosphate, 2'-phosphate or (2', 3')-cyclophosphate. Thereafter, the fragment which includes the original 3' ribose may be eliminated from the mixture through chromatography on an oligo-dT column. Alternatively, a base which lacks the 2', 3'-cis diol may be added to the 3' end of the mRNA

using an RNA ligase such as T4 RNA ligase. Example 1 below describes a method for ligation of pCp to the 3' end of messenger RNA.

EXAMPLE 1

Ligation of the Nucleoside Diphosphate pCp to the 3' End of Messenger RNA

5 1 µg of RNA was incubated in a final reaction medium of 10 µl in the presence of 5 U of T₄ phage RNA ligase in the buffer provided by the manufacturer (Gibco - BRL), 40 U of the RNase inhibitor RNasin (Promega) and, 2 µl of ³²pCp (Amersham #PB 10208).

The incubation was performed at 37°C for 2 hours or overnight at 7-8°C.

Following modification or elimination of the 2', 3'-cis diol at the 3' ribose, the 2', 3'-cis diol present at the 5' end of the mRNA may be oxidized using reagents such as NaBH₄, NaBH₃CN, or sodium periodate, thereby converting the 2', 3'-cis diol to a dialdehyde. Example 2 describes the oxidation of the 2', 3'-cis diol at the 5' end of the mRNA with sodium periodate.

EXAMPLE 2

Oxidation of 2', 3'-cis diol at the 5' End of the mRNA

15 0.1 OD unit of either a capped oligoribonucleotide of 47 nucleotides (including the cap) or an uncapped oligoribonucleotide of 46 nucleotides were treated as follows. The oligoribonucleotides were produced by in vitro transcription using the transcription kit "AmpliScribe T7" (Epicentre Technologies). As indicated below, the DNA template for the RNA transcript contained a single cytosine. To synthesize the uncapped RNA, all four NTPs were included in the in vitro transcription reaction. To obtain the capped RNA, GTP was replaced by an analogue of the cap, m⁷G(5')ppp(5')G. This compound, recognized by polymerase, was incorporated into the 5' end of the nascent transcript during the step of initiation of transcription but was not capable of incorporation during the extension step. Consequently, the resulting RNA contained a cap at its 5' end. The sequences of the oligoribonucleotides produced by the in vitro transcription reaction were:

+Cap:

25 5'm⁷GpppGCAUCCUACUCCCAUCCAAUCCACCCUAAUCCUCCUCCCAUCUCCAC-3' (SEQ ID NO:1)

-Cap:

30 5'-pppGCAUCCUACUCCCAUCCAAUCCACCCUAAUCCUCCUCCCAUCUCCAC-3' (SEQ ID NO:2)

The oligoribonucleotides were dissolved in 9 µl of acetate buffer (0.1 M sodium acetate, pH 5.2) and 3 µl of freshly prepared 0.1 M sodium periodate solution. The mixture was incubated for 1 hour in the dark at 4°C or room temperature. Thereafter, the reaction was stopped by adding 4 µl of 10% ethylene glycol. The product was ethanol precipitated, resuspended in 10 µl or more of water or appropriate buffer and dialyzed against water.


The resulting aldehyde groups may then be coupled to molecules having a reactive amine group, such as hydrazine, carbazide, thiocarbazide or semicarbazide groups, in order to facilitate enrichment of the 5' ends of the mRNAs. Molecules having reactive amine groups which are suitable for use in selecting mRNAs having intact 5'

ends include avidin, proteins, antibodies, vitamins, ligands capable of specifically binding to receptor molecules, or oligonucleotides. Example 3 below describes the coupling of the resulting dialdehyde to biotin.

EXAMPLE 3

Coupling of the Dialdehyde with Biotin

- 5 The oxidation product obtained in Example 2 was dissolved in 50 μ l of sodium acetate at a pH of between 5 and 5.2 and 50 μ l of freshly prepared 0.02 M solution of biotin hydrazide in a methoxyethanol/water mixture (1:1) of formula:



In the compound used in these experiments, $n=5$. However, it will be appreciated that other commercially available hydrazides may also be used, such as molecules of the formula above in which n varies from 0 to 5.

- 10 The mixture was then incubated for 2 hours at 37°C. Following the incubation, the mixture was precipitated with ethanol and dialyzed against distilled water.

Example 4 demonstrates the specificity of the biotinylation reaction.

EXAMPLE 4

Specificity of Biotinylation

- 15 The specificity of the biotinylation for capped mRNAs was evaluated by gel electrophoresis of the following samples:

Sample 1. The 46 nucleotide uncapped in vitro transcript prepared as in Example 2 and labeled with ^{32}pCp as described in Example 1.

- 20 Sample 2. The 46 nucleotide uncapped in vitro transcript prepared as in Example 2, labeled with ^{32}pCp as described in Example 1, treated with the oxidation reaction of Example 2, and subjected to the biotinylation conditions of Example 3.

Sample 3. The 47 nucleotide capped in vitro transcript prepared as in Example 2 and labeled with ^{32}pCp as described in Example 1.

- 25 Sample 4. The 47 nucleotide capped in vitro transcript prepared as in Example 2, labeled with ^{32}pCp as described in Example 1, treated with the oxidation reaction of Example 2, and subjected to the biotinylation conditions of Example 3.

Samples 1 and 2 had identical migration rates, demonstrating that the uncapped RNAs were not oxidized and biotinylated. Sample 3 migrated more slowly than Samples 1 and 2, while Sample 4 exhibited the

slowest migration. The difference in migration of the RNAs in Samples 3 and 4 demonstrates that the capped RNAs were specifically biotinylated.

In some cases, mRNAs having intact 5' ends may be enriched by binding the molecule containing a reactive amine group to a suitable solid phase substrate such as the inside of the vessel containing the mRNAs, magnetic beads, chromatography matrices, or nylon or nitrocellulose membranes. For example, where the molecule having a reactive amine group is biotin, the solid phase substrate may be coupled to avidin or streptavidin. Alternatively, where the molecule having the reactive amine group is an antibody or receptor ligand, the solid phase substrate may be coupled to the cognate antigen or receptor. Finally, where the molecule having a reactive amine group comprises an oligonucleotide, the solid phase substrate may comprise a complementary oligonucleotide.

The mRNAs having intact 5' ends may be released from the solid phase following the enrichment procedure. For example, where the dialdehyde is coupled to biotin hydrazide and the solid phase comprises streptavidin, the mRNAs may be released from the solid phase by simply heating to 95 degrees Celsius in 2% SDS. In some methods, the molecule having a reactive amine group may also be cleaved from the mRNAs having intact 5' ends following enrichment. Example 5 describes the capture of biotinylated mRNAs with streptavidin coated beads and the release of the biotinylated mRNAs from the beads following enrichment.

EXAMPLE 5

Capture and Release of Biotinylated mRNAs Using Streptavidin Coated Beads

The streptavidin-coated magnetic beads were prepared according to the manufacturer's instructions (CPG Inc., USA). The biotinylated mRNAs were added to a hybridization buffer (1.5 M NaCl, pH 5 - 6). After incubating for 30 minutes, the unbound and nonbiotinylated material was removed. The beads were washed several times in water with 1% SDS. The beads obtained were incubated for 15 minutes at 95°C in water containing 2% SDS.

Example 6 demonstrates the efficiency with which biotinylated mRNAs were recovered from the streptavidin coated beads.

EXAMPLE 6

Efficiency of Recovery of Biotinylated mRNAs

The efficiency of the recovery procedure was evaluated as follows. RNAs were labeled with ^{32}P Cp, oxidized, biotinylated and bound to streptavidin coated beads as described above. Subsequently, the bound RNAs were incubated for 5, 15 or 30 minutes at 95°C in the presence of 2% SDS.

The products of the reaction were analyzed by electrophoresis on 12% polyacrylamide gels under denaturing conditions (7 M urea). The gels were subjected to autoradiography. During this manipulation, the hydrazone bonds were not reduced.

Increasing amounts of nucleic acids were recovered as incubation times in 2% SDS increased, demonstrating that biotinylated mRNAs were efficiently recovered.

In an alternative method for obtaining mRNAs having intact 5' ends, an oligonucleotide which has been derivatized to contain a reactive amine group is specifically coupled to mRNAs having an intact cap. Preferably, the 3' end of the mRNA is blocked prior to the step in which the aldehyde groups are joined to the derivatized oligonucleotide, as described above, so as to prevent the derivatized oligonucleotide from being joined to the 3' end of the mRNA. For example, pCp may be attached to the 3' end of the mRNA using T4 RNA ligase. However, as discussed above, blocking the 3' end of the mRNA is an optional step. Derivatized oligonucleotides may be prepared as described below in Example 7.

EXAMPLE 7

Derivatization of the Oligonucleotide

An oligonucleotide phosphorylated at its 3' end was converted to a 3' hydrazide in 3' by treatment with an aqueous solution of hydrazine or of dihydrazide of the formula $H_2N(R1)NH_2$ at about 1 to 3 M, and at pH 4.5, in the presence of a carbodiimide type agent soluble in water such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide at a final concentration of 0.3 M at a temperature of 8°C overnight.

The derivatized oligonucleotide was then separated from the other agents and products using a standard technique for isolating oligonucleotides.

As discussed above, the mRNAs to be enriched may be treated to eliminate the 3' OH groups which may be present thereon. This may be accomplished by enzymatic ligation of sequences lacking a 3' OH, such as pCp, as described above in Example 1. Alternatively, the 3' OH groups may be eliminated by alkaline hydrolysis as described in Example 8 below.

EXAMPLE 8

Alkaline Hydrolysis of mRNA

The mRNAs may be treated with alkaline hydrolysis as follows. In a total volume of 100 μ l of 0.1N sodium hydroxide, 1.5 μ g mRNA is incubated for 40 to 60 minutes at 4°C. The solution is neutralized with acetic acid and precipitated with ethanol.

Following the optional elimination of the 3' OH groups, the diol groups at the 5' ends of the mRNAs are oxidized as described below in Example 9.

EXAMPLE 9

Oxidation of Diols

Up to 1 OD unit of RNA was dissolved in 9 μ l of buffer (0.1 M sodium acetate, pH 6-7 or water) and 3 μ l of freshly prepared 0.1 M sodium periodate solution. The reaction was incubated for 1 h in the dark at 4°C or room temperature. Following the incubation, the reaction was stopped by adding 4 μ l of 10% ethylene glycol. Thereafter the mixture was incubated at room temperature for 15 minutes. After ethanol precipitation, the product was resuspended in 10 μ l or more of water or appropriate buffer and dialyzed against water.

Following oxidation of the diol groups at the 5' ends of the mRNAs, the derivatized oligonucleotide was joined to the resulting aldehydes as described in Example 10.

EXAMPLE 10

Reaction of Aldehydes with Derivatized Oligonucleotides

The oxidized mRNA was dissolved in an acidic medium such as 50 μ l of sodium acetate pH 4-6. 50 μ l of a solution of the derivatized oligonucleotide was added such that an mRNA:derivatized oligonucleotide ratio of 1:20 was obtained and mixture was reduced with a borohydride. The mixture was allowed to incubate for 2 h at 37°C or overnight (14 h) at 10°C. The mixture was ethanol precipitated, resuspended in 10 μ l or more of water or appropriate buffer and dialyzed against distilled water. If desired, the resulting product may be analyzed using acrylamide gel electrophoresis, HPLC analysis, or other conventional techniques.

Following the attachment of the derivatized oligonucleotide to the mRNAs, a reverse transcription reaction may be performed as described in Example 11 below.

EXAMPLE 11

Reverse Transcription of mRNAs

An oligodeoxyribonucleotide was derivatized as follows. 3 OD units of an oligodeoxyribonucleotide of sequence ATCAAGAATTCGCACGAGACCATTA (SEQ ID NO:3) having 5'-OH and 3'-P ends were dissolved in 70 μ l of a 1.5 M hydroxybenzotriazole solution, pH 5.3, prepared in dimethylformamide/water (75:25) containing 2 μ g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. The mixture was incubated for 2 h 30 min at 22°C. The mixture was then precipitated twice in LiClO₄/acetone. The pellet was resuspended in 200 μ l of 0.25 M hydrazine and incubated at 8°C from 3 to 14 h. Following the hydrazine reaction, the mixture was precipitated twice in LiClO₄/acetone.

The messenger RNAs to be reverse transcribed were extracted from blocks of placenta having sides of 2 cm which had been stored at -80°C. The mRNA was extracted using conventional acidic phenol techniques. Oligo-dT chromatography was used to purify the mRNAs. The integrity of the mRNAs was checked by Northern blotting.

The diol groups on 7 μ g of the placental mRNAs were oxidized as described above in Example 9. The derivatized oligonucleotide was joined to the mRNAs as described in Example 10 above except that the precipitation step was replaced by an exclusion chromatography step to remove derivatized oligodeoxyribonucleotides which were not joined to mRNAs. Exclusion chromatography was performed as follows:

10 ml of AcA34 (BioSeptra#230151) gel were equilibrated in 50 ml of a solution of 10 mM Tris pH 8.0, 300 mM NaCl, 1 mM EDTA, and 0.05% SDS. The mixture was allowed to sediment. The supernatant was eliminated and the gel was resuspended in 50 ml of buffer. This procedure was repeated 2 or 3 times.

A glass bead (diameter 3 mm) was introduced into a 2 ml disposable pipette (length 25 cm). The pipette was filled with the gel suspension until the height of the gel stabilized at 1 cm from the top of the pipette. The column was then equilibrated with 20 ml of equilibration buffer (10 mM Tris HCl pH 7.4, 20 mM NaCl).

10 μ l of the mRNA which had been reacted with the derivatized oligonucleotide were mixed in 39 μ l of 10 mM urea and 2 μ l of blue-glycerol buffer, which had been prepared by dissolving 5 mg of bromophenol blue in 60% glycerol (v/v), and passing the mixture through a filter with a filter of diameter 0.45 μ m.

The column was loaded. As soon as the sample had penetrated, equilibration buffer was added. 100 μ l fractions were collected. Derivatized oligonucleotide which had not been attached to mRNA appeared in fraction 16 and later fractions. Fractions 3 to 15 were combined and precipitated with ethanol.

The mRNAs which had been reacted with the derivatized oligonucleotide were spotted on a nylon membrane and hybridized to a radioactive probe using conventional techniques. The radioactive probe used in these hybridizations was an oligodeoxyribonucleotide of sequence TAATGGTCTCGTGCGAATTCTTGAT (SEQ ID NO:4) which was anticomplementary to the derivatized oligonucleotide and was labeled at its 5' end with 32 P. 1/10th of the mRNAs which had been reacted with the derivatized oligonucleotide was spotted in two spots on the membrane and the membrane was visualized by autoradiography after hybridization of the probe. A signal was observed, indicating that the derivatized oligonucleotide had been joined to the mRNA.

The remaining 9/10 of the mRNAs which had been reacted with the derivatized oligonucleotide was reverse transcribed as follows. A reverse transcription reaction was carried out with reverse transcriptase following the manufacturer's instructions. To prime the reaction, 50 pmol of nonamers with random sequence were used.

A portion of the resulting cDNA was spotted on a positively charged nylon membrane using conventional methods. The cDNAs were spotted on the membrane after the cDNA:RNA heteroduplexes had been subjected to an alkaline hydrolysis in order to eliminate the RNAs. An oligonucleotide having a sequence identical to that of the derivatized oligonucleotide was labeled at its 5' end with 32 P and hybridized to the cDNA blots using conventional techniques. Single-stranded cDNAs resulting from the reverse transcription reaction were spotted on the membrane. As controls, the blot contained 1 pmol, 100 fmol, 50 fmol, 10 fmol and 1 fmol respectively of a control oligodeoxyribonucleotide of sequence identical to that of the derivatized oligonucleotide. The signal observed in the spots containing the cDNA indicated that approximately 15 fmol of the derivatized oligonucleotide had been reverse transcribed.

These results demonstrate that the reverse transcription can be performed through the cap and, in particular, that reverse transcriptase crosses the 5'-P-P-P-5' bond of the cap of eukaryotic messenger RNAs.

The single stranded cDNAs obtained after the above first strand synthesis were used as template for PCR reactions. Two types of reactions were carried out. First, specific amplification of the mRNAs for the alpha globin, dehydrogenase, pp15 and elongation factor E4 were carried out using the following pairs of oligodeoxyribonucleotide primers.

alpha-globin

GLO-S: CCG ACA AGA CCA ACG TCA AGG CCG C (SEQ ID NO:5)

GLO-As: TCA CCA GCA GGC AGT GGC TTA GGA G 3' (SEQ ID NO:6)

dehydrogenase

3 DH-S: AGT GAT TCC TGC TAC TTT GGA TGG C (SEQ ID NO:7)

3 DH-As: GCT TGG TCT TGT TCT GGA GTT TAG A (SEQ ID NO:8)

pp15

PP15-S: TCC AGA ATG GGA GAC AAG CCA ATT T (SEQ ID NO:9)

PP15-As: AGG GAG GAG GAA ACA GCG TGA GTC C (SEQ ID NO:10)

5 Elongation factor E4

EFA1-S: ATG GGA AAG GAA AAG ACT CAT ATC A (SEQ ID NO:11)

EF1A-As: AGC AGC AAC AAT CAG GAC AGC ACA G (SEQ ID NO:12)

10 Non specific amplifications were also carried out with the antisense (_As) oligodeoxyribonucleotides of the pairs described above and a primer chosen from the sequence of the derivatized oligodeoxyribonucleotide (ATCAAGAATTTCGCACGAGACCATT A) (SEQ ID NO:13).

A 1.5% agarose gel containing the following samples corresponding to the PCR products of reverse transcription was stained with ethidium bromide. (1/20th of the products of reverse transcription were used for each PCR reaction).

15 Sample 1: The products of a PCR reaction using the globin primers of SEQ ID NOs 5 and 6 in the presence of cDNA.

Sample 2: The products of a PCR reaction using the globin primers of SEQ ID NOs 5 and 6 in the absence of added cDNA.

Sample 3: The products of a PCR reaction using the dehydrogenase primers of SEQ ID NOs 7 and 8 in the presence of cDNA.

20 Sample 4: The products of a PCR reaction using the dehydrogenase primers of SEQ ID NOs 7 and 8 in the absence of added cDNA.

Sample 5: The products of a PCR reaction using the pp15 primers of SEQ ID NOs 9 and 10 in the presence of cDNA.

25 Sample 6: The products of a PCR reaction using the pp15 primers of SEQ ID NOs 9 and 10 in the absence of added cDNA.

Sample 7: The products of a PCR reaction using the EIE4 primers of SEQ ID NOs 11 and 12 in the presence of added cDNA.

Sample 8: The products of a PCR reaction using the EIE4 primers of SEQ ID NOs 11 and 12 in the absence of added cDNA.

30 In Samples 1, 3, 5 and 7, a band of the size expected for the PCR product was observed, indicating the presence of the corresponding sequence in the cDNA population.

PCR reactions were also carried out with the antisense oligonucleotides of the globin and dehydrogenase primers (SEQ ID NOs 6 and 8) and an oligonucleotide whose sequence corresponds to that of the derivatized oligonucleotide. The presence of PCR products of the expected size in the samples corresponding to samples 1
35 and 3 above indicated that the derivatized oligonucleotide had been incorporated.

The above examples summarize the chemical procedure for enriching mRNAs for those having intact 5' ends. Further detail regarding the chemical approaches for obtaining mRNAs having intact 5' ends are disclosed in International Application No. WO96/34981, published November 7, 1996.

Strategies based on the above chemical modifications to the 5' cap structure may be utilized to generate
5 cDNAs which have been selected to include the 5' ends of the mRNAs from which they are derived. In one
version of such procedures, the 5' ends of the mRNAs are modified as described above. Thereafter, a reverse
transcription reaction is conducted to extend a primer complementary to the mRNA to the 5' end of the mRNA.
Single stranded RNAs are eliminated to obtain a population of cDNA/mRNA heteroduplexes in which the mRNA
includes an intact 5' end. The resulting heteroduplexes may be captured on a solid phase coated with a molecule
10 capable of interacting with the molecule used to derivatize the 5' end of the mRNA. Thereafter, the strands of the
heteroduplexes are separated to recover single stranded first cDNA strands which include the 5' end of the mRNA.
Second strand cDNA synthesis may then proceed using conventional techniques. For example, the procedures
disclosed in WO 96/34981 or in Caminci, P. et al. High-Efficiency Full-Length cDNA Cloning by Biotinylated CAP
Trapper. *Genomics* 37:327-336 (1996), may be employed to select cDNAs which include the sequence derived
15 from the 5' end of the coding sequence of the mRNA.

Following ligation of the oligonucleotide tag to the 5' cap of the mRNA, a reverse transcription reaction is
conducted to extend a primer complementary to the mRNA to the 5' end of the mRNA. Following elimination of the
RNA component of the resulting heteroduplex using standard techniques, second strand cDNA synthesis is
conducted with a primer complementary to the oligonucleotide tag.

20 Figure 1 summarizes the above procedures for obtaining cDNAs which have been selected to include the
5' ends of the mRNAs from which they are derived.

B. Enzymatic Methods for Obtaining mRNAs having Intact 5' Ends

Other techniques for selecting cDNAs extending to the 5' end of the mRNA from which they are derived
are fully enzymatic. Some versions of these techniques are disclosed in Dumas Milne Edwards J.B. (Doctoral
25 Thesis of Paris VI University, Le clonage des ADNc complets: difficultes et perspectives nouvelles. Apports pour
l'etude de la regulation de l'expression de la tryptophane hydroxylase de rat, 20 Dec. 1993), EP0 625572 and Kato
et al. Construction of a Human Full-Length cDNA Bank. *Gene* 150:243-250 (1994).

Briefly, in such approaches, isolated mRNA is treated with alkaline phosphatase to remove the phosphate
groups present on the 5' ends of uncapped incomplete mRNAs. Following this procedure, the cap present on full
30 length mRNAs is enzymatically removed with a decapping enzyme such as T4 polynucleotide kinase or tobacco
acid pyrophosphatase. An oligonucleotide, which may be either a DNA oligonucleotide or a DNA-RNA hybrid
oligonucleotide having RNA at its 3' end, is then ligated to the phosphate present at the 5' end of the decapped
mRNA using T4 RNA ligase. The oligonucleotide may include a restriction site to facilitate cloning of the cDNAs
following their synthesis. Example 12 below describes one enzymatic method based on the doctoral thesis of
35 Dumas.

EXAMPLE 12Enzymatic Approach for Obtaining 5' ESTs

Twenty micrograms of PolyA+ RNA were dephosphorylated using Calf Intestinal Phosphatase (Biolabs). After a phenol chloroform extraction, the cap structure of mRNA was hydrolysed using the Tobacco Acid
5 Pyrophosphatase (purified as described by Shinshi et al., Biochemistry 15: 2185-2190, 1976) and a hemi
5'DNA/RNA-3' oligonucleotide having an unphosphorylated 5' end, a stretch of adenosine ribophosphate at the 3'
end, and an EcoRI site near the 5' end was ligated to the 5'P ends of mRNA using the T4 RNA ligase (Biolabs).
Oligonucleotides suitable for use in this procedure are preferably 30-50 bases in length. Oligonucleotides having
an unphosphorylated 5' end may be synthesized by adding a fluorochrome at the 5' end. The inclusion of a
10 stretch of adenosine ribophosphates at the 3' end of the oligonucleotide increases ligation efficiency. It will be
appreciated that the oligonucleotide may contain cloning sites other than EcoRI.

Following ligation of the oligonucleotide to the phosphate present at the 5' end of the decapped mRNA,
first and second strand cDNA synthesis may be carried out using conventional methods or those specified in EP0
625,572 and Kato et al. Construction of a Human Full-Length cDNA Bank. *Gene* 150:243-250 (1994), and Dumas
15 Milne Edwards, *supra*. The resulting cDNA may then be ligated into vectors such as those disclosed in Kato et al.
Construction of a Human Full-Length cDNA Bank. *Gene* 150:243-250 (1994) or other nucleic acid vectors known
to those skilled in the art using techniques such as those described in Sambrook et al., *Molecular Cloning: A
Laboratory Manual* 2d Ed., Cold Spring Harbor Laboratory Press, 1989.

II. Characterization of 5' ESTs

20 The above chemical and enzymatic approaches for enriching mRNAs having intact 5' ends were
employed to obtain 5' ESTs. First, mRNAs were prepared as described in Example 13 below.

EXAMPLE 13Preparation of mRNA

Total human RNAs or PolyA+ RNAs derived from 29 different tissues were respectively purchased from
25 LABIMO and CLONTECH and used to generate 44 cDNA libraries as described below. The purchased RNA had
been isolated from cells or tissues using acid guanidium thiocyanate-phenol-chloroform extraction (Chomczynski,
P and Sacchi, N., *Analytical Biochemistry* 162:156-159, 1987). PolyA+ RNA was isolated from total RNA
(LABIMO) by two passes of oligodT chromatography, as described by Aviv and Leder (Aviv, H. and Leder, P.,
Proc. Natl. Acad. Sci. USA 69:1408-1412, 1972) in order to eliminate ribosomal RNA.

30 The quality and the integrity of the poly A+ were checked. Northern blots hybridized with a globin probe
were used to confirm that the mRNAs were not degraded. Contamination of the PolyA+ mRNAs by ribosomal
sequences was checked using RNAs blots and a probe derived from the sequence of the 28S RNA. Preparations
of mRNAs with less than 5% of ribosomal RNAs were used in library construction. To avoid constructing libraries
with RNAs contaminated by exogenous sequences (prokaryotic or fungal), the presence of bacterial 16S ribosomal
35 sequences or of two highly expressed mRNAs was examined using PCR.

Following preparation of the mRNAs, the above described chemical and/or the enzymatic procedures for enriching mRNAs having intact 5' ends discussed above were employed to obtain 5' ESTs from various tissues. In both approaches an oligonucleotide tag was attached to the cap at the 5' ends of the mRNAs. The oligonucleotide tag had an EcoRI site therein to facilitate later cloning procedures.

- 5 Following attachment of the oligonucleotide tag to the mRNA by either the chemical or enzymatic methods, the integrity of the mRNA was examined by performing a Northern blot with 200-500ng of mRNA using a probe complementary to the oligonucleotide tag.

EXAMPLE 14

cDNA Synthesis Using mRNA Templates Having Intact 5' Ends

- 10 For the mRNAs joined to oligonucleotide tags using both the chemical and enzymatic methods, first strand cDNA synthesis was performed using reverse transcriptase with random nonamers as primers. In order to protect internal EcoRI sites in the cDNA from digestion at later steps in the procedure, methylated dCTP was used for first strand synthesis. After removal of RNA by an alkaline hydrolysis, the first strand of cDNA was precipitated using isopropanol in order to eliminate residual primers.

- 15 For both the chemical and the enzymatic methods, the second strand of the cDNA was synthesized with a Klenow fragment using a primer corresponding to the 5' end of the ligated oligonucleotide described in Example 12. Preferably, the primer is 20-25 bases in length. Methylated dCTP was also used for second strand synthesis in order to protect internal EcoRI sites in the cDNA from digestion during the cloning process.

Following cDNA synthesis, the cDNAs were cloned into pBlueScript as described in Example 15 below.

20

EXAMPLE 15

Insertion of cDNAs into BlueScript

- Following second strand synthesis, the ends of the cDNA were blunted with T4 DNA polymerase (Biolabs) and the cDNA was digested with EcoRI. Since methylated dCTP was used during cDNA synthesis, the EcoRI site present in the tag was the only site which was hemi-methylated. Consequently, only the EcoRI site in the oligonucleotide tag was susceptible to EcoRI digestion. The cDNA was then size fractionated using exclusion chromatography (AcA, Biosepra). Fractions corresponding to cDNAs of more than 150 bp were pooled and ethanol precipitated. The cDNA was directionally cloned into the SmaI and EcoRI ends of the phagemid pBlueScript vector (Stratagene). The ligation mixture was electroporated into bacteria and propagated under appropriate antibiotic selection.

- 30 Clones containing the oligonucleotide tag attached were selected as described in Example 16 below.

EXAMPLE 16

Selection of Clones Having the Oligonucleotide Tag Attached Thereto

- The plasmid DNAs containing 5' EST libraries made as described above were purified (Qiagen). A positive selection of the tagged clones was performed as follows. Briefly, in this selection procedure, the plasmid DNA was converted to single stranded DNA using gene II endonuclease of the phage F1 in combination with an exonuclease (Chang et al., *Gene* 127:95-8, 1993) such as exonuclease III or T7 gene 6 exonuclease. The

resulting single stranded DNA was then purified using paramagnetic beads as described by Fry et al., *Biotechniques*, 13: 124-131, 1992. In this procedure, the single stranded DNA was hybridized with a biotinylated oligonucleotide having a sequence corresponding to the 3' end of the oligonucleotide described in Example 13. Preferably, the primer has a length of 20-25 bases. Clones including a sequence complementary to the biotinylated oligonucleotide were captured by incubation with streptavidin coated magnetic beads followed by magnetic selection. After capture of the positive clones, the plasmid DNA was released from the magnetic beads and converted into double stranded DNA using a DNA polymerase such as the ThermoSequenase obtained from Amersham Pharmacia Biotech. Alternatively, protocols such as the Gene Trapper kit (Gibco BRL) may be used. The double stranded DNA was then electroporated into bacteria. The percentage of positive clones having the 5' tag oligonucleotide was estimated to typically rank between 90 and 98% using dot blot analysis.

Following electroporation, the libraries were ordered in 384-microtiter plates (MTP). A copy of the MTP was stored for future needs. Then the libraries were transferred into 96 MTP and sequenced as described below.

EXAMPLE 17

Sequencing of Inserts in Selected Clones

Plasmid inserts were first amplified by PCR on PE 9600 thermocyclers (Perkin-Elmer), using standard SETA-A and SETA-B primers (Genset SA), AmpliTaqGold (Perkin-Elmer), dNTPs (Boehringer), buffer and cycling conditions as recommended by the Perkin-Elmer Corporation.

PCR products were then sequenced using automatic ABI Prism 377 sequencers (Perkin Elmer, Applied Biosystems Division, Foster City, CA). Sequencing reactions were performed using PE 9600 thermocyclers (Perkin Elmer) with standard dye-primer chemistry and ThermoSequenase (Amersham Life Science). The primers used were either T7 or 21M13 (available from Genset SA) as appropriate. The primers were labeled with the JOE, FAM, ROX and TAMRA dyes. The dNTPs and ddNTPs used in the sequencing reactions were purchased from Boehringer. Sequencing buffer, reagent concentrations and cycling conditions were as recommended by Amersham.

Following the sequencing reaction, the samples were precipitated with EtOH, resuspended in formamide loading buffer, and loaded on a standard 4% acrylamide gel. Electrophoresis was performed for 2.5 hours at 3000V on an ABI 377 sequencer, and the sequence data were collected and analyzed using the ABI Prism DNA Sequencing Analysis Software, version 2.1.2.

The sequence data from the 44 cDNA libraries made as described above were transferred to a proprietary database, where quality control and validation steps were performed. A proprietary base-caller ("Trace"), working using a Unix system automatically flagged suspect peaks, taking into account the shape of the peaks, the inter-peak resolution, and the noise level. The proprietary base-caller also performed an automatic trimming. Any stretch of 25 or fewer bases having more than 4 suspect peaks was considered unreliable and was discarded. Sequences corresponding to cloning vector or ligation oligonucleotides were automatically removed from the EST sequences. However, the resulting EST sequences may contain 1 to 5 bases belonging to the above mentioned sequences at their 5' end. If needed, these can easily be removed on a case by case basis.

Thereafter, the sequences were transferred to the proprietary NETGENE™ Database for further analysis as described below.

Following sequencing as described above, the sequences of the 5' ESTs were entered in a proprietary database called NETGENE™ for storage and manipulation. It will be appreciated by those skilled in the art that the data could be stored and manipulated on any medium which can be read and accessed by a computer. Computer readable media include magnetically readable media, optically readable media, or electronically readable media. For example, the computer readable media may be a hard disc, a floppy disc, a magnetic tape, CD-ROM, RAM, or ROM as well as other types of other media known to those skilled in the art.

In addition, the sequence data may be stored and manipulated in a variety of data processor programs in a variety of formats. For example, the sequence data may be stored as text in a word processing file, such as MicrosoftWORD or WORDPERFECT or as an ASCII file in a variety of database programs familiar to those of skill in the art, such as DB2, SYBASE, or ORACLE.

The computer readable media on which the sequence information is stored may be in a personal computer, a network, a server or other computer systems known to those skilled in the art. The computer or other system preferably includes the storage media described above, and a processor for accessing and manipulating the sequence data. Once the sequence data has been stored it may be manipulated and searched to locate those stored sequences which contain a desired nucleic acid sequence or which encode a protein having a particular functional domain. For example, the stored sequence information may be compared to other known sequences to identify homologies, motifs implicated in biological function, or structural motifs.

Programs which may be used to search or compare the stored sequences include the MacPattern (EMBL), BLAST, and BLAST2 program series (NCBI), basic local alignment search tool programs for nucleotide (BLASTN) and peptide (BLASTX) comparisons (Altschul et al, J. Mol. Biol. 215: 403 (1990)) and FASTA (Pearson and Lipman, Proc. Natl. Acad. Sci. USA, 85: 2444 (1988)). The BLAST programs then extend the alignments on the basis of defined match and mismatch criteria.

Motifs which may be detected using the above programs include sequences encoding leucine zippers, helix-turn-helix motifs, glycosylation sites, ubiquitination sites, alpha helices, and beta sheets, signal sequences encoding signal peptides which direct the secretion of the encoded proteins, sequences implicated in transcription regulation such as homeoboxes, acidic stretches, enzymatic active sites, substrate binding sites, and enzymatic cleavage sites.

Before searching the cDNAs in the NETGENE™ database for sequence motifs of interest, cDNAs derived from mRNAs which were not of interest were identified and eliminated from further consideration as described in Example 18 below.

EXAMPLE 18

Elimination of Undesired Sequences from Further Consideration

5' ESTs in the NETGENE™ database which were derived from undesired sequences such as transfer RNAs, ribosomal RNAs, mitochondrial RNAs, procaryotic RNAs, fungal RNAs, Alu sequences, L1 sequences, or repeat sequences were identified using the FASTA and BLASTN programs with the parameters listed in Table II.

To eliminate 5' ESTs encoding tRNAs from further consideration, the 5' EST sequences were compared
5 to the sequences of 1190 known tRNAs obtained from EMBL release 38, of which 100 were human. The comparison was performed using FASTA on both strands of the 5' ESTs. Sequences having more than 80% homology over more than 60 nucleotides were identified as tRNA. Of the 144,341 sequences screened, 26 were identified as tRNAs and eliminated from further consideration.

To eliminate 5' ESTs encoding rRNAs from further consideration, the 5' EST sequences were compared
10 to the sequences of 2497 known rRNAs obtained from EMBL release 38, of which 73 were human. The comparison was performed using BLASTN on both strands of the 5' ESTs with the parameter S=108. Sequences having more than 80% homology over stretches longer than 40 nucleotides were identified as rRNAs. Of the 144,341 sequences screened, 3,312 were identified as rRNAs and eliminated from further consideration.

To eliminate 5' ESTs encoding mtRNAs from further consideration, the 5' EST sequences were
15 compared to the sequences of the two known mitochondrial genomes for which the entire genomic sequences are available and all sequences transcribed from these mitochondrial genomes including tRNAs, rRNAs, and mRNAs for a total of 38 sequences. The comparison was performed using BLASTN on both strands of the 5' ESTs with the parameter S=108. Sequences having more than 80% homology over stretches longer than 40 nucleotides were identified as mtRNAs. Of the 144,341 sequences screened, 6,110 were identified as mtRNAs and eliminated
20 from further consideration.

Sequences which might have resulted from exogenous contaminants were eliminated from further consideration by comparing the 5' EST sequences to release 46 of the EMBL bacterial and fungal divisions using BLASTN with the parameter S=144. All sequences having more than 90% homology over at least 40 nucleotides were identified as exogenous contaminants. Of the 42 cDNA libraries examined, the average percentages of
25 procaryotic and fungal sequences contained therein were 0.2% and 0.5% respectively. Among these sequences, only one could be identified as a sequence specific to fungi. The others were either fungal or procaryotic sequences having homologies with vertebrate sequences or including repeat sequences which had not been masked during the electronic comparison.

In addition, the 5' ESTs were compared to 6093 Alu sequences and 1115 L1 sequences to mask 5' ESTs
30 containing such repeat sequences from further consideration. 5' ESTs including THE and MER repeats, SSTR sequences or satellite, micro-satellite, or telomeric repeats were also eliminated from further consideration. On average, 11.5% of the sequences in the libraries contained repeat sequences. Of this 11.5%, 7% contained Alu repeats, 3.3% contained L1 repeats and the remaining 1.2% were derived from the other types of repetitive sequences which were screened. These percentages are consistent with those found in cDNA libraries prepared
35 by other groups. For example, the cDNA libraries of Adams et al. contained between 0% and 7.4% Alu repeats

depending on the source of the RNA which was used to prepare the cDNA library (Adams et al., *Nature* 377:174, 1996).

The sequences of those 5' ESTs remaining after the elimination of undesirable sequences were compared with the sequences of known human mRNAs to determine the accuracy of the sequencing procedures described above.

EXAMPLE 19

Measurement of Sequencing Accuracy by Comparison to Known Sequences

To further determine the accuracy of the sequencing procedure described above, the sequences of 5' ESTs derived from known sequences were identified and compared to the known sequences. First, a FASTA analysis with overhangs shorter than 5 bp on both ends was conducted on the 5' ESTs to identify those matching an entry in the public human mRNA database. The 6655 5' ESTs which matched a known human mRNA were then realigned with their cognate mRNA and dynamic programming was used to include substitutions, insertions, and deletions in the list of "errors" which would be recognized. Errors occurring in the last 10 bases of the 5' EST sequences were ignored to avoid the inclusion of spurious cloning sites in the analysis of sequencing accuracy.

This analysis revealed that the sequences incorporated in the NETGENE™ database had an accuracy of more than 99.5%.

To determine the efficiency with which the above selection procedures select cDNAs which include the 5' ends of their corresponding mRNAs, the following analysis was performed.

EXAMPLE 20

Determination of Efficiency of 5' EST Selection

To determine the efficiency at which the above selection procedures isolated 5' ESTs which included sequences close to the 5' end of the mRNAs from which they were derived, the sequences of the ends of the 5' ESTs which were derived from the elongation factor 1 subunit α and ferritin heavy chain genes were compared to the known cDNA sequences for these genes. Since the transcription start sites for the elongation factor 1 subunit α and ferritin heavy chain are well characterized, they may be used to determine the percentage of 5' ESTs derived from these genes which included the authentic transcription start sites.

For both genes, more than 95% of the cDNAs included sequences close to or upstream of the 5' end of the corresponding mRNAs.

To extend the analysis of the reliability of the procedures for isolating 5' ESTs from ESTs in the NETGENE™ database, a similar analysis was conducted using a database composed of human mRNA sequences extracted from GenBank database release 97 for comparison. For those 5' ESTs derived from mRNAs included in the GeneBank database, more than 85% had their 5' ends close to the 5' ends of the known sequence. As some of the mRNA sequences available in the GenBank database are deduced from genomic sequences, a 5' end matching with these sequences will be counted as an internal match. Thus, the method used here underestimates the yield of ESTs including the authentic 5' ends of their corresponding mRNAs.

The EST libraries made above included multiple 5' ESTs derived from the same mRNA. The sequences of such 5' ESTs were compared to one another and the longest 5' ESTs for each mRNA were identified. Overlapping cDNAs were assembled into continuous sequences (contigs). The resulting continuous sequences were then compared to public databases to gauge their similarity to known sequences, as described in Example 21 below.

EXAMPLE 21

Clustering of the 5' ESTs and Calculation of Novelty Indices for cDNA Libraries

For each sequenced EST library, the sequences were clustered by the 5' end. Each sequence in the library was compared to the others with BLASTN2 (direct strand, parameters S=107). ESTs with High Scoring Segment Pairs (HSPs) at least 25 bp long, having 95% identical bases and beginning closer than 10 bp from each EST 5' end were grouped. The longest sequence found in the cluster was used as representative of the cluster. A global clustering between libraries was then performed leading to the definition of super-contigs.

To assess the yield of new sequences within the EST libraries, a novelty rate (NR) was defined as: $NR = 100 \times (\text{Number of new unique sequences found in the library} / \text{Total number of sequences from the library})$. Typically, novelty rating range between 10% and 41% depending on the tissue from which the EST library was obtained. For most of the libraries, the random sequencing of 5' EST libraries was pursued until the novelty rate reached 20%.

Following characterization as described above, the collection of 5' ESTs in NETGENE™ was screened to identify those 5' ESTs bearing potential signal sequences as described in Example 22 below.

EXAMPLE 22

Identification of Potential Signal Sequences in 5' ESTs

The 5' ESTs in the NETGENE™ database were screened to identify those having an uninterrupted open reading frame (ORF) longer than 45 nucleotides beginning with an ATG codon and extending to the end of the EST. Approximately half of the cDNA sequences in NETGENE™ contained such an ORF. The ORFs of these 5' ESTs were searched to identify potential signal motifs using slight modifications of the procedures disclosed in Von Heijne, G. A New Method for Predicting Signal Sequence Cleavage Sites. *Nucleic Acids Res.* 14:4683-4690 (1986). Those 5' EST sequences encoding a 15 amino acid long stretch with a score of at least 3.5 in the Von Heijne signal peptide identification matrix were considered to possess a signal sequence. Those 5' ESTs which matched a known human mRNA or EST sequence and had a 5' end more than 20 nucleotides downstream of the known 5' end were excluded from further analysis. The remaining cDNAs having signal sequences therein were included in a database called SIGNALTAG™.

To confirm the accuracy of the above method for identifying signal sequences, the analysis of Example 23 was performed.

EXAMPLE 23

Confirmation of Accuracy of Identification of Potential Signal Sequences in 5' ESTs

The accuracy of the above procedure for identifying signal sequences encoding signal peptides was evaluated by applying the method to the 43 amino terminal amino acids of all human SwissProt proteins. The computed Von Heijne score for each protein was compared with the known characterization of the protein as being a secreted protein or a non-secreted protein. In this manner, the number of non-secreted proteins having a score
5 higher than 3.5 (false positives) and the number of secreted proteins having a score lower than 3.5 (false negatives) could be calculated.

Using the results of the above analysis, the probability that a peptide encoded by the 5' region of the mRNA is in fact a genuine signal peptide based on its Von Heijne's score was calculated based on either the assumption that 10% of human proteins are secreted or the assumption that 20% of human proteins are secreted.
10 The results of this analysis are shown in Figures 2 and 3.

Using the above method of identifying secretory proteins, 5' ESTs for human glucagon, gamma interferon induced monokine precursor, secreted cyclophilin-like protein, human pleiotropin, and human biotinidase precursor all of which are polypeptides which are known to be secreted, were obtained. Thus, the above method successfully identified those 5' ESTs which encode a signal peptide.

15 To confirm that the signal peptide encoded by the 5' ESTs actually functions as a signal peptide, the signal sequences from the 5' ESTs may be cloned into a vector designed for the identification of signal peptides. Some signal peptide identification vectors are designed to confer the ability to grow in selective medium on host cells which have a signal sequence operably inserted into the vector. For example, to confirm that a 5' EST encodes a genuine signal peptide, the signal sequence of the 5' EST may be inserted upstream and in frame with
20 a non-secreted form of the yeast invertase gene in signal peptide selection vectors such as those described in U.S. Patent No. 5,536,637. Growth of host cells containing signal sequence selection vectors having the signal sequence from the 5' EST inserted therein confirms that the 5' EST encodes a genuine signal peptide.

Alternatively, the presence of a signal peptide may be confirmed by cloning the extended cDNAs obtained using the ESTs into expression vectors such as pXT1 (as described below), or by constructing promoter-signal
25 sequence-reporter gene vectors which encode fusion proteins between the signal peptide and an assayable reporter protein. After introduction of these vectors into a suitable host cell, such as COS cells or NIH 3T3 cells, the growth medium may be harvested and analyzed for the presence of the secreted protein. The medium from these cells is compared to the medium from cells containing vectors lacking the signal sequence or extended cDNA insert to identify vectors which encode a functional signal peptide or an authentic secreted protein.

30 Those 5' ESTs which encoded a signal peptide, as determined by the method of Example 22 above, were further grouped into four categories based on their homology to known sequences. The categorization of the 5' ESTs is described in Example 24 below.

EXAMPLE 24

Categorization of 5' ESTs Encoding a Signal Peptide

Those 5' ESTs having a sequence not matching any known vertebrate sequence nor any publicly available EST sequence were designated "new." Of the sequences in the SIGNALTAG™ database, 947 of the 5' ESTs having a Von Heijne's score of at least 3.5 fell into this category.

Those 5' ESTs having a sequence not matching any vertebrate sequence but matching a publicly known
5 EST were designated "EST-ext", provided that the known EST sequence was extended by at least 40 nucleotides in the 5' direction. Of the sequences in the SIGNALTAG™ database, 150 of the 5' ESTs having a Von Heijne's score of at least 3.5 fell into this category.

Those ESTs not matching any vertebrate sequence but matching a publicly known EST without
10 extending the known EST by at least 40 nucleotides in the 5' direction were designated "EST." Of the sequences in the SIGNALTAG™ database, 599 of the 5' ESTs having a Von Heijne's score of at least 3.5 fell into this category.

Those 5' ESTs matching a human mRNA sequence but extending the known sequence by at least 40
nucleotides in the 5' direction were designated "VERT-ext." Of the sequences in the SIGNALTAG™ database, 23
of the 5' ESTs having a Von Heijne's score of at least 3.5 fell into this category. Included in this category was a 5'
15 EST which extended the known sequence of the human translocase mRNA by more than 200 bases in the 5'
direction. A 5' EST which extended the sequence of a human tumor suppressor gene in the 5' direction was also
identified.

Figure 4 shows the distribution of 5' ESTs in each category and the number of 5' ESTs in each category
having a given minimum von Heijne's score.

20 Each of the 5' ESTs was categorized based on the tissue from which its corresponding mRNA was
obtained, as described below in Example 25.

EXAMPLE 25

Categorization of Expression Patterns

Figure 5 shows the tissues from which the mRNAs corresponding to the 5' ESTs in each of the above
25 described categories were obtained.

In addition to categorizing the 5' ESTs by the tissue from which the cDNA library in which they were first
identified was obtained, the spatial and temporal expression patterns of the mRNAs corresponding to the 5' ESTs,
as well as their expression levels, may be determined as described in Example 26 below. Characterization of the
spatial and temporal expression patterns and expression levels of these mRNAs is useful for constructing
30 expression vectors capable of producing a desired level of gene product in a desired spatial or temporal manner,
as will be discussed in more detail below.

In addition, 5' ESTs whose corresponding mRNAs are associated with disease states may also be
identified. For example, a particular disease may result from lack of expression, over expression, or under
expression of an mRNA corresponding to a 5' EST. By comparing mRNA expression patterns and quantities in

samples taken from healthy individuals with those from individuals suffering from a particular disease, 5' ESTs responsible for the disease may be identified.

It will be appreciated that the results of the above characterization procedures for 5' ESTs also apply to extended cDNAs (obtainable as described below) which contain sequences adjacent to the 5' ESTs. It will also be appreciated that if it is desired to defer characterization until extended cDNAs have been obtained rather than characterizing the ESTs themselves, the above characterization procedures can be applied to characterize the extended cDNAs after their isolation.

EXAMPLE 26

Evaluation of Expression Levels and Patterns of mRNAs

Corresponding to 5' ESTs or Extended cDNAs

Expression levels and patterns of mRNAs corresponding to 5' ESTs or extended cDNAs (obtainable as described below) may be analyzed by solution hybridization with long probes as described in International Patent Application No. WO 97/05277. Briefly, a 5' EST, extended cDNA, or fragment thereof corresponding to the gene encoding the mRNA to be characterized is inserted at a cloning site immediately downstream of a bacteriophage (T3, T7 or SP6) RNA polymerase promoter to produce antisense RNA. Preferably, the 5' EST or extended cDNA has 100 or more nucleotides. The plasmid is linearized and transcribed in the presence of ribonucleotides comprising modified ribonucleotides (i.e. biotin-UTP and DIG-UTP). An excess of this doubly labeled RNA is hybridized in solution with mRNA isolated from cells or tissues of interest. The hybridizations are performed under standard stringent conditions (40-50°C for 16 hours in an 80% formamide, 0.4 M NaCl buffer, pH 7-8). The unhybridized probe is removed by digestion with ribonucleases specific for single-stranded RNA (i.e. RNases CL3, T1, Phy M, U2 or A). The presence of the biotin-UTP modification enables capture of the hybrid on a microtitration plate coated with streptavidin. The presence of the DIG modification enables the hybrid to be detected and quantified by ELISA using an anti-DIG antibody coupled to alkaline phosphatase.

The 5' ESTs, extended cDNAs, or fragments thereof may also be tagged with nucleotide sequences for the serial analysis of gene expression (SAGE) as disclosed in UK Patent Application No. 2 305 241 A. In this method, cDNAs are prepared from a cell, tissue, organism or other source of nucleic acid for which it is desired to determine gene expression patterns. The resulting cDNAs are separated into two pools. The cDNAs in each pool are cleaved with a first restriction endonuclease, called an "anchoring enzyme," having a recognition site which is likely to be present at least once in most cDNAs. The fragments which contain the 5' or 3' most region of the cleaved cDNA are isolated by binding to a capture medium such as streptavidin coated beads. A first oligonucleotide linker having a first sequence for hybridization of an amplification primer and an internal restriction site for a "tagging endonuclease" is ligated to the digested cDNAs in the first pool. Digestion with the second endonuclease produces short "tag" fragments from the cDNAs.

A second oligonucleotide having a second sequence for hybridization of an amplification primer and an internal restriction site is ligated to the digested cDNAs in the second pool. The cDNA fragments in the second

pool are also digested with the "tagging endonuclease" to generate short "tag" fragments derived from the cDNAs in the second pool. The "tags" resulting from digestion of the first and second pools with the anchoring enzyme and the tagging endonuclease are ligated to one another to produce "ditags." In some embodiments, the ditags are concatamerized to produce ligation products containing from 2 to 200 ditags. The tag sequences are then
5 determined and compared to the sequences of the 5' ESTs or extended cDNAs to determine which 5' ESTs or extended cDNAs are expressed in the cell, tissue, organism, or other source of nucleic acids from which the tags were derived. In this way, the expression pattern of the 5' ESTs or extended cDNAs in the cell, tissue, organism, or other source of nucleic acids is obtained.

Quantitative analysis of gene expression may also be performed using arrays. As used herein, the term
10 array means a one dimensional, two dimensional, or multidimensional arrangement of full length cDNAs (i.e. extended cDNAs which include the coding sequence for the signal peptide, the coding sequence for the mature protein, and a stop codon), extended cDNAs, 5' ESTs or fragments of the full length cDNAs, extended cDNAs, or 5' ESTs of sufficient length to permit specific detection of gene expression. Preferably, the fragments are at least 15 nucleotides in length. More preferably, the fragments are at least 100 nucleotides in length. More preferably,
15 the fragments are more than 100 nucleotides in length. In some embodiments the fragments may be more than 500 nucleotides in length.

For example, quantitative analysis of gene expression may be performed with full length cDNAs, extended cDNAs, 5' ESTs, or fragments thereof in a complementary DNA microarray as described by Schena et al. (*Science* 270:467-470, 1995; *Proc. Natl. Acad. Sci. U.S.A.* 93:10614-10619, 1996). Full length cDNAs,
20 extended cDNAs, 5' ESTs or fragments thereof are amplified by PCR and arrayed from 96-well microtiter plates onto silylated microscope slides using high-speed robotics. Printed arrays are incubated in a humid chamber to allow rehydration of the array elements and rinsed, once in 0.2% SDS for 1 min, twice in water for 1 min and once for 5 min in sodium borohydride solution. The arrays are submerged in water for 2 min at 95°C, transferred into 0.2% SDS for 1 min, rinsed twice with water, air dried and stored in the dark at 25°C.

25 Cell or tissue mRNA is isolated or commercially obtained and probes are prepared by a single round of reverse transcription. Probes are hybridized to 1 cm² microarrays under a 14 x 14 mm glass coverslip for 6-12 hours at 60°C. Arrays are washed for 5 min at 25°C in low stringency wash buffer (1 x SSC/0.2% SDS), then for 10 min at room temperature in high stringency wash buffer (0.1 x SSC/0.2% SDS). Arrays are scanned in 0.1 x SSC using a fluorescence laser scanning device fitted with a custom filter set. Accurate differential expression
30 measurements are obtained by taking the average of the ratios of two independent hybridizations.

Quantitative analysis of the expression of genes may also be performed with full length cDNAs, extended cDNAs, 5' ESTs, or fragments thereof in complementary DNA arrays as described by Pietu et al. (*Genome Research* 6:492-503, 1996). The full length cDNAs, extended cDNAs, 5' ESTs or fragments thereof are PCR amplified and spotted on membranes. Then, mRNAs originating from various tissues or cells are labeled with
35 radioactive nucleotides. After hybridization and washing in controlled conditions, the hybridized mRNAs are

detected by phospho-imaging or autoradiography. Duplicate experiments are performed and a quantitative analysis of differentially expressed mRNAs is then performed.

Alternatively, expression analysis of the 5' ESTs or extended cDNAs can be done through high density nucleotide arrays as described by Lockhart et al. (Nature Biotechnology 14: 1675-1680, 1996) and Sosnowsky et al. (Proc. Natl. Acad. Sci. 94:1119-1123, 1997). Oligonucleotides of 15-50 nucleotides corresponding to sequences of the 5' ESTs or extended cDNAs are synthesized directly on the chip (Lockhart et al., *supra*) or synthesized and then addressed to the chip (Sosnowski et al., *supra*). Preferably, the oligonucleotides are about 20 nucleotides in length.

cDNA probes labeled with an appropriate compound, such as biotin, digoxigenin or fluorescent dye, are synthesized from the appropriate mRNA population and then randomly fragmented to an average size of 50 to 100 nucleotides. The said probes are then hybridized to the chip. After washing as described in Lockhart et al., *supra* and application of different electric fields (Sosnowsky et al., Proc. Natl. Acad. Sci. 94:1119-1123), the dyes or labeling compounds are detected and quantified. Duplicate hybridizations are performed. Comparative analysis of the intensity of the signal originating from cDNA probes on the same target oligonucleotide in different cDNA samples indicates a differential expression of the mRNA corresponding to the 5' EST or extended cDNA from which the oligonucleotide sequence has been designed.

III. Use of 5' ESTs to Clone Extended cDNAs and to Clone the Corresponding Genomic DNAs

Once 5' ESTs which include the 5' end of the corresponding mRNAs have been selected using the procedures described above, they can be utilized to isolate extended cDNAs which contain sequences adjacent to the 5' ESTs. The extended cDNAs may include the entire coding sequence of the protein encoded by the corresponding mRNA, including the authentic translation start site, the signal sequence, and the sequence encoding the mature protein remaining after cleavage of the signal peptide. Such extended cDNAs are referred to herein as "full length cDNAs." Alternatively, the extended cDNAs may include only the sequence encoding the mature protein remaining after cleavage of the signal peptide, or only the sequence encoding the signal peptide.

Example 27 below describes a general method for obtaining extended cDNAs. Example 28 below describes the cloning and sequencing of several extended cDNAs, including extended cDNAs which include the entire coding sequence and authentic 5' end of the corresponding mRNA for several secreted proteins.

The methods of Examples 27, 28, and 29 can also be used to obtain extended cDNAs which encode less than the entire coding sequence of the secreted proteins encoded by the genes corresponding to the 5' ESTs. In some embodiments, the extended cDNAs isolated using these methods encode at least 10 amino acids of one of the proteins encoded by the sequences of SEQ ID NOs: 40-84 and 130-154. In further embodiments, the extended cDNAs encode at least 20 amino acids of the proteins encoded by the sequences of SEQ ID NOs: 40-84 and 130-154. In further embodiments, the extended cDNAs encode at least 30 amino acids of the sequences of SEQ ID NOs: 40-84 and 130-154. In a preferred embodiment, the extended cDNAs encode a full length protein sequence, which includes the protein coding sequences of SEQ ID NOs: 40-84 and 130-154.

EXAMPLE 27

General Method for Using 5' ESTs to Clone and Sequence Extended cDNAs

The following general method has been used to quickly and efficiently isolate extended cDNAs including sequence adjacent to the sequences of the 5' ESTs used to obtain them. This method may be applied to obtain
5 extended cDNAs for any 5' EST in the NETGENE™ database, including those 5' ESTs encoding secreted proteins. The method is summarized in Figure 6.

1. Obtaining Extended cDNAsa) First strand synthesis

The method takes advantage of the known 5' sequence of the mRNA. A reverse transcription reaction is
10 conducted on purified mRNA with a poly 14dT primer containing a 49 nucleotide sequence at its 5' end allowing the addition of a known sequence at the end of the cDNA which corresponds to the 3' end of the mRNA. For example, the primer may have the following sequence: 5'-ATC GTT GAG ACT CGT ACC AGC AGA GTC ACG AGA GAG ACT ACA CGG TAC TGG TTT TTT TTT TTVN -3' (SEQ ID NO:14). Those skilled in the art will appreciate that other sequences may also be added to the poly dT sequence and used to prime the first strand synthesis.
15 Using this primer and a reverse transcriptase such as the Superscript II (Gibco BRL) or Rnase H Minus M-MLV (Promega) enzyme, a reverse transcript anchored at the 3' polyA site of the RNAs is generated.

After removal of the mRNA hybridized to the first cDNA strand by alkaline hydrolysis, the products of the alkaline hydrolysis and the residual poly dT primer are eliminated with an exclusion column such as an AcA34 (Biosepra) matrix as explained in Example 11.

20 b) Second strand synthesis

A pair of nested primers on each end is designed based on the known 5' sequence from the 5' EST and the known 3' end added by the poly dT primer used in the first strand synthesis. Software used to design primers are either based on GC content and melting temperatures of oligonucleotides, such as OSP (Illier and Green, *PCR Meth. Appl.* 1:124-128, 1991), or based on the octamer frequency disparity method (Griffais et al., *Nucleic Acids*
25 *Res.* 19: 3887-3891, 1991 such as PC-Rare (<http://bioinformatics.weizmann.ac.il/software/PC-Rare/doc/manual.html>).

Preferably, the nested primers at the 5' end are separated from one another by four to nine bases. The 5' primer sequences may be selected to have melting temperatures and specificities suitable for use in PCR.

Preferably, the nested primers at the 3' end are separated from one another by four to nine bases. For
30 example, the nested 3' primers may have the following sequences: (5'- CCA GCA GAG TCA CGA GAG AGA CTA CAC GG -3'(SEQ ID NO:15), and 5'- CAC GAG AGA GAC TAC ACG GTA CTG G -3' (SEQ ID NO:16). These primers were selected because they have melting temperatures and specificities compatible with their use in PCR. However, those skilled in the art will appreciate that other sequences may also be used as primers.

The first PCR run of 25 cycles is performed using the Advantage Tth Polymerase Mix (Clontech) and the
35 outer primer from each of the nested pairs. A second 20 cycle PCR using the same enzyme and the inner primer

from each of the nested pairs is then performed on 1/2500 of the first PCR product. Thereafter, the primers and nucleotides are removed.

2. Sequencing of Full Length Extended cDNAs or Fragments Thereof

Due to the lack of position constraints on the design of 5' nested primers compatible for PCR use using the OSP software, amplicons of two types are obtained. Preferably, the second 5' primer is located upstream of the translation initiation codon thus yielding a nested PCR product containing the whole coding sequence. Such a full length extended cDNA undergoes a direct cloning procedure as described in section a below. However, in some cases, the second 5' primer is located downstream of the translation initiation codon, thereby yielding a PCR product containing only part of the ORF. Such incomplete PCR products are submitted to a modified procedure described in section b below.

a) Nested PCR products containing complete ORFs

When the resulting nested PCR product contains the complete coding sequence, as predicted from the 5'EST sequence, it is cloned in an appropriate vector such as pED6dpc2, as described in section 3.

b) Nested PCR products containing incomplete ORFs

When the amplicon does not contain the complete coding sequence, intermediate steps are necessary to obtain both the complete coding sequence and a PCR product containing the full coding sequence. The complete coding sequence can be assembled from several partial sequences determined directly from different PCR products as described in the following section.

Once the full coding sequence has been completely determined, new primers compatible for PCR use are designed to obtain amplicons containing the whole coding region. However, in such cases, 3' primers compatible for PCR use are located inside the 3' UTR of the corresponding mRNA, thus yielding amplicons which lack part of this region, i.e. the polyA tract and sometimes the polyadenylation signal, as illustrated in figure 6. Such full length extended cDNAs are then cloned into an appropriate vector as described in section 3.

c) Sequencing extended cDNAs

Sequencing of extended cDNAs can be performed using a Die Terminator approach with the AmpliTaq DNA polymerase FS kit available from Perkin Elmer.

In order to sequence PCR fragments, primer walking is performed using software such as OSP to choose primers and automated computer software such as ASMG (Sutton et al., *Genome Science Technol.* 1: 9-19, 1995) to construct contigs of walking sequences including the initial 5' tag using minimum overlaps of 32 nucleotides. Preferably, primer walking is performed until the sequences of full length cDNAs are obtained.

Completion of the sequencing of a given extended cDNA fragment is assessed as follows. Since sequences located after a polyA tract are difficult to determine precisely in the case of undcloned products, sequencing and primer walking processes for PCR products are interrupted when a polyA tract is identified in extended cDNAs obtained as described in case b. The sequence length is compared to the size of the nested PCR product obtained as described above. Due to the limited accuracy of the determination of the PCR product

size by gel electrophoresis, a sequence is considered complete if the size of the obtained sequence is at least 70 % the size of the first nested PCR product. If the length of the sequence determined from the computer analysis is not at least 70% of the length of the nested PCR product, these PCR products are cloned and the sequence of the insertion is determined. When Northern blot data are available, the size of the mRNA detected for a given PCR product is used to finally assess that the sequence is complete. Sequences which do not fulfill the above criteria are discarded and will undergo a new isolation procedure.

Sequence data of all extended cDNAs are then transferred to a proprietary database, where quality controls and validation steps are carried out as described in example 15.

3. Cloning of Full Length Extended cDNAs

The PCR product containing the full coding sequence is then cloned in an appropriate vector. For example, the extended cDNAs can be cloned into the expression vector pED6dpc2 (DiscoverEase, Genetics Institute, Cambridge, MA) as follows. The structure of pED6dpc2 is shown in Figure 7. pED6dpc2 vector DNA is prepared with blunt ends by performing an EcoRI digestion followed by a fill in reaction. The blunt ended vector is dephosphorylated. After removal of PCR primers and ethanol precipitation, the PCR product containing the full coding sequence or the extended cDNA obtained as described above is phosphorylated with a kinase subsequently removed by phenol-Sevag extraction and precipitation. The double stranded extended cDNA is then ligated to the vector and the resulting expression plasmid introduced into appropriate host cells.

Since the PCR products obtained as described above are blunt ended molecules that can be cloned in either direction, the orientation of several clones for each PCR product is determined. Then, 4 to 10 clones are ordered in microtiter plates and subjected to a PCR reaction using a first primer located in the vector close to the cloning site and a second primer located in the portion of the extended cDNA corresponding to the 3' end of the mRNA. This second primer may be the antisense primer used in anchored PCR in the case of direct cloning (case a) or the antisense primer located inside the 3'UTR in the case of indirect cloning (case b). Clones in which the start codon of the extended cDNA is operably linked to the promoter in the vector so as to permit expression of the protein encoded by the extended cDNA are conserved and sequenced. In addition to the ends of cDNA inserts, approximately 50 bp of vector DNA on each side of the cDNA insert are also sequenced.

The cloned PCR products are then entirely sequenced according to the aforementioned procedure. In this case, contig assembly of long fragments is then performed on walking sequences that have already contigated for uncloned PCR products during primer walking. Sequencing of cloned amplicons is complete when the resulting contigs include the whole coding region as well as overlapping sequences with vector DNA on both ends.

4. Computer Analysis of Full Length Extended cDNA

Sequences of all full length extended cDNAs may then be subjected to further analysis as described below and using the parameters found in Table II with the following modifications. For screening of miscellaneous subdivisions of Genbank, FASTA was used instead of BLASTN and 15 nucleotide of homology was the limit instead of 17. For Alu detection, BLASTN was used with the following parameters: S=72; identity=70%; and length = 40 nucleotides. Polyadenylation signal and polyA tail which were not search for the

5' ESTs were searched. For polyadenylation signal detection the signal (AATAAA) was searched with one permissible mismatch in the last fifty nucleotides preceding the 5' end of the polyA. For the polyA, a stretch of 8 amino acids in the last 20 nucleotides of the sequence was searched with BLAST2N in the sense strand with the following parameters (W=6, S=10, E=1000, and identity=90%). Finally, patented sequences and ORF
5 homologues were searched using, respectively, BLASTN and BLASTP on GenSEQ (Derwent's database of patented nucleotide sequences) and SWISSPROT for ORFs with the following parameters (W=8 and B=10). Before examining the extended full length cDNAs for sequences of interest, extended cDNAs which are not of interest are searched as follows.

a) Elimination of undesired sequences

10 Although 5'ESTs were checked to remove contaminants sequences as described in Example 18, a last verification was carried out to identify extended cDNAs sequences derived from undesired sequences such as vector RNAs, transfer RNAs, ribosomal rRNAs, mitochondrial RNAs, prokaryotic RNAs and fungal RNAs using the FASTA and BLASTN programs on both strands of extended cDNAs as described below.

To identify the extended cDNAs encoding vector RNAs, extended cDNAs are compared to the known
15 sequences of vector RNA using the FASTA program. Sequences of extended cDNAs with more than 90% homology over stretches of 15 nucleotides are identified as vector RNA.

To identify the extended cDNAs encoding tRNAs, extended cDNA sequences were compared to the sequences of 1190 known tRNAs obtained from EMBL release 38, of which 100 were human. Sequences of extended cDNAs having more than 80% homology over 60 nucleotides using FASTA were identified as tRNA.

20 To identify the extended cDNAs encoding rRNAs, extended cDNA sequences were compared to the sequences of 2497 known rRNAs obtained from EMBL release 38, of which 73 were human. Sequences of extended cDNAs having more than 80% homology over stretches longer than 40 nucleotides using BLASTN were identified as rRNAs.

To identify the extended cDNAs encoding mtRNAs, extended cDNA sequences were compared to the
25 sequences of the two known mitochondrial genomes for which the entire genomic sequences are available and all sequences transcribed from these mitochondrial genomes including tRNAs, rRNAs, and mRNAs for a total of 38 sequences. Sequences of extended cDNAs having more than 80% homology over stretches longer than 40 nucleotides using BLASTN were identified as mtRNAs.

Sequences which might have resulted from other exogenous contaminants were identified by comparing
30 extended cDNA sequences to release 105 of Genbank bacterial and fungal divisions. Sequences of extended cDNAs having more than 90% homology over 40 nucleotides using BLASTN were identified as exogenous prokaryotic or fungal contaminants.

In addition, extended cDNAs were searched for different repeat sequences, including Alu sequences, L1 sequences, THE and MER repeats, SSTR sequences or satellite, micro-satellite, or telomeric repeats.
35 Sequences of extended cDNAs with more than 70% homology over 40 nucleotide stretches using BLASTN were identified as repeat sequences and masked in further identification procedures. In addition, clones

showing extensive homology to repeats, i.e., matches of either more than 50 nucleotides if the homology was at least 75% or more than 40 nucleotides if the homology was at least 85% or more than 30 nucleotides if the homology was at least 90%, were flagged.

b) Identification of structural features

5 Structural features, e.g. polyA tail and polyadenylation signal, of the sequences of full length extended cDNAs are subsequently determined as follows.

A polyA tail is defined as a homopolymeric stretch of at least 11 A with at most one alternative base within it. The polyA tail search is restricted to the last 20 nt of the sequence and limited to stretches of 11 consecutive A's because sequencing reactions are often not readable after such a polyA stretch. Stretches
10 with 100% homology over 6 nucleotides are identified as polyA tails.

To search for a polyadenylation signal, the polyA tail is clipped from the full-length sequence. The 50 bp preceding the polyA tail are searched for the canonic polyadenylation AAUAAA signal allowing one mismatch to account for possible sequencing errors and known variation in the canonical sequence of the polyadenylation signal.

15 c) Identification of functional features

Functional features, e.g. ORFs and signal sequences, of the sequences of full length extended cDNAs were subsequently determined as follows.

The 3 upper strand frames of extended cDNAs are searched for ORFs defined as the maximum length fragments beginning with a translation initiation codon and ending with a stop codon. ORFs encoding at least 20
20 amino acids are preferred.

Each found ORF is then scanned for the presence of a signal peptide in the first 50 amino-acids or, where appropriate, within shorter regions down to 20 amino acids or less in the ORF, using the matrix method of von Heijne (Nuc. Acids Res. 14: 4683-4690 (1986)) and the modification described in Example 22.

d) Homology to either nucleotidic or proteic sequences

25 Sequences of full length extended cDNAs are then compared to known sequences on a nucleotidic or proteic basis.

Sequences of full length extended cDNAs are compared to the following known nucleic acid sequences: vertebrate sequences, EST sequences, patented sequences and recently identified sequences available at the time of filing the priority documents. Full length cDNA sequences are also compared to the sequences of a private
30 database (Genset internal sequences) in order to find sequences that have already been identified by applicants. Sequences of full length extended cDNAs with more than 90% homology over 30 nucleotides using either BLASTN or BLAST2N as indicated in Table III are identified as sequences that have already been described. Matching vertebrate sequences are subsequently examined using FASTA; full length extended cDNAs with more than 70% homology over 30 nucleotides are identified as sequences that have already been described.

35 ORFs encoded by full length extended cDNAs as defined in section c) are subsequently compared to known amino acid sequences found in public databases using Swissprot, PIR and Genptpt releases available

at the time of filing the priority documents for the present application. These analyses were performed using BLASTP with the parameter W=8 and allowing a maximum of 10 matches. Sequences of full length extended cDNAs showing extensive homology to known protein sequences are recognized as already identified proteins.

5 In addition, the three-frame conceptual translation products of the top strand of full length extended cDNAs are compared to publicly known amino acid sequences of Swissprot using BLASTX with the parameter E=0.001. Sequences of full length extended cDNAs with more than 70% homology over 30 amino acid stretches are detected as already identified proteins.

As used herein the term "cDNA codes of SEQ ID NOS. 40-84 and 130-154" encompasses the
10 nucleotide sequences of SEQ ID NOS. 40-84 and 130-154, fragments of SEQ ID NOS. 40-84 and 130-154, nucleotide sequences homologous to SEQ ID NOS. 40-84 and 130-154 or homologous to fragments of SEQ ID NOS. 40-84 and 130-154, and sequences complementary to all of the preceding sequences. The fragments include portions of SEQ ID NOS. 40-84 and 130-154 comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of SEQ ID NOS. 40-84 and 130-154. Preferably, the
15 fragments are novel fragments. Homologous sequences and fragments of SEQ ID NOS. 40-84 and 130-154 refer to a sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, or 75% homology to these sequences. Homology may be determined using any of the computer programs and parameters described herein, including BLAST2N with the default parameters or with any modified parameters. Homologous sequences also include RNA sequences in which uridines replace the thymines in the cDNA codes of SEQ ID NOS. 40-84 and 130-154. The
20 homologous sequences may be obtained using any of the procedures described herein or may result from the correction of a sequencing error as described above. It will be appreciated that the cDNA codes of SEQ ID NOS. 40-84 and 130-154 can be represented in the traditional single character format (See the inside back cover of Starier, Lubert. *Biochemistry*, 3rd edition. W. H Freeman & Co., New York.) or in any other format which records the identity of the nucleotides in a sequence.

25 As used herein the term "polypeptide codes of SEQ ID NOS. 85-129 and 155-179" encompasses the polypeptide sequence of SEQ ID NOS. 85-129 and 155-179 which are encoded by the extended cDNAs of SEQ ID NOS. 40-84 and 130-154, polypeptide sequences homologous to the polypeptides of SEQ ID NOS. 85-129 and 155-179, or fragments of any of the preceding sequences. Homologous polypeptide sequences refer to a polypeptide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, 75% homology to one of the
30 polypeptide sequences of SEQ ID NOS. 85-129 and 155-179. Homology may be determined using any of the computer programs and parameters described herein, including FASTA with the default parameters or with any modified parameters. The homologous sequences may be obtained using any of the procedures described herein or may result from the correction of a sequencing error as described above. The polypeptide fragments comprise at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of the polypeptides of SEQ ID
35 NOS. 85-129 and 155-179. Preferably, the fragments are novel fragments. It will be appreciated that the polypeptide codes of the SEQ ID NOS. 85-129 and 155-179 can be represented in the traditional single character

format or three letter format (See the inside back cover of Starrier, Lubert. *Biochemistry*, 3rd edition. W. H Freeman & Co., New York.) or in any other format which relates the identity of the polypeptides in a sequence.

It will be appreciated by those skilled in the art that the cDNA codes of SEQ ID NOs. 40-84 and 130-154 and polypeptide codes of SEQ ID NOS. 85-129 and 155-179 can be stored, recorded, and manipulated on any
5 medium which can be read and accessed by a computer. As used herein, the words "recorded" and "stored" refer to a process for storing information on a computer medium. A skilled artisan can readily adopt any of the presently known methods for recording information on a computer readable medium to generate manufactures comprising one or more of the cDNA codes of SEQ ID NOs. 40-84 and 130-154, one or more of the polypeptide codes of SEQ ID NOS. 85-129 and 155-179. Another aspect of the present invention is a computer readable medium
10 having recorded thereon at least 2, 5, 10, 15, 20, 25, 30, or 50 cDNA codes of SEQ ID NOs. 40-84 and 130-154. Another aspect of the present invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, 20, 25, 30, or 50 polypeptide codes of SEQ ID NOS. 85-129 and 155-179.

Computer readable media include magnetically readable media, optically readable media, electronically readable media and magnetic/optical media. For example, the computer readable media may be a hard disc, a
15 floppy disc, a magnetic tape, CD-ROM, DVD, RAM, or ROM as well as other types of other media known to those skilled in the art.

Embodiments of the present invention include systems, particularly computer systems which contain the sequence information described herein. As used herein, "a computer system" refers to the hardware components, software components, and data storage components used to analyze the nucleotide sequences of the cDNA codes
20 of SEQ ID NOs. 40-84 and 130-154, or the amino acid sequences of the polypeptide codes of SEQ ID NOS. 85-129 and 155-179. The computer system preferably includes the computer readable media described above, and a processor for accessing and manipulating the sequence data.

Preferably, the computer is a general purpose system that comprises a central processing unit (CPU), one or more data storage components for storing data, and one or more data retrieving devices for retrieving the
25 data stored on the data storage components. A skilled artisan can readily appreciate that any one of the currently available computer systems are suitable.

In one particular embodiment, the computer system includes a processor connected to a bus which is connected to a main memory (preferably implemented as RAM) and one or more data storage devices, such as a hard drive and/or other computer readable media having data recorded thereon. In some embodiments, the
30 computer system further includes one or more data retrieving devices for reading the data stored on the data storage components. The data retrieving device may represent, for example, a floppy disk drive, a compact disk drive, a magnetic tape drive, etc. In some embodiments, the data storage component is a removable computer readable medium such as a floppy disk, a compact disk, a magnetic tape, etc. containing control logic and/or data recorded thereon. The computer system may advantageously include or be programmed by appropriate software
35 for reading the control logic and/or the data from the data storage component once inserted in the data retrieving device. Software for accessing and processing the nucleotide sequences of the cDNA codes of SEQ ID NOs. 40-

84 and 130-154, or the amino acid sequences of the polypeptide codes of SEQ ID NOS. 85-129 and 155-179 (such as search tools, compare tools, and modeling tools etc.) may reside in main memory during execution.

In some embodiments, the computer system may further comprise a sequence comparer for comparing the above-described cDNA codes of SEQ ID NOS. 40-84 and 130-154 or polypeptide codes of SEQ ID NOS. 85-129 and 155-179 stored on a computer readable medium to reference nucleotide or polypeptide sequences stored on a computer readable medium. A "sequence comparer" refers to one or more programs which are implemented on the computer system to compare a nucleotide or polypeptide sequence with other nucleotide or polypeptide sequences and/or compounds including but not limited to peptides, peptidomimetics, and chemicals stored within the data storage means. For example, the sequence comparer may compare the nucleotide sequences of the cDNA codes of SEQ ID NOS. 40-84 and 130-154, or the amino acid sequences of the polypeptide codes of SEQ ID NOS. 85-129 and 155-179 stored on a computer readable medium to reference sequences stored on a computer readable medium to identify homologies, motifs implicated in biological function, or structural motifs. The various sequence comparer programs identified elsewhere in this patent specification are particularly contemplated for use in this aspect of the invention.

Accordingly, one aspect of the present invention is a computer system comprising a processor, a data storage device having stored thereon a cDNA code of SEQ ID NOS. 40-84 and 130-154 or a polypeptide code of SEQ ID NOS. 85-129 and 155-179, a data storage device having retrievably stored thereon reference nucleotide sequences or polypeptide sequences to be compared to the cDNA code of SEQ ID NOS. 40-84 and 130-154 or polypeptide code of SEQ ID NOS. 85-129 and 155-179 and a sequence comparer for conducting the comparison. The sequence comparer may indicate a homology level between the sequences compared or identify structural motifs in the above described cDNA code of SEQ ID NOS. 40-84 and 130-154 and polypeptide codes of SEQ ID NOS. 85-129 and 155-179 or it may identify structural motifs in sequences which are compared to these cDNA codes and polypeptide codes. In some embodiments, the data storage device may have stored thereon the sequences of at least 2, 5, 10, 15, 20, 25, 30, or 50 of the cDNA codes of SEQ ID NOS. 40-84 and 130-154 or polypeptide codes of SEQ ID NOS. 85-129 and 155-179.

Another aspect of the present invention is a method for determining the level of homology between a cDNA code of SEQ ID NOS. 40-84 and 130-154 and a reference nucleotide sequence, comprising the steps of reading the cDNA code and the reference nucleotide sequence through the use of a computer program which determines homology levels and determining homology between the cDNA code and the reference nucleotide sequence with the computer program. The computer program may be any of a number of computer programs for determining homology levels, including those specifically enumerated below, including BLAST2N with the default parameters or with any modified parameters. The method may be implemented using the computer systems described above. The method may also be performed by reading 2, 5, 10, 15, 20, 25, 30, or 50 of the above described cDNA codes of SEQ ID NOS. 40-84 and 130-154 through use of the computer program and determining homology between the cDNA codes and reference nucleotide sequences.

Alternatively, the computer program may be a computer program which compares the nucleotide sequences of the cDNA codes of the present invention, to reference nucleotide sequences in order to determine whether the cDNA code of SEQ ID NOS. 40-84 and 130-154 differs from a reference nucleic acid sequence at one or more positions. Optionally such a program records the length and identity of inserted, deleted or substituted nucleotides with respect to the sequence of either the reference polynucleotide or the cDNA code of SEQ ID NOS. 40-84 and 130-154. In one embodiment, the computer program may be a program which determines whether the nucleotide sequences of the cDNA codes of SEQ ID NOS. 40-84 and 130-154 contain a single nucleotide polymorphism (SNP) with respect to a reference nucleotide sequence. This single nucleotide polymorphism may comprise a single base substitution, insertion, or deletion.

Another aspect of the present invention is a method for determining the level of homology between a polypeptide code of SEQ ID NOS. 85-129 and 155-179 and a reference polypeptide sequence, comprising the steps of reading the polypeptide code of SEQ ID NOS. 85-129 and 155-179 and the reference polypeptide sequence through use of a computer program which determines homology levels and determining homology between the polypeptide code and the reference polypeptide sequence using the computer program.

Accordingly, another aspect of the present invention is a method for determining whether a cDNA code of SEQ ID NOS. 40-84 and 130-154 differs at one or more nucleotides from a reference nucleotide sequence comprising the steps of reading the cDNA code and the reference nucleotide sequence through use of a computer program which identifies differences between nucleic acid sequences and identifying differences between the cDNA code and the reference nucleotide sequence with the computer program. In some embodiments, the computer program is a program which identifies single nucleotide polymorphisms. The method may be implemented by the computer systems described above. The method may also be performed by reading at least 2, 5, 10, 15, 20, 25, 30, or 50 of the cDNA codes of SEQ ID NOS. 40-84 and 130-154 and the reference nucleotide sequences through the use of the computer program and identifying differences between the cDNA codes and the reference nucleotide sequences with the computer program.

In other embodiments the computer based system may further comprise an identifier for identifying features within the nucleotide sequences of the cDNA codes of SEQ ID NOS. 40-84 and 130-154 or the amino acid sequences of the polypeptide codes of SEQ ID NOS. 85-129 and 155-179.

An "identifier" refers to one or more programs which identifies certain features within the above-described nucleotide sequences of the cDNA codes of SEQ ID NOS. 40-84 and 130-154 or the amino acid sequences of the polypeptide codes of SEQ ID NOS. 85-129 and 155-179. In one embodiment, the identifier may comprise a program which identifies an open reading frame in the cDNAs codes of SEQ ID NOS. 40-84 and 130-154.

In another embodiment, the identifier may comprise a molecular modeling program which determines the 3-dimensional structure of the polypeptides codes of SEQ ID NOS. 85-129 and 155-179. In some embodiments, the molecular modeling program identifies target sequences that are most compatible with profiles representing the structural environments of the residues in known three-dimensional protein structures.

(See, e.g., Eisenberg et al., U.S. Patent No. 5,436,850 issued July 25, 1995). In another technique, the known three-dimensional structures of proteins in a given family are superimposed to define the structurally conserved regions in that family. This protein modeling technique also uses the known three-dimensional structure of a homologous protein to approximate the structure of the polypeptide codes of SEQ ID NOS. 85-129 and 155-179. (See e.g., Srinivasan, et al., U.S. Patent No. 5,557,535 issued September 17, 1996). Conventional homology modeling techniques have been used routinely to build models of proteases and antibodies. (Sowdhamini et al., Protein Engineering 10:207, 215 (1997)). Comparative approaches can also be used to develop three-dimensional protein models when the protein of interest has poor sequence identity to template proteins. In some cases, proteins fold into similar three-dimensional structures despite having very weak sequence identities. For example, the three-dimensional structures of a number of helical cytokines fold in similar three-dimensional topology in spite of weak sequence homology.

The recent development of threading methods now enables the identification of likely folding patterns in a number of situations where the structural relatedness between target and template(s) is not detectable at the sequence level. Hybrid methods, in which fold recognition is performed using Multiple Sequence Threading (MST), structural equivalencies are deduced from the threading output using a distance geometry program DRAGON to construct a low resolution model, and a full-atom representation is constructed using a molecular modeling package such as QUANTA.

According to this 3-step approach, candidate templates are first identified by using the novel fold recognition algorithm MST, which is capable of performing simultaneous threading of multiple aligned sequences onto one or more 3-D structures. In a second step, the structural equivalencies obtained from the MST output are converted into interresidue distance restraints and fed into the distance geometry program DRAGON, together with auxiliary information obtained from secondary structure predictions. The program combines the restraints in an unbiased manner and rapidly generates a large number of low resolution model confirmations. In a third step, these low resolution model confirmations are converted into full-atom models and subjected to energy minimization using the molecular modeling package QUANTA. (See e.g., Aszodi et al., Proteins: Structure, Function, and Genetics, Supplement 1:38-42 (1997)).

The results of the molecular modeling analysis may then be used in rational drug design techniques to identify agents which modulate the activity of the polypeptide codes of SEQ ID NOS. 85-129 and 155-179.

Accordingly, another aspect of the present invention is a method of identifying a feature within the cDNA codes of SEQ ID NOS. 40-84 and 130-154 or the polypeptide codes of SEQ ID NOS. 85-129 and 155-179 comprising reading the cDNA code(s) or the polypeptide code(s) through the use of a computer program which identifies features therein and identifying features within the cDNA code(s) or polypeptide code(s) with the computer program. In one embodiment, computer program comprises a computer program which identifies open reading frames. In a further embodiment, the computer program identifies structural motifs in a polypeptide sequence. In another embodiment, the computer program comprises a molecular modeling program. The method may be performed by reading a single sequence or at least 2, 5, 10, 15, 20, 25, 30, or 50

of the cDNA codes of SEQ ID NOS. 40-84 and 130-154 or the polypeptide codes of SEQ ID NOS. 85-129 and 155-179 through the use of the computer program and identifying features within the cDNA codes or polypeptide codes with the computer program.

The cDNA codes of SEQ ID NOS. 40-84 and 130-154 or the polypeptide codes of SEQ ID NOS. 85-129 and 155-179 may be stored and manipulated in a variety of data processor programs in a variety of formats. For example, the cDNA codes of SEQ ID NOS. 40-84 and 130-154 or the polypeptide codes of SEQ ID NOS. 85-129 and 155-179 may be stored as text in a word processing file, such as MicrosoftWORD or WORDPERFECT or as an ASCII file in a variety of database programs familiar to those of skill in the art, such as DB2, SYBASE, or ORACLE. In addition, many computer programs and databases may be used as sequence comparers, identifiers, or sources of reference nucleotide or polypeptide sequences to be compared to the cDNA codes of SEQ ID NOS. 40-84 and 130-154 or the polypeptide codes of SEQ ID NOS. 85-129 and 155-179. The following list is intended not to limit the invention but to provide guidance to programs and databases which are useful with the cDNA codes of SEQ ID NOS. 40-84 and 130-154 or the polypeptide codes of SEQ ID NOS. 85-129 and 155-179. The programs and databases which may be used include, but are not limited to: MacPattern (EMBL), DiscoveryBase (Molecular Applications Group), GeneMine (Molecular Applications Group), Look (Molecular Applications Group), MacLook (Molecular Applications Group), BLAST and BLAST2 (NCBI), BLASTN and BLASTX (Altschul et al, *J. Mol. Biol.* 215: 403 (1990)), FASTA (Pearson and Lipman, *Proc. Natl. Acad. Sci. USA*, 85: 2444 (1988)), FASTDB (Brutlag et al. *Comp. App. Biosci.* 6:237-245, 1990), Catalyst (Molecular Simulations Inc.), Catalyst/SHAPE (Molecular Simulations Inc.), Cerius².DBAccess (Molecular Simulations Inc.), HypoGen (Molecular Simulations Inc.), Insight II, (Molecular Simulations Inc.), Discover (Molecular Simulations Inc.), CHARMm (Molecular Simulations Inc.), Felix (Molecular Simulations Inc.), DelPhi, (Molecular Simulations Inc.), QuanteMM, (Molecular Simulations Inc.), Homology (Molecular Simulations Inc.), Modeler (Molecular Simulations Inc.), ISIS (Molecular Simulations Inc.), Quanta/Protein Design (Molecular Simulations Inc.), WebLab (Molecular Simulations Inc.), WebLab Diversity Explorer (Molecular Simulations Inc.), Gene Explorer (Molecular Simulations Inc.), SeqFold (Molecular Simulations Inc.), the EMBL/Swissprotein database, the MDL Available Chemicals Directory database, the MDL Drug Data Report data base, the Comprehensive Medicinal Chemistry database, Derwent's World Drug Index database, the BioByteMasterFile database, the Genbank database, and the Genseq database. Many other programs and data bases would be apparent to one of skill in the art given the present disclosure.

Motifs which may be detected using the above programs include sequences encoding leucine zippers, helix-turn-helix motifs, glycosylation sites, ubiquitination sites, alpha helices, and beta sheets, signal sequences encoding signal peptides which direct the secretion of the encoded proteins, sequences implicated in transcription regulation such as homeoboxes, acidic stretches, enzymatic active sites, substrate binding sites, and enzymatic cleavage sites.

5. Selection of Cloned Full Length Sequences of the Present Invention

Cloned full length extended cDNA sequences that have already been characterized by the aforementioned computer analysis are then submitted to an automatic procedure in order to preselect full length extended cDNAs containing sequences of interest.

a) Automatic sequence preselection

5 All complete cloned full length extended cDNAs clipped for vector on both ends are considered. First, a negative selection is operated in order to eliminate unwanted cloned sequences resulting from either contaminants or PCR artifacts as follows. Sequences matching contaminant sequences such as vector RNA, tRNA, mtRNA, rRNA sequences are discarded as well as those encoding ORF sequences exhibiting extensive homology to repeats as defined in section 4 a). Sequences obtained by direct cloning using nested primers on 5' and 3' tags
10 (section 1. case a) but lacking polyA tail are discarded. Only ORFs containing a signal peptide and ending either before the polyA tail (case a) or before the end of the cloned 3'UTR (case b) are kept. Then, ORFs containing unlikely mature proteins such as mature proteins which size is less than 20 amino acids or less than 25% of the immature protein size are eliminated.

In the selection of the ORF, priority was given to the ORF and the frame corresponding to the
15 polypeptides described in SignalTag Patents (United States Patent Application Serial Nos: 08/905,223; 08/905,135; 08/905,051; 08/905,144; 08/905,279; 08/904,468; 08/905,134; and 08/905,133). If the ORF was not found among the ORFs described in the SignalTag Patents, the ORF encoding the signal peptide with the highest score according to Von Heijne method as defined in Example 22 was chosen. If the scores were identical, then the longest ORF was chosen.

20 Sequences of full length extended cDNA clones are then compared pairwise with BLAST after masking of the repeat sequences. Sequences containing at least 90% homology over 30 nucleotides are clustered in the same class. Each cluster is then subjected to a cluster analysis that detects sequences resulting from internal priming or from alternative splicing, identical sequences or sequences with several frameshifts. This automatic analysis serves as a basis for manual selection of the sequences.

25 b) Manual sequence selection

Manual selection can be carried out using automatically generated reports for each sequenced full length extended cDNA clone. During this manual procedure, a selection is operated between clones belonging to the same class as follows. ORF sequences encoded by clones belonging to the same class are aligned and compared. If the homology between nucleotidic sequences of clones belonging to the same class is more than
30 90% over 30 nucleotide stretches or if the homology between amino acid sequences of clones belonging to the same class is more than 80% over 20 amino acid stretches, then the clones are considered as being identical. The chosen ORF is the best one according to the criteria mentioned below. If the nucleotide and amino acid homologies are less than 90% and 80% respectively, the clones are said to encode distinct proteins which can be both selected if they contain sequences of interest.

35 Selection of full length extended cDNA clones encoding sequences of interest is performed using the following criteria. Structural parameters (initial tag, polyadenylation site and signal) are first checked. Then,

homologies with known nucleic acids and proteins are examined in order to determine whether the clone sequence match a known nucleic/proteic sequence and, in the latter case, its covering rate and the date at which the sequence became public. If there is no extensive match with sequences other than ESTs or genomic DNA, or if the clone sequence brings substantial new information, such as encoding a protein resulting from alternative slicing of an mRNA coding for an already known protein, the sequence is kept. Examples of such cloned full length extended cDNAs containing sequences of interest are described in Example 28. Sequences resulting from chimera or double inserts as assessed by homology to other sequences are discarded during this procedure.

EXAMPLE 28

Cloning and Sequencing of Extended cDNAs

10 The procedure described in Example 27 above was used to obtain the extended cDNAs of the present invention. Using this approach, the full length cDNA of SEQ ID NO:17 was obtained. This cDNA falls into the "EST-ext" category described above and encodes the signal peptide MKKVLLITAILAVAVG (SEQ ID NO: 18) having a von Heijne score of 8.2.

The full length cDNA of SEQ ID NO: 19 was also obtained using this procedure. This cDNA falls into the "EST-ext" category described above and encodes the signal peptide MWWFQQGLSFLPSALVIWVTS (SEQ ID NO:20) having a von Heijne score of 5.5.

Another full length cDNA obtained using the procedure described above has the sequence of SEQ ID NO:21. This cDNA, falls into the "EST-ext" category described above and encodes the signal peptide MVLTLPSANSANSPVNMPTTGPNSLSYASSALSPCLT (SEQ ID NO:22) having a von Heijne score of 5.9.

20 The above procedure was also used to obtain a full length cDNA having the sequence of SEQ ID NO:23. This cDNA falls into the "EST-ext" category described above and encodes the signal peptide ILSTVTALTFAXA (SEQ ID NO:24) having a von Heijne score of 5.5.

The full length cDNA of SEQ ID NO:25 was also obtained using this procedure. This cDNA falls into the "new" category described above and encodes a signal peptide LVLTLCTLPLAVA (SEQ ID NO:26) having a von Heijne score of 10.1.

The full length cDNA of SEQ ID NO:27 was also obtained using this procedure. This cDNA falls into the "new" category described above and encodes a signal peptide LWLLFFLVTAIHA (SEQ ID NO:28) having a von Heijne score of 10.7.

The above procedures were also used to obtain the extended cDNAs of the present invention. 5' ESTs expressed in a variety of tissues were obtained as described above. The appended sequence listing provides the tissues from which the extended cDNAs were obtained. It will be appreciated that the extended cDNAs may also be expressed in tissues other than the tissue listed in the sequence listing.

5' ESTs obtained as described above were used to obtain extended cDNAs having the sequences of SEQ ID NOs: 40-84 and 130-154. Table IV provides the sequence identification numbers of the extended cDNAs of the present invention, the locations of the full coding sequences in SEQ ID NOs: 40-84 and 130-154 (i.e. the nucleotides encoding both the signal peptide and the mature protein, listed under the heading FCS location in

Table IV), the locations of the nucleotides in SEQ ID NOs: 40-84 and 130-154 which encode the signal peptides (listed under the heading SigPep Location in Table IV), the locations of the nucleotides in SEQ ID NOs: 40-84 and 130-154 which encode the mature proteins generated by cleavage of the signal peptides (listed under the heading Mature Polypeptide Location in Table IV), the locations in SEQ ID NOs: 40-84 and 130-154 of stop codons (listed under the heading Stop Codon Location in Table IV), the locations in SEQ ID NOs: 40-84 and 130-154 of polyA signals (listed under the heading Poly A Signal Location in Table IV) and the locations of polyA sites (listed under the heading Poly A Site Location in Table IV).

The polypeptides encoded by the extended cDNAs were screened for the presence of known structural or functional motifs or for the presence of signatures, small amino acid sequences which are well conserved amongst the members of a protein family. The conserved regions have been used to derive consensus patterns or matrices included in the PROSITE data bank, in particular in the file prosite.dat (Release 13.0 of November 1995, located at <http://expasy.hcuge.ch/sprot/prosite.html>. Prosite_convert and prosite_scan programs (http://ulrec3.unil.ch/ftpserveur/prosite_scan) were used to find signatures on the extended cDNAs.

For each pattern obtained with the prosite_convert program from the prosite.dat file, the accuracy of the detection on a new protein sequence has been tested by evaluating the frequency of irrelevant hits on the population of human secreted proteins included in the data bank SWISSPROT. The ratio between the number of hits on shuffled proteins (with a window size of 20 amino acids) and the number of hits on native (unshuffled) proteins was used as an index. Every pattern for which the ration was greater than 20% (one hit on shuffled proteins for 5 hits on native proteins) was skipped during the search with prosite_scan. The program used to shuffle protein sequences (db_shuffled) and the program used to determine the statistics for each pattern in the protein data banks (prosite_statistics) are available on the ftp site http://ulrec3.unil.ch/ftpserveur/prosite_scan.

Table V lists the sequence identification numbers of the polypeptides of SEQ ID NOs: 85-129 and 155-179, the locations of the amino acid residues of SEQ ID NOs: 85-129 and 155-179 in the full length polypeptide (second column), the locations of the amino acid residues of SEQ ID NOs: 85-129 and 155-179 in the signal peptides (third column), and the locations of the amino acid residues of SEQ ID NOs: 85-129 and 155-179 in the mature polypeptide created by cleaving the signal peptide from the full length polypeptide (fourth column).

The nucleotide sequences of the sequences of SEQ ID NOs: 40-84 and 130-154 and the amino acid sequences encoded by SEQ ID NOs: 40-84 and 130-154 (i.e. amino acid sequences of SEQ ID NOs: 85-129 and 155-179) are provided in the appended sequence listing. In some instances, the sequences are preliminary and may include some incorrect or ambiguous sequences or amino acids. The sequences of SEQ ID NOs: 40-84 and 130-154 can readily be screened for any errors therein and any sequence ambiguities can be resolved by resequencing a fragment containing such errors or ambiguities on both strands. Sequences containing such errors will generally be at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% homologous to the sequences of SEQ ID Nos. 85-129 and 155-179 and such sequences are included in the nucleic acids and polypeptides of the present invention. Nucleic acid fragments for resolving sequencing errors or ambiguities may be obtained from the deposited clones or can be isolated using the techniques described herein. Resolution of any

such ambiguities or errors may be facilitated by using primers which hybridize to sequences located close to the ambiguous or erroneous sequences. For example, the primers may hybridize to sequences within 50-75 bases of the ambiguity or error. Upon resolution of an error or ambiguity, the corresponding corrections can be made in the protein sequences encoded by the DNA containing the error or ambiguity. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein, and determining its sequence.

For each amino acid sequence, Applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing. Some of the amino acid sequences may contain "Xaa" designators. These "Xaa" designators indicate either (1) a residue which cannot be identified because of nucleotide sequence ambiguity or (2) a stop codon in the determined sequence where Applicants believe one should not exist (if the sequence were determined more accurately).

Cells containing the extended cDNAs (SEQ ID NOs: 40-84 and 130-154) of the present invention in the vector pED6dpc2, are maintained in permanent deposit by the inventors at Genset, S.A., 24 Rue Royale, 75008 Paris, France.

Pools of cells containing the extended cDNAs (SEQ ID NOs: 40-84), from which cells containing a particular polynucleotide are obtainable, were deposited with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA, U.S.A., 20110-2209. Each extended cDNA clone has been transfected into separate bacterial cells (E-coli) for this composite deposit. Table VI lists the deposit numbers of the clones of SEQ ID Nos: 40-84. A pool of cells designated SignalTag 28011999, which contains the clones of SEQ ID NOs 71-84 was mailed to the European Collection of Cell Cultures, (ECACC) Vaccine Research and Production Laboratory, Public Health Laboratory Service, Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire SP4 OJG, United Kingdom on January 28, 1999 and was received on January 29, 1999. This pool of cells has the ECACC Accession # XXXXXX. One or more pools of cells containing the extended cDNAs of SEQ ID Nos: 130-154, from which the cells containing a particular polynucleotide is obtainable, will be deposited with the European Collection of Cell Cultures, Vaccine Research and Production Laboratory, Public Health Laboratory Service, Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire SP4 OJG, United Kingdom and will be assigned ECACC deposit number XXXXXX. Table VII provides the internal designation number assigned to each SEQ ID NO. and indicates whether the sequence is a nucleic acid sequence or a protein sequence.

Each extended cDNA can be removed from the pED6dpc2 vector in which it was deposited by performing a NotI, PstI double digestion to produce the appropriate fragment for each clone. The proteins encoded by the extended cDNAs may also be expressed from the promoter in pED6dpc2.

Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The design of the oligonucleotide probe should preferably follow these parameters:

(a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;

(b) Preferably, the probe is designed to have a T_m of approx. 80°C (assuming 2 degrees for each A or T and 4 degrees for each G or C). However, probes having melting temperatures between 40 °C and 80 °C
5 may also be used provided that specificity is not lost.

The oligonucleotide should preferably be labeled with $[-^{32}\text{P}]\text{ATP}$ (specific activity 6000 Ci/mmmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantified by
10 measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4×10^6 dpm/pmmole.

The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 μl of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 $\mu\text{g/ml}$. The culture should preferably be grown to saturation at 37°C, and the saturated culture should
15 preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 $\mu\text{g/ml}$ and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.

Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose
20 filters and lyse, denature and bake them.

The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 $\mu\text{g/ml}$ of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to 1×10^6 dpm/mL. The filter is then preferably incubated
25 at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures.
30 The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.

The plasmid DNA obtained using these procedures may then be manipulated using standard cloning techniques familiar to those skilled in the art. Alternatively, a PCR can be done with primers designed at both ends of the extended cDNA insertion. For example, a PCR reaction may be conducted using a primer having the sequence GGCCATACACTTGAGTGAC (SEQ ID NO:38) and a primer having the sequence

ATATAGACAAACGCACACC (SEQ. ID. NO:39). The PCR product which corresponds to the extended cDNA can then be manipulated using standard cloning techniques familiar to those skilled in the art.

In addition to PCR based methods for obtaining extended cDNAs, traditional hybridization based methods may also be employed. These methods may also be used to obtain the genomic DNAs which encode the mRNAs from which the 5' ESTs were derived, mRNAs corresponding to the extended cDNAs, or nucleic acids which are homologous to extended cDNAs or 5' ESTs. Example 29 below provides an example of such methods.

EXAMPLE 29

Methods for Obtaining Extended cDNAs or Nucleic Acids Homologous to Extended cDNAs or 5' ESTs

5'ESTs or extended cDNAs of the present invention may also be used to isolate extended cDNAs or nucleic acids homologous to extended cDNAs from a cDNA library or a genomic DNA library. Such cDNA library or genomic DNA library may be obtained from a commercial source or made using other techniques familiar to those skilled in the art. One example of such cDNA library construction is as follows.

PolyA+ RNAs are prepared and their quality checked as described in Example 13. Then, polyA+ RNAs are ligated to an oligonucleotide tag using either the chemical or enzymatic methods described in above sections 1 and 2. In both cases, the oligonucleotide tag may contain a restriction site such as Eco RI to facilitate further subcloning procedures. Northern blotting is then performed to check the size of ligatured mRNAs and to ensure that the mRNAs were actually tagged.

As described in Example 14, first strand synthesis is subsequently carried out for mRNAs joined to the oligonucleotide tag replacing the random nonamers by an oligodT primer. For instance, this oligodT primer may contain an internal tag of 4 nucleotides which is different from one tissue to the other. Alternatively, the oligonucleotide of SEQ ID NO:14 may be used. Following second strand synthesis using a primer contained in the oligonucleotide tag attached to the 5' end of mRNA, the blunt ends of the obtained double stranded full length DNAs are modified into cohesive ends to allow subcloning into the Eco RI and Hind III sites of a Bluescript vector using the addition of a Hind III adaptor to the 3' end of full length DNAs.

The extended full length DNAs are then separated into several fractions according to their sizes using techniques familiar to those skilled in the art. For example, electrophoretic separation may be applied in order to yield 3 or 6 different fractions. Following gel extraction and purification, the DNA fractions are subcloned into Bluescript vectors, transformed into competent bacteria and propagated under appropriate antibiotic conditions.

Such full length cDNA libraries may then be sequenced as follows or used in screening procedures to obtain nucleic acids homologous to extended cDNAs or 5' ESTs as described below.

The 5' end of extended cDNA isolated from the full length cDNA libraries or of nucleic acid homologous thereto may then be sequenced as described in example 27. In a first step, the sequence corresponding to the 5' end of the mRNA is obtained; If this sequence either corresponds to a SignalTag™ 5'EST or fulfills the criteria to be one, the cloned insert is subcloned into an appropriate vector such as pED6dpc2, double-sequenced and submitted to the analysis and selection procedures described in Example 27.

Such cDNA or genomic DNA libraries may be used to isolate extended cDNAs obtained from 5' EST or nucleic acids homologous to extended cDNAs or 5' EST as follows. The cDNA library or genomic DNA library is hybridized to a detectable probe comprising at least 10 consecutive nucleotides from the 5' EST or extended cDNA using conventional techniques. Preferably, the probe comprises at least 12, 15, or 17 consecutive nucleotides from the 5' EST or extended cDNA. More preferably, the probe comprises at least 20 to 30 consecutive nucleotides from the 5' EST or extended cDNA. In some embodiments, the probe comprises at least 40, at least 50, at least 75, at least 100, at least 150, or at least 200 consecutive nucleotides from the 5' EST or extended cDNA. Techniques for identifying cDNA clones in a cDNA library which hybridize to a given probe sequence are disclosed in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual 2d Ed.*, Cold Spring Harbor Laboratory Press, 1989. The same techniques may be used to isolate genomic DNAs.

Briefly, cDNA or genomic DNA clones which hybridize to the detectable probe are identified and isolated for further manipulation as follows. A probe comprising at least 10 consecutive nucleotides from the 5' EST or extended cDNA is labeled with a detectable label such as a radioisotope or a fluorescent molecule. Preferably, the probe comprises at least 12, 15, or 17 consecutive nucleotides from the 5' EST or extended cDNA. More preferably, the probe comprises 20 to 30 consecutive nucleotides from the 5' EST or extended cDNA. In some embodiments, the probe comprises at least 40, at least 50, at least 75, at least 100, at least 150, or at least 200 consecutive nucleotides from the 5' EST or extended cDNA.

Techniques for labeling the probe are well known and include phosphorylation with polynucleotide kinase, nick translation, *in vitro* transcription, and non radioactive techniques. The cDNAs or genomic DNAs in the library are transferred to a nitrocellulose or nylon filter and denatured. After blocking of non specific sites, the filter is incubated with the labeled probe for an amount of time sufficient to allow binding of the probe to cDNAs or genomic DNAs containing a sequence capable of hybridizing thereto.

By varying the stringency of the hybridization conditions used to identify extended cDNAs or genomic DNAs which hybridize to the detectable probe, extended cDNAs having different levels of homology to the probe can be identified and isolated as described below.

1. Identification of Extended cDNA or Genomic DNA Sequences Having a High Degree of Homology to the Labeled Probe

To identify extended cDNAs or genomic DNAs having a high degree of homology to the probe sequence, the melting temperature of the probe may be calculated using the following formulas:

For probes between 14 and 70 nucleotides in length the melting temperature (T_m) is calculated using the formula: $T_m = 81.5 + 16.6(\log [Na^+]) + 0.41(\text{fraction G+C}) - (600/N)$ where N is the length of the probe.

If the hybridization is carried out in a solution containing formamide, the melting temperature may be calculated using the equation $T_m = 81.5 + 16.6(\log [Na^+]) + 0.41(\text{fraction G+C}) - (0.63\% \text{ formamide}) - (600/N)$ where N is the length of the probe.

Prehybridization may be carried out in 6X SSC, 5X Denhardt's reagent, 0.5% SDS, 100 μ g denatured fragmented salmon sperm DNA or 6X SSC, 5X Denhardt's reagent, 0.5% SDS, 100 μ g denatured fragmented

salmon sperm DNA, 50% formamide. The formulas for SSC and Denhardt's solutions are listed in Sambrook *et al., supra*.

Hybridization is conducted by adding the detectable probe to the prehybridization solutions listed above. Where the probe comprises double stranded DNA, it is denatured before addition to the hybridization solution. The filter is contacted with the hybridization solution for a sufficient period of time to allow the probe to hybridize to extended cDNAs or genomic DNAs containing sequences complementary thereto or homologous thereto. For probes over 200 nucleotides in length, the hybridization may be carried out at 15-25°C below the T_m . For shorter probes, such as oligonucleotide probes, the hybridization may be conducted at 15-25°C below the T_m . Preferably, for hybridizations in 6X SSC, the hybridization is conducted at approximately 68°C. Preferably, for hybridizations in 50% formamide containing solutions, the hybridization is conducted at approximately 42°C.

All of the foregoing hybridizations would be considered to be under "stringent" conditions.

Following hybridization, the filter is washed in 2X SSC, 0.1% SDS at room temperature for 15 minutes. The filter is then washed with 0.1X SSC, 0.5% SDS at room temperature for 30 minutes to 1 hour. Thereafter, the solution is washed at the hybridization temperature in 0.1X SSC, 0.5% SDS. A final wash is conducted in 0.1X SSC at room temperature.

Extended cDNAs, nucleic acids homologous to extended cDNAs or 5' ESTs, or genomic DNAs which have hybridized to the probe are identified by autoradiography or other conventional techniques.

2. Obtaining Extended cDNA or Genomic DNA Sequences Having Lower Degrees of Homology to the Labeled Probe

The above procedure may be modified to identify extended cDNAs, nucleic acids homologous to extended cDNAs, or genomic DNAs having decreasing levels of homology to the probe sequence. For example, to obtain extended cDNAs, nucleic acids homologous to extended cDNAs, or genomic DNAs of decreasing homology to the detectable probe, less stringent conditions may be used. For example, the hybridization temperature may be decreased in increments of 5°C from 68°C to 42°C in a hybridization buffer having a sodium concentration of approximately 1M. Following hybridization, the filter may be washed with 2X SSC, 0.5% SDS at the temperature of hybridization. These conditions are considered to be "moderate" conditions above 50°C and "low" conditions below 50°C.

Alternatively, the hybridization may be carried out in buffers, such as 6X SSC, containing formamide at a temperature of 42°C. In this case, the concentration of formamide in the hybridization buffer may be reduced in 5% increments from 50% to 0% to identify clones having decreasing levels of homology to the probe. Following hybridization, the filter may be washed with 6X SSC, 0.5% SDS at 50°C. These conditions are considered to be "moderate" conditions above 25% formamide and "low" conditions below 25% formamide.

Extended cDNAs, nucleic acids homologous to extended cDNAs, or genomic DNAs which have hybridized to the probe are identified by autoradiography.

3. Determination of the Degree of Homology between the Obtained Extended cDNAs or Genomic DNAs and the Labeled Probe

To determine the level of homology between the hybridized nucleic acid and the extended cDNA or 5'EST from which the probe was derived, the nucleotide sequences of the hybridized nucleic acid and the extended cDNA or 5'EST from which the probe was derived are compared. The sequences of the extended cDNA or 5'EST and the homologous sequences may be stored on a computer readable medium as described in Example 17 above and may be compared using any of a variety of algorithms familiar to those skilled in the art. For example, if it is desired to obtain nucleic acids homologous to extended cDNAs, such as allelic variants thereof or nucleic acids encoding proteins related to the proteins encoded by the extended cDNAs, the level of homology between the hybridized nucleic acid and the extended cDNA or 5' EST used as the probe may be determined using algorithms such as BLAST2N; parameters may be adapted depending on the sequence length and degree of homology studied. For example, the default parameters or the parameters in Table I and II may be used to determine homology levels. Alternatively, the level of homology between the hybridized nucleic acid and the extended cDNA or 5'EST from which the probe was derived may be determined using the FASTDB algorithm described in Brutlag et al. Comp. App. Biosci. 6:237-245, 1990. In such analyses the parameters may be selected as follows: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the sequence which hybridizes to the probe, whichever is shorter. Because the FASTDB program does not consider 5' or 3' truncations when calculating homology levels, if the sequence which hybridizes to the probe is truncated relative to the sequence of the extended cDNA or 5'EST from which the probe was derived the homology level is manually adjusted by calculating the number of nucleotides of the extended cDNA or 5'EST which are not matched or aligned with the hybridizing sequence, determining the percentage of total nucleotides of the hybridizing sequence which the non-matched or non-aligned nucleotides represent, and subtracting this percentage from the homology level. For example, if the hybridizing sequence is 700 nucleotides in length and the extended cDNA sequence is 1000 nucleotides in length wherein the first 300 bases at the 5' end of the extended cDNA are absent from the hybridizing sequence, and wherein the overlapping 700 nucleotides are identical, the homology level would be adjusted as follows. The non-matched, non-aligned 300 bases represent 30% of the length of the extended cDNA. If the overlapping 700 nucleotides are 100% identical, the adjusted homology level would be $100-30=70\%$ homology. It should be noted that the preceding adjustments are only made when the non-matched or non-aligned nucleotides are at the 5' or 3' ends. No adjustments are made if the non-matched or non-aligned sequences are internal or under any other conditions.

For example, using the above methods, nucleic acids having at least 95% nucleic acid homology, at least 96% nucleic acid homology, at least 97% nucleic acid homology, at least 98% nucleic acid homology, at least 99% nucleic acid homology, or more than 99% nucleic acid homology to the extended cDNA or 5'EST from which the probe was derived may be obtained and identified. Such nucleic acids may be allelic variants or related nucleic

acids from other species. Similarly, by using progressively less stringent hybridization conditions one can obtain and identify nucleic acids having at least 90%, at least 85%, at least 80% or at least 75% homology to the extended cDNA or 5'EST from which the probe was derived.

To determine whether a clone encodes a protein having a given amount of homology to the protein encoded by the extended cDNA or 5' EST, the amino acid sequence encoded by the extended cDNA or 5' EST is compared to the amino acid sequence encoded by the hybridizing nucleic acid. The sequences encoded by the extended cDNA or 5'EST and the sequences encoded by the homologous sequences may be stored on a computer readable medium as described in Example 17 above and may be compared using any of a variety of algorithms familiar to those skilled in the art. Homology is determined to exist when an amino acid sequence in the extended cDNA or 5' EST is closely related to an amino acid sequence in the hybridizing nucleic acid. A sequence is closely related when it is identical to that of the extended cDNA or 5' EST or when it contains one or more amino acid substitutions therein in which amino acids having similar characteristics have been substituted for one another. Using the above methods and algorithms such as FASTA with parameters depending on the sequence length and degree of homology studied, for example the default parameters or the parameters in Table I and II, one can obtain nucleic acids encoding proteins having at least 99%, at least 98%, at least 97%, at least 96%, at least 95%, at least 90%, at least 85%, at least 80% or at least 75% homology to the proteins encoded by the extended cDNA or 5'EST from which the probe was derived. In some embodiments, the homology levels can be determined using the "default" opening penalty and the "default" gap penalty, and a scoring matrix such as PAM 250 (a standard scoring matrix; see Dayhoff et al., in: Atlas of Protein Sequence and Structure, Vol. 5, Supp. 3 (1978)).

Alternatively, the level of homology may be determined using the FASTDB algorithm described by Brutlag et al. *Comp. App. Biosci.* 6:237-245, 1990. In such analyses the parameters may be selected as follows: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=Sequence Length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the homologous sequence, whichever is shorter. If the homologous amino acid sequence is shorter than the amino acid sequence encoded by the extended cDNA or 5'EST as a result of an N terminal and/or C terminal deletion the results may be manually corrected as follows. First, the number of amino acid residues of the amino acid sequence encoded by the extended cDNA or 5'EST which are not matched or aligned with the homologous sequence is determined. Then, the percentage of the length of the sequence encoded by the extended cDNA or 5'EST which the non-matched or non-aligned amino acids represent is calculated. This percentage is subtracted from the homology level. For example wherein the amino acid sequence encoded by the extended cDNA or 5'EST is 100 amino acids in length and the length of the homologous sequence is 80 amino acids and wherein the amino acid sequence encoded by the extended cDNA or 5'EST is truncated at the N terminal end with respect to the homologous sequence, the homology level is calculated as follows. In the preceding scenario there are 20 non-matched, non-aligned amino acids in the sequence encoded by the extended cDNA or 5'EST. This represents 20% of the length of the amino acid sequence encoded by the extended cDNA or 5'EST. If the remaining amino

acids are 100% identical between the two sequences, the homology level would be 100%-20%=80% homology. No adjustments are made if the non-matched or non-aligned sequences are internal or under any other conditions.

In addition to the above described methods, other protocols are available to obtain extended cDNAs using 5' ESTs as outlined in the following paragraphs.

5 Extended cDNAs may be prepared by obtaining mRNA from the tissue, cell, or organism of interest using mRNA preparation procedures utilizing polyA selection procedures or other techniques known to those skilled in the art. A first primer capable of hybridizing to the polyA tail of the mRNA is hybridized to the mRNA and a reverse transcription reaction is performed to generate a first cDNA strand.

The first cDNA strand is hybridized to a second primer containing at least 10 consecutive nucleotides of
10 the sequences of the 5' EST for which an extended cDNA is desired. Preferably, the primer comprises at least 12, 15, or 17 consecutive nucleotides from the sequences of the 5' EST. More preferably, the primer comprises 20 to 30 consecutive nucleotides from the sequences of the 5' EST. In some embodiments, the primer comprises more than 30 nucleotides from the sequences of the 5' EST. If it is desired to obtain extended cDNAs containing the full protein coding sequence, including the authentic translation initiation site, the second primer used contains
15 sequences located upstream of the translation initiation site. The second primer is extended to generate a second cDNA strand complementary to the first cDNA strand. Alternatively, RT-PCR may be performed as described above using primers from both ends of the cDNA to be obtained.

Extended cDNAs containing 5' fragments of the mRNA may be prepared by hybridizing an mRNA comprising the sequence of the 5' EST for which an extended cDNA is desired with a primer comprising at least 10
20 consecutive nucleotides of the sequences complementary to the 5' EST and reverse transcribing the hybridized primer to make a first cDNA strand from the mRNAs. Preferably, the primer comprises at least 12, 15, or 17 consecutive nucleotides from the 5' EST. More preferably, the primer comprises 20 to 30 consecutive nucleotides from the 5' EST.

Thereafter, a second cDNA strand complementary to the first cDNA strand is synthesized. The second
25 cDNA strand may be made by hybridizing a primer complementary to sequences in the first cDNA strand to the first cDNA strand and extending the primer to generate the second cDNA strand.

The double stranded extended cDNAs made using the methods described above are isolated and cloned. The extended cDNAs may be cloned into vectors such as plasmids or viral vectors capable of replicating in an appropriate host cell. For example, the host cell may be a bacterial, mammalian, avian, or insect cell.

30 Techniques for isolating mRNA, reverse transcribing a primer hybridized to mRNA to generate a first cDNA strand, extending a primer to make a second cDNA strand complementary to the first cDNA strand, isolating the double stranded cDNA and cloning the double stranded cDNA are well known to those skilled in the art and are described in *Current Protocols in Molecular Biology*, John Wiley 503 Sons, Inc. 1997 and Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989.

Alternatively, other procedures may be used for obtaining full length cDNAs or extended cDNAs. In one approach, full length or extended cDNAs are prepared from mRNA and cloned into double stranded phagemids as follows. The cDNA library in the double stranded phagemids is then rendered single stranded by treatment with an endonuclease, such as the Gene II product of the phage F1, and an exonuclease (Chang *et al.*, *Gene* 127:95-8, 1993). A biotinylated oligonucleotide comprising the sequence of a 5' EST, or a fragment containing at least 10 nucleotides thereof, is hybridized to the single stranded phagemids. Preferably, the fragment comprises at least 12, 15, or 17 consecutive nucleotides from the 5' EST. More preferably, the fragment comprises 20-30 consecutive nucleotides from the 5' EST. In some procedures, the fragment may comprise at least 40, at least 50, at least 75, at least 100, at least 150, or at least 200 consecutive nucleotides from the 5' EST.

Hybrids between the biotinylated oligonucleotide and phagemids having inserts containing the 5' EST sequence are isolated by incubating the hybrids with streptavidin coated paramagnetic beads and retrieving the beads with a magnet (Fry *et al.*, *Biotechniques*, 13: 124-131, 1992). Thereafter, the resulting phagemids containing the 5' EST sequence are released from the beads and converted into double stranded DNA using a primer specific for the 5' EST sequence. Alternatively, protocols such as the Gene Trapper kit (Gibco BRL) may be used. The resulting double stranded DNA is transformed into bacteria. Extended cDNAs containing the 5' EST sequence are identified by colony PCR or colony hybridization.

Using any of the above described methods in section III, a plurality of extended cDNAs containing full length protein coding sequences or sequences encoding only the mature protein remaining after the signal peptide is cleaved off may be provided as cDNA libraries for subsequent evaluation of the encoded proteins or use in diagnostic assays as described below.

IV. Expression of Proteins Encoded by Extended cDNAs Isolated Using 5' ESTs

Extended cDNAs containing the full protein coding sequences of their corresponding mRNAs or portions thereof, such as cDNAs encoding the mature protein, may be used to express the secreted proteins or portions thereof which they encode as described in Example 30 below. If desired, the extended cDNAs may contain the sequences encoding the signal peptide to facilitate secretion of the expressed protein. It will be appreciated that a plurality of extended cDNAs containing the full protein coding sequences or portions thereof may be simultaneously cloned into expression vectors to create an expression library for analysis of the encoded proteins as described below.

EXAMPLE 30

Expression of the Proteins Encoded by Extended cDNAs or Portions Thereof

To express the proteins encoded by the extended cDNAs or portions thereof, nucleic acids containing the coding sequence for the proteins or portions thereof to be expressed are obtained as described in Examples 27-29 and cloned into a suitable expression vector. If desired, the nucleic acids may contain the sequences encoding the signal peptide to facilitate secretion of the expressed protein. For example, the nucleic acid may comprise the sequence of one of SEQ ID NOs: 40-84 and 130-154 listed in Table IV and in the accompanying sequence listing.

Alternatively, the nucleic acid may comprise those nucleotides which make up the full coding sequence of one of the sequences of SEQ ID NOs: 40-84 and 130-154 as defined in Table IV above.

It will be appreciated that should the extent of the full coding sequence (i.e. the sequence encoding the signal peptide and the mature protein resulting from cleavage of the signal peptide) differ from that listed in Table IV as a result of a sequencing error, reverse transcription or amplification error, mRNA splicing, post-translational modification of the encoded protein, enzymatic cleavage of the encoded protein, or other biological factors, one skilled in the art would be readily able to identify the extent of the full coding sequences in the sequences of SEQ ID NOs. 40-84 and 130-154. Accordingly, the scope of any claims herein relating to nucleic acids containing the full coding sequence of one of SEQ ID NOs. 40-84 and 130-154 is not to be construed as excluding any readily identifiable variations from or equivalents to the full coding sequences listed in Table IV. Similarly, should the extent of the full length polypeptides differ from those indicated in Table V as a result of any of the preceding factors, the scope of claims relating to polypeptides comprising the amino acid sequence of the full length polypeptides is not to be construed as excluding any readily identifiable variations from or equivalents to the sequences listed in Table V.

Alternatively, the nucleic acid used to express the protein or portion thereof may comprise those nucleotides which encode the mature protein (i.e. the protein created by cleaving the signal peptide off) encoded by one of the sequences of SEQ ID NOs: 40-84 and 130-154 as defined in Table IV above.

It will be appreciated that should the extent of the sequence encoding the mature protein differ from that listed in Table IV as a result of a sequencing error, reverse transcription or amplification error, mRNA splicing, post-translational modification of the encoded protein, enzymatic cleavage of the encoded protein, or other biological factors, one skilled in the art would be readily able to identify the extent of the sequence encoding the mature protein in the sequences of SEQ ID NOs. 40-84 and 130-154. Accordingly, the scope of any claims herein relating to nucleic acids containing the sequence encoding the mature protein encoded by one of SEQ ID Nos. 40-84 and 130-154 is not to be construed as excluding any readily identifiable variations from or equivalents to the sequences listed in Table IV. Thus, claims relating to nucleic acids containing the sequence encoding the mature protein encompass equivalents to the sequences listed in Table IV, such as sequences encoding biologically active proteins resulting from post-translational modification, enzymatic cleavage, or other readily identifiable variations from or equivalents to the secreted proteins in addition to cleavage of the signal peptide. Similarly, should the extent of the mature polypeptides differ from those indicated in Table V as a result of any of the preceding factors, the scope of claims relating to polypeptides comprising the sequence of a mature protein included in the sequence of one of SEQ ID NOs. 85-129 and 155-179 is not to be construed as excluding any readily identifiable variations from or equivalents to the sequences listed in Table V. Thus, claims relating to polypeptides comprising the sequence of the mature protein encompass equivalents to the sequences listed in Table IV, such as biologically active proteins resulting from post-translational modification, enzymatic cleavage, or other readily identifiable variations from or equivalents to the secreted proteins in addition to cleavage of the signal peptide. It will also be appreciated that should the biologically active form of the polypeptides included in the sequence of one of SEQ ID NOs. 85-129 and 155-179 or the nucleic acids encoding the biologically active form of the polypeptides differ from

those identified as the mature polypeptide in Table V or the nucleotides encoding the mature polypeptide in Table IV as a result of a sequencing error, reverse transcription or amplification error, mRNA splicing, post-translational modification of the encoded protein, enzymatic cleavage of the encoded protein, or other biological factors, one skilled in the art would be readily able to identify the amino acids in the biologically active form of the polypeptides and the nucleic acids encoding the biologically active form of the polypeptides. In such instances, the claims relating to polypeptides comprising the mature protein included in one of SEQ ID NOs. 85-129 and 155-179 or nucleic acids comprising the nucleotides of one of SEQ ID NOs. 40-84 and 130-154 encoding the mature protein shall not be construed to exclude any readily identifiable variations from the sequences listed in Table IV and Table V.

10 In some embodiments, the nucleic acid used to express the protein or portion thereof may comprise those nucleotides which encode the signal peptide encoded by one of the sequences of SEQ ID NOs: 40-84 and 130-154 as defined in Table IV above.

It will be appreciated that should the extent of the sequence encoding the signal peptide differ from that listed in Table IV as a result of a sequencing error, reverse transcription or amplification error, mRNA splicing, post-translational modification of the encoded protein, enzymatic cleavage of the encoded protein, or other biological factors, one skilled in the art would be readily able to identify the extent of the sequence encoding the signal peptide in the sequences of SEQ ID NOs. 40-84 and 130-154. Accordingly, the scope of any claims herein relating to nucleic acids containing the sequence encoding the signal peptide encoded by one of SEQ ID Nos. 40-84 and 130-154 is not to be construed as excluding any readily identifiable variations from the sequences listed in Table IV. Similarly, should the extent of the signal peptides differ from those indicated in Table V as a result of any of the preceding factors, the scope of claims relating to polypeptides comprising the sequence of a signal peptide included in the sequence of one of SEQ ID NOs. 85-129 and 155-179 is not to be construed as excluding any readily identifiable variations from the sequences listed in Table V.

Alternatively, the nucleic acid may encode a polypeptide comprising at least 10 consecutive amino acids of one of the sequences of SEQ ID NOs: 85-129 and 155-179. In some embodiments, the nucleic acid may encode a polypeptide comprising at least 15 consecutive amino acids of one of the sequences of SEQ ID NOs: 85-129 and 155-179. In other embodiments, the nucleic acid may encode a polypeptide comprising at least 25 consecutive amino acids of one of the sequences of SEQ ID NOs: 85-129 and 155-179. In other embodiments, the nucleic acid may encode a polypeptide comprising at least 60, at least 75, at least 100 or more than 100 consecutive amino acids of one of the sequences of SEQ ID Nos: 85-129 and 155-179.

The nucleic acids inserted into the expression vectors may also contain sequences upstream of the sequences encoding the signal peptide, such as sequences which regulate expression levels or sequences which confer tissue specific expression.

The nucleic acid encoding the protein or polypeptide to be expressed is operably linked to a promoter in an expression vector using conventional cloning technology. The expression vector may be any of the mammalian, yeast, insect or bacterial expression systems known in the art. Commercially available vectors and expression

systems are available from a variety of suppliers including Genetics Institute (Cambridge, MA), Stratagene (La Jolla, California), Promega (Madison, Wisconsin), and Invitrogen (San Diego, California). If desired, to enhance expression and facilitate proper protein folding, the codon context and codon pairing of the sequence may be optimized for the particular expression organism in which the expression vector is introduced, as explained by

5 Hatfield, et al., U.S. Patent No. 5,082,767.

The following is provided as one exemplary method to express the proteins encoded by the extended cDNAs corresponding to the 5' ESTs or the nucleic acids described above. First, the methionine initiation codon for the gene and the poly A signal of the gene are identified. If the nucleic acid encoding the polypeptide to be expressed lacks a methionine to serve as the initiation site, an initiating methionine can be introduced next to the

10 first codon of the nucleic acid using conventional techniques. Similarly, if the extended cDNA lacks a poly A signal, this sequence can be added to the construct by, for example, splicing out the Poly A signal from pSG5 (Stratagene) using BglI and SalI restriction endonuclease enzymes and incorporating it into the mammalian expression vector pXT1 (Stratagene). pXT1 contains the LTRs and a portion of the *gag* gene from Moloney Murine Leukemia Virus. The position of the LTRs in the construct allow efficient stable transfection. The vector

15 includes the Herpes Simplex Thymidine Kinase promoter and the selectable neomycin gene. The extended cDNA or portion thereof encoding the polypeptide to be expressed is obtained by PCR from the bacterial vector using oligonucleotide primers complementary to the extended cDNA or portion thereof and containing restriction endonuclease sequences for PstI incorporated into the 5' primer and BglII at the 5' end of the corresponding cDNA

20 3' primer, taking care to ensure that the extended cDNA is positioned in frame with the poly A signal. The purified fragment obtained from the resulting PCR reaction is digested with PstI, blunt ended with an exonuclease, digested with BglII, purified and ligated to pXT1, now containing a poly A signal and digested with BglII.

The ligated product is transfected into mouse NIH 3T3 cells using Lipofectin (Life Technologies, Inc., Grand Island, New York) under conditions outlined in the product specification. Positive transfectants are selected after growing the transfected cells in 600ug/ml G418 (Sigma, St. Louis, Missouri). Preferably the expressed protein

25 is released into the culture medium, thereby facilitating purification.

Alternatively, the extended cDNAs may be cloned into pED6dpc2 as described above. The resulting pED6dpc2 constructs may be transfected into a suitable host cell, such as COS 1 cells. Methotrexate resistant cells are selected and expanded. Preferably, the protein expressed from the extended cDNA is released into the culture medium thereby facilitating purification.

30 Proteins in the culture medium are separated by gel electrophoresis. If desired, the proteins may be ammonium sulfate precipitated or separated based on size or charge prior to electrophoresis.

As a control, the expression vector lacking a cDNA insert is introduced into host cells or organisms and the proteins in the medium are harvested. The secreted proteins present in the medium are detected using techniques such as Coomassie or silver staining or using antibodies against the protein encoded by the extended

35 cDNA. Coomassie and silver staining techniques are familiar to those skilled in the art.

Antibodies capable of specifically recognizing the protein of interest may be generated using synthetic 15-mer peptides having a sequence encoded by the appropriate 5' EST, extended cDNA, or portion thereof. The synthetic peptides are injected into mice to generate antibody to the polypeptide encoded by the 5' EST, extended cDNA, or portion thereof.

5 Secreted proteins from the host cells or organisms containing an expression vector which contains the extended cDNA derived from a 5' EST or a portion thereof are compared to those from the control cells or organism. The presence of a band in the medium from the cells containing the expression vector which is absent in the medium from the control cells indicates that the extended cDNA encodes a secreted protein. Generally, the band corresponding to the protein encoded by the extended cDNA will have a mobility near that expected based
10 on the number of amino acids in the open reading frame of the extended cDNA. However, the band may have a mobility different than that expected as a result of modifications such as glycosylation, ubiquitination, or enzymatic cleavage.

 Alternatively, if the protein expressed from the above expression vectors does not contain sequences directing its secretion, the proteins expressed from host cells containing an expression vector containing an insert
15 encoding a secreted protein or portion thereof can be compared to the proteins expressed in host cells containing the expression vector without an insert. The presence of a band in samples from cells containing the expression vector with an insert which is absent in samples from cells containing the expression vector without an insert indicates that the desired protein or portion thereof is being expressed. Generally, the band will have the mobility expected for the secreted protein or portion thereof. However, the band may have a mobility different than that
20 expected as a result of modifications such as glycosylation, ubiquitination, or enzymatic cleavage.

 The protein encoded by the extended cDNA may be purified using standard immunochromatography techniques. In such procedures, a solution containing the secreted protein, such as the culture medium or a cell extract, is applied to a column having antibodies against the secreted protein attached to the chromatography matrix. The secreted protein is allowed to bind the immunochromatography column. Thereafter, the column is
25 washed to remove non-specifically bound proteins. The specifically bound secreted protein is then released from the column and recovered using standard techniques.

 If antibody production is not possible, the extended cDNA sequence or portion thereof may be incorporated into expression vectors designed for use in purification schemes employing chimeric polypeptides. In such strategies the coding sequence of the extended cDNA or portion thereof is inserted in frame with the gene
30 encoding the other half of the chimera. The other half of the chimera may be β -globin or a nickel binding polypeptide encoding sequence. A chromatography matrix having antibody to β -globin or nickel attached thereto is then used to purify the chimeric protein. Protease cleavage sites may be engineered between the β -globin gene or the nickel binding polypeptide and the extended cDNA or portion thereof. Thus, the two polypeptides of the chimera may be separated from one another by protease digestion.

35 One useful expression vector for generating β -globin chimerics is pSG5 (Stratagene), which encodes rabbit β -globin. Intron II of the rabbit β -globin gene facilitates splicing of the expressed transcript, and the

polyadenylation signal incorporated into the construct increases the level of expression. These techniques as described are well known to those skilled in the art of molecular biology. Standard methods are published in methods texts such as Davis et al., (**Basic Methods in Molecular Biology**, L.G. Davis, M.D. Digner, and J.F. Battey, ed., Elsevier Press, NY, 1986) and many of the methods are available from Stratagene, Life Technologies, Inc., or Promega. Polypeptide may additionally be produced from the construct using in vitro translation systems such as the In vitro Express™ Translation Kit (Stratagene).

Following expression and purification of the secreted proteins encoded by the 5' ESTs, extended cDNAs, or fragments thereof, the purified proteins may be tested for the ability to bind to the surface of various cell types as described in Example 31 below. It will be appreciated that a plurality of proteins expressed from these cDNAs may be included in a panel of proteins to be simultaneously evaluated for the activities specifically described below, as well as other biological roles for which assays for determining activity are available.

EXAMPLE 31

Analysis of Secreted Proteins to Determine Whether they Bind to the Cell Surface

The proteins encoded by the 5' ESTs, extended cDNAs, or fragments thereof are cloned into expression vectors such as those described in Example 30. The proteins are purified by size, charge, immunochromatography or other techniques familiar to those skilled in the art. Following purification, the proteins are labeled using techniques known to those skilled in the art. The labeled proteins are incubated with cells or cell lines derived from a variety of organs or tissues to allow the proteins to bind to any receptor present on the cell surface. Following the incubation, the cells are washed to remove non-specifically bound protein. The labeled proteins are detected by autoradiography. Alternatively, unlabeled proteins may be incubated with the cells and detected with antibodies having a detectable label, such as a fluorescent molecule, attached thereto.

Specificity of cell surface binding may be analyzed by conducting a competition analysis in which various amounts of unlabeled protein are incubated along with the labeled protein. The amount of labeled protein bound to the cell surface decreases as the amount of competitive unlabeled protein increases. As a control, various amounts of an unlabeled protein unrelated to the labeled protein is included in some binding reactions. The amount of labeled protein bound to the cell surface does not decrease in binding reactions containing increasing amounts of unrelated unlabeled protein, indicating that the protein encoded by the cDNA binds specifically to the cell surface.

As discussed above, secreted proteins have been shown to have a number of important physiological effects and, consequently, represent a valuable therapeutic resource. The secreted proteins encoded by the extended cDNAs or portions thereof made according to Examples 27-29 may be evaluated to determine their physiological activities as described below.

EXAMPLE 32

Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof for Cytokine, Cell Proliferation or Cell Differentiation Activity

As discussed above, secreted proteins may act as cytokines or may affect cellular proliferation or differentiation. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of

5 routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7c and CMK. The proteins encoded by the above extended cDNAs or portions thereof may be evaluated for their ability to regulate T cell or thymocyte proliferation in assays such as those described above or in the following references: **Current**

10 **Protocols in Immunology**, Ed. by J.E. Coligan et al., Greene Publishing Associates and Wiley-Interscience; Takai et al. *J. Immunol.* 137:3494-3500, 1986. Bertagnoli et al. *J. Immunol.* 145:1706-1712, 1990. Bertagnoli et al., *Cellular Immunology* 133:327-341, 1991. Bertagnoli, et al. *J. Immunol.* 149:3778-3783, 1992; Bowman et al., *J. Immunol.* 152:1756-1761, 1994.

In addition, numerous assays for cytokine production and/or the proliferation of spleen cells, lymph node cells and thymocytes are known. These include the techniques disclosed in **Current Protocols in Immunology**.

15 J.E. Coligan et al. Eds., Vol 1 pp. 3.12.1-3.12.14 John Wiley and Sons, Toronto. 1994; and Schreiber, R.D. **Current Protocols in Immunology**, *supra* Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

The proteins encoded by the cDNAs may also be assayed for the ability to regulate the proliferation and differentiation of hematopoietic or lymphopoietic cells. Many assays for such activity are familiar to those skilled in the art, including the assays in the following references: Bottomly, K., Davis, L.S. and Lipsky, P.E., Measurement of

20 Human and Murine Interleukin 2 and Interleukin 4, **Current Protocols in Immunology**, J.E. Coligan et al. Eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., *J. Exp. Med.* 173:1205-1211, 1991; Moreau et al., *Nature* 36:690-692, 1988; Greenberger et al., *Proc. Natl. Acad. Sci. U.S.A.* 80:2931-2938, 1983; Nordan, R., Measurement of Mouse and Human Interleukin 6 **Current Protocols in Immunology**. J.E. Coligan et al. Eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., *Proc. Natl. Acad. Sci. U.S.A.*

25 83:1857-1861, 1986; Bennett, F., Giannotti, J., Clark, S.C. and Turner, K.J., Measurement of Human Interleukin 11 **Current Protocols in Immunology**. J.E. Coligan et al. Eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J., Measurement of Mouse and Human Interleukin 9 **Current Protocols in Immunology**. J.E. Coligan et al., Eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

30 The proteins encoded by the cDNAs may also be assayed for their ability to regulate T-cell responses to antigens. Many assays for such activity are familiar to those skilled in the art, including the assays described in the following references: Chapter 3 (In Vitro Assays for Mouse Lymphocyte Function), Chapter 6 (Cytokines and Their Cellular Receptors) and Chapter 7, (Immunologic Studies in Humans) in **Current Protocols in Immunology**, J.E. Coligan et al. Eds. Greene Publishing Associates and Wiley-Interscience; Weinberger et al., *Proc. Natl. Acad. Sci.*

35 *USA* 77:6091-6095, 1980; Weinberger et al., *Eur. J. Immun.* 11:405-411, 1981; Takai et al., *J. Immunol.* 137:3494-3500, 1986; Takai et al., *J. Immunol.* 140:508-512, 1988.

Those proteins which exhibit cytokine, cell proliferation, or cell differentiation activity may then be formulated as pharmaceuticals and used to treat clinical conditions in which induction of cell proliferation or differentiation is beneficial. Alternatively, as described in more detail below, genes encoding these proteins or nucleic acids regulating the expression of these proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

EXAMPLE 33

Assaying the Proteins Expressed from Extended cDNAs or Portions

Thereof for Activity as Immune System Regulators

The proteins encoded by the cDNAs may also be evaluated for their effects as immune regulators. For example, the proteins may be evaluated for their activity to influence thymocyte or splenocyte cytotoxicity. Numerous assays for such activity are familiar to those skilled in the art including the assays described in the following references: Chapter 3 (In Vitro Assays for Mouse Lymphocyte Function 3.1-3.19) and Chapter 7 (Immunologic studies in Humans) in **Current Protocols in Immunology**, J.E. Coligan et al. Eds, Greene Publishing Associates and Wiley-Interscience; Herrmann et al., **Proc. Natl. Acad. Sci. USA** 78:2488-2492, 1981; Herrmann et al., **J. Immunol.** 128:1968-1974, 1982; Handa et al., **J. Immunol.** 135:1564-1572, 1985; Takai et al., **J. Immunol.** 137:3494-3500, 1986; Takai et al., **J. Immunol.** 140:508-512, 1988; Herrmann et al., **Proc. Natl. Acad. Sci. USA** 78:2488-2492, 1981; Herrmann et al., **J. Immunol.** 128:1968-1974, 1982; Handa et al., **J. Immunol.** 135:1564-1572, 1985; Takai et al., **J. Immunol.** 137:3494-3500, 1986; Bowman et al., **J. Virology** 61:1992-1998; Takai et al., **J. Immunol.** 140:508-512, 1988; Bertagnoli et al., **Cellular Immunology** 133:327-341, 1991; Brown et al., **J. Immunol.** 153:3079-3092, 1994.

The proteins encoded by the cDNAs may also be evaluated for their effects on T-cell dependent immunoglobulin responses and isotype switching. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references: Maliszewski, **J. Immunol.** 144:3028-3033, 1990; Mond, J.J. and Brunswick, M Assays for B Cell Function: *In vitro* Antibody Production, Vol 1 pp. 3.8.1-3.8.16 in **Current Protocols in Immunology**. J.E. Coligan et al Eds., John Wiley and Sons, Toronto. 1994.

The proteins encoded by the cDNAs may also be evaluated for their effect on immune effector cells, including their effect on Th1 cells and cytotoxic lymphocytes. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references: Chapter 3 (In Vitro Assays for Mouse Lymphocyte Function 3.1-3.19) and Chapter 7 (Immunologic Studies in Humans) in **Current Protocols in Immunology**, J.E. Coligan et al. Eds., Greene Publishing Associates and Wiley-Interscience; Takai et al., **J. Immunol.** 137:3494-3500, 1986; Takai et al., **J. Immunol.** 140:508-512, 1988; Bertagnoli et al., **J. Immunol.** 149:3778-3783, 1992.

The proteins encoded by the cDNAs may also be evaluated for their effect on dendritic cell mediated activation of naive T-cells. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references: Guery et al., **J. Immunol.** 134:536-544, 1995; Inaba et al., **Journal of Experimental Medicine** 173:549-559, 1991; Macatonia et al., **Journal of Immunology** 154:5071-5079, 1995;

Porgador et al., *Journal of Experimental Medicine* 182:255-260, 1995; Nair et al., *Journal of Virology* 67:4062-4069, 1993; Huang et al., *Science* 264:961-965, 1994; Macatonia et al., *Journal of Experimental Medicine* 169:1255-1264, 1989; Bhardwaj et al., *Journal of Clinical Investigation* 94:797-807, 1994; and Inaba et al., *Journal of Experimental Medicine* 172:631-640, 1990.

- 5 The proteins encoded by the cDNAs may also be evaluated for their influence on the lifetime of lymphocytes. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references: Darzynkiewicz et al., *Cytometry* 13:795-808, 1992; Gorczyca et al., *Leukemia* 7:659-670, 1993; Gorczyca et al., *Cancer Research* 53:1945-1951, 1993; Itoh et al., *Cell* 66:233-243, 1991; Zacharchuk, *Journal of Immunology* 145:4037-4045, 1990; Zamai et al., *Cytometry* 14:891-897, 1993;
- 10 Gorczyca et al., *International Journal of Oncology* 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., *Blood* 84:111-117, 1994; Fine et al., *Cellular Immunology* 155:111-122, 1994; Galy et al., *Blood* 85:2770-2778, 1995; Toki et al., *Proc. Nat. Acad. Sci. USA* 88:7548-7551, 1991.

- Those proteins which exhibit activity as immune system regulators activity may then be formulated as
- 15 pharmaceuticals and used to treat clinical conditions in which regulation of immune activity is beneficial. For example, the protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result
- 20 from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, *Leishmania* spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.

- 25 Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma
- 30 (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.

- Using the proteins of the invention it may also be possible to regulate immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or
- 35 may involve preventing the induction of an immune response. The functions of activated T-cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell

responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon
5 reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as, for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically,
10 in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (e.g., B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the
15 binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking
20 reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of
25 which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al., *Science* 257:789-792 (1992) and Turka et al., *Proc. Natl. Acad. Sci USA*, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., *Fundamental Immunology*, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function in vivo on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor ligand interactions of B lymphocyte antigens
35 can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of

autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythematosus in MRL/pr/pr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in OD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., *Fundamental Immunology*, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory form of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to T cells in vivo, thereby activating the T cells.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected ex vivo with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection in vivo.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acids encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β_2 macroglobulin protein or an MHC class II α chain protein and an MHC class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class II or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the

invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject. Alternatively, as described in more detail below, genes encoding these proteins or nucleic acids regulating the expression of these proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

EXAMPLE 34

Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof for Hematopoiesis Regulating Activity

The proteins encoded by the extended cDNAs or portions thereof may also be evaluated for their hematopoiesis regulating activity. For example, the effect of the proteins on embryonic stem cell differentiation may be evaluated. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references: Johansson et al. **Cellular Biology** 15:141-151, 1995; Keller et al., **Molecular and Cellular Biology** 13:473-486, 1993; McClanahan et al., **Blood** 81:2903-2915, 1993.

The proteins encoded by the extended cDNAs or portions thereof may also be evaluated for their influence on the lifetime of stem cells and stem cell differentiation. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references: Freshney, M.G. Methylcellulose Colony Forming Assays, in **Culture of Hematopoietic Cells**. R.I. Freshney, et al. Eds. pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., **Proc. Natl. Acad. Sci. USA** 89:5907-5911, 1992; McNiece, I.K. and Briddell, R.A. Primitive Hematopoietic Colony Forming Cells with High Proliferative Potential, in **Culture of Hematopoietic Cells**. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., **Experimental Hematology** 22:353-359, 1994; Ploemacher, R.E. Cobblestone Area Forming Cell Assay, In **Culture of Hematopoietic Cells**. R.I. Freshney, et al. Eds. pp. 1-21, Wiley-Liss, Inc., New York, NY. 1994; Spooncer, E., Dexter, M. and Allen, T. Long Term Bone Marrow Cultures in the Presence of Stromal Cells, in **Culture of Hematopoietic Cells**. R.I. Freshney, et al. Eds. pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994; and Sutherland, H.J. Long Term Culture Initiating Cell Assay, in **Culture of Hematopoietic Cells**. R.I. Freshney, et al. Eds. pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

Those proteins which exhibit hematopoiesis regulatory activity may then be formulated as pharmaceuticals and used to treat clinical conditions in which regulation of hematopoiesis is beneficial. For example, a protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and

proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vivo or ex-vivo (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy. Alternatively, as described in more detail below, genes encoding these proteins or nucleic acids regulating the expression of these proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

EXAMPLE 35

Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof for Regulation of Tissue Growth

The proteins encoded by the extended cDNAs or portions thereof may also be evaluated for their effect on tissue growth. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in International Patent Publication No. WO95/16035, International Patent Publication No. WO95/05846 and International Patent Publication No. WO91/07491.

Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, H1 and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).

Those proteins which are involved in the regulation of tissue growth may then be formulated as pharmaceuticals and used to treat clinical conditions in which regulation of tissue growth is beneficial. For example, a protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage

repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e., for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium) muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to generate. A protein of the invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

5 Alternatively, as described in more detail below, genes encoding these proteins or nucleic acids regulating the expression of these proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

EXAMPLE 36

Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof for Regulation of Reproductive Hormones or Cell Movement

10 The proteins encoded by the extended cDNAs or portions thereof may also be evaluated for their ability to regulate reproductive hormones, such as follicle stimulating hormone. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references: Vale et al., **Endocrinology** 91:562-572, 1972; Ling et al., **Nature** 321:779-782, 1986; Vale et al., **Nature** 321:776-779, 1986; 15 Mason et al., **Nature** 318:659-663, 1985; Forage et al., **Proc. Natl. Acad. Sci. USA** 83:3091-3095, 1986. Chapter 6.12 (Measurement of Alpha and Beta Chemokines) **Current Protocols in Immunology**, J.E. Coligan et al. Eds. Greene Publishing Associates and Wiley-Interscience; Taub et al. **J. Clin. Invest.** 95:1370-1376, 1995; Lind et al. **APMIS** 103:140-146, 1995; Muller et al. **Eur. J. Immunol.** 25:1744-1748; Gruber et al. **J. of Immunol.** 152:5860-5867, 1994; Johnston et al. **J. of Immunol.** 153:1762-1768, 1994.

20 Those proteins which exhibit activity as reproductive hormones or regulators of cell movement may then be formulated as pharmaceuticals and used to treat clinical conditions in which regulation of reproductive hormones or cell movement are beneficial. For example, a protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin α family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin-B group, may be useful as a fertility inducing therapeutic, 25 based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

30 Alternatively, as described in more detail below, genes encoding these proteins or nucleic acids regulating the expression of these proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

EXAMPLE 36A

Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof for Chemotactic/Chemokinetic Activity

The proteins encoded by the extended cDNAs or portions thereof may also be evaluated for
5 chemotactic/chemokinetic activity. For example, a protein of the present invention may have chemotactic or
chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes,
fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and
chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action.
Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to
10 tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or
neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting
agent.

A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or
indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the
15 ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a
population of cells can be readily determined by employing such protein or peptide in any known assay for cell
chemotaxis.

The activity of a protein of the invention may, among other means, be measured by the following
methods:

20 Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of
assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the
ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for
movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by
J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and
25 Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin.
Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Mueller et al. Eur. J. Immunol. 25:1744-1748;
Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153:1762-1768, 1994.

EXAMPLE 37

Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof for Regulation of Blood Clotting

30 The proteins encoded by the extended cDNAs or portions thereof may also be evaluated for their effects
on blood clotting. Numerous assays for such activity are familiar to those skilled in the art, including the assays
disclosed in the following references: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al.,
Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins
35 35:467-474, 1988.

Those proteins which are involved in the regulation of blood clotting may then be formulated as pharmaceuticals and used to treat clinical conditions in which regulation of blood clotting is beneficial. For example, a protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulations disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke). Alternatively, as described in more detail below, genes encoding these proteins or nucleic acids regulating the expression of these proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

EXAMPLE 38

Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof for Involvement in Receptor/Ligand Interactions

The proteins encoded by the extended cDNAs or a portion thereof may also be evaluated for their involvement in receptor/ligand interactions. Numerous assays for such involvement are familiar to those skilled in the art, including the assays disclosed in the following references: Chapter 7.28 (Measurement of Cellular Adhesion under Static Conditions 7.28.1-7.28.22) in **Current Protocols in Immunology**, J.E. Coligan et al. Eds. Greene Publishing Associates and Wiley-Interscience; Takai et al., **Proc. Natl. Acad. Sci. USA** 84:6864-6868, 1987; Bierer et al., **J. Exp. Med.** 168:1145-1156, 1988; Rosenstein et al., **J. Exp. Med.** 169:149-160, 1989; Stoltzenberg et al., **J. Immunol. Methods** 175:59-68, 1994; Stitt et al., **Cell** 80:661-670, 1995; Gyuris et al., **Cell** 75:791-803, 1993.

For example, the proteins of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

EXAMPLE 38A

Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof for Anti-Inflammatory Activity

The proteins encoded by the extended cDNAs or a portion thereof may also be evaluated for anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by

inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

10

EXAMPLE 38B

Assaying the Proteins Expressed from Extended cDNAs or
Portions Thereof for Tumor Inhibition Activity

The proteins encoded by the extended cDNAs or a portion thereof may also be evaluated for tumor inhibition activity. In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via ADCC). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

20 A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape);
25 effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain
30 reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or
35 entity which is cross-reactive with such protein.

EXAMPLE 39

Identification of Proteins which Interact with Polypeptides Encoded by Extended cDNAs

Proteins which interact with the polypeptides encoded by extended cDNAs or portions thereof, such as
5 receptor proteins, may be identified using two hybrid systems such as the Matchmaker Two Hybrid System 2
(Catalog No. K1604-1, Clontech). As described in the manual accompanying the Matchmaker Two Hybrid System
2 (Catalog No. K1604-1, Clontech), the extended cDNAs or portions thereof, are inserted into an expression vector
such that they are in frame with DNA encoding the DNA binding domain of the yeast transcriptional activator GAL4.
cDNAs in a cDNA library which encode proteins which might interact with the polypeptides encoded by the
10 extended cDNAs or portions thereof are inserted into a second expression vector such that they are in frame with
DNA encoding the activation domain of GAL4. The two expression plasmids are transformed into yeast and the
yeast are plated on selection medium which selects for expression of selectable markers on each of the expression
vectors as well as GAL4 dependent expression of the HIS3 gene. Transformants capable of growing on medium
lacking histidine are screened for GAL4 dependent lacZ expression. Those cells which are positive in both the
15 histidine selection and the lacZ assay contain plasmids encoding proteins which interact with the polypeptide
encoded by the extended cDNAs or portions thereof.

Alternatively, the system described in Lustig et al., Methods in Enzymology 283: 83-99 (1997) may be
used for identifying molecules which interact with the polypeptides encoded by extended cDNAs. In such systems,
in vitro transcription reactions are performed on a pool of vectors containing extended cDNA inserts cloned
20 downstream of a promoter which drives *in vitro* transcription. The resulting pools of mRNAs are introduced into
Xenopus laevis oocytes. The oocytes are then assayed for a desired activity.

Alternatively, the pooled *in vitro* transcription products produced as described above may be translated *in*
vitro. The pooled *in vitro* translation products can be assayed for a desired activity or for interaction with a known
polypeptide.

25 Proteins or other molecules interacting with polypeptides encoded by extended cDNAs can be found
by a variety of additional techniques. In one method, affinity columns containing the polypeptide encoded by
the extended cDNA or a portion thereof can be constructed. In some versions, of this method the affinity
column contains chimeric proteins in which the protein encoded by the extended cDNA or a portion thereof is
fused to glutathione S-transferase. A mixture of cellular proteins or pool of expressed proteins as described
30 above and is applied to the affinity column. Proteins interacting with the polypeptide attached to the column
can then be isolated and analyzed on 2-D electrophoresis gel as described in Ramunsen et al.
Electrophoresis, 18, 588-598 (1997). Alternatively, the proteins retained on the affinity column can be purified
by electrophoresis based methods and sequenced. The same method can be used to isolate antibodies, to
screen phage display products, or to screen phage display human antibodies.

35 Proteins interacting with polypeptides encoded by extended cDNAs or portions thereof can also be
screened by using an Optical Biosensor as described in Edwards & Leatherbarrow, Analytical Biochemistry,

246, 1-6 (1997). The main advantage of the method is that it allows the determination of the association rate between the protein and other interacting molecules. Thus, it is possible to specifically select interacting molecules with a high or low association rate. Typically a target molecule is linked to the sensor surface (through a carboxymethyl dextran matrix) and a sample of test molecules is placed in contact with the target
5 molecules. The binding of a test molecule to the target molecule causes a change in the refractive index and/or thickness. This change is detected by the Biosensor provided it occurs in the evanescent field (which extend a few hundred nanometers from the sensor surface). In these screening assays, the target molecule can be one of the polypeptides encoded by extended cDNAs or a portion thereof and the test sample can be a collection of proteins extracted from tissues or cells, a pool of expressed proteins, combinatorial peptide and/or chemical libraries, or phage displayed peptides. The tissues or cells from which the test proteins are
10 extracted can originate from any species.

In other methods, a target protein is immobilized and the test population is a collection of unique polypeptides encoded by the extended cDNAs or portions thereof.

To study the interaction of the proteins encoded by the extended cDNAs or portions thereof with
15 drugs, the microdialysis coupled to HPLC method described by Wang et al., *Chromatographia*, 44, 205-208(1997) or the affinity capillary electrophoresis method described by Busch et al., *J. Chromatogr.* 777:311-328 (1997).

The system described in U.S. Patent No. 5,654,150 may also be used to identify molecules which interact with the polypeptides encoded by the extended cDNAs. In this system, pools of extended cDNAs are transcribed
20 and translated *in vitro* and the reaction products are assayed for interaction with a known polypeptide or antibody.

It will be appreciated by those skilled in the art that the proteins expressed from the extended cDNAs or portions may be assayed for numerous activities in addition to those specifically enumerated above. For example, the expressed proteins may be evaluated for applications involving control and regulation of inflammation, tumor proliferation or metastasis, infection, or other clinical conditions. In addition, the proteins expressed from the
25 extended cDNAs or portions thereof may be useful as nutritional agents or cosmetic agents.

The proteins expressed from the extended cDNAs or portions thereof may be used to generate antibodies capable of specifically binding to the expressed protein or fragments thereof as described in Example 40 below. The antibodies may be capable of binding a full length protein encoded by one of the sequences of SEQ ID NOs: 40-59, 61-73, 75, 77-82, and 130-154, a mature protein encoded by one of the sequences of SEQ ID NOs:
30 40-59, 61-75, 77-82, and 130-154, or a signal peptide encoded by one of the sequences of SEQ ID Nos. 40-59, 61-73, 75-82, 84 and 130-154. Alternatively, the antibodies may be capable of binding fragments of the proteins expressed from the extended cDNAs which comprise at least 10 amino acids of the sequences of SEQ ID NOs: 85-129 and 155-179. In some embodiments, the antibodies may be capable of binding fragments of the proteins expressed from the extended cDNAs which comprise at least 15 amino acids of the sequences of SEQ ID NOs:
35 85-129 and 155-179. In other embodiments, the antibodies may be capable of binding fragments of the proteins expressed from the extended cDNAs which comprise at least 25 amino acids of the sequences of SEQ ID NOs:

85-129 and 155-179. In further embodiments, the antibodies may be capable of binding fragments of the proteins expressed from the extended cDNAs which comprise at least 40 amino acids of the sequences of SEQ ID NOs: 85-129 and 155-179.

EXAMPLE 40

Production of an Antibody to a Human Protein

Substantially pure protein or polypeptide is isolated from the transfected or transformed cells as described in Example 30. The concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms/ml. Monoclonal or polyclonal antibody to the protein can then be prepared as follows:

A. Monoclonal Antibody Production by Hybridoma Fusion

Monoclonal antibody to epitopes of any of the peptides identified and isolated as described can be prepared from murine hybridomas according to the classical method of Kohler, G. and Milstein, C., *Nature* **256**:495 (1975) or derivative methods thereof. Briefly, a mouse is repetitively inoculated with a few micrograms of the selected protein or peptides derived therefrom over a period of a few weeks. The mouse is then sacrificed, and the antibody producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as Elisa, as originally described by Engvall, E., *Meth. Enzymol.* **70**:419 (1980), and derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Davis, L. et al. *Basic Methods in Molecular Biology* Elsevier, New York. Section 21-2.

B. Polyclonal Antibody Production by Immunization

Polyclonal antiserum containing antibodies to heterogenous epitopes of a single protein can be prepared by immunizing suitable animals with the expressed protein or peptides derived therefrom described above, which can be unmodified or modified to enhance immunogenicity. Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. For example, small molecules tend to be less immunogenic than others and may require the use of carriers and adjuvant. Also, host animals vary in response to site of inoculations and dose, with both inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appears to be most reliable. An effective immunization protocol for rabbits can be found in Vaitukaitis, J. et al. *J. Clin. Endocrinol. Metab.* **33**:988-991 (1971).

Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony, O. et al., Chap. 19 in: *Handbook of Experimental*

Immunology D. Wier (ed) Blackwell (1973). Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12 μ M). Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher, D., Chap. 42 in: **Manual of Clinical Immunology**, 2d Ed. (Rose and Friedman, Eds.) Amer. Soc. For Microbiol., Washington, D.C. (1980).

5 Antibody preparations prepared according to either protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. The antibodies may also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body.

10 **V. Use of Extended cDNAs or Portions Thereof as Reagents**

The extended cDNAs of the present invention may be used as reagents in isolation procedures, diagnostic assays, and forensic procedures. For example, sequences from the extended cDNAs (or genomic DNAs obtainable therefrom) may be detectably labeled and used as probes to isolate other sequences capable of hybridizing to them. In addition, sequences from the extended cDNAs (or genomic DNAs obtainable therefrom)
15 may be used to design PCR primers to be used in isolation, diagnostic, or forensic procedures.

EXAMPLE 41

Preparation of PCR Primers and Amplification of DNA

The extended cDNAs (or genomic DNAs obtainable therefrom) may be used to prepare PCR primers for a variety of applications, including isolation procedures for cloning nucleic acids capable of hybridizing to such
20 sequences, diagnostic techniques and forensic techniques. The PCR primers are at least 10 bases, and preferably at least 12, 15, or 17 bases in length. More preferably, the PCR primers are at least 20-30 bases in length. In some embodiments, the PCR primers may be more than 30 bases in length. It is preferred that the primer pairs have approximately the same G/C ratio, so that melting temperatures are approximately the same. A variety of PCR techniques are familiar to those skilled in the art. For a review of PCR technology, see Molecular
25 Cloning to Genetic Engineering White, B.A. Ed. in Methods in Molecular Biology 67: Humana Press, Totowa 1997. In each of these PCR procedures, PCR primers on either side of the nucleic acid sequences to be amplified are added to a suitably prepared nucleic acid sample along with dNTPs and a thermostable polymerase such as Taq polymerase, Pfu polymerase, or Vent polymerase. The nucleic acid in the sample is denatured and the PCR primers are specifically hybridized to complementary nucleic acid sequences in the sample. The hybridized
30 primers are extended. Thereafter, another cycle of denaturation, hybridization, and extension is initiated. The cycles are repeated multiple times to produce an amplified fragment containing the nucleic acid sequence between the primer sites.

EXAMPLE 42

Use of Extended cDNAs as Probes

35 Probes derived from extended cDNAs or portions thereof (or genomic DNAs obtainable therefrom) may be labeled with detectable labels familiar to those skilled in the art, including radioisotopes and non-radioactive

labels, to provide a detectable probe. The detectable probe may be single stranded or double stranded and may be made using techniques known in the art, including in vitro transcription, nick translation, or kinase reactions. A nucleic acid sample containing a sequence capable of hybridizing to the labeled probe is contacted with the labeled probe. If the nucleic acid in the sample is double stranded, it may be denatured prior to contacting the probe. In
 5 some applications, the nucleic acid sample may be immobilized on a surface such as a nitrocellulose or nylon membrane. The nucleic acid sample may comprise nucleic acids obtained from a variety of sources, including genomic DNA, cDNA libraries, RNA, or tissue samples.

Procedures used to detect the presence of nucleic acids capable of hybridizing to the detectable probe include well known techniques such as Southern blotting, Northern blotting, dot blotting, colony hybridization, and
 10 plaque hybridization. In some applications, the nucleic acid capable of hybridizing to the labeled probe may be cloned into vectors such as expression vectors, sequencing vectors, or in vitro transcription vectors to facilitate the characterization and expression of the hybridizing nucleic acids in the sample. For example, such techniques may be used to isolate and clone sequences in a genomic library or cDNA library which are capable of hybridizing to the detectable probe as described in Example 30 above.

15 PCR primers made as described in Example 41 above may be used in forensic analyses, such as the DNA fingerprinting techniques described in Examples 43-47 below. Such analyses may utilize detectable probes or primers based on the sequences of the extended cDNAs isolated using the 5' ESTs (or genomic DNAs obtainable therefrom).

EXAMPLE 43

20 Forensic Matching by DNA Sequencing

In one exemplary method, DNA samples are isolated from forensic specimens of, for example, hair, semen, blood or skin cells by conventional methods. A panel of PCR primers based on a number of the extended cDNAs (or genomic DNAs obtainable therefrom), is then utilized in accordance with Example 41 to amplify DNA of approximately 100-200 bases in length from the forensic specimen. Corresponding sequences are obtained from
 25 a test subject. Each of these identification DNAs is then sequenced using standard techniques, and a simple database comparison determines the differences, if any, between the sequences from the subject and those from the sample. Statistically significant differences between the suspect's DNA sequences and those from the sample conclusively prove a lack of identity. This lack of identity can be proven, for example, with only one sequence. Identity, on the other hand, should be demonstrated with a large number of sequences, all matching. Preferably, a
 30 minimum of 50 statistically identical sequences of 100 bases in length are used to prove identity between the suspect and the sample.

EXAMPLE 44

Positive Identification by DNA Sequencing

The technique outlined in the previous example may also be used on a larger scale to provide a unique
 35 fingerprint-type identification of any individual. In this technique, primers are prepared from a large number of sequences from Table IV and the appended sequence listing. Preferably, 20 to 50 different primers are used.

These primers are used to obtain a corresponding number of PCR-generated DNA segments from the individual in question in accordance with Example 41. Each of these DNA segments is sequenced, using the methods set forth in Example 43. The database of sequences generated through this procedure uniquely identifies the individual from whom the sequences were obtained. The same panel of primers may then be used at any later time to

5 absolutely correlate tissue or other biological specimen with that individual.

EXAMPLE 45

Southern Blot Forensic Identification

The procedure of Example 44 is repeated to obtain a panel of at least 10 amplified sequences from an individual and a specimen. Preferably, the panel contains at least 50 amplified sequences. More preferably, the

10 panel contains 100 amplified sequences. In some embodiments, the panel contains 200 amplified sequences. This PCR-generated DNA is then digested with one or a combination of, preferably, four base specific restriction enzymes. Such enzymes are commercially available and known to those of skill in the art. After digestion, the resultant gene fragments are size separated in multiple duplicate wells on an agarose gel and transferred to nitrocellulose using Southern blotting techniques well known to those with skill in the art. For a review of Southern

15 blotting see Davis et al. (Basic Methods in Molecular Biology, 1986, Elsevier Press, pp 62-65).

A panel of probes based on the sequences of the extended cDNAs (or genomic DNAs obtainable therefrom), or fragments thereof of at least 10 bases, are radioactively or colorimetrically labeled using methods known in the art, such as nick translation or end labeling, and hybridized to the Southern blot using techniques known in the art (Davis et al., *supra*). Preferably, the probe comprises at least 12, 15, or 17 consecutive

20 nucleotides from the extended cDNA (or genomic DNAs obtainable therefrom). More preferably, the probe comprises at least 20-30 consecutive nucleotides from the extended cDNA (or genomic DNAs obtainable therefrom). In some embodiments, the probe comprises more than 30 nucleotides from the extended cDNA (or genomic DNAs obtainable therefrom). In other embodiments, the probe comprises at least 40, at least 50, at least 75, at least 100, at least 150, or at least 200 consecutive nucleotides from the extended cDNA (or genomic DNAs

25 obtainable therefrom).

Preferably, at least 5 to 10 of these labeled probes are used, and more preferably at least about 20 or 30 are used to provide a unique pattern. The resultant bands appearing from the hybridization of a large sample of extended cDNAs (or genomic DNAs obtainable therefrom) will be a unique identifier. Since the restriction enzyme cleavage will be different for every individual, the band pattern on the Southern blot will also be unique. Increasing

30 the number of extended cDNA probes will provide a statistically higher level of confidence in the identification since there will be an increased number of sets of bands used for identification.

EXAMPLE 46

Dot Blot Identification Procedure

Another technique for identifying individuals using the extended cDNA sequences disclosed herein

35 utilizes a dot blot hybridization technique.

Genomic DNA is isolated from nuclei of subject to be identified. Oligonucleotide probes of approximately 30 bp in length are synthesized that correspond to at least 10, preferably 50 sequences from the extended cDNAs or genomic DNAs obtainable therefrom. The probes are used to hybridize to the genomic DNA through conditions known to those in the art. The oligonucleotides are end labeled with P^{32} using polynucleotide kinase (Pharmacia).

5 Dot Blots are created by spotting the genomic DNA onto nitrocellulose or the like using a vacuum dot blot manifold (BioRad, Richmond California). The nitrocellulose filter containing the genomic sequences is baked or UV linked to the filter, prehybridized and hybridized with labeled probe using techniques known in the art (Davis et al. *supra*). The ^{32}P labeled DNA fragments are sequentially hybridized with successively stringent conditions to detect minimal differences between the 30 bp sequence and the DNA. Tetramethylammonium chloride is useful for identifying

10 clones containing small numbers of nucleotide mismatches (Wood et al., *Proc. Natl. Acad. Sci. USA* 82(6):1585-1588 (1985)). A unique pattern of dots distinguishes one individual from another individual.

Extended cDNAs or oligonucleotides containing at least 10 consecutive bases from these sequences can be used as probes in the following alternative fingerprinting technique. Preferably, the probe comprises at least 12, 15, or 17 consecutive nucleotides from the extended cDNA (or genomic DNAs obtainable therefrom). More

15 preferably, the probe comprises at least 20-30 consecutive nucleotides from the extended cDNA (or genomic DNAs obtainable therefrom). In some embodiments, the probe comprises more than 30 nucleotides from the extended cDNA (or genomic DNAs obtainable therefrom). In other embodiments, the probe comprises at least 40, at least 50, at least 75, at least 100, at least 150, or at least 200 consecutive nucleotides from the extended cDNA (or genomic DNAs obtainable therefrom).

20 Preferably, a plurality of probes having sequences from different genes are used in the alternative fingerprinting technique. Example 47 below provides a representative alternative fingerprinting procedure in which the probes are derived from extended cDNAs.

EXAMPLE 47

Alternative "Fingerprint" Identification Technique

25 20-mer oligonucleotides are prepared from a large number, e.g. 50, 100, or 200, of extended cDNA sequences (or genomic DNAs obtainable therefrom) using commercially available oligonucleotide services such as Genset, Paris, France. Cell samples from the test subject are processed for DNA using techniques well known to those with skill in the art. The nucleic acid is digested with restriction enzymes such as EcoRI and XbaI. Following digestion, samples are applied to wells for electrophoresis. The procedure, as known in the art, may be modified to

30 accommodate polyacrylamide electrophoresis, however in this example, samples containing 5 ug of DNA are loaded into wells and separated on 0.8% agarose gels. The gels are transferred onto nitrocellulose using standard Southern blotting techniques.

10 ng of each of the oligonucleotides are pooled and end-labeled with P^{32} . The nitrocellulose is prehybridized with blocking solution and hybridized with the labeled probes. Following hybridization and washing,

35 the nitrocellulose filter is exposed to X-Omat AR X-ray film. The resulting hybridization pattern will be unique for each individual.

It is additionally contemplated within this example that the number of probe sequences used can be varied for additional accuracy or clarity.

The antibodies generated in Examples 30 and 40 above may be used to identify the tissue type or cell species from which a sample is derived as described above.

5

EXAMPLE 48

Identification of Tissue Types or Cell Species by Means of Labeled Tissue Specific Antibodies

Identification of specific tissues is accomplished by the visualization of tissue specific antigens by means of antibody preparations according to Examples 30 and 40 which are conjugated, directly or indirectly to a
10 detectable marker. Selected labeled antibody species bind to their specific antigen binding partner in tissue sections, cell suspensions, or in extracts of soluble proteins from a tissue sample to provide a pattern for qualitative or semi-qualitative interpretation.

Antisera for these procedures must have a potency exceeding that of the native preparation, and for that reason, antibodies are concentrated to a mg/ml level by isolation of the gamma globulin fraction, for example, by
15 ion-exchange chromatography or by ammonium sulfate fractionation. Also, to provide the most specific antisera, unwanted antibodies, for example to common proteins, must be removed from the gamma globulin fraction, for example by means of insoluble immunoabsorbents, before the antibodies are labeled with the marker. Either monoclonal or heterologous antisera is suitable for either procedure.

A. Immunohistochemical Techniques

20 Purified, high-titer antibodies, prepared as described above, are conjugated to a detectable marker, as described, for example, by Fudenberg, H., Chap. 26 in: **Basic 503 Clinical Immunology**, 3rd Ed. Lange, Los Altos, California (1980) or Rose, N. et al., Chap. 12 in: **Methods in Immunodiagnosis**, 2d Ed. John Wiley 503 Sons, New York (1980).

A fluorescent marker, either fluorescein or rhodamine, is preferred, but antibodies can also be labeled
25 with an enzyme that supports a color producing reaction with a substrate, such as horseradish peroxidase. Markers can be added to tissue-bound antibody in a second step, as described below. Alternatively, the specific antitissue antibodies can be labeled with ferritin or other electron dense particles, and localization of the ferritin coupled antigen-antibody complexes achieved by means of an electron microscope. In yet another approach, the antibodies are radiolabeled, with, for example ¹²⁵I, and detected by overlaying the antibody treated preparation with
30 photographic emulsion.

Preparations to carry out the procedures can comprise monoclonal or polyclonal antibodies to a single protein or peptide identified as specific to a tissue type, for example, brain tissue, or antibody preparations to several antigenically distinct tissue specific antigens can be used in panels, independently or in mixtures, as required.

35 Tissue sections and cell suspensions are prepared for immunohistochemical examination according to common histological techniques. Multiple cryostat sections (about 4 μm, unfixed) of the unknown tissue and

known control, are mounted and each slide covered with different dilutions of the antibody preparation. Sections of known and unknown tissues should also be treated with preparations to provide a positive control, a negative control, for example, pre-immune sera, and a control for non-specific staining, for example, buffer.

Treated sections are incubated in a humid chamber for 30 min at room temperature, rinsed, then washed
5 in buffer for 30-45 min. Excess fluid is blotted away, and the marker developed.

If the tissue specific antibody was not labeled in the first incubation, it can be labeled at this time in a second antibody-antibody reaction, for example, by adding fluorescein- or enzyme-conjugated antibody against the immunoglobulin class of the antiserum-producing species, for example, fluorescein labeled antibody to mouse IgG. Such labeled sera are commercially available.

10 The antigen found in the tissues by the above procedure can be quantified by measuring the intensity of color or fluorescence on the tissue section, and calibrating that signal using appropriate standards.

B. Identification of Tissue Specific Soluble Proteins

The visualization of tissue specific proteins and identification of unknown tissues from that procedure is carried out using the labeled antibody reagents and detection strategy as described for immunohistochemistry;
15 however the sample is prepared according to an electrophoretic technique to distribute the proteins extracted from the tissue in an orderly array on the basis of molecular weight for detection.

A tissue sample is homogenized using a Virtis apparatus; cell suspensions are disrupted by Dounce homogenization or osmotic lysis, using detergents in either case as required to disrupt cell membranes, as is the practice in the art. Insoluble cell components such as nuclei, microsomes, and membrane fragments are removed
20 by ultracentrifugation, and the soluble protein-containing fraction concentrated if necessary and reserved for analysis.

A sample of the soluble protein solution is resolved into individual protein species by conventional SDS polyacrylamide electrophoresis as described, for example, by Davis, L. et al., Section 19-2 in: **Basic Methods in Molecular Biology** (P. Leder, ed), Elsevier, New York (1986), using a range of amounts of polyacrylamide in a set
25 of gels to resolve the entire molecular weight range of proteins to be detected in the sample. A size marker is run in parallel for purposes of estimating molecular weights of the constituent proteins. Sample size for analysis is a convenient volume of from 5 to 55 μ l, and containing from about 1 to 100 μ g protein. An aliquot of each of the resolved proteins is transferred by blotting to a nitrocellulose filter paper, a process that maintains the pattern of resolution. Multiple copies are prepared. The procedure, known as Western Blot Analysis, is well described in
30 Davis, L. et al., (above) Section 19-3. One set of nitrocellulose blots is stained with Coomassie Blue dye to visualize the entire set of proteins for comparison with the antibody bound proteins. The remaining nitrocellulose filters are then incubated with a solution of one or more specific antisera to tissue specific proteins prepared as described in Examples 30 and 40. In this procedure, as in procedure A above, appropriate positive and negative sample and reagent controls are run.

35 In either procedure A or B, a detectable label can be attached to the primary tissue antigen-primary antibody complex according to various strategies and permutations thereof. In a straightforward approach, the

primary specific antibody can be labeled; alternatively, the unlabeled complex can be bound by a labeled secondary anti-IgG antibody. In other approaches, either the primary or secondary antibody is conjugated to a biotin molecule, which can, in a subsequent step, bind an avidin conjugated marker. According to yet another strategy, enzyme labeled or radioactive protein A, which has the property of binding to any IgG, is bound in a final step to either the primary or secondary antibody.

The visualization of tissue specific antigen binding at levels above those seen in control tissues to one or more tissue specific antibodies, prepared from the gene sequences identified from extended cDNA sequences, can identify tissues of unknown origin, for example, forensic samples, or differentiated tumor tissue that has metastasized to foreign bodily sites.

In addition to their applications in forensics and identification, extended cDNAs (or genomic DNAs obtainable therefrom) may be mapped to their chromosomal locations. Example 49 below describes radiation hybrid (RH) mapping of human chromosomal regions using extended cDNAs. Example 50 below describes a representative procedure for mapping an extended cDNA (or a genomic DNA obtainable therefrom) to its location on a human chromosome. Example 51 below describes mapping of extended cDNAs (or genomic DNAs obtainable therefrom) on metaphase chromosomes by Fluorescence In Situ Hybridization (FISH).

EXAMPLE 49

Radiation hybrid mapping of Extended cDNAs to the human genome

Radiation hybrid (RH) mapping is a somatic cell genetic approach that can be used for high resolution mapping of the human genome. In this approach, cell lines containing one or more human chromosomes are lethally irradiated, breaking each chromosome into fragments whose size depends on the radiation dose. These fragments are rescued by fusion with cultured rodent cells, yielding subclones containing different portions of the human genome. This technique is described by Benham et al. (*Genomics* 4:509-517, 1989) and Cox et al., (*Science* 250:245-250, 1990). The random and independent nature of the subclones permits efficient mapping of any human genome marker. Human DNA isolated from a panel of 80-100 cell lines provides a mapping reagent for ordering extended cDNAs (or genomic DNAs obtainable therefrom). In this approach, the frequency of breakage between markers is used to measure distance, allowing construction of fine resolution maps as has been done using conventional ESTs (Schuler et al., *Science* 274:540-546, 1996).

RH mapping has been used to generate a high-resolution whole genome radiation hybrid map of human chromosome 17q22-q25.3 across the genes for growth hormone (GH) and thymidine kinase (TK) (Foster et al., *Genomics* 33:185-192, 1996), the region surrounding the Gorlin syndrome gene (Obermayr et al., *Eur. J. Hum. Genet.* 4:242-245, 1996), 60 loci covering the entire short arm of chromosome 12 (Raeymaekers et al., *Genomics* 29:170-178, 1995), the region of human chromosome 22 containing the neurofibromatosis type 2 locus (Frazer et al., *Genomics* 14:574-584, 1992) and 13 loci on the long arm of chromosome 5 (Warrington et al., *Genomics* 11:701-708, 1991).

EXAMPLE 50

Mapping of Extended cDNAs to Human

Chromosomes using PCR techniques

Extended cDNAs (or genomic DNAs obtainable therefrom) may be assigned to human chromosomes using PCR based methodologies. In such approaches, oligonucleotide primer pairs are designed from the extended cDNA sequence (or the sequence of a genomic DNA obtainable therefrom) to minimize the chance of
5 amplifying through an intron. Preferably, the oligonucleotide primers are 18-23 bp in length and are designed for PCR amplification. The creation of PCR primers from known sequences is well known to those with skill in the art. For a review of PCR technology see Erlich, H.A., PCR Technology: Principles and Applications for DNA Amplification, 1992. W.H. Freeman and Co., New York.

The primers are used in polymerase chain reactions (PCR) to amplify templates from total human
10 genomic DNA. PCR conditions are as follows: 60 ng of genomic DNA is used as a template for PCR with 80 ng of each oligonucleotide primer, 0.6 unit of Taq polymerase, and 1 μ Cu of a 32 P-labeled deoxycytidine triphosphate. The PCR is performed in a microplate thermocycler (Technique) under the following conditions: 30 cycles of 94°C, 1.4 min; 55°C, 2 min; and 72°C, 2 min; with a final extension at 72°C for 10 min. The amplified products are analyzed on a 6% polyacrylamide sequencing gel and visualized by autoradiography. If the length of the resulting PCR
15 product is identical to the distance between the ends of the primer sequences in the extended cDNA from which the primers are derived, then the PCR reaction is repeated with DNA templates from two panels of human-rodent somatic cell hybrids, BIOS PCRable DNA (BIOS Corporation) and NIGMS Human-Rodent Somatic Cell Hybrid Mapping Panel Number 1 (NIGMS, Camden, NJ).

PCR is used to screen a series of somatic cell hybrid cell lines containing defined sets of human
20 chromosomes for the presence of a given extended cDNA (or genomic DNA obtainable therefrom). DNA is isolated from the somatic hybrids and used as starting templates for PCR reactions using the primer pairs from the extended cDNAs (or genomic DNAs obtainable therefrom). Only those somatic cell hybrids with chromosomes containing the human gene corresponding to the extended cDNA (or genomic DNA obtainable therefrom) will yield an amplified fragment. The extended cDNAs (or genomic DNAs obtainable therefrom) are assigned to a
25 chromosome by analysis of the segregation pattern of PCR products from the somatic hybrid DNA templates. The single human chromosome present in all cell hybrids that give rise to an amplified fragment is the chromosome containing that extended cDNA (or genomic DNA obtainable therefrom). For a review of techniques and analysis of results from somatic cell gene mapping experiments. (See Ledbetter et al., *Genomics* 6:475-481 (1990).)

Alternatively, the extended cDNAs (or genomic DNAs obtainable therefrom) may be mapped to individual
30 chromosomes using FISH as described in Example 51 below.

EXAMPLE 51

Mapping of Extended 5' ESTs to Chromosomes

Using Fluorescence in situ Hybridization

Fluorescence in situ hybridization allows the extended cDNA (or genomic DNA obtainable therefrom) to
35 be mapped to a particular location on a given chromosome. The chromosomes to be used for fluorescence in situ hybridization techniques may be obtained from a variety of sources including cell cultures, tissues, or whole blood.

In a preferred embodiment, chromosomal localization of an extended cDNA (or genomic DNA obtainable therefrom) is obtained by FISH as described by Cherif et al. (*Proc. Natl. Acad. Sci. U.S.A.*, **87**:6639-6643, 1990). Metaphase chromosomes are prepared from phytohemagglutinin (PHA)-stimulated blood cell donors. PHA-stimulated lymphocytes from healthy males are cultured for 72 h in RPMI-1640 medium. For synchronization, methotrexate (10 μ M) is added for 17 h, followed by addition of 5-bromodeoxyuridine (5-BudR, 0.1 mM) for 6 h. Colcemid (1 μ g/ml) is added for the last 15 min before harvesting the cells. Cells are collected, washed in RPMI, incubated with a hypotonic solution of KCl (75 mM) at 37°C for 15 min and fixed in three changes of methanol:acetic acid (3:1). The cell suspension is dropped onto a glass slide and air dried. The extended cDNA (or genomic DNA obtainable therefrom) is labeled with biotin-16 dUTP by nick translation according to the manufacturer's instructions (Bethesda Research Laboratories, Bethesda, MD), purified using a Sephadex G-50 column (Pharmacia, Upssala, Sweden) and precipitated. Just prior to hybridization, the DNA pellet is dissolved in hybridization buffer (50% formamide, 2 X SSC, 10% dextran sulfate, 1 mg/ml sonicated salmon sperm DNA, pH 7) and the probe is denatured at 70°C for 5-10 min.

Slides kept at -20°C are treated for 1 h at 37°C with RNase A (100 μ g/ml), rinsed three times in 2 X SSC and dehydrated in an ethanol series. Chromosome preparations are denatured in 70% formamide, 2 X SSC for 2 min at 70°C, then dehydrated at 4°C. The slides are treated with proteinase K (10 μ g/100 ml in 20 mM Tris-HCl, 2 mM CaCl₂) at 37°C for 8 min and dehydrated. The hybridization mixture containing the probe is placed on the slide, covered with a coverslip, sealed with rubber cement and incubated overnight in a humid chamber at 37°C. After hybridization and post-hybridization washes, the biotinylated probe is detected by avidin-FITC and amplified with additional layers of biotinylated goat anti-avidin and avidin-FITC. For chromosomal localization, fluorescent R-bands are obtained as previously described (Cherif et al., *supra.*). The slides are observed under a LEICA fluorescence microscope (DMRXA). Chromosomes are counterstained with propidium iodide and the fluorescent signal of the probe appears as two symmetrical yellow-green spots on both chromatids of the fluorescent R-band chromosome (red). Thus, a particular extended cDNA (or genomic DNA obtainable therefrom) may be localized to a particular cytogenetic R-band on a given chromosome.

Once the extended cDNAs (or genomic DNAs obtainable therefrom) have been assigned to particular chromosomes using the techniques described in Examples 49-51 above, they may be utilized to construct a high resolution map of the chromosomes on which they are located or to identify the chromosomes in a sample.

EXAMPLE 52

Use of Extended cDNAs to Construct or Expand Chromosome Maps

Chromosome mapping involves assigning a given unique sequence to a particular chromosome as described above. Once the unique sequence has been mapped to a given chromosome, it is ordered relative to other unique sequences located on the same chromosome. One approach to chromosome mapping utilizes a series of yeast artificial chromosomes (YACs) bearing several thousand long inserts derived from the chromosomes of the organism from which the extended cDNAs (or genomic DNAs obtainable therefrom) are obtained. This approach is described in Ramaiah Nagaraja et al. *Genome Research* 7:210-222, March 1997.

Briefly, in this approach each chromosome is broken into overlapping pieces which are inserted into the YAC vector. The YAC inserts are screened using PCR or other methods to determine whether they include the extended cDNA (or genomic DNA obtainable therefrom) whose position is to be determined. Once an insert has been found which includes the extended cDNA (or genomic DNA obtainable therefrom), the insert can be analyzed by PCR or other methods to determine whether the insert also contains other sequences known to be on the chromosome or in the region from which the extended cDNA (or genomic DNA obtainable therefrom) was derived. This process can be repeated for each insert in the YAC library to determine the location of each of the extended cDNAs (or genomic DNAs obtainable therefrom) relative to one another and to other known chromosomal markers. In this way, a high resolution map of the distribution of numerous unique markers along each of the organisms chromosomes may be obtained.

As described in Example 53 below extended cDNAs (or genomic DNAs obtainable therefrom) may also be used to identify genes associated with a particular phenotype, such as hereditary disease or drug response.

EXAMPLE 53

Identification of genes associated with hereditary diseases or drug response

This example illustrates an approach useful for the association of extended cDNAs (or genomic DNAs obtainable therefrom) with particular phenotypic characteristics. In this example, a particular extended cDNA (or genomic DNA obtainable therefrom) is used as a test probe to associate that extended cDNA (or genomic DNA obtainable therefrom) with a particular phenotypic characteristic.

Extended cDNAs (or genomic DNAs obtainable therefrom) are mapped to a particular location on a human chromosome using techniques such as those described in Examples 49 and 50 or other techniques known in the art. A search of Mendelian Inheritance in Man (V. McKusick, **Mendelian Inheritance in Man** (available on line through Johns Hopkins University Welch Medical Library) reveals the region of the human chromosome which contains the extended cDNA (or genomic DNA obtainable therefrom) to be a very gene rich region containing several known genes and several diseases or phenotypes for which genes have not been identified. The gene corresponding to this extended cDNA (or genomic DNA obtainable therefrom) thus becomes an immediate candidate for each of these genetic diseases.

Cells from patients with these diseases or phenotypes are isolated and expanded in culture. PCR primers from the extended cDNA (or genomic DNA obtainable therefrom) are used to screen genomic DNA, mRNA or cDNA obtained from the patients. Extended cDNAs (or genomic DNAs obtainable therefrom) that are not amplified in the patients can be positively associated with a particular disease by further analysis. Alternatively, the PCR analysis may yield fragments of different lengths when the samples are derived from an individual having the phenotype associated with the disease than when the sample is derived from a healthy individual, indicating that the gene containing the extended cDNA may be responsible for the genetic disease.

VI. Use of Extended cDNAs (or genomic DNAs obtainable therefrom) to Construct Vectors

The present extended cDNAs (or genomic DNAs obtainable therefrom) may also be used to construct secretion vectors capable of directing the secretion of the proteins encoded by genes inserted in the vectors. Such

secretion vectors may facilitate the purification or enrichment of the proteins encoded by genes inserted therein by reducing the number of background proteins from which the desired protein must be purified or enriched. Exemplary secretion vectors are described in Example 54 below.

EXAMPLE 54

5

Construction of Secretion Vectors

The secretion vectors of the present invention include a promoter capable of directing gene expression in the host cell, tissue, or organism of interest. Such promoters include the Rous Sarcoma Virus promoter, the SV40 promoter, the human cytomegalovirus promoter, and other promoters familiar to those skilled in the art.

10 A signal sequence from an extended cDNA (or genomic DNA obtainable therefrom), such as one of the signal sequences in SEQ ID NOs: 40-59, 61-73, 75-82, 84, and 130-154 as defined in Table IV above, is operably linked to the promoter such that the mRNA transcribed from the promoter will direct the translation of the signal peptide. The host cell, tissue, or organism may be any cell, tissue, or organism which recognizes the signal peptide encoded by the signal sequence in the extended cDNA (or genomic DNA obtainable therefrom). Suitable hosts include mammalian cells, tissues or organisms, avian cells, tissues, or organisms, insect cells, tissues or
15 organisms, or yeast.

In addition, the secretion vector contains cloning sites for inserting genes encoding the proteins which are to be secreted. The cloning sites facilitate the cloning of the insert gene in frame with the signal sequence such that a fusion protein in which the signal peptide is fused to the protein encoded by the inserted gene is expressed from the mRNA transcribed from the promoter. The signal peptide directs the extracellular secretion of the fusion
20 protein.

The secretion vector may be DNA or RNA and may integrate into the chromosome of the host, be stably maintained as an extrachromosomal replicon in the host, be an artificial chromosome, or be transiently present in the host. Many nucleic acid backbones suitable for use as secretion vectors are known to those skilled in the art, including retroviral vectors, SV40 vectors, Bovine Papilloma Virus vectors, yeast integrating plasmids, yeast
25 episomal plasmids, yeast artificial chromosomes, human artificial chromosomes, P element vectors, baculovirus vectors, or bacterial plasmids capable of being transiently introduced into the host.

The secretion vector may also contain a polyA signal such that the polyA signal is located downstream of the gene inserted into the secretion vector.

After the gene encoding the protein for which secretion is desired is inserted into the secretion vector, the
30 secretion vector is introduced into the host cell, tissue, or organism using calcium phosphate precipitation, DEAE-Dextran, electroporation, liposome-mediated transfection, viral particles or as naked DNA. The protein encoded by the inserted gene is then purified or enriched from the supernatant using conventional techniques such as ammonium sulfate precipitation, immunoprecipitation, immunochromatography, size exclusion chromatography, ion exchange chromatography, and hplc. Alternatively, the secreted protein may be in a sufficiently enriched or
35 pure state in the supernatant or growth media of the host to permit it to be used for its intended purpose without further enrichment.

The signal sequences may also be inserted into vectors designed for gene therapy. In such vectors, the signal sequence is operably linked to a promoter such that mRNA transcribed from the promoter encodes the signal peptide. A cloning site is located downstream of the signal sequence such that a gene encoding a protein whose secretion is desired may readily be inserted into the vector and fused to the signal sequence. The vector is introduced into an appropriate host cell. The protein expressed from the promoter is secreted extracellularly, thereby producing a therapeutic effect.

The extended cDNAs or 5' ESTs may also be used to clone sequences located upstream of the extended cDNAs or 5' ESTs which are capable of regulating gene expression, including promoter sequences, enhancer sequences, and other upstream sequences which influence transcription or translation levels. Once identified and cloned, these upstream regulatory sequences may be used in expression vectors designed to direct the expression of an inserted gene in a desired spatial, temporal, developmental, or quantitative fashion. Example 55 describes a method for cloning sequences upstream of the extended cDNAs or 5' ESTs.

EXAMPLE 55

Use of Extended cDNAs or 5' ESTs to Clone Upstream

Sequences from Genomic DNA

Sequences derived from extended cDNAs or 5' ESTs may be used to isolate the promoters of the corresponding genes using chromosome walking techniques. In one chromosome walking technique, which utilizes the GenomeWalker™ kit available from Clontech, five complete genomic DNA samples are each digested with a different restriction enzyme which has a 6 base recognition site and leaves a blunt end. Following digestion, oligonucleotide adapters are ligated to each end of the resulting genomic DNA fragments.

For each of the five genomic DNA libraries, a first PCR reaction is performed according to the manufacturer's instructions using an outer adaptor primer provided in the kit and an outer gene specific primer. The gene specific primer should be selected to be specific for the extended cDNA or 5' EST of interest and should have a melting temperature, length, and location in the extended cDNA or 5' EST which is consistent with its use in PCR reactions. Each first PCR reaction contains 5ng of genomic DNA, 5 µl of 10X Tth reaction buffer, 0.2 mM of each dNTP, 0.2 µM each of outer adaptor primer and outer gene specific primer, 1.1 mM of Mg(OAc)₂, and 1 µl of the Tth polymerase 50X mix in a total volume of 50 µl. The reaction cycle for the first PCR reaction is as follows: 1 min @ 94°C / 2 sec @ 94°C, 3 min @ 72°C (7 cycles) / 2 sec @ 94°C, 3 min @ 67°C (32 cycles) / 5 min @ 67°C.

The product of the first PCR reaction is diluted and used as a template for a second PCR reaction according to the manufacturer's instructions using a pair of nested primers which are located internally on the amplicon resulting from the first PCR reaction. For example, 5 µl of the reaction product of the first PCR reaction mixture may be diluted 180 times. Reactions are made in a 50 µl volume having a composition identical to that of the first PCR reaction except the nested primers are used. The first nested primer is specific for the adaptor, and is provided with the GenomeWalker™ kit. The second nested primer is specific for the particular extended cDNA or 5' EST for which the promoter is to be cloned and should have a melting temperature, length, and location in the

extended cDNA or 5' EST which is consistent with its use in PCR reactions. The reaction parameters of the second PCR reaction are as follows: 1 min @ 94°C / 2 sec @ 94°C, 3 min @ 72°C (6 cycles) / 2 sec @ 94°C, 3 min @ 67°C (25 cycles) / 5 min @ 67°C.

- The product of the second PCR reaction is purified, cloned, and sequenced using standard techniques.
- 5 Alternatively, two or more human genomic DNA libraries can be constructed by using two or more restriction enzymes. The digested genomic DNA is cloned into vectors which can be converted into single stranded, circular, or linear DNA. A biotinylated oligonucleotide comprising at least 15 nucleotides from the extended cDNA or 5' EST sequence is hybridized to the single stranded DNA. Hybrids between the biotinylated oligonucleotide and the single stranded DNA containing the extended cDNA or EST sequence are isolated as described in Example 29
 - 10 above. Thereafter, the single stranded DNA containing the extended cDNA or EST sequence is released from the beads and converted into double stranded DNA using a primer specific for the extended cDNA or 5' EST sequence or a primer corresponding to a sequence included in the cloning vector. The resulting double stranded DNA is transformed into bacteria. DNAs containing the 5' EST or extended cDNA sequences are identified by colony PCR or colony hybridization.
 - 15 Once the upstream genomic sequences have been cloned and sequenced as described above, prospective promoters and transcription start sites within the upstream sequences may be identified by comparing the sequences upstream of the extended cDNAs or 5' ESTs with databases containing known transcription start sites, transcription factor binding sites, or promoter sequences.

In addition, promoters in the upstream sequences may be identified using promoter reporter vectors as

- 20 described in Example 56.

EXAMPLE 56

Identification of Promoters in Cloned Upstream Sequences

- The genomic sequences upstream of the extended cDNAs or 5' ESTs are cloned into a suitable promoter reporter vector, such as the pSEAP-Basic, pSEAP-Enhancer, pβgal-Basic, pβgal-Enhancer, or pEGFP-1 Promoter
- 25 Reporter vectors available from Clontech. Briefly, each of these promoter reporter vectors include multiple cloning sites positioned upstream of a reporter gene encoding a readily assayable protein such as secreted alkaline phosphatase, β galactosidase, or green fluorescent protein. The sequences upstream of the extended cDNAs or 5' ESTs are inserted into the cloning sites upstream of the reporter gene in both orientations and introduced into an appropriate host cell. The level of reporter protein is assayed and compared to the level obtained from a vector
 - 30 which lacks an insert in the cloning site. The presence of an elevated expression level in the vector containing the insert with respect to the control vector indicates the presence of a promoter in the insert. If necessary, the upstream sequences can be cloned into vectors which contain an enhancer for augmenting transcription levels from weak promoter sequences. A significant level of expression above that observed with the vector lacking an insert indicates that a promoter sequence is present in the inserted upstream sequence.

Appropriate host cells for the promoter reporter vectors may be chosen based on the results of the above described determination of expression patterns of the extended cDNAs and ESTs. For example, if the expression pattern analysis indicates that the mRNA corresponding to a particular extended cDNA or 5' EST is expressed in fibroblasts, the promoter reporter vector may be introduced into a human fibroblast cell line.

- 5 Promoter sequences within the upstream genomic DNA may be further defined by constructing nested deletions in the upstream DNA using conventional techniques such as Exonuclease III digestion. The resulting deletion fragments can be inserted into the promoter reporter vector to determine whether the deletion has reduced or obliterated promoter activity. In this way, the boundaries of the promoters may be defined. If desired, potential individual regulatory sites within the promoter may be identified using site directed mutagenesis or linker scanning
- 10 to obliterate potential transcription factor binding sites within the promoter individually or in combination. The effects of these mutations on transcription levels may be determined by inserting the mutations into the cloning sites in the promoter reporter vectors.

EXAMPLE 57

Cloning and Identification of Promoters

- 15 Using the method described in Example 55 above with 5' ESTs, sequences upstream of several genes were obtained. Using the primer pairs GGG AAG ATG GAG ATA GTA TTG CCT G (SEQ ID NO:29) and CTG CCA TGT ACA TGA TAG AGA GAT TC (SEQ ID NO:30), the promoter having the internal designation P13H2 (SEQ ID NO:31) was obtained.

- Using the primer pairs GTA CCA GGGG ACT GTG ACC ATT GC (SEQ ID NO:32) and CTG TGA CCA
- 20 TTG CTC CCA AGA GAG (SEQ ID NO:33), the promoter having the internal designation P15B4 (SEQ ID NO:34) was obtained.

Using the primer pairs CTG GGA TGG AAG GCA CGG TA (SEQ ID NO:35) and GAG ACC ACA CAG CTA GAC AA (SEQ ID NO:36), the promoter having the internal designation P29B6 (SEQ ID NO:37) was obtained.

- 25 Figure 8 provides a schematic description of the promoters isolated and the way they are assembled with the corresponding 5' tags. The upstream sequences were screened for the presence of motifs resembling transcription factor binding sites or known transcription start sites using the computer program MatInspector release 2.0, August 1996.

- Figure 9 describes the transcription factor binding sites present in each of these promoters. The columns
- 30 labeled matrice provides the name of the MatInspector matrix used. The column labeled position provides the 5' position of the promoter site. Numeration of the sequence starts from the transcription site as determined by matching the genomic sequence with the 5' EST sequence. The column labeled "orientation" indicates the DNA strand on which the site is found, with the + strand being the coding strand as determined by matching the genomic sequence with the sequence of the 5' EST. The column labeled "score" provides the MatInspector score found for this site. The column labeled "length" provides the length of the site in nucleotides. The column labeled
- 35 "sequence" provides the sequence of the site found.

The promoters and other regulatory sequences located upstream of the extended cDNAs or 5' ESTs may be used to design expression vectors capable of directing the expression of an inserted gene in a desired spatial, temporal, developmental, or quantitative manner. A promoter capable of directing the desired spatial, temporal, developmental, and quantitative patterns may be selected using the results of the expression analysis described in Example 26 above. For example, if a promoter which confers a high level of expression in muscle is desired, the promoter sequence upstream of an extended cDNA or 5' EST derived from an mRNA which is expressed at a high level in muscle, as determined by the method of Example 26, may be used in the expression vector.

Preferably, the desired promoter is placed near multiple restriction sites to facilitate the cloning of the desired insert downstream of the promoter, such that the promoter is able to drive expression of the inserted gene. The promoter may be inserted in conventional nucleic acid backbones designed for extrachromosomal replication, integration into the host chromosomes or transient expression. Suitable backbones for the present expression vectors include retroviral backbones, backbones from eukaryotic episomes such as SV40 or Bovine Papilloma Virus, backbones from bacterial episomes, or artificial chromosomes.

Preferably, the expression vectors also include a polyA signal downstream of the multiple restriction sites for directing the polyadenylation of mRNA transcribed from the gene inserted into the expression vector.

Following the identification of promoter sequences using the procedures of Examples 55-57, proteins which interact with the promoter may be identified as described in Example 58 below.

EXAMPLE 58

Identification of Proteins Which Interact with Promoter Sequences, Upstream

Regulatory Sequences, or mRNA

Sequences within the promoter region which are likely to bind transcription factors may be identified by homology to known transcription factor binding sites or through conventional mutagenesis or deletion analyses of reporter plasmids containing the promoter sequence. For example, deletions may be made in a reporter plasmid containing the promoter sequence of interest operably linked to an assayable reporter gene. The reporter plasmids carrying various deletions within the promoter region are transfected into an appropriate host cell and the effects of the deletions on expression levels is assessed. Transcription factor binding sites within the regions in which deletions reduce expression levels may be further localized using site directed mutagenesis, linker scanning analysis, or other techniques familiar to those skilled in the art. Nucleic acids encoding proteins which interact with sequences in the promoter may be identified using one-hybrid systems such as those described in the manual accompanying the Matchmaker One-Hybrid System kit available from Clontech (Catalog No. K1603-1). Briefly, the Matchmaker One-hybrid system is used as follows. The target sequence for which it is desired to identify binding proteins is cloned upstream of a selectable reporter gene and integrated into the yeast genome. Preferably, multiple copies of the target sequences are inserted into the reporter plasmid in tandem.

A library comprised of fusions between cDNAs to be evaluated for the ability to bind to the promoter and the activation domain of a yeast transcription factor, such as GAL4, is transformed into the yeast strain containing the integrated reporter sequence. The yeast are plated on selective media to select cells expressing the selectable

marker linked to the promoter sequence. The colonies which grow on the selective media contain genes encoding proteins which bind the target sequence. The inserts in the genes encoding the fusion proteins are further characterized by sequencing. In addition, the inserts may be inserted into expression vectors or in vitro transcription vectors. Binding of the polypeptides encoded by the inserts to the promoter DNA may be confirmed by techniques familiar to those skilled in the art, such as gel shift analysis or DNase protection analysis.

VII. Use of Extended cDNAs (or Genomic DNAs Obtainable Therefrom) in Gene Therapy

The present invention also comprises the use of extended cDNAs (or genomic DNAs obtainable therefrom) in gene therapy strategies, including antisense and triple helix strategies as described in Examples 57 and 58 below. In antisense approaches, nucleic acid sequences complementary to an mRNA are hybridized to the mRNA intracellularly, thereby blocking the expression of the protein encoded by the mRNA. The antisense sequences may prevent gene expression through a variety of mechanisms. For example, the antisense sequences may inhibit the ability of ribosomes to translate the mRNA. Alternatively, the antisense sequences may block transport of the mRNA from the nucleus to the cytoplasm, thereby limiting the amount of mRNA available for translation. Another mechanism through which antisense sequences may inhibit gene expression is by interfering with mRNA splicing. In yet another strategy, the antisense nucleic acid may be incorporated in a ribozyme capable of specifically cleaving the target mRNA.

EXAMPLE 59

Preparation and Use of Antisense Oligonucleotides

The antisense nucleic acid molecules to be used in gene therapy may be either DNA or RNA sequences. They may comprise a sequence complementary to the sequence of the extended cDNA (or genomic DNA obtainable therefrom). The antisense nucleic acids should have a length and melting temperature sufficient to permit formation of an intracellular duplex having sufficient stability to inhibit the expression of the mRNA in the duplex. Strategies for designing antisense nucleic acids suitable for use in gene therapy are disclosed in Green et al., *Ann. Rev. Biochem.* **55**:569-597 (1986) and Izant and Weintraub, *Cell* **36**:1007-1015 (1984).

In some strategies, antisense molecules are obtained from a nucleotide sequence encoding a protein by reversing the orientation of the coding region with respect to a promoter so as to transcribe the opposite strand from that which is normally transcribed in the cell. The antisense molecules may be transcribed using in vitro transcription systems such as those which employ T7 or SP6 polymerase to generate the transcript. Another approach involves transcription of the antisense nucleic acids in vivo by operably linking DNA containing the antisense sequence to a promoter in an expression vector.

Alternatively, oligonucleotides which are complementary to the strand normally transcribed in the cell may be synthesized in vitro. Thus, the antisense nucleic acids are complementary to the corresponding mRNA and are capable of hybridizing to the mRNA to create a duplex. In some embodiments, the antisense sequences may contain modified sugar phosphate backbones to increase stability and make them less sensitive to RNase activity. Examples of modifications suitable for use in antisense strategies are described by Rossi et al., *Pharmacol. Ther.* **50**(2):245-254, (1991).

Various types of antisense oligonucleotides complementary to the sequence of the extended cDNA (or genomic DNA obtainable therefrom) may be used. In one preferred embodiment, stable and semi-stable antisense oligonucleotides described in International Application No. PCT WO94/23026 are used. In these molecules, the 3' end or both the 3' and 5' ends are engaged in intramolecular hydrogen bonding between complementary base pairs. These molecules are better able to withstand exonuclease attacks and exhibit increased stability compared to conventional antisense oligonucleotides.

In another preferred embodiment, the antisense oligodeoxynucleotides against herpes simplex virus types 1 and 2 described in International Application No. WO 95/04141 are used.

In yet another preferred embodiment, the covalently cross-linked antisense oligonucleotides described in International Application No. WO 96/31523 are used. These double- or single-stranded oligonucleotides comprise one or more, respectively, inter- or intra-oligonucleotide covalent cross-linkages, wherein the linkage consists of an amide bond between a primary amine group of one strand and a carboxyl group of the other strand or of the same strand, respectively, the primary amine group being directly substituted in the 2' position of the strand nucleotide monosaccharide ring, and the carboxyl group being carried by an aliphatic spacer group substituted on a nucleotide or nucleotide analog of the other strand or the same strand, respectively.

The antisense oligodeoxynucleotides and oligonucleotides disclosed in International Application No. WO 92/18522 may also be used. These molecules are stable to degradation and contain at least one transcription control recognition sequence which binds to control proteins and are effective as decoys therefor. These molecules may contain "hairpin" structures, "dumbbell" structures, "modified dumbbell" structures, "cross-linked" decoy structures and "loop" structures.

In another preferred embodiment, the cyclic double-stranded oligonucleotides described in European Patent Application No. 0 572 287 A2. These ligated oligonucleotide "dumbbells" contain the binding site for a transcription factor and inhibit expression of the gene under control of the transcription factor by sequestering the factor.

Use of the closed antisense oligonucleotides disclosed in International Application No. WO 92/19732 is also contemplated. Because these molecules have no free ends, they are more resistant to degradation by exonucleases than are conventional oligonucleotides. These oligonucleotides may be multifunctional, interacting with several regions which are not adjacent to the target mRNA.

The appropriate level of antisense nucleic acids required to inhibit gene expression may be determined using in vitro expression analysis. The antisense molecule may be introduced into the cells by diffusion, injection, infection or transfection using procedures known in the art. For example, the antisense nucleic acids can be introduced into the body as a bare or naked oligonucleotide, oligonucleotide encapsulated in lipid, oligonucleotide sequence encapsulated by viral protein, or as an oligonucleotide operably linked to a promoter contained in an expression vector. The expression vector may be any of a variety of expression vectors known in the art, including retroviral or viral vectors, vectors capable of extrachromosomal replication, or integrating vectors. The vectors may be DNA or RNA.

The antisense molecules are introduced onto cell samples at a number of different concentrations preferably between $1 \times 10^{-10} \text{M}$ to $1 \times 10^{-4} \text{M}$. Once the minimum concentration that can adequately control gene expression is identified, the optimized dose is translated into a dosage suitable for use in vivo. For example, an inhibiting concentration in culture of 1×10^{-7} translates into a dose of approximately 0.6 mg/kg bodyweight. Levels of oligonucleotide approaching 100 mg/kg bodyweight or higher may be possible after testing the toxicity of the oligonucleotide in laboratory animals. It is additionally contemplated that cells from the vertebrate are removed, treated with the antisense oligonucleotide, and reintroduced into the vertebrate.

It is further contemplated that the antisense oligonucleotide sequence is incorporated into a ribozyme sequence to enable the antisense to specifically bind and cleave its target mRNA. For technical applications of ribozyme and antisense oligonucleotides see Rossi et al., *supra*.

In a preferred application of this invention, the polypeptide encoded by the gene is first identified, so that the effectiveness of antisense inhibition on translation can be monitored using techniques that include but are not limited to antibody-mediated tests such as RIAs and ELISA, functional assays, or radiolabeling.

The extended cDNAs of the present invention (or genomic DNAs obtainable therefrom) may also be used in gene therapy approaches based on intracellular triple helix formation. Triple helix oligonucleotides are used to inhibit transcription from a genome. They are particularly useful for studying alterations in cell activity as it is associated with a particular gene. The extended cDNAs (or genomic DNAs obtainable therefrom) of the present invention or, more preferably, a portion of those sequences, can be used to inhibit gene expression in individuals having diseases associated with expression of a particular gene. Similarly, a portion of the extended cDNA (or genomic DNA obtainable therefrom) can be used to study the effect of inhibiting transcription of a particular gene within a cell. Traditionally, homopurine sequences were considered the most useful for triple helix strategies. However, homopyrimidine sequences can also inhibit gene expression. Such homopyrimidine oligonucleotides bind to the major groove at homopurine:homopyrimidine sequences. Thus, both types of sequences from the extended cDNA or from the gene corresponding to the extended cDNA are contemplated within the scope of this invention.

EXAMPLE 60

Preparation and use of Triple Helix Probes

The sequences of the extended cDNAs (or genomic DNAs obtainable therefrom) are scanned to identify 10-mer to 20-mer homopyrimidine or homopurine stretches which could be used in triple-helix based strategies for inhibiting gene expression. Following identification of candidate homopyrimidine or homopurine stretches, their efficiency in inhibiting gene expression is assessed by introducing varying amounts of oligonucleotides containing the candidate sequences into tissue culture cells which normally express the target gene. The oligonucleotides may be prepared on an oligonucleotide synthesizer or they may be purchased commercially from a company specializing in custom oligonucleotide synthesis, such as GENSET, Paris, France.

The oligonucleotides may be introduced into the cells using a variety of methods known to those skilled in the art, including but not limited to calcium phosphate precipitation, DEAE-Dextran, electroporation, liposome-mediated transfection or native uptake.

5 Treated cells are monitored for altered cell function or reduced gene expression using techniques such as Northern blotting, RNase protection assays, or PCR based strategies to monitor the transcription levels of the target gene in cells which have been treated with the oligonucleotide. The cell functions to be monitored are predicted based upon the homologies of the target gene corresponding to the extended cDNA from which the oligonucleotide was derived with known gene sequences that have been associated with a particular function. The cell functions can also be predicted based on the presence of abnormal physiologies within cells derived from
10 individuals with a particular inherited disease, particularly when the extended cDNA is associated with the disease using techniques described in Example 53.

The oligonucleotides which are effective in inhibiting gene expression in tissue culture cells may then be introduced in vivo using the techniques described above and in Example 59 at a dosage calculated based on the in vitro results, as described in Example 59.

15 In some embodiments, the natural (beta) anomers of the oligonucleotide units can be replaced with alpha anomers to render the oligonucleotide more resistant to nucleases. Further, an intercalating agent such as ethidium bromide, or the like, can be attached to the 3' end of the alpha oligonucleotide to stabilize the triple helix. For information on the generation of oligonucleotides suitable for triple helix formation see Griffin et al. (*Science* 245:967-971 (1989)).

20 EXAMPLE 61

Use of Extended cDNAs to Express an Encoded Protein in a Host Organism

The extended cDNAs of the present invention may also be used to express an encoded protein in a host organism to produce a beneficial effect. In such procedures, the encoded protein may be transiently expressed in the host organism or stably expressed in the host organism. The encoded protein may have any of the activities
25 described above. The encoded protein may be a protein which the host organism lacks or, alternatively, the encoded protein may augment the existing levels of the protein in the host organism.

A full length extended cDNA encoding the signal peptide and the mature protein, or an extended cDNA encoding only the mature protein is introduced into the host organism. The extended cDNA may be introduced into the host organism using a variety of techniques known to those of skill in the art. For example, the extended cDNA
30 may be injected into the host organism as naked DNA such that the encoded protein is expressed in the host organism, thereby producing a beneficial effect.

Alternatively, the extended cDNA may be cloned into an expression vector downstream of a promoter which is active in the host organism. The expression vector may be any of the expression vectors designed for use in gene therapy, including viral or retroviral vectors.

35 The expression vector may be directly introduced into the host organism such that the encoded protein is expressed in the host organism to produce a beneficial effect. In another approach, the expression vector may be

introduced into cells in vitro. Cells containing the expression vector are thereafter selected and introduced into the host organism, where they express the encoded protein to produce a beneficial effect.

EXAMPLE 62

Use Of Signal Peptides Encoded By 5' Ests Or Sequences

Obtained Therefrom To Import Proteins Into Cells

The short core hydrophobic region (h) of signal peptides encoded by the 5'ESTS or extended cDNAs derived from the 5'ESTs of the present invention may also be used as a carrier to import a peptide or a protein of interest, so-called cargo, into tissue culture cells (Lin *et al.*, *J. Biol. Chem.*, **270**: 14225-14258 (1995); Du *et al.*, *J. Peptide Res.*, **51**: 235-243 (1998); Rojas *et al.*, *Nature Biotech.*, **16**: 370-375 (1998)).

When cell permeable peptides of limited size (approximately up to 25 amino acids) are to be translocated across cell membrane, chemical synthesis may be used in order to add the h region to either the C-terminus or the N-terminus to the cargo peptide of interest. Alternatively, when longer peptides or proteins are to be imported into cells, nucleic acids can be genetically engineered, using techniques familiar to those skilled in the art, in order to link the extended cDNA sequence encoding the h region to the 5' or the 3' end of a DNA sequence coding for a cargo polypeptide. Such genetically engineered nucleic acids are then translated either *in vitro* or *in vivo* after transfection into appropriate cells, using conventional techniques to produce the resulting cell permeable polypeptide. Suitable hosts cells are then simply incubated with the cell permeable polypeptide which is then translocated across the membrane.

This method may be applied to study diverse intracellular functions and cellular processes. For instance, it has been used to probe functionally relevant domains of intracellular proteins and to examine protein-protein interactions involved in signal transduction pathways (Lin *et al.*, *supra*; Lin *et al.*, *J. Biol. Chem.*, **271**: 5305-5308 (1996); Rojas *et al.*, *J. Biol. Chem.*, **271**: 27456-27461 (1996); Liu *et al.*, *Proc. Natl. Acad. Sci. USA*, **93**: 11819-11824 (1996); Rojas *et al.*, *Bioch. Biophys. Res. Commun.*, **234**: 675-680 (1997)).

Such techniques may be used in cellular therapy to import proteins producing therapeutic effects. For instance, cells isolated from a patient may be treated with imported therapeutic proteins and then re-introduced into the host organism.

Alternatively, the h region of signal peptides of the present invention could be used in combination with a nuclear localization signal to deliver nucleic acids into cell nucleus. Such oligonucleotides may be antisense oligonucleotides or oligonucleotides designed to form triple helixes, as described in examples 59 and 60 respectively, in order to inhibit processing and maturation of a target cellular RNA.

EXAMPLE 63

Reassembling & Resequencing of Clones

Full length cDNA clones obtained by the procedure described in Example 27 were double-sequenced. These sequences were assembled and the resulting consensus sequences were then reanalyzed. Open reading frames were reassigned following essentially the same process as the one described in Example 27.

After this reanalysis process a few abnormalities were revealed. The sequence presented in SEQ ID NO: 84 is apparently unlikely to be genuine full length cDNAs. This clone is more probably a 3' truncated cDNA sequence based on homology studies with existing protein sequences. Similarly, the sequences presented in SEQ ID NOs: 60, 76, 83 and 84 may also not be genuine full length cDNAs based on homology studies with existing protein sequences. Although these sequences encode a potential start methionine, except for SEQ ID NO:60, they could represent a 5' truncated cDNA.

Finally, after the reassignment of open reading frames for the clones, new open reading frames were chosen in some instances. For example, in the case of SEQ ID NOs: 60, 74 and 83 the new open reading frames were no longer predicted to contain a signal peptide.

As discussed above, Table IV provides the sequence identification numbers of the extended cDNAs of the present invention, the locations of the full coding sequences in SEQ ID NOs: 40-84 and 130-154 (i.e. the nucleotides encoding both the signal peptide and the mature protein, listed under the heading FCS location in Table IV), the locations of the nucleotides in SEQ ID NOs: 40-84 and 130-154 which encode the signal peptides (listed under the heading SigPep Location in Table IV), the locations of the nucleotides in SEQ ID NOs: 40-84 and 130-154 which encode the mature proteins generated by cleavage of the signal peptides (listed under the heading Mature Polypeptide Location in Table IV), the locations in SEQ ID NOs: 40-84 and 130-154 of stop codons (listed under the heading Stop Codon Location in Table IV) the locations in SEQ ID NOs: 40-84 and 130-154 of polyA signals (listed under the heading g PolyA Signal Location in Table IV) and the locations of polyA sites (listed under the heading PolyA Site Location in Table IV).

As discussed above, Table V lists the sequence identification numbers of the polypeptides of SEQ ID NOs: 85-129 and 155-179, the locations of the amino acid residues of SEQ ID NOs: 85-129 and 155-179 in the full length polypeptide (second column), the locations of the amino acid residues of SEQ ID NOs: 85-129 and 155-179 in the signal peptides (third column), and the locations of the amino acid residues of SEQ ID NOs: 85-129 and 155-179 in the mature polypeptide created by cleaving the signal peptide from the full length polypeptide (fourth column). In Table V, and in the appended sequence listing, the first amino acid of the mature protein resulting from cleavage of the signal peptide is designated as amino acid number 1 and the first amino acid of the signal peptide is designated with the appropriate negative number, in accordance with the regulations governing sequence listings.

Example 64

Functional Analysis of Predicted Protein Sequences

Following double-sequencing, new contigs were assembled for each of the extended cDNAs of the present invention and each was compared to known sequences available at the time of filing. These sequences originate from the following databases: Genbank (release 108 and daily releases up to October, 15, 1998), Genseq (release 32) PIR (release 53) and Swissprot (release 35). The predicted proteins of the present invention matching known proteins were further classified into 3 categories depending on the level of homology.

The first category contains proteins of the present invention exhibiting more than 80% identical amino acid residues on the whole length of the matched protein. They are clearly close homologues which most probably have the same function or a very similar function as the matched protein.

The second category contains proteins of the present invention exhibiting more remote homologies (30 to 80% over the whole protein) indicating that the protein of the present invention is susceptible to have a function similar to the one of the matched protein.

The third category contains proteins exhibiting either high homology (90 to 100%) to a short domain or more remote homology (40 to 60%) to a larger domain of a known protein indicating that the matched protein and the protein of the invention may share similar features.

It should be noted that the numbering of amino acids in the protein sequences discussed in Figures 10 to 12, and Table VIII, the first methionine encountered is designated as amino acid number 1. In the appended sequence listing, the first amino acid of the mature protein resulting from cleavage of the signal peptide is designated as amino acid number 1 and the first amino acid of the signal peptide is designated with the appropriate negative number, in accordance with the regulations governing sequence listings.

In addition, all of the corrected amino acid sequences (SEQ ID NOs: 85-129 and 155-179) were scanned for the presence of known protein signatures and motifs. This search was performed against the Prosite 15.0 database, using the Proscan software from the GCG package. Functional signatures and their locations are indicated in Table VIII.

A) Proteins which are closely related to known proteins

Protein of SEQ ID NO: 120 (internal designation 26-44-1-B5-CL3_1)

The protein of SEQ ID NO: 120 encoded by the extended cDNA SEQ ID NO: 75 isolated from ovary shows extensive homology to a human protein called phospholemman or PLM and its homologues in rodent and canine species. PLM is encoded by the nucleic acid sequence of Genbank accession number U72245 and has the amino acid sequence of SEQ ID NO: 180. Phospholemman is a prominent plasma membrane protein whose phosphorylation correlates with an increase in contractility of myocardium and skeletal muscle. Initially described as a simple chloride channel, it has recently been shown to be a channel for taurine that acts as an osmolyte in the regulation of cell volume (Moorman *et al*, *Adv Exp. Med. Biol.*, **442**:219-228 (1998)).

As shown by the alignment in Figure 10 between the protein of SEQ ID NO:120 and PLM, the amino acid residues are identical except for positions 3 and 5 in the 92 amino acid long matched protein. The substitution of a proline residue at position 3 par another neutral residue, serine, is conservative. In addition, the protein of the invention also exhibits the typical ATP1G /PLM/MAT8 PROSITE signature (position 27 to 40 in bold in Figure 10) for a family containing mostly proteins known to be either chloride channels or chloride channel regulators. In addition, the protein of invention contains 2 short transmembrane segments from positions 1 to 21 and from 37 to 57 as predicted by the software TopPred II (Claros and von Heijne, *CABIOS applic. Notes*, **10**:685-686 (1994)). The first segment (in italic) corresponds to the signal peptide of PLM and

the second transmembrane domains (underlined) matches the transmembrane region (double-underlined) shown to be the chloride channel itself (Chen *et al.*, *Circ. Res.*, **82**:367-374 (1998)).

Taken together, these data suggest that the protein of SEQ ID NO: 120 may be involved in the regulation of cell volume and in tissue contractility. Thus, this protein may be useful in diagnosing and/or treating several types of disorders including, but not limited to, cancer, diarrhea, fertility disorders, and in contractility disorders including muscle disorders, pulmonary disorders and myocardial disorders.

Proteins of SEQ ID NOs: 121 (internal designation 47-4-4-C6-CL2_3)

The protein of SEQ ID NO: 121 encoded by the extended cDNA SEQ ID NO: 76 found in substantia nigra shows extensive homology with the human E25 protein. The E25 protein is encoded by the nucleic acid sequence of Genbank accession number AF038953 and has the amino acid sequence of SEQ ID NO: 181. The matched protein might be involved in the development and differentiation of haematopoietic stem/progenitor cells. In addition, it is the human homologue of a murine protein thought to be involved in chondro-osteogenic differentiation and belonging to a novel multigene family of integral membrane proteins (Deleersnijder *et al.*, *J. Biol. Chem.*, **271**:19475-19482 (1996)).

As shown by the alignments in Figure 11 between the protein of SEQ ID NO:121 and E25, the amino acid residues are identical except for positions 9, 24 and 121 in the 263 amino acid long matched sequence. All these substitutions are conservative. In addition, the protein of invention contains one short transmembrane segment from positions 1 to 21 (underlined in Figure 11) matching the one predicted for the murine E25 protein as predicted by the software TopPred II (Claros and von Heijne, *CABIOS applic. Notes*, **10**:685-686 (1994)).

Taken together, these data suggest that the protein of SEQ ID NO: 121 may be involved in cellular proliferation and differentiation, and/or in haematopoiesis. Thus, this protein may be useful in diagnosing and/or treating several types of disorders including, but not limited to, cancer, hematological, chondro-osteogenic and embryogenetic disorders.

Proteins of SEQ ID NO: 128 (internal designation 58-34-2-H8-CL1_3)

The protein of SEQ ID NO: 128 encoded by the extended cDNA SEQ ID NO: 83 isolated from kidney shows extensive homology to the murine WW-domain binding protein 1 or WWBP-1. WWBP-1 is encoded by the nucleic acid sequence of Genbank accession number U40825 and has the amino acid sequence of SEQ ID NO: 182. This protein is expressed in placenta, lung, liver and kidney is thought to play a role in intracellular signaling by binding to the WW domain of the Yes protooncogene-associated protein via its so-called PY domain (Chen and Sudol, *Proc. Natl. Acad. Sci.*, **92**:7819-7823 (1995)). The WW - PY domains are thought to represent a new set of modular protein-binding sequences just like the SH3 - PXXP domains (Sudol *et al.*, *FEBS Lett.*, **369**:67-71 (1995)).

As shown by the alignments of Figure 12 between the protein of SEQ ID NO:128 and WWBP-1, the amino acid residues are identical to those of the 305 amino acid long matched protein except for positions 53, 66, 78, 89, 92, 94, 96, 100, 102, 106, 110, 113, 124, 128, 136, 139, 140, 142-144, 166, 168, 173, 176, 178, 181, 182, 188, 196, 199, 201, 202, 207 and 210 of the matched protein. 68% of these substitutions are

conservative. Indeed the histidine-rich PY domain is present in the protein of the invention (positions 82-86 in bold in Figure 12).

Taken together, these data suggest that the protein of SEQ ID NO: 128 may play a role in intracellular signaling. Thus, this protein may be useful in diagnosing and/or treating several types of disorders including, but not limited to, cancer, neurodegenerative diseases, cardiovascular disorders, hypertension, renal injury and repair and septic shock.

B) Proteins which are remotely related to proteins with known functions

Protein of SEQ ID NO: 97 (internal designation 108-004-5-0-G6-FL)

The protein SEQ ID N°: 97 found in liver encoded by the extended cDNA SEQ ID NO: 52 shows
10 homology to a lectin-like oxidized LDL receptor (LOX-1) found in human, bovine and murine species. Such type II proteins with a C-lectin-like domain, expressed in vascular endothelium and vascular-rich organs, bind and internalize oxidatively modified low-density lipoproteins (Sawamura *et al*, *Nature*, **386**:73-77, (1997)). The oxidized lipoproteins have been implicated in the pathogenesis of atherosclerosis, a leading cause of death in industrialized countries (see review by Parthasarathy *et al*, *Biochem. Pharmacol.* **56**:279-284 (1998)). In
15 addition, type II membrane proteins with a C-terminus C-type lectin domain, also known as carbohydrate-recognition domains, also include proteins involved in target-cell recognition and cell activation.

The protein of invention has the typical structure of a type II protein belonging to the C-type lectin family. Indeed, it contains a short 31-amino-acid-long N-terminal tail, a transmembrane segment from positions 32 to 52 matching the one predicted for human LOX-1 and a large 177-amino-acid-long C-terminal
20 tail as predicted by the software TopPred II (Claros and von Heijne, *CABIOS applic. Notes*, **10**:685-686 (1994)). All six cysteines of LOX-1 C-type lectin domain are also conserved in the protein of the invention (positions 102, 113, 130, 195, 208 and 216) although the characteristic PROSITE signature of this family is not. The LOX-1 protein is encoded by the nucleic acid sequence of Genbank accession number: AB010710.

Taken together, these data suggest that the protein of SEQ ID NO: 97 may be involved in the
25 metabolism of lipids and/or in cell-cell or cell-matrix interactions and/or in cell activation. Thus, this protein or part therein, may be useful in diagnosing and treating several disorders including, but not limited to, cancer, hyperlipidaemia, cardiovascular disorders and neurodegenerative disorders.

Protein of SEQ ID NO: 111 (internal designation 108-008-5-0-G12-FL)

The protein SEQ ID NO: 111 encoded by the extended cDNA SEQ ID NO:66 shows homology to a
30 mitochondrial protein found in *Saccharomyces Cerevisiae* (PIR:S72254) which is similar to *E. Coli* ribosomal protein L36. The typical PROSITE signature for ribosomal L36 is present in the protein of the invention (positions 76-102) except for a substitution of a tryptophane residue instead of a valine, leucine, isoleucine, methionine or asparagine residue.

Taken together, these data suggest that the protein of SEQ ID NO: 111 may be involved in protein
35 biosynthesis. Thus, this protein may be useful in diagnosing and/or treating several types of disorders including, but not limited to, cancer.

Protein of SEQ ID NO: 94 (internal designation 108-004-5-0-D10-FL)

The protein SEQ ID NO: 94 encoded by the extended cDNA SEQ ID NO: 49 shows remote homology to a subfamily of beta4-galactosyltransferases widely conserved in animals (human, rodents, cow and chicken). Such enzymes, usually type II membrane proteins located in the endoplasmic reticulum or in the Golgi apparatus, catalyzes the biosynthesis of glycoproteins, glycolipid glycans and lactose. Their characteristic features defined as those of subfamily A in Breton *et al*, *J. Biochem.*, **123**:1000-1009 (1998) are pretty well conserved in the protein of the invention, especially the region I containing the DVD motif (positions 163-165) thought to be involved either in UDP binding or in the catalytic process itself.

In addition, the protein of invention has the typical structure of a type II protein. Indeed, it contains a short 28-amino-acid-long N-terminal tail, a transmembrane segment from positions 29 to 49 and a large 278-amino-acid-long C-terminal tail as predicted by the software TopPred II (Claros and von Heijne, *CABIOS applic. Notes*, **10**:685-686 (1994)).

Taken together, these data suggest that the protein of SEQ ID NO: 94 may play a role in the biosynthesis of polysaccharides, and of the carbohydrate moieties of glycoproteins and glycolipids and/or in cell-cell recognition. Thus, this protein may be useful in diagnosing and/or treating several types of disorders including, but not limited to, cancer, atherosclerosis, cardiovascular disorders, autoimmune disorders and rheumatic diseases including rheumatoid arthritis.

Protein of SEQ ID NO: 104 (internal designation 108-006-5-0-G2-FL)

The protein of SEQ ID NO: 104 encoded by the extended cDNA SEQ ID NO: 59 shows homology to a neuronal murine protein NP15.6 whose expression is developmentally regulated. NP15.6 protein is encoded by the nucleic acid sequence of Genbank accession number Y08702.

Taken together, these data suggest that the protein of SEQ ID NO: 104 may be involved in cellular proliferation and differentiation. Thus, this protein may be useful in diagnosing and/or treating several types of disorders including, but not limited to, cancer, neurodegenerative disorders and embryogenetic disorders.

C) Proteins homologous to a domain of a protein with known function

Protein of SEQ ID NO: 113 (internal designation 108-009-5-0-A2-FL)

The protein of SEQ ID NO: 113 encoded by the extended cDNA SEQ ID NO: 68 shows extensive homology to the bZIP family of transcription factors, and especially to the human human protein. (Lu *et al.*, *Mol. Cell. Biol.*, **17**:5117-5126 (1997)). The human human protein is encoded by the nucleic acid sequence of Genbank accession number : AF009368. The match include the whole bZIP domain composed of a basic DNA-binding domain and of a leucine zipper allowing protein dimerization. The basic domain is conserved in the protein of the invention as shown by the characteristic PROSITE signature (positions 224-237) except for a conservative substitution of a glutamic acid with an aspartic acid in position 233. The typical PROSITE signature for leucine zipper is also present (positions 259 to 280). Secreted proteins may have nucleic acid binding domain as shown by a nematode protein thought to regulate gene expression which exhibits zinc fingers as well as a functional signal peptide (Holst and Zipfel, *J. Biol. Chem.*, **271**:16275-16733, 1996).

Taken together, these data suggest that the protein of SEQ ID NO: 113 may bind to DNA, hence regulating gene expression as a transcription factor. Thus, this protein may be useful in diagnosing and/or treating several types of disorders including, but not limited to, cancer.

Proteins of SEQ ID NO: 129 (internal designation 76-13-3-A9-CL1 1)

5 The protein of SEQ ID NO: 129 encoded by the extended cDNA SEQ ID NO: 84 shows homology with part of a human seven transmembrane protein. The human seven transmembrane protein is encoded by the nucleic acid sequence of Genbank accession number Y11395. The matched protein potentially associated to stomatin may act as a G-protein coupled receptor and is likely to be important for the signal transduction in neurons and haematopoietic cells (Mayer *et al*, *Biochem. Biophys. Acta.*, **1395**:301-308 (1998)).

10 Taken together, these data suggest that the protein of SEQ ID NO: 129 may be involved in signal transduction. Thus, this protein may be useful in diagnosing and/or treating several types of disorders including, but not limited to, cancer, neurodegenerative diseases, cardiovascular disorders, hypertension, renal injury and repair and septic shock.

Proteins of SEQ ID NO: 95 (internal designation 108-004-5-0-E8-FL)

15 The protein of SEQ ID NO: 95 encoded by the extended cDNA SEQ ID NO: 50 exhibit the typical PROSITE signature for amino acid permeases (positions 5 to 66) which are integral membrane proteins involved in the transport of amino acids into the cell. In addition, the protein of invention has a transmembrane segment from positions 9 to 29 as predicted by the software TopPred II (Claros and von Heijne, *CABIOS applic. Notes*, **10**:685-686 (1994)).

20 Taken together, these data suggest that the protein of SEQ ID NO: 95 may be involved in amino acid transport. Thus, this protein may be useful in diagnosing and/or treating several types of disorders including, but not limited to, cancer, aminoacidurias, neurodegenerative diseases, anorexia, chronic fatigue, coronary vascular disease, diphtheria, hypoglycemia, male infertility, muscular and myopathies.

As discussed above, the extended cDNAs of the present invention or portions thereof can be used for
25 various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic
30 disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination for expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for
35 example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as,

for example, that described in Gyuris et al., Cell 75:791-803 (1993)) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

5 The proteins or polypeptides provided by the present invention can similarly be used in assays to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

15 Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning; A Laboratory Manual", 2d ed., Cole Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology; Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

20 Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

25 Although this invention has been described in terms of certain preferred embodiments, other embodiments which will be apparent to those of ordinary skill in the art in view of the disclosure herein are also within the scope of this invention. Accordingly, the scope of the invention is intended to be defined only by reference to the appended claims.

SEQUENCE LISTING FREE TEXT

The following free text appears in the accompanying Sequence Listing:

In vitro transcription product

Oligonucleotide

5 Complement

Von Heijne matrix

Score

Promoter

Sequence

10 Transcription start site

Matinspector prediction

Name

TABLE I

SEQ ID NO. in Present Application	Provisional Application Disclosing Sequence	SEQ ID NO. in Provisional Application
40	U.S. Application No. 60/096,116, filed on August 10, 1998	40
41	U.S. Application No. 60/096,116, filed on August 10, 1998	41
42	U.S. Application No. 60/099,273, filed on September 4, 1998	62
43	U.S. Application No. 60/099,273, filed on September 4, 1998	47
44	U.S. Application No. 60/099,273, filed on September 4, 1998	43
45	U.S. Application No. 60/096,116, filed on August 10, 1998	42
46	U.S. Application No. 60/096,116, filed on August 10, 1998	43
47	U.S. Application No. 60/099,273, filed on September 4, 1998	45
48	U.S. Application No. 60/099,273, filed on September 4, 1998	44
49	U.S. Application No. 60/099,273, filed on September 4, 1998	50
50	U.S. Application No. 60/099,273, filed on September 4, 1998	49
51	U.S. Application No. 60/096,116, filed on August 10, 1998	44
52	U.S. Application No. 60/096,116, filed on August 10, 1998	45
53	U.S. Application No. 60/096,116, filed on August 10, 1998	46
54	U.S. Application No. 60/099,273, filed on September 4, 1998	51
55	U.S. Application No. 60/099,273, filed on September 4, 1998	59
56	U.S. Application No. 60/099,273, filed on September 4, 1998	61
57	U.S. Application No. 60/099,273, filed on September 4, 1998	53
58	U.S. Application No. 60/099,273, filed on September 4, 1998	52
59	U.S. Application No. 60/099,273, filed on September 4, 1998	54
60	U.S. Application No. 60/096,116, filed on August 10, 1998	47
61	U.S. Application No. 60/099,273, filed on September 4, 1998	63
62	U.S. Application No. 60/099,273, filed on September 4, 1998	46
63	U.S. Application No. 60/096,116, filed on August 10, 1998	48
64	U.S. Application No. 60/099,273, filed on September 4, 1998	58
65	U.S. Application No. 60/099,273, filed on September 4, 1998	56
66	U.S. Application No. 60/096,116, filed on August 10, 1998	49
67	U.S. Application No. 60/099,273, filed on September 4, 1998	57
68	U.S. Application No. 60/099,273, filed on September 4, 1998	55
69	U.S. Application No. 60/099,273, filed on September 4, 1998	42
70	U.S. Application No. 60/099,273, filed on September 4, 1998	41
71	U.S. Application No. 60/099,273, filed on September 4, 1998	48
72	U.S. Application No. 60/099,273, filed on September 4, 1998	60
73	U.S. Application No. 60/096,116, filed on August 10, 1998	50
74	U.S. Application No. 60/099,273, filed on September 4, 1998	40
75	U.S. Application No. 60/074,121, filed on February 9, 1998	42

SEQ ID NO. in Present Application	Provisional Application Disclosing Sequence	SEQ ID NO. in Provisional Application
76	U.S. Application No. 60/074,121, filed on February 9, 1998	56
77	U.S. Application No. 60/074,121, filed on February 9, 1998	57
78	U.S. Application No. 60/081,563, filed on April 13, 1998	84
79	U.S. Application No. 60/081,563, filed on April 13, 1998	69
80	U.S. Application No. 60/074,121, filed on February 9, 1998	62
81	U.S. Application No. 60/081,563, filed on April 13, 1998	79
82	U.S. Application No. 60/074,121, filed on February 9, 1998	64
83	U.S. Application No. 60/081,563, filed on April 13, 1998	51
84	U.S. Application No. 60/074,121, filed on February 9, 1998	71
130	U.S. Application No. 60/081,563, filed on April 13, 1998	40
131	U.S. Application No. 60/081,563, filed on April 13, 1998	41
132	U.S. Application No. 60/081,563, filed on April 13, 1998	42
133	U.S. Application No. 60/081,563, filed on April 13, 1998	43
134	U.S. Application No. 60/081,563, filed on April 13, 1998	44
135	U.S. Application No. 60/081,563, filed on April 13, 1998	45
136	U.S. Application No. 60/081,563, filed on April 13, 1998	46
137	U.S. Application No. 60/081,563, filed on April 13, 1998	47
138	U.S. Application No. 60/081,563, filed on April 13, 1998	48
139	U.S. Application No. 60/081,563, filed on April 13, 1998	49
140	U.S. Application No. 60/081,563, filed on April 13, 1998	50
141	U.S. Application No. 60/081,563, filed on April 13, 1998	53
142	U.S. Application No. 60/081,563, filed on April 13, 1998	54
143	U.S. Application No. 60/081,563, filed on April 13, 1998	55
144	U.S. Application No. 60/081,563, filed on April 13, 1998	56
145	U.S. Application No. 60/081,563, filed on April 13, 1998	57
146	U.S. Application No. 60/081,563, filed on April 13, 1998	58
147	U.S. Application No. 60/081,563, filed on April 13, 1998	59
148	U.S. Application No. 60/081,563, filed on April 13, 1998	60
149	U.S. Application No. 60/081,563, filed on April 13, 1998	61
150	U.S. Application No. 60/081,563, filed on April 13, 1998	62
151	U.S. Application No. 60/081,563, filed on April 13, 1998	63
152	U.S. Application No. 60/081,563, filed on April 13, 1998	64
153	U.S. Application No. 60/081,563, filed on April 13, 1998	65
154	U.S. Application No. 60/081,563, filed on April 13, 1998	66

TABLE II : Parameters used for each step of EST analysis

Step	Search Characteristics			Selection Characteristics	
	Program	Strand	Parameters	Identity (%)	Length (bp)
Miscellaneous	Blastn	both	S=61 X=16	90	17
tRNA	Fasta	both	-	80	60
rRNA	Blastn	both	S=108	80	40
mtRNA	Blastn	both	S=108	80	40
Procaryotic	Blastn	both	S=144	90	40
Fungal	Blastn	both	S=144	90	40
Alu	fasta*	both	-	70	40
L1	Blastn	both	S=72	70	40
Repeats	Blastn	both	S=72	70	40
Promoters	Blastn	top	S=54 X=16	90	15 _L
Vertebrate	fasta*	both	S=108	90	30
ESTs	Blatsn	both	S=108 X=16	90	30
Proteins	blastx _η	top	E=0.001	-	-

5 * use "Quick Fast" Database Scanner

_L alignment further constrained to begin closer than 10bp to EST's end

_η using BLOSUM62 substitution matrix

TABLE III: Parameters used for each step of extended cDNA analysis

Step	Search characteristics		Selection characteristics			
	Program	Strand	Parameters	Identity (%)	Length (bp)	Comments
miscellaneous*	FASTA	both	-	90	15	
tRNA [§]	FASTA	both	-	80	90	
rRNA [§]	BLASTN	both	S=108	80	40	
mtRNA [§]	BLASTN	both	S=108	80	40	
Procaryotic [§]	BLASTN	both	S=144	90	40	
Fungal*	BLASTN	both	S=144	90	40	
Alu*	BLASTN	both	S=72	70	40	max 5 matches, masking
L1 [§]	BLASTN	both	S=72	70	40	max 5 matches, masking
Repeats [§]	BLASTN	both	S=72	70	40	masking
PolyA	BLAST2N	top	W=6, S=10, E=1000	90	8	in the last 20 nucleotides
Polyadenylation signal	-	top	AATAAA allowing 1 mismatch			in the 50 nucleotides preceding the 5' end of the polyA
Vertebrate*	BLASTN then FASTA	both	-	90 then 70	30	first BLASTN and then FASTA on matching sequences
ESTs*	BLAST2N	both	-	90	30	
Geneseq	BLASTN	both	W=8, B=10	90	30	
ORF	BLASTP	top	W=8, B=10	-	-	on ORF proteins, max 10 matches
Proteins*	BLASTX	top	E=0.001	70	30	

5 [§] steps common to EST analysis and using the same algorithms and parameters

* steps also used in EST analysis but with different algorithms and/or parameters

TABLE IV

Id	FCS Location	SigPep Location	Mature Polypeptide Location	Stop Codon Location	PolyA Signal Location	PolyA Site Location
40	35 through 568	35 through 100	101 through 568	569	667 through 672	685 through 699
41	68 through 337	68 through 124	125 through 337	338	462 through 467	482 through 497
42	39 through 413	39 through 83	84 through 413	414	566 through 571	583 through 598
43	235 through 642	235 through 336	337 through 642	643	1540 through 1545	1564 through 1579
44	42 through 755	42 through 200	201 through 755	756	860 through 865	878 through 893
45	23 through 340	23 through 235	236 through 340	341	611 through 616	629 through 644
46	12 through 380	12 through 263	264 through 380	381	-	523 through 538
47	8 through 232	8 through 154	155 through 232	233	-	737 through 752
48	183 through 422	183 through 302	303 through 422	423	505 through 510	523 through 537
49	24 through 1004	24 through 170	171 through 1004	1005	-	1586 through 1602
50	80 through 784	80 through 139	140 through 784	785	910 through 915	933 through 948
51	67 through 222	67 through 159	160 through 222	223	-	673 through 687
52	46 through 732	46 through 186	187 through 732	733	781 through 786	806 through 821
53	81 through 356	81 through 152	153 through 356	357	406 through 411	429 through 445
54	72 through 1346	72 through 140	141 through 1346	1347	1482 through 1487	1502 through 1517
55	194 through 454	194 through 379	380 through 454	455	-	1545 through 1560
56	48 through 494	48 through 347	348 through 494	495	1031 through 1036	1051 through 1066
57	111 through 671	111 through 215	216 through 671	672	990 through 995	1045 through 1061
58	5 through 373	5 through 82	83 through 373	374	1986 through 1991	2010 through 2025
59	14 through 472	14 through 319	320 through 472	473	555 through 560	576 through 591
60	2 through 217	-	2 through 217	218	489 through 494	529 through 544
61	51 through 575	51 through 110	111 through 575	576	1653 through 1658	1674 through 1689
62	69 through 977	69 through 128	129 through 977	978	1076 through 1081	1096 through 1111
63	44 through 238	44 through 160	161 through 238	239	443 through 448	540 through 554
64	114 through 524	114 through 164	165 through 524	525	1739 through 1744	1758 through 1773
65	26 through 487	26 through 64	65 through 487	488	883 through 888	901 through 917
66	80 through 388	80 through 187	188 through 388	389	609 through 614	627 through 641

Id	FCS Location	SigPep Location	Mature Polypeptide Location	Stop Codon Location	PolyA Signal Location	PolyA Site Location
67	186 through 443	186 through 407	408 through 443	444	827 through 832	839 through 854
68	75 through 1259	75 through 1004	1005 through 1259	1260	1536 through 1541	1553 through 1568
69	98 through 376	98 through 151	152 through 376	377	471 through 476	491 through 506
70	72 through 254	72 through 134	135 through 254	255	506 through 511	528 through 542
71	148 through 1140	148 through 240	241 through 1140	1141	1590 through 1595	1614 through 1629
72	109 through 738	109 through 405	406 through 738	739	1633 through 1638	1650 through 1665
73	55 through 291	55 through 255	256 through 291	292	390 through 395	410 through 425
74	25 through 276	-	25 through 276	277	508 through 513	533 through 546
75	32 through 307	32 through 91	92 through 307	308	452 through 457	472 through 485
76	46 through 675	46 through 87	88 through 675	676	1363 through 1368	1382 through 1394
77	329 through 943	329 through 745	746 through 943	944	-	1322 through 1333
78	27 through 281	27 through 77	78 through 281	282	-	-
79	61 through 405	61 through 213	214 through 405	406	675 through 680	692 through 703
80	137 through 379	137 through 229	230 through 379	380	728 through 733	755 through 768
81	37 through 741	37 through 153	154 through 741	742	969 through 974	994 through 1007
82	80 through 265	80 through 142	143 through 265	266	491 through 496	517 through 527
83	612 through 644	-	612 through 644	645	829 through 834	850 through 861
84	61 through 228	61 through 162	163 through 228	229	208 through 213	-
130	15 through 311	15 through 110	111 through 311	312	507 through 512	531 through 542
131	50 through 529	50 through 130	131 through 529	530	877 through 882	899 through 909
132	240 through 416	240 through 305	306 through 416	417	1117 through 1122	1139 through 1149
133	111 through 446	111 through 254	255 through 446	447	890 through 895	909 through 921
134	123 through 455	123 through 290	291 through 455	456	886 through 891	904 through 916
135	2 through 433	2 through 232	233 through 433	434	488 through 493	510 through 520
136	34 through 363	34 through 87	88 through 363	364	536 through 541	558 through 568
137	50 through 286	50 through 157	158 through 286	287	385 through 390	405 through 416
138	50 through 637	50 through 151	152 through 637	638	-	1277 through 1289
139	72 through 602	72 through 125	126 through 602	603	-	704 through 715
140	120 through	120 through 185	186 through 434	435	899 through 904	918 through 931

Id	FCS Location	SigPep Location	Mature Polypeptide Location	Stop Codon Location	PolyA Signal Location	PolyA Site Location
	434					
141	4 through 447	4 through 147	148 through 447	448	858 through 863	880 through 891
142	28 through 804	28 through 96	97 through 804	805	-	806 through 817
143	27 through 359	27 through 212	213 through 359	360	988 through 993	1009 through 1020
144	25 through 957	25 through 93	94 through 957	958	1368 through 1373	1388 through 1399
145	47 through 319	47 through 226	227 through 319	320	-	656 through 666
146	80 through 940	80 through 130	131 through 940	941	1101 through 1106	1119 through 1130
147	146 through 457	146 through 292	293 through 457	458	442 through 447	465 through 475
148	100 through 351	100 through 207	208 through 351	352	-	940 through 949
149	177 through 569	177 through 236	237 through 569	570	-	931 through 939
150	67 through 459	67 through 135	136 through 459	460	856 through 861	875 through 887
151	65 through 1069	65 through 112	113 through 1069	1070	1978 through 1983	1999 through 2010
152	70 through 321	70 through 234	235 through 321	322	364 through 369	375 through 387
153	38 through 877	38 through 91	92 through 877	878	947 through 952	974 through 983
154	51 through 470	51 through 203	204 through 470	471	1585 through 1590	1604 through 1614

TABLE V

Id	Full Length Polypeptide Location	Signal Peptide Location	Mature Polypeptide Location
85	-22 through 156	-22 through -1	1 through 156
86	-19 through 71	-19 through -1	1 through 71
87	-15 through 110	-15 through -1	1 through 110
88	-34 through 102	-34 through -1	1 through 102
89	-53 through 185	-53 through -1	1 through 185
90	-71 through 35	-71 through -1	1 through 35
91	-84 through 39	-84 through -1	1 through 39
92	-49 through 26	-49 through -1	1 through 26
93	-40 through 40	-40 through -1	1 through 40
94	-49 through 278	-49 through -1	1 through 278
95	-20 through 215	-20 through -1	1 through 215
96	-31 through 21	-31 through -1	1 through 21
97	-47 through 182	-47 through -1	1 through 182
98	-24 through 68	-24 through -1	1 through 68
99	-23 through 402	-23 through -1	1 through 402
100	-62 through 25	-62 through -1	1 through 25
101	-100 through 49	-100 through -1	1 through 49
102	-35 through 152	-35 through -1	1 through 152
103	-26 through 97	-26 through -1	1 through 97
104	-102 through 51	-102 through -1	1 through 51
105	1 through 72	-	1 through 72
106	-20 through 155	-20 through -1	1 through 155
107	-20 through 283	-20 through -1	1 through 283
108	-39 through 26	-39 through -1	1 through 26
109	-17 through 120	-17 through -1	1 through 120
110	-13 through 141	-13 through -1	1 through 141
111	-36 through 67	-36 through -1	1 through 67
112	-74 through 12	-74 through -1	1 through 12
113	-310 through 85	-310 through -1	1 through 85
114	-18 through 75	-18 through -1	1 through 75
115	-21 through 40	-21 through -1	1 through 40
116	-31 through 300	-31 through -1	1 through 300
117	-99 through 111	-99 through -1	1 through 111
118	-67 through 12	-67 through -1	1 through 12
119	1 through 84	-	1 through 84
120	-20 through 72	-20 through -1	1 through 72
121	-14 through 196	-14 through -1	1 through 196

Id	Full Length Polypeptide Location	Signal Peptide Location	Mature Polypeptide Location
122	-139 through 66	-139 through -1	1 through 66
123	-17 through 68	-17 through -1	1 through 68
124	-51 through 64	-51 through -1	1 through 64
125	-31 through 50	-31 through -1	1 through 50
126	-39 through 196	-39 through -1	1 through 196
127	-21 through 41	-21 through -1	1 through 41
128	1 through 11	-	1 through 11
129	-34 through 22	-34 through -1	1 through 22
155	-32 through 67	-32 through -1	1 through 67
156	-27 through 133	-27 through -1	1 through 133
157	-22 through 37	-22 through -1	1 through 37
158	-48 through 64	-48 through -1	1 through 64
159	-56 through 55	-56 through -1	1 through 55
160	-77 through 67	-77 through -1	1 through 67
161	-18 through 92	-18 through -1	1 through 92
162	-36 through 43	-36 through -1	1 through 43
163	-34 through 162	-34 through -1	1 through 162
164	-18 through 159	-18 through -1	1 through 159
165	-22 through 83	-22 through -1	1 through 83
166	-48 through 100	-48 through -1	1 through 100
167	-23 through 236	-23 through -1	1 through 236
168	-62 through 49	-62 through -1	1 through 49
169	-23 through 288	-23 through -1	1 through 288
170	-60 through 31	-60 through -1	1 through 31
171	-17 through 270	-17 through -1	1 through 270
172	-49 through 55	-49 through -1	1 through 55
173	-36 through 48	-36 through -1	1 through 48
174	-20 through 111	-20 through -1	1 through 111
175	-23 through 108	-23 through -1	1 through 108
176	-16 through 319	-16 through -1	1 through 319
177	-55 through 29	-55 through -1	1 through 29
178	-18 through 262	-18 through -1	1 through 262
179	-51 through 89	-51 through -1	1 through 89

TABLE VI

Id	Collection refs	Deposit Name
40	ATCC# 98921	SignalTag 121-144
41	ATCC# 98921	SignalTag 121-144
42	ATCC# 98919	SignalTag 145-165
43	ATCC# 98919	SignalTag 145-165
44	ATCC# 98919	SignalTag 145-165
45	ATCC# 98921	SignalTag 121-144
46	ATCC# 98921	SignalTag 121-144
47	ATCC# 98919	SignalTag 145-165
48	ATCC# 98919	SignalTag 145-165
49	ATCC# 98919	SignalTag 145-165
50	ATCC# 98919	SignalTag 145-165
51	ATCC# 98921	SignalTag 121-144
52	ATCC# 98921	SignalTag 121-144
53	ATCC# 98921	SignalTag 121-144
54	ATCC# 98919	SignalTag 145-165
55	ATCC# 98919	SignalTag 145-165
56	ATCC# 98919	SignalTag 145-165
57	ATCC# 98919	SignalTag 145-165
58	ATCC# 98919	SignalTag 145-165
59	ATCC# 98919	SignalTag 145-165
60	ATCC# 98921	SignalTag 121-144
61	ATCC# 98919	SignalTag 145-165
62	ATCC# 98919	SignalTag 145-165
63	ATCC# 98921	SignalTag 121-144
64	ATCC# 98919	SignalTag 145-165
65	ATCC# 98919	SignalTag 145-165
66	ATCC# 98921	SignalTag 121-144
67	ATCC# 98919	SignalTag 145-165
68	ATCC# 98919	SignalTag 145-165
69	ATCC# 98919	SignalTag 145-165
70	ATCC# 98919	SignalTag 145-165
71	ECACC# XXXX	Signal Tag 28011 999
72	ECACC# XXXX	Signal Tag 28011 999
73	ECACC# XXXX	Signal Tag 28011 999
74	ECACC# XXXX	Signal Tag 28011 999
75	ECACC# XXXX	Signal Tag 28011 999
76	ECACC# XXXX	Signal Tag 28011 999
77	ECACC# XXXX	Signal Tag 28011 999
78	ECACC# XXXX	Signal Tag 28011 999
79	ECACC# XXXX	Signal Tag 28011 999
80	ECACC# XXXX	Signal Tag 28011 999
81	ECACC# XXXX	Signal Tag 28011 999
82	ECACC# XXXX	Signal Tag 28011 999
83	ECACC# XXXX	Signal Tag 28011 999
84	ECACC# XXXX	Signal Tag 28011 999

TABLE VII

Internal designation	Id	Type of sequence
108-002-5-0-B1-FL	40	DNA
108-002-5-0-F3-FL	41	DNA
108-002-5-0-F4-FL	42	DNA
108-003-5-0-A8-FL	43	DNA
108-003-5-0-D2-FL	44	DNA
108-003-5-0-E5-FL	45	DNA
108-003-5-0-H2-FL	46	DNA
108-004-5-0-B7-FL	47	DNA
108-004-5-0-C8-FL	48	DNA
108-004-5-0-D10-FL	49	DNA
108-004-5-0-E8-FL	50	DNA
108-004-5-0-F5-FL	51	DNA
108-004-5-0-G6-FL	52	DNA
108-005-5-0-B11-FL	53	DNA
108-005-5-0-C1-FL	54	DNA
108-005-5-0-F11-FL	55	DNA
108-005-5-0-F6-FL	56	DNA
108-006-5-0-C2-FL	57	DNA
108-006-5-0-E6-FL	58	DNA
108-006-5-0-G2-FL	59	DNA
108-006-5-0-G4-FL	60	DNA
108-008-5-0-A6-FL	61	DNA
108-008-5-0-A8-FL	62	DNA
108-008-5-0-C10-FL	63	DNA
108-008-5-0-E6-FL	64	DNA
108-008-5-0-F6-FL	65	DNA
108-008-5-0-G12-FL	66	DNA
108-008-5-0-G4-FL	67	DNA
108-009-5-0-A2-FL	68	DNA
108-013-5-0-C12-FL	69	DNA
108-013-5-0-G11-FL	70	DNA
108-003-5-0-E4-FL	71	DNA
108-005-5-0-D6-FL	72	DNA
108-008-5-0-G3-FL	73	DNA
108-013-5-0-B5-FL	74	DNA
26-44-1-B5-CL3_1	75	DNA
47-4-4-C6-CL2_3	76	DNA
47-40-4-G9-CL1_1	77	DNA
48-25-4-D8-CL1_7	78	DNA
48-28-3-A9-CL0_1	79	DNA
51-25-1-A2-CL3_1	80	DNA
55-10-3-F5-CL0_3	81	DNA
57-19-2-G8-CL1_3	82	DNA
58-34-2-H8-CL1_3	83	DNA
76-13-3-A9-CL1_1	84	DNA
78-7-2-B8-FL1	130	DNA
77-8-4-F9-FL1	131	DNA
58-8-1-F2-FL2	132	DNA

Internal designation	Id	Type of sequence
77-13-1-A7-FL2	133	DNA
47-2-3-G9-FL1	134	DNA
33-75-4-H7-FL1	135	DNA
51-41-1-F10-FL1	136	DNA
48-51-4-C11-FL1	137	DNA
33-58-3-C8-FL1	138	DNA
76-20-4-C11-FL1	139	DNA
76-28-3-A12-FL1	140	DNA
76-25-4-F11-FL1	141	DNA
58-20-4-G7-FL1	142	DNA
33-54-1-B9-FL1	143	DNA
76-20-3-H1-FL1	144	DNA
47-20-2-G3-FL1	145	DNA
78-25-1-H11-FL1	146	DNA
78-6-2-B10-FL1	147	DNA
58-49-3-G10-FL1	148	DNA
78-21-1-B7-FL1	149	DNA
57-28-4-B12-FL1	150	DNA
33-77-4-E2-FL1	151	DNA
58-19-3-D3-FL2	152	DNA
37-7-4-E7-FL1	153	DNA
60-14-2-H10-FL1	154	DNA
108-002-5-0-B1-FL	85	PRT
108-002-5-0-F3-FL	86	PRT
108-002-5-0-F4-FL	87	PRT
108-003-5-0-A8-FL	88	PRT
108-003-5-0-D2-FL	89	PRT
108-003-5-0-E5-FL	90	PRT
108-003-5-0-H2-FL	91	PRT
108-004-5-0-B7-FL	92	PRT
108-004-5-0-C8-FL	93	PRT
108-004-5-0-D10-FL	94	PRT
108-004-5-0-E8-FL	95	PRT
108-004-5-0-F5-FL	96	PRT
108-004-5-0-G6-FL	97	PRT
108-005-5-0-B11-FL	98	PRT
108-005-5-0-C1-FL	99	PRT
108-005-5-0-F11-FL	100	PRT
108-005-5-0-F6-FL	101	PRT
108-006-5-0-C2-FL	102	PRT
108-006-5-0-E6-FL	103	PRT
108-006-5-0-G2-FL	104	PRT
108-006-5-0-G4-FL	105	PRT
108-008-5-0-A6-FL	106	PRT
108-008-5-0-A8-FL	107	PRT
108-008-5-0-C10-FL	108	PRT
108-008-5-0-E6-FL	109	PRT
108-008-5-0-F6-FL	110	PRT
108-008-5-0-G12-FL	111	PRT
108-008-5-0-G4-FL	112	PRT
108-009-5-0-A2-FL	113	PRT

Internal designation	Id	Type of sequence
108-013-5-0-C12-FL	114	PRT
108-013-5-0-G11-FL	115	PRT
108-003-5-0-E4-FL	116	PRT
108-005-5-0-D6-FL	117	PRT
108-008-5-0-G3-FL	118	PRT
108-013-5-0-B5-FL	119	PRT
26-44-1-B5-CL3_1	120	PRT
47-4-4-C6-CL2_3	121	PRT
47-40-4-G9-CL1_1	122	PRT
48-25-4-D8-CL1_7	123	PRT
48-28-3-A9-CL0_1	124	PRT
51-25-1-A2-CL3_1	125	PRT
55-10-3-F5-CL0_3	126	PRT
57-19-2-G8-CL1_3	127	PRT
58-34-2-H8-CL1_3	128	PRT
76-13-3-A9-CL1_1	129	PRT
78-7-2-B8-FL1	155	PRT
77-8-4-F9-FL1	156	PRT
58-8-1-F2-FL2	157	PRT
77-13-1-A7-FL2	158	PRT
47-2-3-G9-FL1	159	PRT
33-75-4-H7-FL1	160	PRT
51-41-1-F10-FL1	161	PRT
48-51-4-C11-FL1	162	PRT
33-58-3-C8-FL1	163	PRT
76-20-4-C11-FL1	164	PRT
76-28-3-A12-FL1	165	PRT
76-25-4-F11-FL1	166	PRT
58-20-4-G7-FL1	167	PRT
33-54-1-B9-FL1	168	PRT
76-20-3-H1-FL1	169	PRT
47-20-2-G3-FL1	170	PRT
78-25-1-H11-FL1	171	PRT
78-6-2-B10-FL1	172	PRT
58-49-3-G10-FL1	173	PRT
78-21-1-B7-FL1	174	PRT
57-28-4-B12-FL1	175	PRT
33-77-4-E2-FL1	176	PRT
58-19-3-D3-FL2	177	PRT
37-7-4-E7-FL1	178	PRT
60-14-2-H10-FL1	179	PRT

TABLE VIII

Id	Locations	PROSITE signature Name
89	205-226	Leucine zipper
95	5-66	Amino acid permease
103	46-67	Leucine zipper
113	259-280	Leucine zipper
120	27-40	MAT8 family
122	123-125	Cell attachment sequence

CLAIMS

1. A purified or isolated nucleic acid comprising the sequence of one of SEQ ID NOs: 40-84 and 130-154 or a sequence complementary thereto.
2. A purified or isolated nucleic acid comprising at least 10 consecutive bases of the sequence
5 of one of SEQ ID NOs: 40-84 and 130-154 or one of the sequences complementary thereto.
3. A purified or isolated nucleic acid comprising the full coding sequences of one of SEQ ID NOs: 40-59, 61-73, 75, 77-82, and 130-154 wherein the full coding sequence comprises the sequence encoding signal peptide and the sequence encoding mature protein.
4. A purified or isolated nucleic acid comprising the nucleotides of one of SEQ ID NOs: 40-59,
10 61-75, 77-82, and 130-154 which encode a mature protein.
5. A purified or isolated nucleic acid comprising the nucleotides of one of SEQ ID NOs: 40-59, 61-73, 75-82, 84, and 130-154 which encode the signal peptide.
6. A purified or isolated nucleic acid encoding a polypeptide having the sequence of one of the sequences of SEQ ID NOs: 85-129 and 155-179.
- 15 7. A purified or isolated nucleic acid encoding a polypeptide having the sequence of a mature protein included in one of the sequences of SEQ ID NOs: 85-104, 106-120, 122-127, and 155-179.
8. A purified or isolated nucleic acid encoding a polypeptide having the sequence of a signal peptide included in one of the sequences of SEQ ID NOs: 85-104, 106-118, 120-127, 129, and 155-179.
9. A purified or isolated protein comprising the sequence of one of SEQ ID NOs: 85-129 and
20 155-179.
10. A purified or isolated polypeptide comprising at least 10 consecutive amino acids of one of the sequences of SEQ ID NOs: 85-129 and 155-179.
11. An isolated or purified polypeptide comprising a signal peptide of one of the polypeptides of SEQ ID NOs: 85-104, 106-118, 120-127, 129, and 155-179.
- 25 12. An isolated or purified polypeptide comprising a mature protein of one of the polypeptides of SEQ ID NOs: 85-104, 106-120, 122-127, and 155-179.
13. A method of making a protein comprising one of the sequences of SEQ ID NO: 85-129 and 155-179, comprising the steps of:
obtaining a cDNA comprising one of the sequences of sequence of SEQ ID NO: 40-84 and
30 130-154;
inserting said cDNA in an expression vector such that said cDNA is operably linked to a promoter; and
introducing said expression vector into a host cell whereby said host cell produces the protein encoded by said cDNA.
- 35 14. The method of Claim 13, further comprising the step of isolating said protein.

15. A protein obtainable by the method of Claim 14.
16. A host cell containing a recombinant nucleic acid of Claim 1.
17. A purified or isolated antibody capable of specifically binding to a protein having the sequence of one of SEQ ID NOs: 85-129 and 155-179.
- 5 18. In an array of polynucleotides of at least 15 nucleotides in length, the improvement comprising inclusion in said array of at least one of the sequences of SEQ ID NOs: 40-84 and 130-154, or one of the sequences complementary to the sequences of SEQ ID NOs: 40-84 and 130-154, or a fragment thereof of at least 15 consecutive nucleotides.
- 19 A purified or isolated nucleic acid of at least 15 bases capable of hybridizing under stringent
10 conditions to the sequence of one of SEQ ID NOs: 40-84 and 130-154 or a sequence complementary to one of the sequences of SEQ ID NOs: 40-84 and 130-154.
- 20 A purified or isolated antibody capable of binding to a polypeptide comprising at least 10 consecutive amino acids of the sequence of one of SEQ ID NOs: 85-129 and 155-179.
- 21 A computer readable medium having stored thereon a sequence selected from the group
15 consisting of a cDNA code of SEQ ID NOs. 40-84 and 130-154 and a polypeptide code of SEQ ID NOs. 85-129 and 155-179.
- 22 A computer system comprising a processor and a data storage device wherein said data storage device has stored thereon a sequence selected from the group consisting of a cDNA code of SEQ ID NOs. 40-84 and 130-154 and a polypeptide code of SEQ ID NOs. 85-129 and 155-179.
- 20 23 The computer system of Claim 22 further comprising a sequence comparer and a data storage device having reference sequences stored thereon.
- 24 The computer system of Claim 23 wherein said sequence comparer comprises a computer program which indicates polymorphisms.
- 25 25 The computer system of Claim 22 further comprising an identifier which identifies features in said sequence.
- 26 A method for comparing a first sequence to a reference sequence wherein said first sequence is selected from the group consisting of a cDNA code of SEQ ID NOs. 40-84 and 130-154 and a polypeptide code of SEQ ID NOs. 85-129 and 155-179 comprising the steps of:
30 reading said first sequence and said reference sequence through use of a computer program which compares sequences; and
determining differences between said first sequence and said reference sequence with said computer program.
- 27 The method of Claim 26, wherein said step of determining differences between the first sequence and the reference sequence comprises identifying polymorphisms.

28 A method for identifying a feature in a sequence selected from the group consisting of a cDNA code of SEQ ID NOs. 40-84 and 130-154 and a polypeptide code of SEQ ID NOs. 85-129 and 155-179 comprising the steps of:

- reading said sequence through the use of a computer program which identifies features in sequences;
- 5 and
- identifying features in said sequence with said computer program.

1/12




Figure 1

Minimum signal peptide score	false positive rate	false negative rate	proba(0.1)	proba(0.2)
3,5	0,121	0,036	0,467	0,664
4	0,096	0,06	0,519	0,708
4,5	0,078	0,079	0,565	0,745
5	0,062	0,098	0,615	0,782
5,5	0,05	0,127	0,659	0,813
6	0,04	0,163	0,694	0,836
6,5	0,033	0,202	0,725	0,855
7	0,025	0,248	0,763	0,878
7,5	0,021	0,304	0,78	0,889
8	0,015	0,368	0,816	0,909
8,5	0,012	0,418	0,836	0,92
9	0,009	0,512	0,856	0,93
9,5	0,007	0,581	0,863	0,934
10	0,006	0,679	0,835	0,919

FIGURE 2




FIGURE 3

4/12

Minimum signal peptide score	All ESTs	New ESTs	ESTs matching public EST closer than 40 bp from beginning	ESTs extending known mRNA more than 40 bp	ESTs extending public EST more than 40 bp
3,5	2674	947	599	23	150
4	2278	784	499	23	126
4,5	1943	647	425	22	112
5	1657	523	353	21	96
5,5	1417	419	307	19	80
6	1190	340	238	18	68
6,5	1035	280	186	18	60
7	893	219	161	15	48
7,5	753	173	132	12	36
8	636	133	101	11	29
8,5	543	104	83	8	26
9	456	81	63	6	24
9,5	364	57	48	6	18
10	303	47	35	6	15

FIGURE 4

5/12

Tissue	All ESTs	New ESTs	ESTs matching public EST closer than 40 bp from beginning	ESTs extending known mRNA more than 40 bp	ESTs extending public EST more than 40 bp
Brain	329	131	75	3	24
Cancerous prostate	134	40	37	1	6
Cerebellum	17	9	1	0	6
Colon	21	11	4	0	0
Dystrophic muscle	41	18	8	0	1
Fetal brain	70	37	16	0	1
Fetal kidney	227	116	46	1	19
Fetal liver	13	7	2	0	0
Heart	30	15	7	0	1
Hypertrophic prostate	86	23	22	2	2
Kidney	10	7	3	0	0
Large intestine	21	8	4	0	1
Liver	23	9	6	0	0
Lung	24	12	4	0	1
Lung (cells)	57	38	6	0	4
Lymph ganglia	163	60	23	2	12
Lymphocytes	23	6	4	0	2
Muscle	33	16	6	0	4
Normal prostate	181	61	45	7	11
Ovary	90	57	12	1	2
Pancreas	48	11	6	0	1
Placenta	24	5	1	0	0
Prostate	34	16	4	0	2
Spleen	56	28	10	0	1
Substantia nigra	108	47	27	1	6
Surrenals	15	3	3	1	0
Testis	131	68	25	1	8
Thyroid	17	8	2	0	2
Umbilical cord	55	17	12	1	3
Uterus	28	15	3	0	2
Non tissue-specific	568	48	177	2	28
Total	2677	947	601	23	150

FIGURE 5





FIGURE 6

7/12



Plasmid name: pED6dpc2
Plasmid size: 5374 bp

FIGURE 7

Description of promoters structure isolated from SignalTag 5 'ESTs




FIGURE 8

9/12

Description of Transcription Factor Binding Sites present on promoters isolated from SignalTag sequences

Promoter sequence P13H2 (546 bp):

Matrix	Position	Orientation	Score	Length	Sequence
CMYB_01	-502	+	0.983	9	TGTCAGTTG
MYOD_Q6	-501	-	0.961	10	CCCAACTGAC
S8_01	-444	-	0.960	11	AATAGAATTAG
S8_01	-425	+	0.966	11	AACTAAATTAG
DELTAEF1_01	-390	-	0.960	11	GCACACCTCAG
GATA_C	-364	-	0.964	11	AGATAAATCCA
CMYB_01	-349	+	0.958	9	CTTCAGTTG
GATA1_02	-343	+	0.959	14	TTGTAGATAGGACA
GATA_C	-339	+	0.953	11	AGATAGGACAT
TAL1ALPHA47_01	-235	+	0.973	16	CATAACAGATGGTAAG
TAL1BETA47_01	-235	+	0.983	16	CATAACAGATGGTAAG
TAL1BETA1TF2_01	-235	+	0.978	16	CATAACAGATGGTAAG
MYOD_Q6	-232	-	0.954	10	ACCATCTGTT
GATA1_04	-217	-	0.953	13	TCAAGATAAAGTA
IK1_01	-126	+	0.963	13	AGTTGGGAATTCC
IK2_01	-126	+	0.985	12	AGTTGGGAATTCC
CREL_01	-123	+	0.962	10	TGGGAATTCC
GATA1_02	-96	+	0.950	14	TCAGTGATATGGCA
SRF_02	-41	-	0.951	12	TAAACAAAACA
E2F_02	-33	+	0.957	8	TTAGCGC
MZF1_01	-5	-	0.975	8	TGAGGGGA

Promoter sequence P15B4 (861bp) :

Matrix	Position	Orientation	Score	Length	Sequence
NFY_Q6	-748	-	0.956	11	GGACCAATCAT
MZF1_01	-738	+	0.962	8	CCTGGGGA
CMYB_01	-684	+	0.994	9	TGACCGTTG
VMYB_02	-682	-	0.985	9	TCCAACGGT
STAT_01	-673	+	0.968	9	TTCTTGGA
STAT_01	-673	-	0.951	9	TTCCAGGAA
MZF1_01	-556	-	0.956	8	TTGGGGGA
IK2_01	-451	+	0.965	12	GAATGGGATTTC
MZF1_01	-424	+	0.986	8	AGAGGGGA
SRF_02	-398	-	0.955	12	GAAACAAAACA
MZF1_01	-216	+	0.960	8	GAAGGGGA
MYOD_Q6	-190	+	0.981	10	AGCATCTGCC
DELTAEF1_01	-176	+	0.958	11	TCCACCTTCC
S8_01	5	-	0.992	11	GAGGCAATTAT
MZF1_01	16	-	0.986	8	AGAGGGGA

Promoter sequence P29B6 (555 bp) :

Matrix	Position	Orientation	Score	Length	Sequence
ARNT_01	-311	+	0.964	16	GGACTCACGTGCTGCT
NMYC_01	-309	+	0.965	12	ACTCACGTGCTG
USF_01	-309	+	0.985	12	ACTCACGTGCTG
USF_01	-309	-	0.985	12	CAGCACGTGAGT
NMYC_01	-309	-	0.956	12	CAGCACGTGAGT
MYCMAx_02	-309	-	0.972	12	CAGCACGTGAGT
USF_C	-307	+	0.997	8	TCACGTGC
USF_C	-307	-	0.991	8	GCACGTGA
MZF1_01	-292	-	0.968	8	CATGGGGA
ELK1_02	-105	+	0.963	14	CTCTCCGGAAGCCT
CETS1P54_01	-102	+	0.974	10	TCCGGAAGCC
AP1_Q4	-42	-	0.963	11	AGTGACTGAAC
AP1FJ_Q2	-42	-	0.961	11	AGTGACTGAAC
PADS_C	45	+	1.000	9	TGTGGTCTC

Figure 9

97.8% identity in 92 aa overlap

```

      10          20          30          40          50          60
SEQ ID NO:120 MASLGHILVFCVGLLTMAKAESPKEHDPTFYDQSLQIGGLVIAGILFILGILIVLSRRC
      :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.:
SEQ ID NO:180 MAPLHHILVFCVGLLTMAKAESPKEHDPTFYDQSLQIGGLVIAGILFILGILIVLSRRC
      10          20          30          40          50          60

      70          80          90
SEQ ID NO:120 RCKFNQQORTGEPDEEEGTFRSSIRRLSTRRR
      :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.:
SEQ ID NO:180 RCKFNQQORTGEPDEEEGTFRSSIRRLSTRRR
      70          80          90

```

FIGURE 10

98.6% identity in 210 aa overlap

```

10      20      30
SEQ ID NO:121      MLTLLGLSLILAGLIVGGACIYKHFM PKST
                        ::::::::::::::::::::::::::::::
10      20      30
SEQ ID NO:181      LLSRTVVRTQILTGKELRVATQEKEGSSGR CMLTLLGLSFI LAGLIVGGACIYKYFMPKST
                        30      40      50      60      70      80

40      50      60      70      80      90
SEQ ID NO:121      IYRGEMCFFDSED PANSLRGGE PNFLPVTEEADIREDDNIAIIDVPVPSFSDSDPAAIIH
                        ::::::::::::::::::::::::::::::::::::::::::::
10      20      30
SEQ ID NO:181      IYRGEMCFFDSED PANSLRGGE PNFLPVTEEADIREDDNIAIIDVPVPSFSDSDPAAIIH
                        90      100      110      120      130      140

100      110      120      130      140      150
SEQ ID NO:121      DFEKGMTAYLDLLLGN CYLMPLNTSIVMPPENLVELFGK LASGRYLPQTYVVREDLVAVE
                        ::::::::::::::::::::::::::::::::::::::::::::
10      20      30
SEQ ID NO:181      DFEKGMTAYLDLLLGN CYLMPLNTSIVMPPKNLVELFGK LASGRYLPQTYVVREDLVAVE
                        150      160      170      180      190      200

160      170      180      190      200      210
SEQ ID NO:121      EIRDVSNLGI FIYQLCNNRKS FRLRRRDLLLGFNKRAIDKCWKIRHFPNEFIVETKICQE
                        ::::::::::::::::::::::::::::::::::::::::::::
10      20      30
SEQ ID NO:181      EIRDVSNLGI FIYQLCNNRKS FRLRRRDLLLGFNKRAIDKCWKIRHFPNEFIVETKICQE
                        210      220      230      240      250      260

```

FIGURE 11

12/12

83.4% identity in 211 aa overlap

```

                                10      20      30
SEQ ID NO:128                LWWFWLLWTVLILFSCCFAFRHRRAKLRLQ
                                : : : : : : : : : : : : : : : :
SEQ ID NO:182 ELCPGVNTQPYLCETGHCCGETGCCTYYYELWWFWLLWTVLILFSCCFAFRHRRAKLRLQ
                                70      80      90      100     110     120

                                40      50      60      70      80      90
SEQ ID NO:128 QQQRQREINLLAYHGACHGAGPFPTGSLDLRLSTFKPPAYEDVVHRPGTPPPPYTVAP
                                : : : : : : : : : : : : : : : :
SEQ ID NO:182 QQQRQREINLLAYHGACHGAGPVPTGSLDLRLLSAFKPPAYEDVVHHPGTTPPPPYTVGP
                                130     140     150     160     170     180

                                100     110     120     130     140     150
SEQ ID NO:128 GRPLTASSEQTCCSSSSSCPAHFEGTNVEGVSSHQSAPPHQEGEPGAGVTPASTPPSCRY
                                : : : : : : : : : : : : : : : :
SEQ ID NO:182 GYPWTTSSSECTRCSSSESSCSAHLEGTNVEGVSSQQSALPHQEGEPAGLSPVHIPPSCRY
                                190     200     210     220     230     240

                                160     170     180     190     200     210
SEQ ID NO:128 RRLTGDSGIELCPCPASGEGEPVKEVRVSATLPDLEDYSPCALPPESVPQIFPMGLSSSE
                                : : : : : : : : : : : : : : : :
SEQ ID NO:182 RRLTGDSGIELCPCPDSSSEGEPLKEARASASQPDLEDHSPCALPPDSVSQVPPMGLASSC
                                250     260     270     280     290     300

SEQ ID NO:128 GDIP
:
SEQ ID NO:182 GTSHK

```

FIGURE 12

SEQUENCE LISTING

<110> Genset SA
 <120> Complementary DNAs
 <130> 339 719/D.18010
 <150> 60/074,121
 <151> 1998-02-09
 <150> 60/081,563
 <151> 1998-04-13
 <150> 60/096,116
 <151> 1998-08-10
 <150> 60/099,273
 <151> 1998-09-04
 <160> 182
 <170> Patent.pm
 <210> 1
 <211> 47
 <212> RNA
 <213> Artificial Sequence
 <220>
 <223> In vitro transcription product
 <222> 1...47
 <223> modified_base
 <222> (1)...(1)
 <223> m7g added to 1
 <400> 1
 ngcauccuac ucccauccaa uuccacccua acuccuccca ucuccac 47
 <210> 2
 <211> 46
 <212> RNA
 <213> Artificial Sequence
 <220>
 <223> In vitro transcription product
 <222> 1...46
 <400> 2
 gcauccuacu cccauccaau uccacccuaa cuccucccau cuccac 46
 <210> 3
 <211> 25
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> In vitro transcription product
 <222> 1...25
 <400> 3
 atcaagaatt cgcacgagac catta 25
 <210> 4
 <211> 25
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Oligonucleotide
 <400> 4
 taatggtctc gtgcgaattc ttgat 25
 <210> 5
 <211> 25
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Oligonucleotide
 <400> 5
 ccgacaagac caacgtcaag gccgc 25
 <210> 6

<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Oligonucleotide
<400> 6
tcaccagcag gcagtggctt aggag 25
<210> 7
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Oligonucleotide
<400> 7
agtgattcct gctacttttg atggc 25
<210> 8
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Oligonucleotide
<400> 8
gcttggtctt gttctggagt ttaga 25
<210> 9
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Oligonucleotide
<400> 9
tccagaatgg gagacaagcc aattt 25
<210> 10
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Oligonucleotide
<400> 10
agggaggagg aaacagcgtg agtcc 25
<210> 11
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Oligonucleotide
<400> 11
atgggaaagg aaaagactca tatca 25
<210> 12
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Oligonucleotide
<400> 12
agcagcaaca atcaggacag cacag 25
<210> 13
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Oligonucleotide

```

<400> 13
atcaagaatt cgcacgagac catta
<210> 14
<211> 67
<212> DNA
<213> Artificial Sequence
<220>
<223> Oligonucleotide
<400> 14
atcgttgaga ctcgtaccag cagagtcacg agagagacta cacggtactg gttttttttt
tttttvn
<210> 15
<211> 29
<212> DNA
<213> Artificial Sequence
<220>
<223> Oligonucleotide
<400> 15
ccagcagagt cacgagagag actacacgg
<210> 16
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Oligonucleotide
<400> 16
cacgagagag actacacggt actgg
<210> 17
<211> 526
<212> DNA
<213> Homo Sapiens
<220>
<223> misc_feature
<222> complement(261..376)
<223> blastn
<223> misc_feature
<222> complement(380..486)
<223> blastn
<223> misc_feature
<222> complement(110..145)
<223> blastn
<223> misc_feature
<222> complement(196..229)
<223> blastn
<223> sig_peptide
<222> 90..140
<223> Von Heijne matrix
<400> 17
aatatrarac agctacaata ttccagggcc artcacttgc catttctcat aacagcggtca
gagagaaaga actgactgar acgtttgag atg aag aaa gtt ctc ctc ctg atc
Met Lys Lys Val Leu Leu Leu Ile
-15 -10
aca gcc atc ttg gca gtg gct gtw ggt ttc cca gtc tct caa gac cag
Thr Ala Ile Leu Ala Val Ala Val Gly Phe Pro Val Ser Gln Asp Gln
-5 1 5
gaa cga gaa aaa aga agt atc agt gac agc gat gaa tta gct tca ggr
Glu Arg Glu Lys Arg Ser Ile Ser Asp Ser Asp Glu Leu Ala Ser Gly
10 15 20
wtt ttt gtg ttc cct tac cca tat cca ttt cgc cca ctt cca cca att
Xaa Phe Val Phe Pro Tyr Pro Tyr Pro Phe Arg Pro Leu Pro Pro Ile
25 30 35

```

```

cca ttt cca aga ttt cca tgg ttt aga cgt aan ttt cct att cca ata      305
Pro Phe Pro Arg Phe Pro Trp Phe Arg Arg Xaa Phe Pro Ile Pro Ile
40                               45                               50                               55
cct gaa tct gcc cct aca act ccc ctt cct agc gaa aag taaacaaraa      354
Pro Glu Ser Ala Pro Thr Thr Pro Leu Pro Ser Glu Lys
60                               65
ggaaaagtca crataaacct ggtcacctga aattgaaatt gagccacttc cttgaaraat      414
caaaattcct gttaataaaa raaaaacaaa tgtaattgaa atagcacaca gcattctcta      474
gtcaatatct ttagtgatct tctttaataa acatgaaagc aaaaaaaaaa aa      526
<210> 18
<211> 17
<212> PRT
<213> Homo Sapiens
<220>
<223> SIGNAL
<222> 1..17
<223> Von Heijne matrix
      score 8.2
      seq LLLITAILAVAVG/FP
<400> 18
Met Lys Lys Val Leu Leu Leu Ile Thr Ala Ile Leu Ala Val Ala Val
1                               5                               10                               15
Gly
<210> 19
<211> 822
<212> DNA
<213> Homo Sapiens
<220>
<223> misc_feature
<222> 260..464
<223> blastn
<223> misc_feature
<222> 118..184
<223> blastn
<223> misc_feature
<222> 56..113
<223> blastn
<223> misc_feature
<222> 454..485
<223> blastn
<223> misc_feature
<222> 118..545
<223> blastn
<223> misc_feature
<222> 65..369
<223> blastn
<223> misc_feature
<222> 61..399
<223> blastn
<223> misc_feature
<222> 408..458
<223> blastn
<223> misc_feature
<222> 60..399
<223> blastn
<223> misc_feature
<222> 393..432
<223> blastn
<223> sig_peptide
<222> 346..408
<223> Von Heijne matrix

```

<400> 19
 actcctttta gcataggggc ttcggcgcca gcgccagcg ctagtcggtc tggtaagtgc 60
 ctgatgccga gttccgtctc tcgcgtcttt tcctgggtccc aggcaaagcg gasgnagatc 120
 ctcaaacggc ctagtgcttc gcgcttccgg agaaaatcag cgggtctaatt aattcctctg 180
 gtttggtgaa gcagttacca agaattctta accctttccc acaaaagcta attgagtaca 240
 cgctcctgtt gagtacacgt tcctgttgat ttacaaaagg tgcaggatg agcaggctctg 300
 aagactaaca ttttgtgaag ttgtaaaaca gaaaacctgt tagaa atg tgg tgg ttt 357
 Met Trp Trp Phe
 -20
 cag caa ggc ctc agt ttc ctt cct tca gcc ctt gta att tgg aca tct 405
 Gln Gln Gly Leu Ser Phe Leu Pro Ser Ala Leu Val Ile Trp Thr Ser
 -15 -10 -5
 gct gct ttc ata ttt tca tac att act gca gta aca ctc cac cat ata 453
 Ala Ala Phe Ile Phe Ser Tyr Ile Thr Ala Val Thr Leu His His Ile
 1 5 10 15
 gac ccg gct tta cct tat atc agt gac act ggt aca gta gct cca raa 501
 Asp Pro Ala Leu Pro Tyr Ile Ser Asp Thr Gly Thr Val Ala Pro Xaa
 20 25 30
 aaa tgc tta ttt ggg gca atg cta aat att gcg gca gtt tta tgt caa 549
 Lys Cys Leu Phe Gly Ala Met Leu Asn Ile Ala Ala Val Leu Cys Gln
 35 40 45
 aaa tagaaatcag gaarataatt caacttaaag aakttcattt catgaccaa 602
 Lys
 ctcttcaraa acatgtcttt acaagcatat ctcttgatt gctttctaca ctgttgaatt 662
 gtctggcaat atttctgcag tggaaaattt gatttarmta gttcttgact gataaatatg 722
 gtaagtgagg cttttcccc tgtgtaattg gctactatgt cttactgagc caagttgtaw 782
 tttgaaataa aatgatatga gagtgacaca aaaaaaaaaa 822
 <210> 20
 <211> 21
 <212> PRT
 <213> Homo Sapiens
 <220>
 <223> SIGNAL
 <222> 1..21
 <223> Von Heijne matrix
 score 5.5
 seq SFLPSALVIWTS/AF
 <400> 20
 Met Trp Trp Phe Gln Gln Gly Leu Ser Phe Leu Pro Ser Ala Leu Val
 1 5 10 15
 Ile Trp Thr Ser Ala
 20
 <210> 21
 <211> 405
 <212> DNA
 <213> Homo Sapiens
 <220>
 <223> misc_feature
 <222> complement(103..398)
 <223> blastn
 <223> sig_peptide
 <222> 185..295
 <223> Von Heijne matrix
 <400> 21
 atcaccttct tctccatcct tstctgggcc agtcccaccc ccagtccttc tcttgacctg 60
 cccagcccaa gtcagccttc agcagcgct tttctgcaca cagatattcc aggcctacct 120
 ggcattccag gacctccgma atgatgtctc agtcccttac aagcgcttcc tggatgaggg 180
 tggc atg gtg ctg acc acc ctc ccc ttg ccc tct gcc aac agc cct gtg 229
 Met Val Leu Thr Thr Leu Pro Leu Pro Ser Ala Asn Ser Pro Val
 -35 -30 -25
 aac atg ccc acc act ggc ccc aac agc ctg agt tat gct agc tct gcc 277

```

Asn Met Pro Thr Thr Gly Pro Asn Ser Leu Ser Tyr Ala Ser Ser Ala
-20 -15 -10
ctg tcc ccc tgt ctg acc gct cca aak tcc ccc cgg ctt gct atg atg 325
Leu Ser Pro Cys Leu Thr Ala Pro Xaa Ser Pro Arg Leu Ala Met Met
-5 1 5 10
cct gac aac taaatatacct tatccaaatc aataaarwra raatcctccc 374
Pro Asp Asn
tccaraagggttttctaaaaa caaaaaaaaaa a 405
<210> 22
<211> 37
<212> PRT
<213> Homo Sapiens
<220>
<223> SIGNAL
<222> 1..37
<223> Von Heijne matrix
score 5.9
seq LSYASSALSPCLT/AP
<400> 22
Met Val Leu Thr Thr Leu Pro Leu Pro Ser Ala Asn Ser Pro Val Asn
1 5 10 15
Met Pro Thr Thr Gly Pro Asn Ser Leu Ser Tyr Ala Ser Ser Ala Leu
20 25 30
Ser Pro Cys Leu Thr
35
<210> 23
<211> 496
<212> DNA
<213> Homo Sapiens
<220>
<223> misc_feature
<222> 149..331
<223> blastn
<223> misc_feature
<222> 328..485
<223> blastn
<223> misc_feature
<222> complement(182..496)
<223> blastn
<223> sig_peptide
<222> 196..240
<223> Von Heijne matrix
<400> 23
aaaaaattgg tcccagtttt caccctgccg cagggtggc tggggagggc agcggtttag 60
attagccgtg gcctaggccg tttaacgggg tgacacgagc ntgcagggcc gagtccaagg 120
cccggagata ggaccaaccg tcaggaatgc gaggaatgtt tttcttcgga ctctatcgag 180
gcacacagac agacc atg ggg att ctg tct aca gtg aca gcc tta aca ttt 231
Met Gly Ile Leu Ser Thr Val Thr Ala Leu Thr Phe
-15 -10 -5
gcc ara gcc ctg gac ggc tgc aga aat ggc att gcc cac cct gca agt 279
Ala Xaa Ala Leu Asp Gly Cys Arg Asn Gly Ile Ala His Pro Ala Ser
1 5 10
gag aag cac aga ctc gag aaa tgt agg gaa ctc gag asc asc cac tcg 327
Glu Lys His Arg Leu Glu Lys Cys Arg Glu Leu Glu Xaa Xaa His Ser
15 20 25
gcc cca gga tca acc cas cac cga aga aaa aca acc aga aga aat tat 375
Ala Pro Gly Ser Thr Xaa His Arg Arg Lys Thr Thr Arg Arg Asn Tyr
30 35 40 45
tct tca gcc tgaaatgaak ccgggatcaa atggttgctg atcaragccc 424
Ser Ser Ala
atatttaaat tggaaaagtc aaattgasca ttattaaata aagcttggtt aatatgtctc 484

```

aaacaaaaaa aa
 <210> 24
 <211> 15
 <212> PRT
 <213> Homo Sapiens
 <220>
 <223> SIGNAL
 <222> 1..15
 <223> Von Heijne matrix
 score 5.5
 seq ILSTVTALTFAXA/LD
 <400> 24
 Met Gly Ile Leu Ser Thr Val Thr Ala Leu Thr Phe Ala Xaa Ala
 1 5 10 15
 <210> 25
 <211> 623
 <212> DNA
 <213> Homo Sapiens
 <220>
 <223> sig_peptide
 <222> 49..96
 <223> Von Heijne matrix
 <400> 25
 aaagatccct gcagcccggc aggagagaag gctgagcctt ctggcgctc atg gag agg 57
 Met Glu Arg
 -15
 ctc gtc cta acc ctg tgc acc ctc ccg ctg gct gtg gcg tct gct ggc 105
 Leu Val Leu Thr Leu Cys Thr Leu Pro Leu Ala Val Ala Ser Ala Gly
 -10 -5 1
 tgc gcc acg acg cca gct cgc aac ctg agc tgc tac cag tgc ttc aag 153
 Cys Ala Thr Thr Pro Ala Arg Asn Leu Ser Cys Tyr Gln Cys Phe Lys
 5 10 15
 gtc agc agc tgg acg gag tgc ccg ccc acc tgg tgc agc ccg ctg gac 201
 Val Ser Ser Trp Thr Glu Cys Pro Pro Thr Trp Cys Ser Pro Leu Asp
 20 25 30 35
 caa gtc tgc atc tcc aac gag gtg gtc gtc tct ttt aaa tgg agt gta 249
 Gln Val Cys Ile Ser Asn Glu Val Val Val Ser Phe Lys Trp Ser Val
 40 45 50
 cgc gtc ctg ctc agc aaa cgc tgt gct ccc aga tgt ccc aac gac aac 297
 Arg Val Leu Leu Ser Lys Arg Cys Ala Pro Arg Cys Pro Asn Asp Asn
 55 60 65
 atg aak ttc gaa tgg tcg ccg gcc ccc atg gtg caa ggc gtg atc acc 345
 Met Xaa Phe Glu Trp Ser Pro Ala Pro Met Val Gln Gly Val Ile Thr
 70 75 80
 agg cgc tgc tgt tcc tgg gct ctc tgc aac agg gca ctg acc cca cag 393
 Arg Arg Cys Cys Ser Trp Ala Leu Cys Asn Arg Ala Leu Thr Pro Gln
 85 90 95
 gag ggg cgc tgg gcc ctg cra ggg ggg ctc ctg ctc cag gac cct tcg 441
 Glu Gly Arg Trp Ala Leu Xaa Gly Gly Leu Leu Leu Gln Asp Pro Ser
 100 105 110 115
 agg ggc ara aaa acc tgg gtg cgg cca cag ctg ggg ctc cca ctc tgc 489
 Arg Gly Xaa Lys Thr Trp Val Arg Pro Gln Leu Gly Leu Pro Leu Cys
 120 125 130
 ctt ccc awt tcc aac ccc ctc tgc cca rgg gaa acc cag gaa gga 534
 Leu Pro Xaa Ser Asn Pro Leu Cys Pro Xaa Glu Thr Gln Glu Gly
 135 140 145
 taacactgtg ggtgccccca cctgtgcatt gggaccacra cttaccctc ttggaracaa 594
 taaactctca tgcccccaaa aaaaaaaaaa 623
 <210> 26
 <211> 16
 <212> PRT

<213>	Homo Sapiens	
<220>		
<223>	SIGNAL	
<222>	1..16	
<223>	Von Heijne matrix	
	score 10.1	
	seq LVLTLCTPLAVA/SA	
<400>	26	
Met	Glu Arg Leu Val Leu Thr Leu Cys Thr Leu Pro Leu Ala Val Ala	
1	5 10 15	
<210>	27	
<211>	848	
<212>	DNA	
<213>	Homo Sapiens	
<220>		
<223>	sig_peptide	
<222>	32..73	
<223>	Von Heijne matrix	
<400>	27	
aactttgcct	tgtgttttcc accctgaaag a atg ttg tgg ctg ctc ttt ttt	52
	Met Leu Trp Leu Leu Phe Phe	
	-10	
ctg gtg act gcc att cat gct gaa ctc tgt caa cca ggt gca gaa aat		100
Leu Val Thr Ala Ile His Ala Glu Leu Cys Gln Pro Gly Ala Glu Asn		
	-5 1 5 20	
gct ttt aaa gtg aga ctt agt atc aga aca gct ctg gga gat aaa gca		148
Ala Phe Lys Val Arg Leu Ser Ile Arg Thr Ala Leu Gly Asp Lys Ala		
10 15 20 25		
tat gcc tgg gat acc aat gaa gaa tac ctc ttc aaa gcg atg gta gct		196
Tyr Ala Trp Asp Thr Asn Glu Glu Tyr Leu Phe Lys Ala Met Val Ala		
	30 35 40	
ttc tcc atg aga aaa gtt ccc aac aga gaa gca aca gaa att tcc cat		244
Phe Ser Met Arg Lys Val Pro Asn Arg Glu Ala Thr Glu Ile Ser His		
	45 50 55	
gtc cta ctt tgc aat gta acc cag agg gta tca ttc tgg ttt gtg gtt		292
Val Leu Leu Cys Asn Val Thr Gln Arg Val Ser Phe Trp Phe Val Val		
	60 65 70	
aca gac cct tca aaa aat cac acc ctt cct gct gtt gag gtg caa tca		340
Thr Asp Pro Ser Lys Asn His Thr Leu Pro Ala Val Glu Val Gln Ser		
	75 80 85	
gcc ata aga atg aac aag aac cgg atc aac aat gcc ttc ttt cta aat		388
Ala Ile Arg Met Asn Lys Asn Arg Ile Asn Asn Ala Phe Phe Leu Asn		
	90 95 100 105	
gac caa act ctg gaa ttt tta aaa atc cct tcc aca ctt gca cca ccc		436
Asp Gln Thr Leu Glu Phe Leu Lys Ile Pro Ser Thr Leu Ala Pro Pro		
	110 115 120	
atg gac cca tct gtg ccc atc tgg att att ata ttt ggt gtg ata ttt		484
Met Asp Pro Ser Val Pro Ile Trp Ile Ile Ile Phe Gly Val Ile Phe		
	125 130 135	
tgc atc atc ata gtt gca att gca cta ctg att tta tca ggg atc tgg		532
Cys Ile Ile Ile Val Ala Ile Ala Leu Leu Ile Leu Ser Gly Ile Trp		
	140 145 150	
caa cgt ada ara aag aac aaa gaa cca tct gaa gtg gat gac gct gaa		580
Gln Arg Xaa Xaa Lys Asn Lys Glu Pro Ser Glu Val Asp Asp Ala Glu		
	155 160 165	
rat aak tgt gaa aac atg atc aca att gaa aat ggc atc ccc tct gat		628
Xaa Xaa Cys Glu Asn Met Ile Thr Ile Glu Asn Gly Ile Pro Ser Asp		
	170 175 180 185	
ccc ctg gac atg aag gga ggg cat att aat gat gcc ttc atg aca gag		676
Pro Leu Asp Met Lys Gly Gly His Ile Asn Asp Ala Phe Met Thr Glu		
	190 195 200	

gat gag agg ctc acc cct ctc tgaagggctg ttgttctgct tcctcaaraa 727
 Asp Glu Arg Leu Thr Pro Leu
 205
 attaaacatt tgtttctgtg tgactgctga gcatcctgaa ataccaagag cagatcatat 787
 wttttgtttc accattcttc ttttgtaata aattttgaat gtgcttgaaa aaaaaaaaaa 847
 c 848
 <210> 28
 <211> 14
 <212> PRT
 <213> Homo Sapiens
 <220>
 <223> SIGNAL
 <222> 1..14
 <223> Von Heijne matrix
 score 10.7
 seq LWLLFFLVTAIHA/EL
 <400> 28
 Met Leu Trp Leu Leu Phe Phe Leu Val Thr Ala Ile His Ala
 1 5 10
 <210> 29
 <211> 25
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Oligonucleotide
 <400> 29
 ggggaagatgg agatagtatt gcctg 25
 <210> 30
 <211> 26
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Oligonucleotide
 <400> 30
 ctgccatgta catgatagag agattc 26
 <210> 31
 <211> 546
 <212> DNA
 <213> Homo Sapiens
 <220>
 <223> promoter
 <222> 1..517
 <223> transcription start site
 <222> 518
 <223> protein_bind
 <222> 17..25
 <223> matinspector prediction
 name CMYB_01
 score 0.983
 sequence tgtcagttg
 <223> protein_bind
 <222> complement(18..27)
 <223> matinspector prediction
 name MYOD_Q6
 score 0.961
 sequence cccaactgac
 <223> protein_bind
 <222> complement(75..85)
 <223> matinspector prediction
 name S8_01
 score 0.960

sequence aatagaattag
<223> protein_bind
<222> 94..104
<223> matinspector prediction
name S8_01
score 0.966
sequence aactaaattag
<223> protein_bind
<222> complement(129..139)
<223> matinspector prediction
name DELTAEF1_01
score 0.960
sequence gcacacctcag
<223> protein_bind
<222> complement(155..165)
<223> matinspector prediction
name GATA_C
score 0.964
sequence agataaatcca
<223> protein_bind
<222> 170..178
<223> matinspector prediction
name CMYB_01
score 0.958
sequence cttcagttg
<223> protein_bind
<222> 176..189
<223> matinspector prediction
name GATA1_02
score 0.959
sequence ttgtagataggaca
<223> protein_bind
<222> 180..190
<223> matinspector prediction
name GATA_C
score 0.953
sequence agataggacat
<223> protein_bind
<222> 284..299
<223> matinspector prediction
name TAL1ALPHA47_01
score 0.973
sequence cataacagatggtaag
<223> protein_bind
<222> 284..299
<223> matinspector prediction
name TAL1BETAE47_01
score 0.983
sequence cataacagatggtaag
<223> protein_bind
<222> 284..299
<223> matinspector prediction
name TAL1BETAITF2_01
score 0.978
sequence cataacagatggtaag
<223> protein_bind
<222> complement(287..296)
<223> matinspector prediction
name MYOD_Q6
score 0.954
sequence accatctgtt

protein_bind
 > complement(302..314)
 <223> matinspector prediction
 name GATA1_04
 score 0.953
 sequence tcaagataaagta
 <223> protein_bind
 <222> 393..405
 <223> matinspector prediction
 name IK1_01
 score 0.963
 sequence agttgggaattcc
 <223> protein_bind
 <222> 393..404
 <223> matinspector prediction
 name IK2_01
 score 0.985
 sequence agttgggaattc
 <223> protein_bind
 <222> 396..405
 <223> matinspector prediction
 name CREL_01
 score 0.962
 sequence tgggaattcc
 <223> protein_bind
 <222> 423..436
 <223> matinspector prediction
 name GATA1_02
 score 0.950
 sequence tcagtgatatggca
 <223> protein_bind
 <222> complement(478..489)
 <223> matinspector prediction
 name SRY_02
 score 0.951
 sequence taaaacaaaaca
 <223> protein_bind
 <222> 486..493
 <223> matinspector prediction
 name E2F_02
 score 0.957
 sequence tttagcgc
 <223> protein_bind
 <222> complement(514..521)
 <223> matinspector prediction
 name MZF1_01
 score 0.975
 sequence tgagggga
 <400> 31
 tgagtgcagt gttacatgtc agttgggtta agtttggttaa tgtcattcaa atcttctatg 60
 tcttgatttg cctgctaatt ctattatttc tggaactaaa ttagtttgat ggttctatta 120
 gttattgact gaggtgtgct aatctcccat tatgtggatt tatctatttc ttcagttgta 180
 gataggacat tgatagatac ataagtacca ggacaaaagc agggagatct ttttccaaa 240
 atcaggagaa aaaaatgaca tctggaaaac ctatagggaa aggcataaca gatggtaagg 300
 atactttatc ttgagtagga gagccttcct gtggcaacgt ggagaaggga agaggtcgtgta 360
 gaattgagga gtcagctcag ttagaagcag ggagttggga attccgttca tgtgatttag 420
 catcagtgat atggcaaagtg tgggactaag ggtagtgatc agaggggttaa aattgtgtgt 480
 tttgttttag cgctgctggg gcatcgccct gggtcccctc aaacagattc ccatgaatct 540
 cttcat
 <210> 32 546
 <211> 23

<212> DNA
 <213> Artificial Sequence
 <220>
 <223> Oligonucleotide
 <400> 32
 gtaccaggga ctgtgaccat tgc
 <210> 33 23
 <211> 24
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Oligonucleotide
 <400> 33
 ctgtgaccat tgctcccaag agag
 <210> 34 24
 <211> 861
 <212> DNA
 <213> Homo Sapiens
 <220>
 <223> promoter
 <222> 1..806
 <223> transcription start site
 <222> 807
 <223> protein_bind
 <222> complement(60..70)
 <223> matinspector prediction
 name NFY_Q6
 score 0.956
 sequence ggaccaatcat
 <223> protein_bind
 <222> 70..77
 <223> matinspector prediction
 name MZF1_01
 score 0.962
 sequence cctgggga
 <223> protein_bind
 <222> 124..132
 <223> matinspector prediction
 name CMYB_01
 score 0.994
 sequence tgaccgttg
 <223> protein_bind
 <222> complement(126..134)
 <223> matinspector prediction
 name VMYB_02
 score 0.985
 sequence tccaacggt
 <223> protein_bind
 <222> 135..143
 <223> matinspector prediction
 name STAT_01
 score 0.968
 sequence ttcctggaa
 <223> protein_bind
 <222> complement(135..143)
 <223> matinspector prediction
 name STAT_01
 score 0.951
 sequence ttccaggaa
 <223> protein_bind
 <222> complement(252..259)

```

<223> matinspector prediction
      name MZF1_01
      score 0.956
      sequence ttggggga
<223> protein_bind
<222> 357..368
<223> matinspector prediction
      name IK2_01
      score 0.965
      sequence gaatgggatttc
<223> protein_bind
<222> 384..391
<223> matinspector prediction
      name MZF1_01
      score 0.986
      sequence agagggga
<223> protein_bind
<222> complement(410..421)
<223> matinspector prediction
      name SRY_02
      score 0.955
      sequence gaaaacaaaaca
<223> protein_bind
<222> 592..599
<223> matinspector prediction
      name MZF1_01
      score 0.960
      sequence gaagggga
<223> protein_bind
<222> 618..627
<223> matinspector prediction
      name MYOD_Q6
      score 0.981
      sequence agcatctgcc
<223> protein_bind
<222> 632..642
<223> matinspector prediction
      name DELTAEF1_01
      score 0.958
      sequence tcccaccttcc
<223> protein_bind
<222> complement(813..823)
<223> matinspector prediction
      name S8_01
      score 0.992
      sequence gaggcaattat
<223> protein_bind
<222> complement(824..831)
<223> matinspector prediction
      name MZF1_01
      score 0.986
      sequence agagggga
<400> 34
tactataggg cacgcgtggt cgacggccgg gctgttctgg agcagagggc atgtcagtaa      60
tgattggtcc ctggggaagg tctggctggc tccagcacag tgaggcattt aggtatctct      120
cggtgaccgt tggattcctg gaagcagtag ctgttctgtt tggatctggt agggacaggg      180
ctcagagggc taggcacgag ggaaggtcag aggagaaggs aggsarggcc cagtgaarg      240
ggagcatgcc ttcccccaac cctggcttsc ycttggymam agggcgkttt tgggmacttr      300
aaytcagggc ccaascagaa scacaggccc aktcntggct smaagcaca tagcctgaat      360
gggatttcag gttagncagg gtgagagggg aggcctctct gcttagtttt gttttgtttt      420
ccaaatcaag gtaacttgct cccttctgct acgggccttg gtcttggtt gtcctcacc      480

```

```

agtcggaact ccctaccact ttcaggagag tggtttttagg cccgtggggc tgttctgttc 540
caagcagtgt gagaacatgg ctggttagagg ctctagctgt gtgcggggcc tgaaggggag 600
tgggttctcg cccaaagagc atctgcccat ttcccacctt cccttctccc accagaagct 660
tgcttgagct gtttgacaa aaatccaaac cccacttggc tactctggcc tggcttcagc 720
ttggaaccca atacctaggc ttacaggcca tcttgagcca ggggcctctg gaaattctct 780
tcctgatggt cctttagggt tgggcacaaa atataattgc ctctcccctc tcccattttc 840
tctcttggga gcaatggtca c 861
<210> 35
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Oligonucleotide
<400> 35
ctgggatgga aggcacggtg 20
<210> 36
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Oligonucleotide
<400> 36
gagaccacac agctagacaa 20
<210> 37
<211> 555
<212> DNA
<213> Homo Sapiens
<220>
<223> promoter
<222> 1..500
<223> transcription start site
<222> 501
<223> protein_bind
<222> 191..206
<223> matinspector prediction
      name ARNT_01
      score 0.964
      sequence ggactcacgtgctgct
<223> protein_bind
<222> 193..204
<223> matinspector prediction
      name NMYC_01
      score 0.965
      sequence actcacgtgctg
<223> protein_bind
<222> 193..204
<223> matinspector prediction
      name USF_01
      score 0.985
      sequence actcacgtgctg
<223> protein_bind
<222> complement(193..204)
<223> matinspector prediction
      name USF_01
      score 0.985
      sequence cagcacgtgagt
<223> protein_bind
<222> complement(193..204)
<223> matinspector prediction
      name NMYC_01
      score 0.956

```

```

sequence cagcacgtgagt
<223> protein_bind
<222> complement(193..204)
<223> matinspector prediction
name MYCMAX_02
score 0.972
sequence cagcacgtgagt
<223> protein_bind
<222> 195..202
<223> matinspector prediction
name USF_C
score 0.997
sequence tcacgtgc
<223> protein_bind
<222> complement(195..202)
<223> matinspector prediction
name USF_C
score 0.991
sequence gcacgtga
<223> protein_bind
<222> complement(210..217)
<223> matinspector prediction
name MZF1_01
score 0.968
sequence catgggga
<223> protein_bind
<222> 397..410
<223> matinspector prediction
name ELK1_02
score 0.963
sequence ctctccggaagcct
<223> protein_bind
<222> 400..409
<223> matinspector prediction
name CETS1P54_01
score 0.974
sequence tccggaagcc
<223> protein_bind
<222> complement(460..470)
<223> matinspector prediction
name AP1_Q4
score 0.963
sequence agtgactgaac
<223> protein_bind
<222> complement(460..470)
<223> matinspector prediction
name AP1FJ_Q2
score 0.961
sequence agtgactgaac
<223> protein_bind
<222> 547..555
<223> matinspector prediction
name PADS_C
score 1.000
sequence tgtgtctc
<400> 37
ctatagggca cgcktggctg acggcccggg ctggtctggg ctgktgtgga gtcggggtga 60
aggacagcat ttgtkacatc tgggtacttg caccttcctt ctgccgtgca cttggccttt 120
kawaagctca gcaccgggtg ccatcacagg gccggcagca cacacatccc attactcaga 180
aggaactgac ggactcacgt gctgctccgt ccccatgagc tcagtggacc tgtctatgta 240
gagcagtcag acagtgcctg ggatagagtg agagttcagc cagtaaacc aagtgattgt 300

```


cattcctgtc tgcattagta actcccaacc tagatgtgaa aacttagttc tttctcatag 360
 gttgctctgc ccattggctcc actgcagacc caggcactct ccggaagcct ggaaatcacc 420
 cgtgtcttct gcctgtctcc gctcacatcc cacacttggtg ttcagtcact gagttacaga 480
 ttttgctcc tcaatttctc ttgtcttagt cccatcctct gttcccctgg ccagtttgtc 540
 tagctgtgtg gtctc 555
 <210> 38
 <211> 19
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Oligonucleotide
 <400> 38
 ggccatacac ttgagtgc 19
 <210> 39
 <211> 19
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Oligonucleotide
 <400> 39
 atatagacaa acgcacacc 19
 <210> 40
 <211> 699
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 35..568
 <223> sig_peptide
 <222> 35..100
 <223> Von Heijne matrix
 score 10.7
 seq LLTLALLGGPTWA/GK
 <223> polyA_signal
 <222> 667..672
 <223> polyA_site
 <222> 685..699
 <400> 40
 aaccagacgc ccagtcacag gcgagagccc tggg atg cac cgg cca gag gcc atg 55
 Met His Arg Pro Glu Ala Met
 -20
 ctg ctg ctg ctc acg ctt gcc ctc ctg ggg ggc ccc acc tgg gca ggg 103
 Leu Leu Leu Leu Thr Leu Ala Leu Leu Gly Gly Pro Thr Trp Ala Gly
 -15 -10 -5 1
 aag atg tat ggc cct gga gga ggc aag tat ttc agc acc act gaa gac 151
 Lys Met Tyr Gly Pro Gly Gly Gly Lys Tyr Phe Ser Thr Thr Glu Asp
 5 10 15
 tac gac cat gaa atc aca ggg ctg cgg gtg tct gta ggt ctt ctc ctg 199
 Tyr Asp His Glu Ile Thr Gly Leu Arg Val Ser Val Gly Leu Leu Leu
 20 25 30
 gtg aaa agt gtc cag gtg aaa ctt gga gac tcc tgg gac gtg aaa ctg 247
 Val Lys Ser Val Gln Val Lys Leu Gly Asp Ser Trp Asp Val Lys Leu
 35 40 45
 gga gcc tta ggt ggg aat acc cag gaa gtc acc ctg cag cca ggc gaa 295
 Gly Ala Leu Gly Gly Asn Thr Gln Glu Val Thr Leu Gln Pro Gly Glu
 50 55 60 65
 tac atc aca aaa gtc ttt gtc gcc ttc caa act ttc ctc cgg ggt atg 343
 Tyr Ile Thr Lys Val Phe Val Ala Phe Gln Thr Phe Leu Arg Gly Met
 70 75 80
 gtc atg tac acc agc aag gac cgc tat ttc tat ttt ggg aag ctt gat 391
 Val Met Tyr Thr Ser Lys Asp Arg Tyr Phe Tyr Phe Gly Lys Leu Asp

```

      85              90              95
ggc cag atc tcc tct gcc tac ccc agc caa gag ggg cag gtg ctg gtg      439
Gly Gln Ile Ser Ser Ala Tyr Pro Ser Gln Glu Gly Gln Val Leu Val
      100              105              110
ggc atc tat ggc cag tat caa ctc ctt ggc atc aag agc att ggc ttt      487
Gly Ile Tyr Gly Gln Tyr Gln Leu Leu Gly Ile Lys Ser Ile Gly Phe
      115              120              125
gaa tgg aat tat cca cta gag gag ccg acc act gag cca cca gtt aat      535
Glu Trp Asn Tyr Pro Leu Glu Glu Pro Thr Thr Glu Pro Pro Val Asn
      130              135              140              145
ctc aca tac tca gca aac tca ccc gtg ggt cgc taggggtgggg tatggggcca      588
Leu Thr Tyr Ser Ala Asn Ser Pro Val Gly Arg
      150              155
tccgagctga ggccatctgg gtgggtggtg ctgatggtac tggagtaact gagtcgggac      648
gctgaatctg aatccaccaa taaataaagg ttctgcaaaa aaaaaaaaaa a      699
<210> 41
<211> 497
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 68..337
<223> sig_peptide
<222> 68..124
<223> Von Heijne matrix
      score 10
      seq LVLLGVSIFLVSA/QN
<223> polyA_signal
<222> 462..467
<223> polyA_site
<222> 482..497
<400> 41
agcgccttgc cttctcttag gctttgaagc atttttgtct gtgctccctg atcttcaggt      60
caccacc atg aag ttc tta gca gtc ctg gta ctc ttg gga gtt tcc atc      109
      Met Lys Phe Leu Ala Val Leu Val Leu Leu Gly Val Ser Ile
              -15              -10
ttt ctg gtc tct gcc cag aat ccg aca aca gct gct cca gct gac acg      157
Phe Leu Val Ser Ala Gln Asn Pro Thr Thr Ala Ala Pro Ala Asp Thr
-5              1              5              10
tat cca gct act ggt cct gct gat gat gaa gcc cct gat gct gaa acc      205
Tyr Pro Ala Thr Gly Pro Ala Asp Asp Glu Ala Pro Asp Ala Glu Thr
      15              20              25
act gct gct gca acc act gcg acc act gct gct cct acc act gca acc      253
Thr Ala Ala Ala Thr Thr Ala Thr Thr Ala Ala Pro Thr Thr Ala Thr
      30              35              40
acc gct gct tct acc act gct cgt aaa gac att cca gtt tta ccc aaa      301
Thr Ala Ala Ser Thr Thr Ala Arg Lys Asp Ile Pro Val Leu Pro Lys
      45              50              55
tgg gtt ggg gat ctc ccg aat ggt aga gtg tgt ccc tgagatggaa      347
Trp Val Gly Asp Leu Pro Asn Gly Arg Val Cys Pro
      60              65              70
tcagcttgag tcttctgcaa ttggtcacaa ctattcatgc ttctgtgat ttcaccaac      407
tacttacctt gcctacgata tcccctttat ctctaatacag tttattttct ttcaaataaa      467
aaataactat gagcaaaaaa aaaaaaaaaa      497
<210> 42
<211> 598
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 39..413

```


ctc ttc tcg ctc cgg gag ctg gtg cag tgg cta ggc ttc gcc acc ttc Met
 Leu Phe Ser Leu Arg Glu Leu Val Gln Trp Leu Gly Phe Ala Thr Phe 285
 -30 -25 -20
 gag atc ttc gtg cac ctg ctg gcc ctg ttg gtg ttc tct gtg ctg ctg 333
 Glu Ile Phe Val His Leu Leu Ala Leu Leu Val Phe Ser Val Leu Leu
 -15 -10 -5
 gca ctg cgt gtg gat ggc ctg gtc ccg ggc ctc tcc tgg tgg aac gtg 381
 Ala Leu Arg Val Asp Gly Leu Val Pro Gly Leu Ser Trp Trp Asn Val
 1 5 10 15
 ttc gtg cct ttc ttc gcc gct gac ggg ctc agc acc tac ttc acc acc 429
 Phe Val Pro Phe Phe Ala Ala Asp Gly Leu Ser Thr Tyr Phe Thr Thr
 20 25 30
 atc gtg tcc gtg cgc ctc ttc cag gat gga gag aag cgg ctg gcg gtg 477
 Ile Val Ser Val Arg Leu Phe Gln Asp Gly Glu Lys Arg Leu Ala Val
 35 40 45
 ctc cgc ctt ttc tgg gta ctt acg gtc ctg agt ctc aag ttc gtc ttc 525
 Leu Arg Leu Phe Trp Val Leu Thr Val Leu Ser Leu Lys Phe Val Phe
 50 55 60
 gag atg ctg ttg tgc cag aag ctg gcg gag cag act cgg gag ctc tgg 573
 Glu Met Leu Leu Cys Gln Lys Leu Ala Glu Gln Thr Arg Glu Leu Trp
 65 70 75
 ttc ggc ctc att acg tcc ccg ctc ttc att ctc ctg cag ctg ctc atg 621
 Phe Gly Leu Ile Thr Ser Pro Leu Phe Ile Leu Leu Gln Leu Leu Met
 80 85 90 95
 atc cgc gcc tgt cgg gtc aac tagcctcacc gaggtgcccg agagggagcg 672
 Ile Arg Ala Cys Arg Val Asn
 100
 ctggacaact agaattgtga cctcgagccg aggccctact tgcagcgcac cggaggagag 732
 gctctctagt ctgaaggcac cgccggcttg cgccgagctg agtgccgggt ttccctattc 792
 caatcctgtt tgaattggtt tcttcagcag ggcttaaaag agcagccttc atcctgaaaa 852
 tgtatttcct tttgtttaat gctttgagta gataatcctg aattgaggtc atgaggaggc 912
 cccccaggcc agacagtcct gaacccctct gacacttgga aactgaatat aagtaaaatg 972
 tccagggtgga ctctgagtat ttcctgtgga tcctgggaaa gtactgttgc acaaaggctg 1032
 caaagctgga ctcaggaatg tcctccaacc agcagcgcta acctaagagc tccctgtgcc 1092
 gtctatccag accagacttc ggtagatgcc tttgttagat ctatcacatg taaacgagct 1152
 tgtatctcct tccctgtgcc acgagagaga ttggcttttt attccagtct aggcagagac 1212
 agaagaatgt tgaataagag cacgattaga gtctgtctgt gttatctgtt gccaagaaa 1272
 agaactctgc tgtccaggca ctgcttggt tactatccca gcaaagactg cagttttgtg 1332
 gacttttgac caccttgggc tggcactctt agcacacctg agacagattt aagcctccct 1392
 aagagactga agagaggaac aggtgtcaga tactcatagg cactgagatc taaaaatggg 1452
 aagcttgtga gtggcccatc tttgttggtc tacgaacttt ggtttgatgc cagtcagggtg 1512
 ccacatgaga acctttgctg agatgcaaataaagtaagag aatgttttcc caaaaaaaaa 1572
 aaaaaaa 1579
 <210> 44
 <211> 893
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 42..755
 <223> sig_peptide
 <222> 42..200
 <223> Von Heijne matrix
 score 5.8
 seq ILSLQVLLTTVTS/TV
 <223> polyA_signal
 <222> 860..865
 <223> polyA_site
 <222> 878..893
 <400> 44

gcggttagtg gaccgggacc ggtaggggtg ctgttgccat c atg gct gac ccc gac 56
Met Ala Asp Pro Asp
-50
ccc cgg tac cct cgc tcc tcg atc gag gac gac ttc aac tat ggc agc 104
Pro Arg Tyr Pro Arg Ser Ser Ile Glu Asp Asp Phe Asn Tyr Gly Ser
-45 -40 -35
agc gtg gcc tcc gcc acc gtg cac atc cga atg gcc ttt ctg aga aaa 152
Ser Val Ala Ser Ala Thr Val His Ile Arg Met Ala Phe Leu Arg Lys
-30 -25 -20
gtc tac agc att ctt tct ctg cag gtt ctc tta act aca gtg act tca 200
Val Tyr Ser Ile Leu Ser Leu Gln Val Leu Leu Thr Thr Val Thr Ser
-15 -10 -5
aca gtt ttt tta tac ttt gag tct gta cgg aca ttt gta cat gag agt 248
Thr Val Phe Leu Tyr Phe Glu Ser Val Arg Thr Phe Val His Glu Ser
1 5 10 15
cct gcc tta att ttg ctg ttt gcc ctc gga tct ctg ggt ttg att ttt 296
Pro Ala Leu Ile Leu Leu Phe Ala Leu Gly Ser Leu Gly Leu Ile Phe
20 25 30
gcg ttg att tta aac aga cat aag tat ccc ctt aac ctg tac cta ctt 344
Ala Leu Ile Leu Asn Arg His Lys Tyr Pro Leu Asn Leu Tyr Leu Leu
35 40 45
ttt gga ttt acg ctg ttg gaa gct ctg act gtg gca gtt gtt gtt act 392
Phe Gly Phe Thr Leu Leu Glu Ala Leu Thr Val Ala Val Val Val Thr
50 55 60
ttc tat gat gta tat att att ctg caa gct ttc ata ctg act act aca 440
Phe Tyr Asp Val Tyr Ile Ile Leu Gln Ala Phe Ile Leu Thr Thr Thr
65 70 75 80
gta ttt ttt ggt ttg act gtg tat act cta caa tct aag aag gat ttc 488
Val Phe Phe Gly Leu Thr Val Tyr Thr Leu Gln Ser Lys Lys Asp Phe
85 90 95
agc aaa ttt gga gca ggg ctg ttt gct ctt ttg tgg ata ttg tgc ctg 536
Ser Lys Phe Gly Ala Gly Leu Phe Ala Leu Leu Trp Ile Leu Cys Leu
100 105 110
tca gga ttc ttg aag ttt ttt tta tat agt gag ata atg gag ttg gtc 584
Ser Gly Phe Leu Lys Phe Phe Leu Tyr Ser Glu Ile Met Glu Leu Val
115 120 125
tta gcc gct gca gga gcc ctt ctt ttc tgt gga ttc atc atc tat gac 632
Leu Ala Ala Ala Gly Ala Leu Leu Phe Cys Gly Phe Ile Ile Tyr Asp
130 135 140
aca cac tca ctg atg cat aaa ctg tca cct gaa gag tac gta tta gct 680
Thr His Ser Leu Met His Lys Leu Ser Pro Glu Glu Tyr Val Leu Ala
145 150 155 160
gcc atc agc ctc tac ttg gat atc atc aat cta ttc ctg cac ctg tta 728
Ala Ile Ser Leu Tyr Leu Asp Ile Ile Asn Leu Phe Leu His Leu Leu
165 170 175
cgg ttt ctg gaa gca gtt aat aaa aag taattaaaag tatctcagct 775
Arg Phe Leu Glu Ala Val Asn Lys Lys
180 185
caactgaaga acaacaaaaa aaatttaacg agaaaaaagg attaaagtaa ttggaagcag 835
tatatagaaa ctgtttcatt aagtaataaa gtttgaacca ataaaaaaaa aaaaaaaa 893
<210> 45
<211> 644
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 23..340
<223> sig_peptide
<222> 23..235
<223> Von Heijne matrix
score 3.9

```

seq VAVYCSFISFANS/RS
<223> polyA_signal
<222> 611..616
<223> polyA_site
<222> 629..644
<400> 45
gtgatctggc cttcgactcg ct atg tcc act aac aat atg tgc gac cca cgg      52
                               Met Ser Thr Asn Asn Met Ser Asp Pro Arg
                               -70                               -65
agg ccg aac aaa gtg ctg agg tac aag ccc ccg ccg agc gaa tgt aac      100
Arg Pro Asn Lys Val Leu Arg Tyr Lys Pro Pro Pro Ser Glu Cys Asn
-60                               -55                               -50
ccg gcc ttg gac gac ccg acg ccg gac tac atg aac ctg ctg ggc atg      148
Pro Ala Leu Asp Asp Pro Thr Pro Asp Tyr Met Asn Leu Leu Gly Met
-45                               -40                               -35
atc ttc agc atg tgc ggc ctc atg ctt aag ctg aag tgg tgt gct tgg      196
Ile Phe Ser Met Cys Gly Leu Met Leu Lys Leu Lys Trp Cys Ala Trp
-25                               -20                               -15
gtc gct gtc tac tgc tcc ttc atc agc ttt gcc aac tct cgg agc tgc      244
Val Ala Val Tyr Cys Ser Phe Ile Ser Phe Ala Asn Ser Arg Ser Ser
-10                               -5                               1
gag gac acg aag caa atg atg agt agc ttc atg ctg tcc atc tct gcc      292
Glu Asp Thr Lys Gln Met Met Ser Ser Phe Met Leu Ser Ile Ser Ala
5                               10                               15
gtg gtg atg tcc tat ctg cag aat cct cag ccc atg acg ccc cca tgg      340
Val Val Met Ser Tyr Leu Gln Asn Pro Gln Pro Met Thr Pro Pro Trp
20                               25                               30                               35
tgataccagc ctagaagggt cacatttttg accctgtcta tccactaggc ctgggctttg      400
gctgctaacc ctgctgcctt cagctgccat cctggacttc cctgaatgag gccgtctcgg      460
tgccccagc tggatagagg gaacctggcc ctttcctagg gaacacccta ggcttaccce      520
tcctgcctcc ctccccctgc ctgctgctgg gggagatgct gtccatgttt ctagggggtat      580
tcatttgctt tctcgttgaa acctgttggt aataaagttt ttcactctaa aaaaaaaaaa      640
aaaa
<210> 46
<211> 538
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 12..380
<223> sig_peptide
<222> 12..263
<223> Von Heijne matrix
score 6.2
seq GLFRAAWLPGSRP/SP
<223> polyA site
<222> 523..538
<400> 46
ctgaattcct t atg tcc ggt ggg cca gaa gcc cgt cct cct atg ctg gtg      50
                               Met Ser Gly Gly Pro Glu Ala Arg Pro Pro Met Leu Val
                               -80                               -75
gaa ggc gga gga ccg gag tcc ctg cag aag gcc ccg tgc act cgg ggg      98
Glu Gly Gly Gly Pro Glu Ser Leu Gln Lys Ala Pro Cys Thr Arg Gly
-70                               -65                               -60
cct ccc tca cat ccc gtg ccc cct gcg ctg gcc ttc aca gta ggt aat      146
Pro Pro Ser His Pro Val Pro Pro Ala Leu Ala Phe Thr Val Gly Asn
-55                               -50                               -45                               -40
ggc tcc ggc ccg ggt gtt cgc tgt cca cgg aac atg gca gag ggg cac      194
Gly Ser Gly Pro Gly Val Arg Cys Pro Arg Asn Met Ala Glu Gly His
-35                               -30                               -25
ccc ggc ccg gaa aga cgc cag agc cag cag ggg ctg ttt cgg gcc gcg      242

```

Pro Gly Pro Glu Arg Arg Gln Ser Gln Gln Gly Leu Phe Arg Ala Ala
 -20 -15 -10
 tgg ctc ccc ggg tct cgg ccg tct ccc ctc ttc tgc gtc tgt tcc gtg 290
 Trp Leu Pro Gly Ser Arg Pro Ser Pro Leu Phe Cys Val Cys Ser Val
 -5 1 5
 act tcg cct ggg tgg gat gta ccg cag gtg cat cgc gtc gag gtg ggg 338
 Thr Ser Pro Gly Trp Asp Val Pro Gln Val His Arg Val Glu Val Gly
 10 15 20 25
 cac ggc cgc cgg caa gaa acc cac cct gtc cgg agg cgg gcg 380
 His Gly Arg Arg Gln Glu Thr His Pro Val Arg Arg Arg Ala
 30 35
 tgagacaagc ccagcccgcg cgcgcctcctc tttcttcggt ttttgatcag tttattcaga 440
 attgctctat aatttaccac ttgtatgtat ttaacctatt cttgtggaaa aaaaaggctc 500
 ttcattatat ctttatttct gcaaaaaaaaa aaaaaaaaa 538
 <210> 47
 <211> 752
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 8..232
 <223> sig_peptide
 <222> 8..154
 <223> Von Heijne matrix
 score 4.7
 seq DTFLLSFLSTTWL/KT
 <223> polyA_site
 <222> 737..752
 <400> 47
 ggggggtg atg ccg cgc ggt cgc agg ctt ggg atg gtg ttc gcg cct ccg 49
 Met Pro Arg Gly Arg Arg Leu Gly Met Val Phe Ala Pro Pro
 -45 -40
 aga ccc gga cag agg caa gca ggg gcg ccg tgg gtg cca gag agg cgg 97
 Arg Pro Gly Gln Arg Gln Ala Gly Ala Pro Trp Val Pro Glu Arg Arg
 -35 -30 -25 -20
 aag agg agg cct gat ggg gat acc ttc ctg ctg tcc ttc ctg agc aca 145
 Lys Arg Arg Pro Asp Gly Asp Thr Phe Leu Leu Ser Phe Leu Ser Thr
 -15 -10 -5
 acc tgg ctg aaa acc tgg agg tca caa cag tac aaa gaa tca aag tca 193
 Thr Trp Leu Lys Thr Trp Arg Ser Gln Gln Tyr Lys Glu Ser Lys Ser
 1 5 10
 aga tct tgt gcc aga gag caa atg aac tct tcc tct tgc tgagaaaacc 242
 Arg Ser Cys Ala Arg Glu Gln Met Asn Ser Ser Ser Cys
 15 20 25
 caccctgctc acctaaaccc tggccttgcc tggtaattcc atccatgcgc ctggaaggcc 302
 ccagacatca aggtcttgag gggccaggca cggggagAAC ccagcagtgc cctgccctgc 362
 agtctgagct accagattcc ttgtgaagat aatttgagga ccatgactca cccaaccaca 422
 tttcctgggg cctcaaattg aaaattcagg atgggctttt ctatatgact ggctgatatc 482
 caactatgcc atggtcttta catgccatga acattctttc ctgccagagt tctaagaatc 542
 tgtgttctct gccttagacc ttctgcagat gagcccacag gaagctccac gtgtagctga 602
 gctacatgca ccaggcctca gtttgcccca agtcccctgt gtactctctc atggcctgtg 662
 gccaaagaaat gtattctctc actttggact taggagtcca aagagaagcc cagaaacaaa 722
 attgcttgaa cttgaaaaaa aaaaaaaaaa 752
 <210> 48
 <211> 537
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 183..422
 <223> sig_peptide

<222>	183..302	
<223>	Von Heijne matrix	
	score 5.8	
	seq VLFALFVAFLLRG/KL	
<223>	polyA_signal	
<222>	505..510	
<223>	polyA_site	
<222>	523..537	
<400>	48	
agtatctcac	catttctttc	tctttctgaa
tggttctcttt	caaaattacc	aacatggacc
cgcttgactg	atcatctgat	acagcagttc
ag	atg	gat
Met	Asp	Gly
-40		
caa	cta	ctg
Gln	Leu	Leu
-25		
ttg	ttt	gtg
Leu	Phe	Val
-5		
tcg	cag	aaa
Ser	Gln	Lys
10		
ctc	aat	gac
Leu	Asn	Asp
25		
ctc	taacaacgca	gtagcatgtt
Leu		
40		
gtcaaaataa	gtcttagtag	atttccttgt
aaaaa		
<210>	49	
<211>	1602	
<212>	DNA	
<213>	Homo sapiens	
<220>		
<223>	CDS	
<222>	24..1004	
<223>	sig_peptide	
<222>	24..170	
<223>	Von Heijne matrix	
	score 5.6	
	seq ACLSLGFFSLWL/QL	
<223>	polyA_site	
<222>	1586..1602	
<400>	49	
atgcgccgcc	gcctctccgc	acg
	Met	Phe
	-45	
ctg	ccc	tgg
Leu	Pro	Trp
	-35	
cgg	aag	tgt
Arg	Lys	Cys
-20		
ttc	ttc	tcc
Phe	Phe	Ser
-5		
cgg	gca	gtc
Arg	Ala	Val

10	15	20	25	
tgc ccc cca gag ccg ccc cct gag cac tgg gaa gaa gac gca tcc tgg				293
Cys Pro Pro Glu Pro Pro Glu His Trp Glu Glu Asp Ala Ser Trp				
30	35	40		
ggc ccc cac cgc ctg gca gtg ctg gtg ccc ttc cgc gaa cgc ttc gag				341
Gly Pro His Arg Leu Ala Val Leu Val Pro Phe Arg Glu Arg Phe Glu				
45	50	55		
gag ctg ctg gtc ttc gtg ccc cac atg cgc cgc ttc ctg agc agg aag				389
Glu Leu Leu Val Phe Val Pro His Met Arg Arg Phe Leu Ser Arg Lys				
60	65	70		
aag atc cgg cac cac atc tac gtg ctg aac cag gtg gac cac ttc agg				437
Lys Ile Arg His His Ile Tyr Val Leu Asn Gln Val Asp His Phe Arg				
75	80	85		
ttc aac cgg gca gcg ctg atc aac gtg ggc ttc ctg gag agc agc aac				485
Phe Asn Arg Ala Ala Leu Ile Asn Val Gly Phe Leu Glu Ser Ser Asn				
90	95	100	105	
agc acg gac tac att gcc atg cac gac gtt gac ctg ctg cct ctg aac				533
Ser Thr Asp Tyr Ile Ala Met His Asp Val Asp Leu Leu Pro Leu Asn				
110	115	120		
gag gag ctg gac tat ggc ttt cct gag gct ggg ccc ttc cac gtg gcc				581
Glu Glu Leu Asp Tyr Gly Phe Pro Glu Ala Gly Pro Phe His Val Ala				
125	130	135		
tcc ccg gag ctg cac cct ctg tac cac tac aag acc tat gtc ggc ggc				629
Ser Pro Glu Leu His Pro Leu Tyr His Tyr Lys Thr Tyr Val Gly Gly				
140	145	150		
atc ctg ctg ctg tcc aag cag cac tac cgg ctg tgc aat ggg atg tcc				677
Ile Leu Leu Leu Ser Lys Gln His Tyr Arg Leu Cys Asn Gly Met Ser				
155	160	165		
aac cgc ttc tgg ggc tgg ggc cgc gag gac gag ttc tac cgg cgc				725
Asn Arg Phe Trp Gly Trp Gly Arg Glu Asp Asp Glu Phe Tyr Arg Arg				
170	175	180	185	
att aag gga gct ggg ctg cag ctt ttc cgc ccc tgc gga atc aca act				773
Ile Lys Gly Ala Gly Leu Gln Leu Phe Arg Pro Ser Gly Ile Thr Thr				
190	195	200		
ggg tac aag aca ttt cgc cac ctg cat gac cca gcc tgg cgg aag agg				821
Gly Tyr Lys Thr Phe Arg His Leu His Asp Pro Ala Trp Arg Lys Arg				
205	210	215		
gac cag aag cgc atc gca gct caa aaa cag gag cag ttc aag gtg gac				869
Asp Gln Lys Arg Ile Ala Ala Gln Lys Gln Glu Gln Phe Lys Val Asp				
220	225	230		
agg gag gga ggc ctg aac act gtg aag tac cat gtg gct tcc cgc act				917
Arg Glu Gly Gly Leu Asn Thr Val Lys Tyr His Val Ala Ser Arg Thr				
235	240	245		
gcc ctg tct gtg ggc ggg gcc ccc tgc act gtc ctg aac atc atg ttg				965
Ala Leu Ser Val Gly Gly Ala Pro Cys Thr Val Leu Asn Ile Met Leu				
250	255	260	265	
gac tgt gac aag acc gcc aca ccc tgg tgc aca ttc agc tgagctggat				1014
Asp Cys Asp Lys Thr Ala Thr Pro Trp Cys Thr Phe Ser				
270	275			
ggacagtgag gaagcctgta cctacaggcc atattgctca ggctcaggac aaggcctcag				1074
gtcgtgggcc cagctctgac aggatgtgga gtggccagga ccaagacagc aagctacgca				1134
attgcagcca cccggccgcc aaggcaggct tgggctgggc caggacacgt ggggtgacctg				1194
ggacgctgct tgccatgcac agtgatcaga gagaggctgg ggtgtgtcct gtccgggacc				1254
ccccctgcct tctgtctcac cctactctga cctccttcac gtgcccaggc ctgtgggtag				1314
tggggaggggc tgaacaggac aacctctcat cccccccact ttgttccctt cctgctgggc				1374
tgcctcgtgc agagacacag tgtagggggc atgcagctgg cgtaggtggc agttgggcct				1434
ggtgagggtt aggacttcag aaaccagagc acaagcccca cagaggggga acagccagca				1494
ccgctctagc tggttgttgcc catgccggaa tgtgggccta gtgttgccag atcttctgat				1554
ttttcgaaag aaactagaat gctggattct caaaaaaaaa aaaaaaaaaa				1602
<210> 50				
<211> 948				

<212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 80..784
 <223> sig_peptide
 <222> 80..139
 <223> Von Heijne matrix
 score 4
 seq LLKVVFVVFASLC/AW
 <223> polyA_signal
 <222> 910..915
 <223> polyA_site
 <222> 933..948
 <400> 50
 cttcctgacc caggggctcc gctggctgcg gtcgcctggg agctgccgcc agggccagga 60
 ggggagcggc acctggaag atg cgc cca ttg gct ggt ggc ctg ctc aag gtg 112
 Met Arg Pro Leu Ala Gly Gly Leu Leu Lys Val
 -20 -15 -10
 gtg ttc gtg gtc ttc gcc tcc ttg tgt gcc tgg tat tcg ggg tac ctg 160
 Val Phe Val Val Phe Ala Ser Leu Cys Ala Trp Tyr Ser Gly Tyr Leu
 -5 1 5
 ctc gca gag ctc att cca gat gca ccc ctg tcc agt gct gcc tat agc 208
 Leu Ala Glu Leu Ile Pro Asp Ala Pro Leu Ser Ser Ala Ala Tyr Ser
 10 15 20
 atc cgc agc atc ggg gag agg cct gtc ctc aaa gct cca gtc ccc aaa 256
 Ile Arg Ser Ile Gly Glu Arg Pro Val Leu Lys Ala Pro Val Pro Lys
 25 30 35
 agg caa aaa tgt gac cac tgg act ccc tgc cca tct gac acc tat gcc 304
 Arg Gln Lys Cys Asp His Trp Thr Pro Cys Pro Ser Asp Thr Tyr Ala
 40 45 50 55
 tac agg tta ctc agc gga ggt ggc aga agc aag tac gcc aaa atc tgc 352
 Tyr Arg Leu Leu Ser Gly Gly Gly Arg Ser Lys Tyr Ala Lys Ile Cys
 60 65 70
 ttt gag gat aac cta ctt atg gga gaa cag ctg gga aat gtt gcc aga 400
 Phe Glu Asp Asn Leu Leu Met Gly Glu Gln Leu Gly Asn Val Ala Arg
 75 80 85
 gga ata aac att gcc att gtc aac tat gta act ggg aat gtg aca gca 448
 Gly Ile Asn Ile Ala Ile Val Asn Tyr Val Thr Gly Asn Val Thr Ala
 90 95 100
 aca cga tgt ttt gat atg tat gaa ggc gat aac tct gga ccg atg aca 496
 Thr Arg Cys Phe Asp Met Tyr Glu Gly Asp Asn Ser Gly Pro Met Thr
 105 110 115
 aag ttt att cag agt gct gct cca aaa tcc ctg ctc ttc atg gtg acc 544
 Lys Phe Ile Gln Ser Ala Ala Pro Lys Ser Leu Leu Phe Met Val Thr
 120 125 130 135
 tat gac gac gga agc aca aga ctg aat aac gat gcc aag aat gcc ata 592
 Tyr Asp Asp Gly Ser Thr Arg Leu Asn Asn Asp Ala Lys Asn Ala Ile
 140 145 150
 gaa gca ctt gga agt aaa gaa atc agg aac atg aaa ttc agg tct agc 640
 Glu Ala Leu Gly Ser Lys Glu Ile Arg Asn Met Lys Phe Arg Ser Ser
 155 160 165
 tgg gta ttt att gca gca aaa ggc ttg gaa ctc cct tcc gaa att cag 688
 Trp Val Phe Ile Ala Ala Lys Gly Leu Glu Leu Pro Ser Glu Ile Gln
 170 175 180
 aga gaa aag atc aac cac tct gat gct aag aac aac aga tat tct ggc 736
 Arg Glu Lys Ile Asn His Ser Asp Ala Lys Asn Asn Arg Tyr Ser Gly
 185 190 195
 tgg cct gca gag atc cag ata gaa ggc tgc ata ccc aaa gaa cga agc 784
 Trp Pro Ala Glu Ile Gln Ile Glu Gly Cys Ile Pro Lys Glu Arg Ser
 200 205 210 215

```

tgacactgca gggctctgag taaatgtgtt ctgtataaac aaatgcagct ggaatcgctc      844
aagaatctta tttttctaaa tccaacagcc catatttgat gagtattttg ggtttgttgt      904
aaaccaatga acatttgcta gttgtaccaa aaaaaaaaaa aaaa                        948
<210> 51
<211> 687
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 67..222
<223> sig_peptide
<222> 67..159
<223> Von Heijne matrix
      score 5.8
      seq VLFSASSFPSISG/NI
<223> polyA_site
<222> 673..687
<400> 51
tacaattgga aaatctttat acattgaaaa aagcaacttt tcctccccct ctcaataggt      60
acaaga atg cgg gtt tat aaa agg aca cag ttg agg caa gag acc gga      108
      Met Arg Val Tyr Lys Arg Thr Gln Leu Arg Gln Glu Thr Gly
      -30 -25 -20
ccc aaa agt tat gtg ctc ttt agt gcc tca agt ttt cca agc atc tct      156
Pro Lys Ser Tyr Val Leu Phe Ser Ala Ser Ser Phe Pro Ser Ile Ser
      -15 -10 -5
ggt aac ata agg agt aga aat tat ttt caa aaa caa aat aat cac tgg      204
Gly Asn Ile Arg Ser Arg Asn Tyr Phe Gln Lys Gln Asn Asn His Trp
      1 5 10 15
ttc cag acc agt gat tat taaccctttt tgaattatga acccctttaa      252
Phe Gln Thr Ser Asp Tyr
      20
aacctaatga aatttaagga ccctctcccc caaaatatat atataaaaaa acaaggcagt      312
ctatggacct actgagtaac tctcaagata gtaagtaagg agagaaagat ctatgtttcc      372
ctcttttgata agtatgaaat atttgaggga gatgctaatt tttgcacgtt tatgatattt      432
gcaatctttc attttttagt cagattatac tcaaaaattt gatccagaac ttggccccta      492
ttctttttatc agcactttta cttgtaaact gaaaagttaa ccatcatctg tatgacatcc      552
taatgagggtt aaaaagataa aatgcagtta tgattatgat aggtataact gtatccaggt      612
ttccacagca aaaacaaaac aaaacataca ccatgttctg gggttattga cagcctcctc      672
aaaaaaaaaa aaaaaa                        687
<210> 52
<211> 821
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 46..732
<223> sig_peptide
<222> 46..186
<223> Von Heijne matrix
      score 9.4
      seq LILLILCVGMVVG/LV
<223> polyA_signal
<222> 781..786
<223> polyA_site
<222> 806..821
<400> 52
gcaaagtcac tgaactctga gctcagttgc agtactcggg aagcc atg cag gat gaa      57
      Met Gln Asp Glu
      -45
gat gga tac atc acc tta aat att aaa act cgg aaa cca gct ctc gtc      105
Asp Gly Tyr Ile Thr Leu Asn Ile Lys Thr Arg Lys Pro Ala Leu Val

```

```

-40          -35          -30
tcc gtt ggc cct gca tcc tcc ttc tgg tgg cgt gtg atg gct ttg att      153
Ser Val Gly Pro Ala Ser Ser Phe Trp Trp Arg Val Met Ala Leu Ile
-25          -20          -15
ctg ctg atc ctg tgc gtg ggg atg gtt gtc ggg ctg gtg gct ctg ggg      201
Leu Leu Ile Leu Cys Val Gly Met Val Val Gly Leu Val Ala Leu Gly
-10          -5          1          5
att tgg tct gtc atg cag cgc aat tac cta caa gat gag aat gaa aat      249
Ile Trp Ser Val Met Gln Arg Asn Tyr Leu Gln Asp Glu Asn Glu Asn
10          15          20
cgc aca gga act ctg caa caa tta gca aag cgc ttc tgt caa tat gtg      297
Arg Thr Gly Thr Leu Gln Gln Leu Ala Lys Arg Phe Cys Gln Tyr Val
25          30          35
gta aaa caa tca gaa cta aag ggc act ttc aaa ggt cat aaa tgc agc      345
Val Lys Gln Ser Glu Leu Lys Gly Thr Phe Lys Gly His Lys Cys Ser
40          45          50
ccc tgt gac aca aac tgg aga tat tat gga gat agc tgc tat ggg ttc      393
Pro Cys Asp Thr Asn Trp Arg Tyr Tyr Gly Asp Ser Cys Tyr Gly Phe
55          60          65
ttc agg cac aac tta aca tgg gaa gag agt aag cag tac tgc act gac      441
Phe Arg His Asn Leu Thr Trp Glu Glu Ser Lys Gln Tyr Cys Thr Asp
70          75          80          85
atg aat gct act ctc ctg aag att gac aac cgg aac att gtg gag tac      489
Met Asn Ala Thr Leu Leu Lys Ile Asp Asn Arg Asn Ile Val Glu Tyr
90          95          100
atc aaa gcc agg act cat tta att cgt tgg gtc gga tta tct cgc cag      537
Ile Lys Ala Arg Thr His Leu Ile Arg Trp Val Gly Leu Ser Arg Gln
105          110          115
aag tcg aat gag gtc tgg aag tgg gag gat ggc tcg gtt atc tca gaa      585
Lys Ser Asn Glu Val Trp Lys Trp Glu Asp Gly Ser Val Ile Ser Glu
120          125          130
aat atg ttt gag ttt ttg gaa gat gga aaa gga aat atg aat tgt gct      633
Asn Met Phe Glu Phe Leu Glu Asp Gly Lys Gly Asn Met Asn Cys Ala
135          140          145
tat ttt cat aat ggg aaa atg cac cct acc ttc tgt gag aac aaa cat      681
Tyr Phe His Asn Gly Lys Met His Pro Thr Phe Cys Glu Asn Lys His
150          155          160          165
tat tta atg tgt gag agg aag gct ggc atg acc aag gtg gac caa cta      729
Tyr Leu Met Cys Glu Arg Lys Ala Gly Met Thr Lys Val Asp Gln Leu
170          175          180
cct taatgcaaag aggtggacag gataacacag ataagggctt tattgtacaa      782
Pro
taaaagatat gtatgaatgc aacaaaaaaaa aaaaaaaaaa      821
<210> 53
<211> 445
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 81..356
<223> sig_peptide
<222> 81..152
<223> Von Heijne matrix
score 6.2
seq AILGSTWVALTTG/AL
<223> polyA_signal
<222> 406..411
<223> polyA_site
<222> 429..445
<400> 53
ngaaaaaaaa catccgggcc gcgcggggaa ggggagacgt ggggtagagg ggagcattgc      60

```


Glu Ala Leu	Leu Gly Met Asp Leu	Leu Arg Leu Ala Leu	Glu Arg Ser			
90	95	100				
agc tct gcc	cag gag gcc ttg cat	gtg atc aca ggg tta	ctg gag cac	494		
Ser Ser Ala	Gln Glu Ala Leu His	Val Ile Thr Gly Leu	Glu His			
105	110	115				
tat ggg cag	ggg ggc aac tgc	ctg gag gat gct	gcg cca ttc tcc tac	542		
Tyr Gly Gln	Gly Gly Asn Cys Leu	Glu Asp Ala Ala	Pro Phe Ser Tyr			
120	125	130				
cat agc acc	ttc ctg ctg gct	gac cgc act gag	gcg tgg gtg ctg gag	590		
His Ser Thr	Phe Leu Leu Ala	Asp Arg Thr Glu	Ala Trp Val Leu Glu			
135	140	145	150			
aca gct ggg	agg ctc tgg gct	gca cag agg atc	cag gag ggg gcc cgc	638		
Thr Ala Gly	Arg Leu Trp Ala	Ala Gln Arg Ile	Gln Glu Gly Ala Arg			
155	160	165				
aac atc tcc	aac cag ctg agc	att ggc acg gac	atc tcg gcc caa cac	686		
Asn Ile Ser	Asn Gln Leu Ser	Ile Gly Thr Asp	Ile Ser Ala Gln His			
170	175	180				
ccg gag ctg	cgg act cat gcc	cag gcc aag ggc	tgg tgg gat ggg cag	734		
Pro Glu Leu	Arg Thr His Ala	Gln Ala Lys Gly	Trp Trp Asp Gly Gln			
185	190	195				
ggt gcc ttt	gac ttt gct cag	atc ttc tcc ctg	acc cag cag cct gtg	782		
Gly Ala Phe	Asp Phe Ala Gln	Ile Phe Ser Leu	Thr Gln Gln Pro Val			
200	205	210				
cgc atg gag	gct gcc aag gcc	cgc ttc cag gca	ggg cgg gag ctg ctg	830		
Arg Met Glu	Ala Ala Lys Ala	Arg Phe Gln Ala	Gly Arg Glu Leu Leu			
215	220	225	230			
cgg caa cgg	caa ggg ggc atc	acg gca gag gtg	atg atg ggc atc ctc	878		
Arg Gln Arg	Gln Gly Ile Thr	Ala Glu Val Met	Met Gly Ile Leu			
235	240	245				
aga gac aag	gag agt ggt atc	tgt atg gac tcg	gga ggc ttt cgc acc	926		
Arg Asp Lys	Glu Ser Gly Ile	Cys Met Asp Ser	Gly Gly Phe Arg Thr			
250	255	260				
acg gcc agc	atg gtg tct gtc	ctg ccc cag gat	ccc acg cag ccc tgc	974		
Thr Ala Ser	Met Val Ser Val	Leu Pro Gln Asp	Pro Thr Gln Pro Cys			
265	270	275				
gtg cac ttt	ctt acc gcc acg	cca gac cca tcc	agg tct gtg ttc aaa	1022		
Val His Phe	Leu Thr Ala Thr	Pro Asp Pro Ser	Arg Ser Val Phe Lys			
280	285	290				
cct ttc atc	ttc ggg gtg ggg	gtg gcc cag gcc	ccc cag gtg ctg tcc	1070		
Pro Phe Ile	Phe Gly Val Gly	Val Ala Gln Ala	Pro Gln Val Leu Ser			
295	300	305	310			
ccc act ttt	gga gca caa gac	cct gtt cgg acc	ctg ccc cga ttc cag	1118		
Pro Thr Phe	Gly Ala Gln Asp	Pro Val Arg Thr	Leu Pro Arg Phe Gln			
315	320	325				
act cag gta	gat cgt cgg cat	acc ctc tac cgt	gga cac cag gca gcc	1166		
Thr Gln Val	Asp Arg Arg His	Thr Leu Tyr Arg	Gly His Gln Ala Ala			
330	335	340				
ctg ggg ctg	atg gag aga gat	cag gat cgg ggg	cag cag ctc cag cag	1214		
Leu Gly Leu	Met Glu Arg Asp	Gln Asp Arg Gly	Gln Gln Leu Gln Gln			
345	350	355				
aaa cag cag	gat ctg gag cag	gaa ggc ctc gag	gcc aca cag ggg ctg	1262		
Lys Gln Gln	Asp Leu Glu Gln	Gly Leu Glu Ala	Thr Gln Gly Leu			
360	365	370				
ctg gcc ggc	gag tgg gcc cca	ccc ctc tgg gag	ctg ggc agc ctc ttc	1310		
Leu Ala Gly	Glu Trp Ala Pro	Pro Leu Trp Glu	Leu Gly Ser Leu Phe			
375	380	385	390			
cag gcc ttc	gtg aag agg gag	agc cag gct tat	gcg taagcttcat	1356		
Gln Ala Phe	Val Lys Arg Glu	Ser Gln Ala Tyr	Ala			
395	400					
agcttctgct	ggcctggggt	ggacccagga	cccctggggc	ctgggtgccc	tgagtgggtgg	1416
taaagtggag	caatcccttc	acgctccttg	gccatgttct	gagcggccag	cttggccttt	1476

gccttaataa atgtgcttta ttttcaaaaa aaaaaaaaaa a 1517

<210> 55

<211> 1560

<212> DNA

<213> Homo sapiens

<220>

<223> CDS

<222> 194..454

<223> sig_peptide

<222> 194..379

<223> Von Heijne matrix
score 4.6
seq HILTVPLLEPARC/SG

<223> polyA_site

<222> 1545..1560

<400> 55

cattcataaa tattctctta ccattttact tgacaattat tttaggctta cagaaaagtg 60

gccagagtag tgcagggtc ctatagtgg cttcccctgt tgccatcatc tcgtctgac 120

gtagggcagg ttagcattgc tacaggctc ttaccggcc tacagctctt aggcacatct 180

gtccatttga cta atg gcc att ttc tgg ata gtc cat gct cac ttc tgg 229

Met Ala Ile Phe Trp Ile Val His Ala His Phe Trp

-60 -55

agc ccc ctc cca ccc agg ctc cca cat ggc cgg tgc tgt tgc ctg aag 277

Ser Pro Leu Pro Pro Arg Leu Pro His Gly Arg Cys Cys Cys Leu Lys

-50 -45 -40 -35

gcc cct ctt cct cct gac gtg gga ccc ctt cag gta gcc ccg cat ctt 325

Ala Pro Leu Pro Pro Asp Val Gly Pro Leu Gln Val Ala Pro His Leu

-30 -25 -20

ttc agc gtg ccc ctt cac att ctg act gtt cct ctt ctg gaa cct gca 373

Phe Ser Val Pro Leu His Ile Leu Thr Val Pro Leu Leu Glu Pro Ala

-15 -10 -5

aga tgc tct ggg atc ctt gta ttt ttc ctg cac cag ccc gtt tca tcc 421

Arg Cys Ser Gly Ile Leu Val Phe Phe Leu His Gln Pro Val Ser Ser

1 5 10

ctg agc ttc tgt tat ttt att gga gga tgg tgc tagaaacaca ggtctggatg 474

Leu Ser Phe Cys Tyr Phe Ile Gly Gly Trp Cys

15 20 25

caggcaggag acacacgct ccacactagc atgcgtgtgt acacacatct acatgtgctt 534

atcccccgcg ttcattgttaa aaaccatggg atcataccgg tgtttcagat tcacatccac 594

cccagcaggg tttctcgccc ccattgctta taaccttagc aggtgttgag aaccctggcg 654

ctcactgtcc acagttaggt tgcttattcg ttgaaacctg gcgtgcctgt agagtgtgga 714

gagttgccgg ccgcaccccc tgcgagacac agactttctg accgcagccc tcatgtgtgt 774

ggctcttctt gtccttggcc ttacagtga gtcggatcgc tgctttccag agttgcctgg 834

gggtaggtcc ctctcttct gtgctctgcg gcgcagttag cggcctttgc ctcaggcctc 894

ccgcggcttc cttaagcctc tggcctgccc ggtccctggc gccaggctctg ttttcctgc 954

tccttctct ctgacccctgc tttggtctga gccgtgcctc tgggccccag cattgctggg 1014

ccgcattgtc gttttatttc tcttgtgtcg ttgcgtctag tgtaagacat tcagtggatc 1074

attgtggatg gtcattagt gtcacagagt gaaagttagg tcgttggttg tgggtgacct 1134

acagtgcctg ttagggagct gttcctggtg ttgcccgtga atattagact tgctcccag 1194

cctgcgccac agcccatccc tagcgactta gcgacagtgg ctgccagggt cgggtggctg 1254

tgtcttgat acactgtgtg ggcagcccag ggccaggggc ctccctctc catggcagcc 1314

tctgtctga tcacagagat aaggccgcgg ctgccaccag gataaggagc cagcagctgc 1374

tctcggagga gccgcctga cccctccca tcatgccgc gtgggggttc catgcagaat 1434

tttccctggg cagagttgct ttttgattct agtttttaa aaaactgtt tttccatcat 1494

gataaaaaga aagacatgct catttcaaat agtttaggag atgtggaagc aaaaaaaaaa 1554

aaaaaa 1560

<210> 56

<211> 1066

<212> DNA

<213> Homo sapiens

<220>

<223>	CDS	
<222>	48..494	
<223>	sig_peptide	
<222>	48..347	
<223>	Von Heijne matrix	
	score 3.7	
	seq LASSFLFTMGGLG/FI	
<223>	polyA_signal	
<222>	1031..1036	
<223>	polyA_site	
<222>	1051..1066	
<400>	56	
gaggcgcggtg gggccttgagg ccgagaacgg cccttgctgc caccaac atg gag act		56
	Met Glu Thr	
	-100	
ttg tac cgt gtc ccg ttc tta gtg ctc gaa tgt ccc aac ctg aag ctg		104
Leu Tyr Arg Val Pro Phe Leu Val Leu Glu Cys Pro Asn Leu Lys Leu		
-95 -90 -85		
aag aag ccg ccc tgg ttg cac atg ccg tcg gcc atg act gtg tat gct		152
Lys Lys Pro Pro Trp Leu His Met Pro Ser Ala Met Thr Val Tyr Ala		
-80 -75 -70		
ctg gtg gtg gtg tct tac ttc ctc atc acc gga gga ata att tat gat		200
Leu Val Val Val Ser Tyr Phe Leu Ile Thr Gly Gly Ile Ile Tyr Asp		
-65 -60 -55 -50		
ggt att gtt gaa cct cca agt gtc ggt tct atg act gat gaa cat ggg		248
Val Ile Val Glu Pro Pro Ser Val Gly Ser Met Thr Asp Glu His Gly		
-45 -40 -35		
cat cag agg cca gta gct ttc ttg gcc tac aga gta aat gga caa tat		296
His Gln Arg Pro Val Ala Phe Leu Ala Tyr Arg Val Asn Gly Gln Tyr		
-30 -25 -20		
att atg gaa gga ctt gca tcc agc ttc cta ttt aca atg gga ggt tta		344
Ile Met Glu Gly Leu Ala Ser Ser Phe Leu Phe Thr Met Gly Gly Leu		
-15 -10 -5		
ggt ttc ata atc ctg gac cga tcg aat gca cca aat atc cca aaa ctc		392
Gly Phe Ile Ile Leu Asp Arg Ser Asn Ala Pro Asn Ile Pro Lys Leu		
1 5 10 15		
aat aga ttc ctt ctt ctg ttc att gga ttc gtc tgt gtc cta ttg agt		440
Asn Arg Phe Leu Leu Phe Ile Gly Phe Val Cys Val Leu Leu Ser		
20 25 30		
ttt ttc atg gct aga gta ttc atg aga atg aaa ctg ccg ggc tat ctg		488
Phe Phe Met Ala Arg Val Phe Met Arg Met Lys Leu Pro Gly Tyr Leu		
35 40 45		
atg ggt tagagtgcct ttgagaagaa atcagtggtat actggatttg ctctgtcaa		544
Met Gly		
tgaagtttta aaggctgtac caatcctcta atatgaaatg tggaaaagaa tgaagagcag		604
cagtaaaaaga aatatctagt gaaaaaacag gaagcgtatt gaagcttgga ctagaatttc		664
ttcttggtat taaagagaca agttttatcac agaatttttt ttcttgctgg cctattgcta		724
taccaatgat gttgagtggc attttctttt tagtttttca ttaaaaatata ttccatatct		784
acaactataa tatcaaataa agtgattatt ttttacaacc ctcttaacat tttttggaga		844
tgacatttct gattttcaga aattaacata aaatccagaa gcaagattcc gtaagctgag		904
aactctggac agttgatcag ctttacctat ggtgctttgc ctttaactag agtgtgtgat		964
ggtagattat ttcatgatg tatgtaaaac tgtttcctga acaataagat gtatgaacgg		1024
agcagaataa aatacttttt ctaattaaaa aaaaaaaaaa aa		1066
<210>	57	
<211>	1061	
<212>	DNA	
<213>	Homo sapiens	
<220>		
<223>	CDS	
<222>	111..671	
<223>	sig peptide	


```

<223> CDS
<222> 5..373
<223> sig_peptide
<222> 5..82
<223> Von Heijne matrix
      score 4
      seq SLFWFTVITLSFG/YY
<223> polyA_signal
<222> 1986..1991
<223> polyA_site
<222> 2010..2025
<400> 58
agcc atg gct acg gca gcc ggc gcg acc tac ttt cag cga ggc agt ctg      49
      Met Ala Thr Ala Ala Gly Ala Thr Tyr Phe Gln Arg Gly Ser Leu
      -25 -20 -15
      ttc tgg ttc aca gtc atc acc ctc agc ttt ggc tac tac aca tgg gtt      97
      Phe Trp Phe Thr Val Ile Thr Leu Ser Phe Gly Tyr Tyr Thr Trp Val
      -10 -5 1 5
      gtc ttc tgg cct cag agt atc cct tat cag aac ctt ggg ccc ctg ggc      145
      Val Phe Trp Pro Gln Ser Ile Pro Tyr Gln Asn Leu Gly Pro Leu Gly
      10 15 20
      ccc ttc act cag tac ttg gtg gac cac cat cac acc ctc ctg tgc aat      193
      Pro Phe Thr Gln Tyr Leu Val Asp His His His Thr Leu Leu Cys Asn
      25 30 35
      ggg tat tgg ctt gcc tgg ctg att cat gtg gga gag tcc ttg tat gcc      241
      Gly Tyr Trp Leu Ala Trp Leu Ile His Val Gly Glu Ser Leu Tyr Ala
      40 45 50
      ata gta ttg tgc aag cat aaa ggc atc aca agt ggt cgg gct cag cta      289
      Ile Val Leu Cys Lys His Lys Gly Ile Thr Ser Gly Arg Ala Gln Leu
      55 60 65
      ctc tgg ttc cta cag act ttc ttc ttt ggg ata gcg tct ctc acc atc      337
      Leu Trp Phe Leu Gln Thr Phe Phe Phe Gly Ile Ala Ser Leu Thr Ile
      70 75 80 85
      ttg att gct tac aaa cgg aag cgc caa aaa caa act tgaagttgtc      383
      Leu Ile Ala Tyr Lys Arg Lys Arg Gln Lys Gln Thr
      90 95
      tgaagcttg ctctacactt ttacattcat cctcaccctt ttttttgtgg ggtagaggag      443
      gtgcagtaat ttactcagtg atctttctac ttcttagaaa ctgtccttca aagctcttta      503
      agacccctc gttagtcagt tttttctctt atatgctctg gttgagcttg aatagaccag      563
      ttgttactta agaaagaaac agagaaagat tttagctttt caatcctatt tggcagagga      623
      cttcagctac cttcttacag tctttggctg tgttggtacc ctctgtgtgct ctgagctaag      683
      ccacatacta aactgacttt ttggtttgta tacccttgct cccgccttct gatgaaaaca      743
      ccttaccctc acaaccacca tctttcctct cctttccaaa gctctttcca ccttgctgca      803
      ctaagataaa gtgacacttc cactatatgt caattccaca cacatttatt aggtacctgt      863
      gaggtaggat cctatcctct caaacttcca tttctcatgc tacagagaaa gataaggaag      923
      atgagcaagt gcctggaatg gggcaggctg agcagtcaca caggcataga ggcacgctga      983
      gaacctggag gggagactgc agagtgcctt ccctgatgct gcagccggaa gtgatccttc      1043
      cctccacctg gcccctggga cactgtgctc tgcagtgtgc agggcctgat ggcactgcta      1103
      gattgctcct tcagctcagg gccacagctt aaacagcttt acctttcccc tcagcacctg      1163
      tcccactatc ttgcacacag gtgctctaac catgtttatt gaacaaagga gggaaactga      1223
      tttcactttc acttgttcat tatcattcca atttttatgt gaaaatggca caaccattt      1283
      ggggtaccct caccctaaaa taaaagccca agtctacctt tgactggtac cacctttttt      1343
      gtggtttcgt ttgttgagaaa cctttatctt ttctatacct ttctattctc aatcacttct      1403
      ccaaaagtgt tgctttccag ctctgattta ttcaaaacac aagcatttct gtttagagat      1463
      tctagcccat gggttatctg gctagttatt acctctcctg ttcacttagt tatactttat      1523
      tattgtcac aggctgggga ggcagaatga ctctgtcacc actaggagcc attagggctt      1583
      cttccctgga ggactgcctg cttgctttct ggggacacta gccctcattt cccttctgtg      1643
      gtacagtggg gcaaattatt tgtattaagc aaacatttat gggaaacaac ccgctcccga      1703
      aaacggagcc cccaagtaaa gcacaaccct gaaagattat gaactatgaa ttgtctctgg      1763
      tagagataaa tttctgcaaa catatctcag tcttccctct gtttctctgg tgattaagaa      1823
      gttccttttt ggtaaggaaa aggattttta accatagagt taggcatcat ggaaattcaa      1883

```

```

accagatttc ttaatacctg gtcttcctca aagagaaata ataacagtaa tagtggtgct 1943
gggaacaata tggcagatta ttgaatgaaa ttgattaact tgaataaaat gctgtgaatt 2003
ttctctaaaa aaaaaaaaaa aa 2025
<210> 59
<211> 591
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 14..472
<223> sig_peptide
<222> 14..319
<223> Von Heijne matrix
      score 4.9
      seq VFFFGVSIILVLG/ST
<223> polyA_signal
<222> 555..560
<223> polyA_site
<222> 576..591
<400> 59
agcaccatct gtc atg gcg gct ggg ctg ttt ggt ttg agc gct cgc cgt 49
          Met Ala Ala Gly Leu Phe Gly Leu Ser Ala Arg Arg
          -100
          -95
ctt ttg gcg gca gcg gcg acg cga ggg ctg ccg gcc gcc cgc gtc cgc 97
Leu Leu Ala Ala Ala Ala Thr Arg Gly Leu Pro Ala Ala Arg Val Arg
-90          -85          -80          -75
tgg gaa tct agc ttc tcc agg act gtg gtc gcc ccg tcc gct gtg gcg 145
Trp Glu Ser Ser Phe Ser Arg Thr Val Val Ala Pro Ser Ala Val Ala
          -70          -65          -60
gga aag cgg ccc cca gaa ccg acc aca ccg tgg caa gag gac cca gaa 193
Gly Lys Arg Pro Pro Glu Pro Thr Thr Pro Trp Gln Glu Asp Pro Glu
          -55          -50          -45
ccc gag gac gaa aac ttg tat gag aag aac cca gac tcc cat ggt tat 241
Pro Glu Asp Glu Asn Leu Tyr Glu Lys Asn Pro Asp Ser His Gly Tyr
          -40          -35          -30
gac aag gac ccc gtt ttg gac gtc tgg aac atg cga ctt gtc ttc ttc 289
Asp Lys Asp Pro Val Leu Asp Val Trp Asn Met Arg Leu Val Phe Phe
          -25          -20          -15
ttt ggc gtc tcc atc atc ctg gtc ctt ggc agc acc ttt gtg gcc tat 337
Phe Gly Val Ser Ile Ile Leu Val Leu Gly Ser Thr Phe Val Ala Tyr
-10          -5          1          5
ctg cct gac tac agg atg aaa gag tgg tcc cgc cgc gaa gct gag agg 385
Leu Pro Asp Tyr Arg Met Lys Glu Trp Ser Arg Arg Glu Ala Glu Arg
          10          15          20
ctt gtg aaa tac cga gag gcc aat ggc ctt ccc atc atg gaa tcc aac 433
Leu Val Lys Tyr Arg Glu Ala Asn Gly Leu Pro Ile Met Glu Ser Asn
          25          30          35
tgc ttc gac ccc agc aag atc cag ctg cca gag gat gag tgaccagttg 482
Cys Phe Asp Pro Ser Lys Ile Gln Leu Pro Glu Asp Glu
          40          45          50
ctaagtgggg ctcaagaagc accgccttcc ccaccacctg cctgccattc tgacctcttc 542
tcagagcacc taattaaagg ggctgaaagt ctgaaaaaaaa aaaaaaaaaa 591
<210> 60
<211> 544
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 2..217
<223> polyA_signal
<222> 489..494

```

```

<223> polyA_site
<222> 529..544
<400> 60
t cta cct gtg agt act agg atc atc aat cat atc tac agc ttc ccc tca      49
  Leu Pro Val Ser Thr Arg Ile Ile Asn His Ile Tyr Ser Phe Pro Ser
    1             5             10             15
gtt gat tta tgg ata gtt tgt att ttc act gta tct gtc tca cac ctt      97
Val Asp Leu Trp Ile Val Cys Ile Phe Thr Val Ser Val Ser His Leu
    20             25             30
ttt gaa aag gga aca ttg tat ggc tac ttt tat gtg att aac tcc tcc      145
Phe Glu Lys Gly Thr Leu Tyr Gly Tyr Phe Tyr Val Ile Asn Ser Ser
    35             40             45
atc aat tta tgt gtc aat gat tgc ctt cct gta atg gat tca att tct      193
Ile Asn Leu Cys Val Asn Asp Cys Leu Pro Val Met Asp Ser Ile Ser
    50             55             60
ctg tct cca ttg ttt ctt tct cac tagagaagtt ctttaaaatt ctatgaaaat      247
Leu Ser Pro Leu Phe Leu Ser His
    65             70
gaaactgtgc taaattaaaa atctactcat gataacagga gacactcaaa attatgggtt      307
tcagtttcag gcttctcacc atgtcttcag attgtactcc ctttctagcc cttctgcagc      367
aaataaacct ttgccatcag ttcacaaaaa gcaactcatga gaggaaaaaat ggcatatcac      427
taaatataga gttctttgtc acttcttgat ttcaaattta caactaatac tcaacacttt      487
aattaaatct ttcttttctc ttcttcttaa aacatacatg caaaaaaaaa aaaaaaa      544
<210> 61
<211> 1689
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 51..575
<223> sig_peptide
<222> 51..110
<223> Von Heijne matrix
      score 11.2
      seq AFLLLVALSYTLA/RD
<223> polyA_signal
<222> 1653..1658
<223> polyA_site
<222> 1674..1689
<400> 61
agaagcttgg accgcatacct agccgccgac tcacacaagg cagagttgcc atg gag      56
                               Met Glu
                               -20
aaa att cca gtg tca gca ttc ttg ctc ctt gtg gcc ctc tcc tac act      104
Lys Ile Pro Val Ser Ala Phe Leu Leu Leu Val Ala Leu Ser Tyr Thr
      -15             -10             -5
ctg gcc aga gat acc aca gtc aaa cct gga gcc aaa aag gac aca aag      152
Leu Ala Arg Asp Thr Thr Val Lys Pro Gly Ala Lys Lys Asp Thr Lys
    1             5             10
gac tct cga ccc aaa ctg ccc cag acc ctc tcc aga ggt tgg ggt gac      200
Asp Ser Arg Pro Lys Leu Pro Gln Thr Leu Ser Arg Gly Trp Gly Asp
    15             20             25             30
caa ctc atc tgg act cag aca tat gaa gaa gct cta tat aaa tcc aag      248
Gln Leu Ile Trp Thr Gln Thr Tyr Glu Glu Ala Leu Tyr Lys Ser Lys
    35             40             45
aca agc aac aaa ccc ttg atg att att cat cac ttg gat gag tgc cca      296
Thr Ser Asn Lys Pro Leu Met Ile Ile His His Leu Asp Glu Cys Pro
    50             55             60
cac agt caa gct tta aag aaa gtg ttt gct gaa aat aaa gaa atc cag      344
His Ser Gln Ala Leu Lys Lys Val Phe Ala Glu Asn Lys Glu Ile Gln
    65             70             75

```

[illegible]

caa gtg tgt cag ctt cct ggt ctc ttt agt tat gct cag cac att gcc 254
 Gln Val Cys Gln Leu Pro Gly Leu Phe Ser Tyr Ala Gln His Ile Ala
 30 35 40
 agt atc gat ggg agg cgc ggg ttg ttc aca ggc tta act cca aga ctg 302
 Ser Ile Asp Gly Arg Arg Gly Leu Phe Thr Gly Leu Thr Pro Arg Leu
 45 50 55
 tgt tcg gga gtc ctt gga act gtg gtc cat ggt aaa gtt tta cag cat 350
 Cys Ser Gly Val Leu Gly Thr Val Val His Gly Lys Val Leu Gln His
 60 65 70
 tac cag gag agt gac aag ggt gag gag tta gga cct gga aat gta cag 398
 Tyr Gln Glu Ser Asp Lys Gly Glu Glu Leu Gly Pro Gly Asn Val Gln
 75 80 85 90
 aaa gaa gtc tca tct tcc ttt gac cac gtt atc aag gag aca act cga 446
 Lys Glu Val Ser Ser Ser Phe Asp His Val Ile Lys Glu Thr Thr Arg
 95 100 105
 gag atg atc gct cgt tct gct gct acc ctc atc aca cat ccc ttc cat 494
 Glu Met Ile Ala Arg Ser Ala Ala Thr Leu Ile Thr His Pro Phe His
 110 115 120
 gtg atc act ctg aga tct atg gta cag ttc att ggc aga gaa tcc aag 542
 Val Ile Thr Leu Arg Ser Met Val Gln Phe Ile Gly Arg Glu Ser Lys
 125 130 135
 tac tgt gga ctt tgt gat tcc ata ata acc atc tat cgg gaa gag ggc 590
 Tyr Cys Gly Leu Cys Asp Ser Ile Ile Thr Ile Tyr Arg Glu Glu Gly
 140 145 150
 att cta gga ttt ttc gcg ggt ctt gtt cct cgc ctt cta ggt gac atc 638
 Ile Leu Gly Phe Phe Ala Gly Leu Val Pro Arg Leu Leu Gly Asp Ile
 155 160 165 170
 ctt tct ttg tgg ctg tgt aac tca ctg gcc tac ctc gtc aat acc tat 686
 Leu Ser Leu Trp Leu Cys Asn Ser Leu Ala Tyr Leu Val Asn Thr Tyr
 175 180 185
 gca ctg gac agt ggg gtt tct acc atg aat gaa atg aag agt tat tct 734
 Ala Leu Asp Ser Gly Val Ser Thr Met Asn Glu Met Lys Ser Tyr Ser
 190 195 200
 caa gct gtc aca gga ttt ttt gcg agt atg ttg acc tat ccc ttt gtg 782
 Gln Ala Val Thr Gly Phe Phe Ala Ser Met Leu Thr Tyr Pro Phe Val
 205 210 215
 ctt gtc tcc aat ctt atg gct gtc aac aac tgt ggt ctt gct ggt gga 830
 Leu Val Ser Asn Leu Met Ala Val Asn Asn Cys Gly Leu Ala Gly Gly
 220 225 230
 tgc cct cct tac tcc cca ata tat acg tct tgg ata gac tgt tgg tgc 878
 Cys Pro Pro Tyr Ser Pro Ile Tyr Thr Ser Trp Ile Asp Cys Trp Cys
 235 240 245 250
 atg cta caa aaa gag ggg aat atg agc cga gga aat agc tta ttt ttc 926
 Met Leu Gln Lys Glu Gly Asn Met Ser Arg Gly Asn Ser Leu Phe Phe
 255 260 265
 cgg aag gtc ccc ttt ggg aag act tat tgt gac ctg aaa atg tta 974
 Arg Lys Val Pro Phe Gly Lys Thr Tyr Cys Asp Leu Lys Met Leu
 270 275 280
 att tgaagatgtg gggcagggac agtgacattt ctgtagtccc agatgcacag 1027
 Ile
 aattatggga gagaatgttg atttctatac agtgtggcgc gcttttttaa taatcattta 1087
 atcttgcaaa aaaaaaaaaa aaaa 1111
 <210> 63
 <211> 554
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 44..238
 <223> sig_peptide
 <222> 44..160

```

<223> Von Heijne matrix
      score 3.9
      seq FKTI AFLLLYVSA/GP
<223> polyA_signal
<222> 443..448
<223> polyA_site
<222> 540..554
<400> 63
atcctcaaca gaataattgc tgacaaactc tcttgcccag aaa atg tct act gga      55
                                     Met Ser Thr Gly
att atg gag tac aaa aaa act aca aaa gca atg aaa aaa aag aag gat      103
Ile Met Glu Tyr Lys Lys Thr Thr Lys Ala Met Lys Lys Lys Lys Asp
-35                               -25      -20
gtt tta ttt aca tcc tat ttc aaa acc att gct ttc ttg cta ttg tat      151
Val Leu Phe Thr Ser Tyr Phe Lys Thr Ile Ala Phe Leu Leu Leu Tyr
-15                               -10      -5
gtc tct gca ggc cca ata tcg cga atc ttc ata aga agt tta gaa ttg      199
Val Ser Ala Gly Pro Ile Ser Arg Ile Phe Ile Arg Ser Leu Glu Leu
      1                               5      10
ttc ctt atg ttt cct tct aac aaa cac tgg tat att tca tgaaagtgt      248
Phe Leu Met Phe Pro Ser Asn Lys His Trp Tyr Ile Ser
      15                               20      25
tattttattc acttccaaaa cagtttagctc ataattcaga acattgaggt ttgcaaaatg      308
actgaaggaa actttaccta aacaatagtt gccagttctg ctgagaatta tcacgggccc      368
acaacggctg tgtgtttttc catacagata ttctaatttt tttattatgc agctaatttt      428
tttttagact cgcaataaaa atagcaagtc agtctgtgca taagcatatg tttaaatcta      488
ccaggagaaa tgtctggaat ctttttggtt attaaaatta aaattcagga taaaaaaaaa      548
aaaaaa                                         554
<210> 64
<211> 1773
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 114..524
<223> sig_peptide
<222> 114..164
<223> Von Heijne matrix
      score 5.2
      seq ATLAVGLTIFVLS/VV
<223> polyA_signal
<222> 1739..1744
<223> polyA_site
<222> 1758..1773
<400> 64
gatttgcttt ctttttctcc aaaaggggag gaaattgaaa ctgagtggcc cacgatggga      60
agaggggaaa gccaggggt acaggaggcc tctgggtgaa ggcagaggct aac atg      116
                                     Met
ggg ttc gga gcg acc ttg gcc gtt ggc ctg acc atc ttt gtg ctg tct      164
Gly Phe Gly Ala Thr Leu Ala Val Gly Leu Thr Ile Phe Val Leu Ser
-15                               -10      -5
gtc gtc act atc atc atc tgc ttc acc tgc tcc tgc tgc tgc ctt tac      212
Val Val Thr Ile Ile Ile Cys Phe Thr Cys Ser Cys Cys Cys Leu Tyr
      1                               5      10      15
aag acg tgc cgc cga cca cgt ccg gtt gtc acc acc acc aca tcc acc      260
Lys Thr Cys Arg Arg Pro Arg Pro Val Val Thr Thr Thr Thr Ser Thr
      20                               25      30
act gtg gtg cat gcc cct tat cct cag cct cca agt gtg ccg ccc agc      308
Thr Val Val His Ala Pro Tyr Pro Gln Pro Pro Ser Val Pro Pro Ser
      35                               40      45
tac cct gga cca agc tac cag ggc tac cac acc atg ccg cct cag cca      356

```

Tyr Pro Gly Pro Ser Tyr Gln Gly Tyr His Thr Met Pro Pro Gln Pro
 50 55 60
 ggg atg cca gca gca ccc tac cca atg cag tac cca cca cct tac cca 404
 Gly Met Pro Ala Ala Pro Tyr Pro Met Gln Tyr Pro Pro Pro Tyr Pro
 65 70 75 80
 gcc cag ccc atg gcc cca ccg gcc tac cac gag acc ctg gct gga gga 452
 Ala Gln Pro Met Gly Pro Pro Ala Tyr His Glu Thr Leu Ala Gly Gly
 85 90 95
 gca gcc gcg ccc tac ccc gcc agc cag cct cct tac aac ccg gcc tac 500
 Ala Ala Ala Pro Tyr Pro Ala Ser Gln Pro Pro Tyr Asn Pro Ala Tyr
 100 105 110
 atg gat gcc ccg aag gcg gcc ctc tgagcattcc ctggcctctc tggctgccac 554
 Met Asp Ala Pro Lys Ala Ala Leu
 115 120
 ttggttatgt tgtgtgtgtg cgtgagtggc gtgcaggcgc gggttccttac gccccatgtg 614
 tgctgtgtgt gtccaggcac gggttccttac gccccatgtg tgctgtgtgt gtcctgcctg 674
 tatatgtggc ttctctgat gctgacaagg tggggaacaa tccttgccag agtgggctgg 734
 gaccagactt tgttctcttc ctcacctgaa attatgcttc ctaaaatctc aagccaaact 794
 caaagaatgg ggtggtgggg ggcaccctgt gaggtggccc ctgagagggt ggggcctctc 854
 cagggcacat ctggagttct tctccagctt accctagggt gaccaagtag ggctgtcac 914
 accaggggtg cgagctttc tgtgtgatgc agatgtgtcc tggtttcggc agcgtagcca 974
 gctgctgctt gaggccatgg ctctccccg gagttggggg taccggttgc agagccaggg 1034
 acatgatgca ggcgaagctt gggatctggc caagttggac ttgatcctt tgggcagatg 1094
 tcccattgct ccctggagcc tgtcatgcct gttggggatc aggcagcctc ctgatgccag 1154
 aacacctcag gcagagccct actcagctgt acctgtctgc ctggactgtc ccctgtcccc 1214
 gcatctcccc tgggaccagc tggagggcca catgcacaca cagcctagct gccccaggg 1274
 agctctgctg cccttgctgg ccctgccctt cccacaggtg agcagggtc ctgtccacca 1334
 gcacactcag ttctcttccc tgcagtgttt tcatattatt ttagccaaac attttgctg 1394
 ttttctgttt caaacatgat agttgatatg agactgaac ccctgggttg tggagggaaa 1454
 ttggctcaga gatggacaac ctggcaactg tgagtcctct cttcccagca ccagcctcat 1514
 ggaatatgca acaactcctg taccacagtc cacggtgttc tggcagcagg gacacctggg 1574
 ccaatggggc atctggacca aaggtggggg gtggggccct ggatggcagc tctggcccag 1634
 acatgaatac ctctgtttcc tctccctct attactgttt caccagagct gtcttagctc 1694
 aaatctgttg tgtttctgag tctagggtct gtacacttgt ttataataaa tgcaatcggt 1754
 tgcaaaaaaa aaaaaaaa 1773
 <210> 65
 <211> 917
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 26..487
 <223> sig_peptide
 <222> 26..64
 <223> Von Heijne matrix
 score 6.4
 seq MALLLSVLRVLLG/GF
 <223> polyA_signal
 <222> 883..888
 <223> polyA_site
 <222> 901..917
 <400> 65
 aaccacaggt ggggggagcg cggcc atg gcg ctc ctg ctt tcg gtg ctg cgt 52
 Met Ala Leu Leu Leu Ser Val Leu Arg
 -10 -5
 gta ctg ctg ggc ggc ttc ttc gcg ctc gtg ggg ttg gcc aag ctc tcg 100
 Val Leu Leu Gly Gly Phe Phe Ala Leu Val Gly Leu Ala Lys Leu Ser
 1 5 10
 gag gag atc tcg gct cca gtt tcg gag cgg atg aat gcc ctg ttc gtg 148
 Glu Glu Ile Ser Ala Pro Val Ser Glu Arg Met Asn Ala Leu Phe Val
 15 20 25

cag ttt gct gag gtg ttc ccg ctg aag gta ttt ggc tac cag cca gat	196
Gln Phe Ala Glu Val Phe Pro Leu Lys Val Phe Gly Tyr Gln Pro Asp	
30 35 40	
ccc ctg aac tac caa ata gct gtg ggc ttt ctg gaa ctg ctg gct ggg	244
Pro Leu Asn Tyr Gln Ile Ala Val Gly Phe Leu Glu Leu Leu Ala Gly	
45 50 55 60	
ttg ctg ctg gtc atg ggc cca ccg atg ctg caa gag atc agt aac ttg	292
Leu Leu Leu Val Met Gly Pro Pro Met Leu Gln Glu Ile Ser Asn Leu	
65 70 75	
ttc ttg att ctg ctc atg atg ggg gct atc ttc acc ttg gca gct ctg	340
Phe Leu Ile Leu Leu Met Met Gly Ala Ile Phe Thr Leu Ala Ala Leu	
80 85 90	
aaa gag tca cta agc acc tgt atc cca gcc att gtc tgc ctg ggg ttc	388
Lys Glu Ser Leu Ser Thr Cys Ile Pro Ala Ile Val Cys Leu Gly Phe	
95 100 105	
ctg ctg ctg ctg aat gtc ggc cag ctc tta gcc cag act aag aag gtg	436
Leu Leu Leu Leu Asn Val Gly Gln Leu Leu Ala Gln Thr Lys Lys Val	
110 115 120	
gtc aga ccc act agg aag aag act cta agt aca ttc aag gaa tcc tgg	484
Val Arg Pro Thr Arg Lys Lys Thr Leu Ser Thr Phe Lys Glu Ser Trp	
125 130 135 140	
aag tagagcatct ctgtctcttt atgccatgca gctgtcacag caggaacatg	537
Lys	
gtagaacaca gagtctatca tcttggtacc agtataatat ccagggtcag ccagtgtga	597
aagagacatt ttgtctacct ggcactgctt tctcttttta gctttactac tctttgtga	657
ggagtacatg ttatgcatat taacattcct catatcatat gaaaatacaa aataagcaga	717
aaagaaatatt aaatcaacca aaattctgat gccccaaata accactttta atgccttggt	777
gtaagtatac ctctgaactt ttttctgtgc ctttaaacag atatatattt tttttaaag	837
aaaataaaac catatatcct attttatttc ctccttttaa aaccttataa actataacac	897
tgcaaaaaaaaa aaaaaaaaaa	917
<210> 66	
<211> 641	
<212> DNA	
<213> Homo sapiens	
<220>	
<223> CDS	
<222> 80..388	
<223> sig_peptide	
<222> 80..187	
<223> Von Heijne matrix	
score 3.6	
seq RALSTFLFGSIRG/AA	
<223> polyA_signal	
<222> 609..614	
<223> polyA_site	
<222> 627..641	
<400> 66	
gccagtgcgc agacgcaggg gtcggcgccg ggtgagagcg tgcggccggg taagggcgtg	60
tggccggatt caccacaac atg gca aat ctt ttt ata agg aaa atg gtg aac	112
Met Ala Asn Leu Phe Ile Arg Lys Met Val Asn	
-35 -30	
cct ctg ctc tat ctc agt cgt cac acg gtg aag cct cga gcc ctc tcc	160
Pro Leu Leu Tyr Leu Ser Arg His Thr Val Lys Pro Arg Ala Leu Ser	
-25 -20 -15 -10	
aca ttt cta ttt gga tcc att cga ggt gca gcc ccc gtg gct gtg gaa	208
Thr Phe Leu Phe Gly Ser Ile Arg Gly Ala Ala Pro Val Ala Val Glu	
-5 1 5	
ccc ggg gca gca gtg cgc tca ctt ctc tca ccc ggc ctc ctg ccc cat	256
Pro Gly Ala Ala Val Arg Ser Leu Leu Ser Pro Gly Leu Leu Pro His	
10 15 20	
ctg ctg cct gcg ctg ggg ttc aaa aac aag act gtc ctt aat aag cgc	304

Leu Leu Pro Ala Leu Gly Phe Lys Asn Lys Thr Val Leu Asn Lys Arg
 25 30 35
 tgc aag gac tgt tac ctg gtg aag agg cgg ggt cgg tgg tac gtc tac 352
 Cys Lys Asp Cys Tyr Leu Val Lys Arg Arg Gly Arg Trp Tyr Val Tyr
 40 45 50 55
 tgt aaa acc cat ccg agg cac aag cag aga cag atg tagacccttt 398
 Cys Lys Thr His Pro Arg His Lys Gln Arg Gln Met
 60 65
 ccctccagac tcacgcacat actcgtcatc gcatcacttg ggagaatggt tgtatcttat 458
 ggaaggaatt atcacatcaa ggagtcaggg gaaagtgact ggaagcaaac gccctaaaaag 518
 ttacccatca cgtttcagtg taaatgagta actatagaag acattgcgtt atcttatttc 578
 caaaacgttc caactaaaaa acattttcct attaaaaatag accttccgaa aaaaaaaaaa 638
 aaa 641
 <210> 67
 <211> 854
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 186..443
 <223> sig_peptide
 <222> 186..407
 <223> Von Heijne matrix
 score 3.9
 seq ISCTCLLLYLTHC/IL
 <223> polyA_signal
 <222> 827..832
 <223> polyA_site
 <222> 839..854
 <400> 67
 aaatgttaat attagaaaga gtctcatagt gcttatgtga catcattctt tgcctaaagc 60
 ctttgtacct actgtaatga agctaaactc cttggcacag gatataaggc tcacgatctg 120
 gcctggactc attttcactc ccattctcag tcatccctca actccccac agtcagtcctc 180
 caaag atg cca tat gct ttc act tct cca tgc cct tgc tca ttt gtc tca 230
 Met Pro Tyr Ala Phe Thr Ser Pro Cys Pro Cys Ser Phe Val Ser
 -70 -65 -60
 ttg cct gaa ata tcc ttt tat ttc acc aaa ctg ctg ctc atc ctc aag 278
 Leu Pro Glu Ile Ser Phe Tyr Phe Thr Lys Leu Leu Leu Ile Leu Lys
 -55 -50 -45
 gcc ctg cct gag tca cct ttc ctt ctt gct tcc tcc ccc ttg cct cct 326
 Ala Leu Pro Glu Ser Pro Phe Leu Leu Ala Ser Ser Pro Leu Pro Pro
 -40 -35 -30
 ctc ccc act acc cta aga aaa ttc atc cct ccc cct tca tta ata tca 374
 Leu Pro Thr Thr Leu Arg Lys Phe Ile Pro Pro Pro Ser Leu Ile Ser
 -25 -20 -15
 tgc aca tgc ttg tta tta tat tta aca cat tgt ata tta ggt att tgt 422
 Cys Thr Cys Leu Leu Leu Tyr Leu Thr His Cys Ile Leu Gly Ile Cys
 -10 -5 1 5
 ttt gct tat cct ttt atc cta tgaaattgtg aacaatttgt tgaataattg 473
 Phe Ala Tyr Pro Phe Ile Leu
 10
 aataatcaca tatcaaaatg tagagaggtt atttgtctct tccctgtagg actccatttt 533
 caggcagtggt ctgctaagaa tccccttgac ctgggattgg aagttgtttc tcccactgct 593
 gagctccttt atattagctc ttcacctctc actcctttgt ttcttctctt ggcactttac 653
 gtctttctac ccatttaatt tgataaatgt ctcatgtcat ctttaaaact gaaggtgaca 713
 catgtctggt ttatctttat aactcaaaaa tggtgagctt aatgcagaat ggagaatagc 773
 tacttagtaa atttttaaaa tacatgctac catttttaag gggagaagaa gacaatatac 833
 atgacaaaaa aaaaaaaaaa a 854
 <210> 68
 <211> 1568
 <212> DNA

<213> Homo sapiens
 <220>
 <223> CDS
 <222> 75..1259
 <223> sig_peptide
 <222> 75..1004
 <223> Von Heijne matrix
 score 4.4
 seq VLILLFSLALIIL/PS
 <223> polyA_signal
 <222> 1536..1541
 <223> polyA_site
 <222> 1553..1568
 <400> 68
 agaaaagggtg tagtggtttgg ggcggtcaac gggctatgct ggcttgacag ggctgggctc 60
 ttcagaacag aagc atg gat ctc gga atc cct gac ctg ctg gac gcg tgg 110
 Met Asp Leu Gly Ile Pro Asp Leu Leu Asp Ala Trp
 -310 -305 -300
 ctg gag ccc cca gag gat atc ttc tcg aca gga tcc gtc ctg gag ctg 158
 Leu Glu Pro Pro Glu Asp Ile Phe Ser Thr Gly Ser Val Leu Glu Leu
 -295 -290 -285
 gga ctc cac tgc ccc cct cca gag gtt ccg gta act agg cta cag gaa 206
 Gly Leu His Cys Pro Pro Pro Glu Val Pro Val Thr Arg Leu Gln Glu
 -280 -275 -270
 cag gga ctg caa ggc tgg aag tcc ggt ggg gac cgt ggc tgt ggc ctt 254
 Gln Gly Leu Gln Gly Trp Lys Ser Gly Gly Asp Arg Gly Cys Gly Leu
 -265 -260 -255
 caa gag agt gag cct gaa gat ttc ttg aag ctt ttc att gat ccc aat 302
 Gln Glu Ser Glu Pro Glu Asp Phe Leu Lys Leu Phe Ile Asp Pro Asn
 -250 -245 -240 -235
 gag gtg tac tgc tca gaa gca tct cct ggc agt gac agt ggc atc tct 350
 Glu Val Tyr Cys Ser Glu Ala Ser Pro Gly Ser Asp Ser Gly Ile Ser
 -230 -225 -220
 gag gac tcc tgc cat cca gac agt ccc cct gcc ccc agg gca acc agt 398
 Glu Asp Ser Cys His Pro Asp Ser Pro Pro Ala Pro Arg Ala Thr Ser
 -215 -210 -205
 tct cct atg ctc tat gag gtt gtc tat gag gca ggg gcc ctg gag agg 446
 Ser Pro Met Leu Tyr Glu Val Val Tyr Glu Ala Gly Ala Leu Glu Arg
 -200 -195 -190
 atg cag ggg gaa act ggg cca aat gta ggc ctt atc tcc atc cag cta 494
 Met Gln Gly Glu Thr Gly Pro Asn Val Gly Leu Ile Ser Ile Gln Leu
 -185 -180 -175
 gat cag tgg agc cca gca ttt atg gtg cct gat tcc tgc atg gtc agt 542
 Asp Gln Trp Ser Pro Ala Phe Met Val Pro Asp Ser Cys Met Val Ser
 -170 -165 -160 -155
 gag ctg ccc ttt gat gct cat gcc cac atc ctg ccc aga gca ggc acc 590
 Glu Leu Pro Phe Asp Ala His Ala His Ile Leu Pro Arg Ala Gly Thr
 -150 -145 -140
 gta gcc cca gtg ccc tgt aca acc ctg ctg ccc tgt caa acc ctg ttc 638
 Val Ala Pro Val Pro Cys Thr Thr Leu Leu Pro Cys Gln Thr Leu Phe
 -135 -130 -125
 ctg acc gat gag gag aag cgt ctg ctg ggg cag gaa ggg gtt tcc ctg 686
 Leu Thr Asp Glu Glu Lys Arg Leu Leu Gly Gln Glu Gly Val Ser Leu
 -120 -115 -110
 ccc tct cac ctg ccc ctc acc aag gca gag gag agg gtc ctc aag aag 734
 Pro Ser His Leu Pro Leu Thr Lys Ala Glu Glu Arg Val Leu Lys Lys
 -105 -100 -95
 gtc agg agg aaa atc cgt aac aag cag tca gct cag gac agt cgg cgg 782
 Val Arg Arg Lys Ile Arg Asn Lys Gln Ser Ala Gln Asp Ser Arg Arg
 -90 -85 -80 -75
 cgg aag aag gag tac att gat ggg ctg gag agc agg gtg gca gcc tgt 830

Arg Lys Lys Glu Tyr Ile Asp Gly Leu Glu Ser Arg Val Ala Ala Cys
 -70 -65 -60
 tct gca cag aac caa gaa tta cag aaa aaa gtc cag gag ctg gag agg 878
 Ser Ala Gln Asn Gln Glu Leu Gln Lys Lys Val Gln Glu Leu Glu Arg
 -55 -50 -45
 cac aac atc tcc ttg gta gct cag ctc cgc cag ctg cag acg cta att 926
 His Asn Ile Ser Leu Val Ala Gln Leu Arg Gln Leu Gln Thr Leu Ile
 -40 -35 -30
 gct caa act tcc aac aaa gct gcc cag acc agc act tgt gtt ttg att 974
 Ala Gln Thr Ser Asn Lys Ala Ala Gln Thr Ser Thr Cys Val Leu Ile
 -25 -20 -15
 ctt ctt ttt tcc ctg gct ctc atc atc ctg ccc agc ttc agt cca ttc 1022
 Leu Leu Phe Ser Leu Ala Leu Ile Ile Leu Pro Ser Phe Ser Pro Phe
 -10 -5 1 5
 cag agt cga cca gaa gct ggg tct gag gat tac cag cct cac gga gtg 1070
 Gln Ser Arg Pro Glu Ala Gly Ser Glu Asp Tyr Gln Pro His Gly Val
 10 15 20
 act tcc aga aat atc ctg acc cac aag gac gta aca gaa aat ctg gag 1118
 Thr Ser Arg Asn Ile Leu Thr His Lys Asp Val Thr Glu Asn Leu Glu
 25 30 35
 acc caa gtg gta gag tcc aga ctg agg gag cca cct gga gcc aag gat 1166
 Thr Gln Val Val Glu Ser Arg Leu Arg Glu Pro Pro Gly Ala Lys Asp
 40 45 50
 gca aat ggc tca aca agg aca ctg ctt gag aag atg gga ggg aag cca 1214
 Ala Asn Gly Ser Thr Arg Thr Leu Leu Glu Lys Met Gly Gly Lys Pro
 55 60 65 70
 aga ccc agt ggg cgc atc cgg tcc gtg ctg cat gca gat gag atg 1259
 Arg Pro Ser Gly Arg Ile Arg Ser Val Leu His Ala Asp Glu Met
 75 80 85
 tgagctggaa cagaccttcc tggcccactt cctgatcaca aggaatcctg ggcttcctta 1319
 tggcttttctt cccactggga ttctacttta ggtgtctgcc ctccaggggtc caaatcactt 1379
 caggacaccc caagagatgt ccttttagtct ctgcctgagg cctagtctgc atttggttgc 1439
 atatatgaga ggggtacctca aatacttctg ttatgtatct gtgattttat ttcttcttgc 1499
 ggtatagggt tgaggggaaa taagtgttga gtgagaaata aacgttttag ctgaaaaaaa 1559
 aaaaaaaaaa 1568
 <210> 69
 <211> 506
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 98..376
 <223> sig_peptide
 <222> 98..151
 <223> Von Heijne matrix
 score 12.3
 seq HILFLLLPVAAA/QT
 <223> polyA_signal
 <222> 471..476
 <223> polyA_site
 <222> 491..506
 <400> 69
 gacatccgct attgctactt ctctgctccc ccacagttcc tctggacttc tctggaccac 60
 agtcctctgc cagaccctg ccagacccca gtccacc atg atc cat ctg ggt cac 115
 Met Ile His Leu Gly His
 -15
 atc ctc ttc ctg ctt ttg ctc cca gtg gct gca gct cag acg act cca 163
 Ile Leu Phe Leu Leu Leu Leu Pro Val Ala Ala Ala Gln Thr Thr Pro
 -10 -5 1
 gga gag aga tca tca ctc cct gcc ttt tac cct ggc act tca ggc tct 211
 Gly Glu Arg Ser Ser Leu Pro Ala Phe Tyr Pro Gly Thr Ser Gly Ser

```

5          10          15          20
tgt tcc gga tgt ggg tcc ctc tct ctg ccg ctc ctg gca ggc ctc gtg      259
Cys Ser Gly Cys Gly Ser Leu Ser Leu Pro Leu Leu Ala Gly Leu Val
          25          30          35
gct gct gat gcg gtg gca tcg ctg ctc atc gtg ggg gcg gtg ttc ctg      307
Ala Ala Asp Ala Val Ala Ser Leu Leu Ile Val Gly Ala Val Phe Leu
          40          45          50
tgc gca cgc cca cgc cgc agc ccc gcc caa gaa tat ggc aaa gtc tac      355
Cys Ala Arg Pro Arg Arg Ser Pro Ala Gln Glu Tyr Gly Lys Val Tyr
          55          60          65
atc aac atg cca ggc agg ggc tgaccctcct gcagcttgga cctttgactt      406
Ile Asn Met Pro Gly Arg Gly
          70          75
ctgaccctct catcctggat ggtgtgtggt ggcacaggaa cccccgcccc aacttttgga      466
ttgtaataaaa acaattgaaa caccaaaaaa aaaaaaaaaa      506
<210> 70
<211> 542
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 72..254
<223> sig_peptide
<222> 72..134
<223> Von Heijne matrix
      score 4.2
      seq LINLAASRTLSFC/IS
<223> polyA_signal
<222> 506..511
<223> polyA_site
<222> 528..542
<400> 70
gaccttaaga agagctaaac gggctgccac ctgtagctga agagtgcctt aacgccgagg      60
cccacggctc c atg cga gag atg cct gtt cct tct ctg ata aat ttg gca      110
      Met Arg Glu Met Pro Val Pro Ser Leu Ile Asn Leu Ala
          -20          -15          -10
gct tca cgt acc cta agt ttt tgc att tct gac aac cac gtg tcc tca      158
Ala Ser Arg Thr Leu Ser Phe Cys Ile Ser Asp Asn His Val Ser Ser
          -5          1          5
cct gga ccc gcc aac cca tcc tgt ggc ctc cac cct cac tgg ctt cgt      206
Pro Gly Pro Ala Asn Pro Ser Cys Gly Leu His Pro His Trp Leu Arg
          10          15          20
cca ctt aaa ctt tta acg tac aca tgt aga gag ctg aaa ctc cag ggg      254
Pro Leu Lys Leu Leu Thr Tyr Thr Cys Arg Glu Leu Lys Leu Gln Gly
          25          30          35          40
taacatggga caggtcctct tgatttaatg aaaacagaag atcaactgga ccgggtagca      314
agaaataagg cttaagaagc actggtttct ctgcagaaga cagcaagatg ccccagggaa      374
tgtttgtaa aaaggatgac tggatgggaa gcaagctgaa gaaaaagaag gaaagaaaga      434
gagaaatcag taaatcacca cacaagaggt ggagaagagg acttataaat attgtttcta      494
tgacatttga aaataaatgt tttactccat gctaaaaaaaa aaaaaaaaaa      542
<210> 71
<211> 1629
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 148..1140
<223> sig_peptide
<222> 148..240
<223> Von Heijne matrix
      score 10

```

```

seq LVLLLVTRSPVNA/CL
<223> polyA_signal
<222> 1590..1595
<223> polyA_site
<222> 1614..1629
<400> 71
gtctgtgtgcc gccattgtgc ggcgctggtc ccctcagagg gttcctgctg ctgccgggtgc      60
cttggaccct cccctcgtct tctcgttcta ctgccccagg agcccggcgg gtccgggact      120
cccgtccgtg ccggtgcggg cgccggc atg tgg ctg tgg gag gac cag ggc ggc      174
Met Trp Leu Trp Glu Asp Gln Gly Gly
-30 -25
ctc ctg ggc cct ttc tcc ttc ctg ctg cta gtg ctg ctg ctg gtg acg      222
Leu Leu Gly Pro Phe Ser Phe Leu Leu Leu Val Leu Leu Leu Val Thr
-20 -15 -10
cgg agc ccg gtc aat gcc tgc ctc ctc acc ggc agc ctc ttc gtt cta      270
Arg Ser Pro Val Asn Ala Cys Leu Leu Thr Gly Ser Leu Phe Val Leu
-5 1 5 10
ctg cgc gtc ttc agc ttt gag ccg gtg ccc tct tgc agg gcc ctg cag      318
Leu Arg Val Phe Ser Phe Glu Pro Val Pro Ser Cys Arg Ala Leu Gln
15 20 25
gtg ctc aag ccc ccg gac cgc att tct gcc atc gcc cac cgt ggc ggc      366
Val Leu Lys Pro Arg Asp Arg Ile Ser Ala Ile Ala His Arg Gly Gly
30 35 40
agc cac gac gcg ccc gag aac acg ctg gcg gcc att ccg cag gca gct      414
Ser His Asp Ala Pro Glu Asn Thr Leu Ala Ala Ile Arg Gln Ala Ala
45 50 55
aag aat gga gca aca ggc gtg gag ttg gac att gag ttt act tct gac      462
Lys Asn Gly Ala Thr Gly Val Glu Leu Asp Ile Glu Phe Thr Ser Asp
60 65 70
ggg att cct gtc tta atg cac gat aac aca gta gat agg acg act gat      510
Gly Ile Pro Val Leu Met His Asp Asn Thr Val Asp Arg Thr Thr Asp
75 80 85 90
ggg act ggg cga ttg tgt gat ttg aca ttt gaa caa att agg aag ctg      558
Gly Thr Gly Arg Leu Cys Asp Leu Thr Phe Glu Gln Ile Arg Lys Leu
95 100 105
aat cct gca gca aac cac aga ctc agg aat gat ttc cct gat gaa aag      606
Asn Pro Ala Ala Asn His Arg Leu Arg Asn Asp Phe Pro Asp Glu Lys
110 115 120
atc cct acc cta atg gaa gct gtt gca gag tgc cta aac cat aac ctc      654
Ile Pro Thr Leu Met Glu Ala Val Ala Glu Cys Leu Asn His Asn Leu
125 130 135
aca atc ttc ttt gat gtc aaa ggc cat gca cac aag gct act gag gct      702
Thr Ile Phe Phe Asp Val Lys Gly His Ala His Lys Ala Thr Glu Ala
140 145 150
cta aag aaa atg tat atg gaa ttt cct caa ctg tat aat aat agt gtg      750
Leu Lys Lys Met Tyr Met Glu Phe Pro Gln Leu Tyr Asn Asn Ser Val
155 160 165 170
gtc tgt tct ttc ttg cca gaa gtt atc tac aag atg aga caa aca gat      798
Val Cys Ser Phe Leu Pro Glu Val Ile Tyr Lys Met Arg Gln Thr Asp
175 180 185
cgg gat gta ata aca gca tta act cac aga cct tgg agc cta agc cat      846
Arg Asp Val Ile Thr Ala Leu Thr His Arg Pro Trp Ser Leu Ser His
190 195 200
aca gga gat ggg aaa cca cgc tat gat act ttc tgg aaa cat ttt ata      894
Thr Gly Asp Gly Lys Pro Arg Tyr Asp Thr Phe Trp Lys His Phe Ile
205 210 215
ttt gtt atg atg gac att ttg ctc gat tgg agc atg cat aat atc ttg      942
Phe Val Met Met Asp Ile Leu Leu Asp Trp Ser Met His Asn Ile Leu
220 225 230
tgg tac ctg tgt gga att tca gct ttc ctc atg caa aag gat ttt gta      990
Trp Tyr Leu Cys Gly Ile Ser Ala Phe Leu Met Gln Lys Asp Phe Val

```

235 240 245 250
 tcc ccg gcc tac ttg aag aag tgg tca gct aaa gga atc cag gtt gtt 1038
 Ser Pro Ala Tyr Leu Lys Lys Trp Ser Ala Lys Gly Ile Gln Val Val
 255 260 265
 ggt tgg act gtt aat acc ttt gat gaa aag agt tac tac gaa tcc cat 1086
 Gly Trp Thr Val Asn Thr Phe Asp Glu Lys Ser Tyr Tyr Glu Ser His
 270 275 280
 ctt ggt tcc agc tat atc act gac agc atg gta gaa gac tgc gaa cct 1134
 Leu Gly Ser Ser Tyr Ile Thr Asp Ser Met Val Glu Asp Cys Glu Pro
 285 290 295
 cac ttc tagactttca cgggtgggacg aaacggggttc agaaactgcc aggggcctca 1190
 His Phe
 300
 tacagggata tcaaaatacc ctttgtgcta gccaggcccc tggggaatca ggtgactcac 1250
 acaaatgcaa tagttgggtca ctgcattttt acctgaacca aagctaaacc cgggtgttgcc 1310
 accatgcacc atggcatgcc agagttcaac actggtgctc ttgaaaatct gggtctgaaa 1370
 aaacgcacaa gagcccctgc cctgccctag ctgaggcaca cagggagacc cagtggagat 1430
 aagcacagat tgaattgtac aatttgcaga tgcagatgta aatgcatggg acatgcatga 1490
 taactcagag ttgacatttt aaaacttgcc acacttattt caaatatttg tactcagcta 1550
 tgtaacatg tactgtagac atcaaacttg tggccatact aataaaatta ttaaaaggag 1610
 cacaaaaaaa aaaaaaaaaa 1629
 <210> 72
 <211> 1665
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 109..738
 <223> sig_peptide
 <222> 109..405
 <223> Von Heijne matrix
 score 4.5
 seq LAPGSFLAAVDA/LE
 <223> polyA_signal
 <222> 1633..1638
 <223> polyA_site
 <222> 1650..1665
 <400> 72
 cccagcgttc ctctccggc cccagggtcac cgccagcacg cgctgcttc ccgtctgcgc 60
 gagtccacgc agctccccag gcccttcacc agcacagcag cagcaggc atg gca gca 117
 Met Ala Ala
 agc gtg gag cag cgc gag ggc acc atc cag gtg cag ggc cag gcc ctc 165
 Ser Val Glu Gln Arg Glu Gly Thr Ile Gln Val Gln Gly Gln Ala Leu
 -95 -90 -85
 ttc ttc cga gag gcc ctg ccc ggc agt ggg cag gct cgc ttc tct gta 213
 Phe Phe Arg Glu Ala Leu Pro Gly Ser Gly Gln Ala Arg Phe Ser Val
 -80 -75 -70 -65
 ctg ctg ctg cat ggt att cgc ttc tcc tcc gag acc tgg cag aac ctg 261
 Leu Leu Leu His Gly Ile Arg Phe Ser Ser Glu Thr Trp Gln Asn Leu
 -60 -55 -50
 ggt aca ctg cac agg ctg gcc cag gct ggc tac cgg gct gtg gcc att 309
 Gly Thr Leu His Arg Leu Ala Gln Ala Gly Tyr Arg Ala Val Ala Ile
 -45 -40 -35
 gac ctg cca ggt ctg ggg cac tcc aag gaa gca gca gcc cct gcc cct 357
 Asp Leu Pro Gly Leu Gly His Ser Lys Glu Ala Ala Ala Pro Ala Pro
 -30 -25 -20
 att ggg gag ctg gcc cct ggc agc ttc ctg gcg gct gtg gtg gat gcc 405
 Ile Gly Glu Leu Ala Pro Gly Ser Phe Leu Ala Ala Val Val Asp Ala
 -15 -10 -5
 ttg gag ctg ggc ccc ccg gtt gtg atc agt cca tca ctg agt ggc atg 453
 Leu Glu Leu Gly Pro Pro Val Val Ile Ser Pro Ser Leu Ser Gly Met

```

1          5          10          15
tac tcc ctg ccc ttc ctc acg gcc cct ggc tcc cag ctc ccg ggc ttt      501
Tyr Ser Leu Pro Phe Leu Thr Ala Pro Gly Ser Gln Leu Pro Gly Phe
          20          25          30
gtg cca gtg gcc ccc atc tgc act gac aaa atc aat gct gcc aac tat      549
Val Pro Val Ala Pro Ile Cys Thr Asp Lys Ile Asn Ala Ala Asn Tyr
          35          40          45
gcc agt gtg aag act cca gct ctg att gta tat gga gac cag gac ccc      597
Ala Ser Val Lys Thr Pro Ala Leu Ile Val Tyr Gly Asp Gln Asp Pro
          50          55          60
atg ggt cag acc agc ttt gag cac ctg aag cag ctg ccc aac cac cgg      645
Met Gly Gln Thr Ser Phe Glu His Leu Lys Gln Leu Pro Asn His Arg
          65          70          75          80
gtg ctg atc atg aag ggg gcg ggg cac ccc tgt tac ctg gac aaa cca      693
Val Leu Ile Met Lys Gly Ala Gly His Pro Cys Tyr Leu Asp Lys Pro
          85          90          95
gag gag tgg cat aca ggg ctg ctg gac ttc ctg cag ggg ctc cag      738
Glu Glu Trp His Thr Gly Leu Leu Asp Phe Leu Gln Gly Leu Gln
          100          105          110
tgaagccag cactgctgca gggggtgggc tgcctgcctg ctctgagctc tctcttgac      798
gctctctctt ctctcccagg ctctggctca tgcacatgca acagggtgcgt ctgtctatat      858
gtctgggttc ttgtcttttg tggctctgtt gtcttttcta cctctttctc ttgcagtgat      918
agactgaggg ggtaaaatca agagaaaaaa ctctcaggaa tcaaggaaca taatcctgtg      978
gagggtaatc cattacatga gcttctctg ttcttccact ttctgacctg gctttcactc      1038
cttcccctgc tctgccagc ctttcccctcc caccactcc tacttctgca aatgccctga      1098
aggccagccc ttaccccaac acccaattcc ccacctcctt agggcccaga tacatacatg      1158
cccacatgca cgcttacatg tttagagcca tccttggttc caaatatgac ccttcgcttg      1218
agggcaactg cataggtaca tctaactctg gactggcatg cacattgtca tgtgcagctt      1278
tgcatataca cacatgcata catgagcctc cacacaagca cttgcacaca tgtggactcc      1338
taacctatgct aacctcactg gctgggaagg tggggacccc atgggccagc ccttgcaagga      1398
ggcccttttg caaggcttag ggtgtggcca gccctgaaag ctacttgga acaggtttca      1458
gctggcccca gcccagaagt gacccccaga aaggaggagg caccgctttg cccctgctt      1518
ttacccttcc ttctgggtgc tctacacctc aggttaccag gcctgaggca tctcagccaa      1578
gcttggttcc tgctctgagg cttgtggggg gggagccaga gtggagggtc gtgaaataaa      1638
gtgatgcaat taaaaaaaa aaaaaaa      1665
<210> 73
<211> 425
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 55..291
<223> sig_peptide
<222> 55..255
<223> Von Heijne matrix
      score 4.4
      seq LISLVASLFMGFG/VL
<223> polyA_signal
<222> 390..395
<223> polyA_site
<222> 410..425
<400> 73
ctgccgacgt gttcttccgg tggcggagcg gcggattagc cttcgcgggg caaa atg      57
Met
gag ctc gag gcc atg agc aga tat acc agc cca gtg aac cca gct gtc      105
Glu Leu Glu Ala Met Ser Arg Tyr Thr Ser Pro Val Asn Pro Ala Val
      -65      -60      -55
ttc ccc cat ctg acc gtg gtg ctt ttg gcc att ggc atg ttc ttc acc      153
Phe Pro His Leu Thr Val Val Leu Leu Ala Ile Gly Met Phe Phe Thr
      -50      -45      -40      -35
gcc tgg ttc ttc gtt tac gag gtc acc tct acc aag tac act cgt gat      201

```


Ala Trp Phe Phe Val Tyr Glu Val Thr Ser Thr Lys Tyr Thr Arg Asp
 -30 -25 -20
 atc tat aaa gag ctc ctc atc tcc tta gtg gcc tca ctc ttc atg ggc 249
 Ile Tyr Lys Glu Leu Leu Ile Ser Leu Val Ala Ser Leu Phe Met Gly
 -15 -10 -5
 ttt gga gtc ctc ttc ctg ctg ctc tgg gtt ggc atc tac gtg 291
 Phe Gly Val Leu Phe Leu Leu Leu Trp Val Gly Ile Tyr Val
 1 5 10
 tgagcaccga agggtaacaa ccagatggct tcaactgaaac ctgcttttgt aaattacttt 351
 tttttactgt tgctggaaat gtcccacctg ctgctcataa taaatgcaga tgtataacaa 411
 aaaaaaaaaa aaaa 425
 <210> 74
 <211> 546
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 25..276
 <223> polyA_signal
 <222> 508..513
 <223> polyA_site
 <222> 533..546
 <400> 74
 gttgcaccag gcgatgcaag acac atg gca gtc tgg cct gaa gtt tcc caa 51
 Met Ala Val Trp Pro Glu Val Ser Gln
 1 5
 aac agg ctg act agg ggc cta ctg ctt ccc aac tac cag ctg agg ggg 99
 Asn Arg Leu Thr Arg Gly Leu Leu Leu Pro Asn Tyr Gln Leu Arg Gly
 10 15 20 25
 tcc gtc ccg aaa agg gag aag agg cct aag agg aaa cat caa cat ctt 147
 Ser Val Pro Lys Arg Glu Lys Arg Pro Lys Arg Lys His Gln His Leu
 30 35 40
 ttt act cct agc gag cgg cat tct gtc tgc ctt gat tgt ctt ctg gaa 195
 Phe Thr Pro Ser Glu Arg His Ser Val Cys Leu Asp Cys Leu Leu Glu
 45 50 55
 ata tcg ctt tca ggg aaa caa tgg cga aat gtc atc agt ttc aac tgc 243
 Ile Ser Leu Ser Gly Lys Gln Trp Arg Asn Val Ile Ser Phe Asn Cys
 60 65 70
 ttt tgc act act aag acg ctt ttc tgg gtt aat tagcagcaat acagacaacg 296
 Phe Cys Thr Thr Lys Thr Leu Phe Trp Val Asn
 75 80
 atctttttatt caacaacctc tctcgagata ttttaaataa tttctcacac tcgaaaaaca 356
 tgcagaagcg actattggca aacctgaaga ggggtggaata ccaaattggct gaactggaat 416
 attttctagt tagcgagggt ttgagagggt cgtcagggtt ccagaaattc acctcaaaag 476
 cgtacaggat gtaatgccag tgggtggaat cattaagac actttgagta gattcaaaaa 536
 aaaaaaaaaa 546
 <210> 75
 <211> 485
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 32..307
 <223> sig_peptide
 <222> 32..91
 <223> Von Heijne matrix
 score 7.4
 seq LVFCVGLLTMAKA/ES
 <223> polyA_signal
 <222> 452..457
 <223> polyA_site


```

Pro Ala Ala Ile Ile His Asp Phe Glu Lys Gly Met Thr Ala Tyr Leu
75      80      85
gac ttg ttg ctg ggg aac tgc tat ctg atg ccc ctc aat act tct att      393
Asp Leu Leu Leu Gly Asn Cys Tyr Leu Met Pro Leu Asn Thr Ser Ile
90      95      100
gtt atg cct cca gaa aat ctg gta gag ctc ttt ggc aaa ctg gcg agt      441
Val Met Pro Pro Glu Asn Leu Val Glu Leu Phe Gly Lys Leu Ala Ser
105     110     115
ggc aga tat ctg cct caa act tat gtg gtt cga gaa gac cta gtt gct      489
Gly Arg Tyr Leu Pro Gln Thr Tyr Val Val Arg Glu Asp Leu Val Ala
120     125     130
gtg gag gaa att cgt gat gtt agt aac ctt ggc atc ttt att tac caa      537
Val Glu Glu Ile Arg Asp Val Ser Asn Leu Gly Ile Phe Ile Tyr Gln
135     140     145     150
ctt tgc aat aac aga aag tcc ttc cgc ctt cgt cgc aga gac ctc ttg      585
Leu Cys Asn Asn Arg Lys Ser Phe Arg Leu Arg Arg Arg Asp Leu Leu
155     160     165
ctg ggt ttc aac aaa cgt gcc att gat aaa tgc tgg aag att aga cac      633
Leu Gly Phe Asn Lys Arg Ala Ile Asp Lys Cys Trp Lys Ile Arg His
170     175     180
ttc ccc aac gaa ttt att gtt gag acc aag atc tgt caa gag      675
Phe Pro Asn Glu Phe Ile Val Glu Thr Lys Ile Cys Gln Glu
185     190     195
taagaggcaa cagatagagt gtccttgcta acaagaagtc agagatttac aatatgactt      735
taacattaag gtttatggga tactcaagat atttactcat gcatttactc tattgcttat      795
gctttaaaaa aaggaaaaaa aaaaactact aaccactgca agctcttgtc aaattttagt      855
ttaattggca ttgcttggtt ttgaaactg aaattacctg agtttcattt tttctttgaa      915
tttatagggt ttagatttct gaaagcagca tgaatatatc acctaacatc ctgacaataa      975
attccatccg ttgttttttt tgtttgtttg ttttttcttt tcctttaagt aagctcttta      1035
ttcatcttat ggtgcagcaa ttttaaaatt tgaaatatatt taaattgttt ttgaactttt      1095
tgtgtaaaat atatcagatc tcaacattgt tggtttcttt tgtttttcat tttgtacaac      1155
tttcttgaat ttagaaatta catctttgca gctctgtag gtgctctgta attaacctga      1215
cttatatgtg aacaattttc atgagacagt catttttaaa taatgcagtg attctttctc      1275
actactatct gtattgtgga atgcacaaaa ttgtgtagggt gctgaatgct gtaaggagtt      1335
taggttggtat gaattctaca accctataat aaattttact ctatacaaaa aaaaaaaaaa      1394
<210> 77
<211> 1333
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 329..943
<223> sig_peptide
<222> 329..745
<223> Von Heijne matrix
score 4.2
seq SLSLALKTGPTSG/LC
<223> polyA_site
<222> 1322..1333
<400> 77
cgccagtgtc agtgggtgtg gcatcagctt gggcaggtgt gcgggctcag gatggggcgg      60
ccgtgggtgag gaaccctgga ctctcagcat cacaagaggc aacaccagga gccaacatga      120
gctcgggact gaactgctgt ggcccggagc agcgtgctg gtgctgttgg ggggtggcagc      180
cagtctgtgt gtgcgctgct cagccccagg tgcaaagagg tcagagagaa tctaccagca      240
gagaagtctg cgtgaggacc aacagagctt tacgggggtcc cggacctact ccttggtcgg      300
gcaggcatgg ccaggacccc tggcggac atg gca ccc aca agg aag gac aag      352
Met Ala Pro Thr Arg Lys Asp Lys
-135
ctg ttg caa ttc tac ccc agc ctg gag gat cca gca tct tcc agg tac      400
Leu Leu Gln Phe Tyr Pro Ser Leu Glu Asp Pro Ala Ser Ser Arg Tyr
-130      -125      -120

```

cag aac ttc agc aaa gga agc aga cac ggg tcg gag gaa gcc tac ata Gln Asn Phe Ser Lys Gly Ser Arg His Gly Ser Glu Glu Ala Tyr Ile -115 -110 -105 -100	448
gac ccc att gcc atg gag tat tac aac tgg ggg cgg ttc tcg aag ccc Asp Pro Ile Ala Met Glu Tyr Tyr Asn Trp Gly Arg Phe Ser Lys Pro -95 -90 -85	496
cca gaa ggt gag gcg aag gac aaa gcc gga ggt gga gga agt ggt gtg Pro Glu Gly Glu Ala Lys Asp Lys Ala Gly Gly Gly Gly Ser Gly Val -80 -75 -70	544
gga gct cag ggc aga agc cat acc tcc agg cag gag agg agg ctg ggc Gly Ala Gln Gly Arg Ser His Thr Ser Arg Gln Glu Arg Arg Leu Gly -65 -60 -55	592
ctg ggt tcg gat gat gat gcc aat tcc tac gag aat gtg ctc att tgc Leu Gly Ser Asp Asp Asp Ala Asn Ser Tyr Glu Asn Val Leu Ile Cys -50 -45 -40	640
aag cag aaa acc aca gag aca ggt gcc cag cag gag gac gta ggt ggc Lys Gln Lys Thr Thr Glu Thr Gly Ala Gln Gln Glu Asp Val Gly Gly -35 -30 -25 -20	688
ctc tgc aga ggg gac ctc agc ctg tca ctg gcc ctg aag act ggc ccc Leu Cys Arg Gly Asp Leu Ser Leu Ser Leu Ala Leu Lys Thr Gly Pro -15 -10 -5	736
act tct ggt ctc tgt ccc tct gcc tcc ccg gaa gaa gat ggg gaa tct Thr Ser Gly Leu Cys Pro Ser Ala Ser Pro Glu Glu Asp Gly Glu Ser 1 5 10	784
gag gat tat cag aac tca gca tcc atc cat caa tgg cgc gag tcc agg Glu Asp Tyr Gln Asn Ser Ala Ser Ile His Gln Trp Arg Glu Ser Arg 15 20 25	832
aag gtc atg ggg caa ctc cag aga gaa gca tcc cct ggc ccg gtg gga Lys Val Met Gly Gln Leu Gln Arg Glu Ala Ser Pro Gly Pro Val Gly 30 35 40 45	880
agc cca gac gag gag gac ggg gaa ccg gat tac gtg aat ggg gag gtg Ser Pro Asp Glu Glu Asp Gly Glu Pro Asp Tyr Val Asn Gly Glu Val 50 55 60	928
gca gcc aca gaa gcc tagggcagac caagaagaaa ggagccaagg caaagagggg Ala Ala Thr Glu Ala 65	983
ccactgtgct catggaccca tcgctgcctt ccaaggacca tttcccagag ctactcaact tttaagcccc tgccatggtt gtccttgaa ggagaaccag ccaccctgag gaccacctgg ccatgcgtgc acagcctggg aaaagacagt tactcacggg agctgcaggc ccgtcaccaa gcccctctccc gaccaggct ttgtggggca ggcacctggt accatgggta acccggtcc tggtatggac ggatgcgcag gatttaggat aagctgtcac ccagtcccca taacaaaacc actgtccaac actggtatct gtgttctttt gtgctatgaa aaaaaaaaaa <210> 78 <211> 326 <212> DNA <213> Homo sapiens <220> <223> CDS <222> 27..281 <223> sig_peptide <222> 27..77 <223> Von Heijne matrix score 8.2 seq LLLITAILAVAVG/FP <400> 78 gaaaagaact gactgaaacg tttgag atg aag aaa gtt ctc ctc ctg atc aca Met Lys Lys Val Leu Leu Leu Ile Thr -15 -10 gcc atc ttg gca gtg gct gtt ggt ttc cca gtc tct caa gac cag gaa Ala Ile Leu Ala Val Ala Val Gly Phe Pro Val Ser Gln Asp Gln Glu -5 1 5	1043 1103 1163 1223 1283 1333
	53
	101

cga gaa aaa aga agt atc agt gac agc gat gaa tta gct tca ggg ttt 149
 Arg Glu Lys Arg Ser Ile Ser Asp Ser Asp Glu Leu Ala Ser Gly Phe
 10 15 20
 ttt gtg ttc cct tac cca tat cca ttt cgc cca ctt cca cca att cca 197
 Phe Val Phe Pro Tyr Pro Tyr Pro Phe Arg Pro Leu Pro Pro Ile Pro
 25 30 35 40
 ttt cca aga ttt cca tgg ttt aga cgt aat ttt cct att cca ata cct 245
 Phe Pro Arg Phe Pro Trp Phe Arg Arg Asn Phe Pro Ile Pro Ile Pro
 45 50 55
 gaa tct gcc cct aca act ccc ctt cct agc gaa aag taaacaagaa 291
 Glu Ser Ala Pro Thr Thr Pro Leu Pro Ser Glu Lys
 60 65
 ggaaaagtca cgataaacct ggtcacctga aattg 326
 <210> 79
 <211> 703
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 61..405
 <223> sig_peptide
 <222> 61..213
 <223> Von Heijne matrix
 score 8.1
 seq VCLCGTFCFPCLG/CQ
 <223> polyA_signal
 <222> 675..680
 <223> polyA_site
 <222> 692..703
 <400> 79
 catttctctgc tcggaacctt gtttactaat ttccactgct tttaaggccc tgcactgaaa 60
 atg caa gct cag gcg ccg gtg gtc gtt gtg acc caa cct gga gtc ggt 108
 Met Gln Ala Gln Ala Pro Val Val Val Val Thr Gln Pro Gly Val Gly
 -50 -45 -40
 ccc ggt ccg gcc ccc cag aac tcc aac tgg cag aca ggc atg tgt gac 156
 Pro Gly Pro Ala Pro Gln Asn Ser Asn Trp Gln Thr Gly Met Cys Asp
 -35 -30 -25 -20
 tgt ttc agc gac tgc gga gtc tgt ctc tgt ggc aca ttt tgt ttc ccg 204
 Cys Phe Ser Asp Cys Gly Val Cys Leu Cys Gly Thr Phe Cys Phe Pro
 -15 -10 -5
 tgc ctt ggg tgt caa gtt gca gct gat atg aat gaa tgc tgt ctg tgt 252
 Cys Leu Gly Cys Gln Val Ala Ala Asp Met Asn Glu Cys Cys Leu Cys
 1 5 10
 gga aca agc gtc gca atg agg act ctc tac agg acc cga tat ggc atc 300
 Gly Thr Ser Val Ala Met Arg Thr Leu Tyr Arg Thr Arg Tyr Gly Ile
 15 20 25
 cct gga cct att tgt gat gac tat atg gca act ctt tgc tgt cct cat 348
 Pro Gly Pro Ile Cys Asp Asp Tyr Met Ala Thr Leu Cys Cys Pro His
 30 35 40 45
 tgt act ctt tgc caa atc aag aga gat atc aac aga agg aga gcc atg 396
 Cys Thr Leu Cys Gln Ile Lys Arg Asp Ile Asn Arg Arg Arg Ala Met
 50 55 60
 cgt act ttc taaaaactga tggtgaaaag ctcttaccga agcaacaaaa 445
 Arg Thr Phe
 ttcagcagac acctctccag cttgagttct tcaccatctt ttgcaactga aatatgatgg 505
 atatgcttaa gtacaactga tggcatgaaa aaaatcaaat ttttgattta ttataaatga 565
 atgttgctcc tgaacttagc taaatggtgc aacttagttt ctccttgctt tcatattatc 625
 gaatttcttg gcttataaac tttttaaatt acatttgaaa tataaaccaa atgaaatatt 685
 ttactcaaaa aaaaaaaaaa
 <210> 80
 <211> 768

```

<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 137..379
<223> sig_peptide
<222> 137..229
<223> Von Heijne matrix
      score 4.4
      seq TCCHLGLPHPVRA/PR
<223> polyA_signal
<222> 728..733
<223> polyA_site
<222> 755..768
<400> 80
tcggagattgg aaagggacgc ctggtttccc cccaagcgaa ccgggatggg aagtgacttc      60
aatgagattg aacttcagct ggattgaaag agaggctaga agttccgctt gccagcagcc      120
cccttagtag agcgga atg agt aat acc cac acg gtg ctt gtc tca ctt ccc      172
               Met Ser Asn Thr His Thr Val Leu Val Ser Leu Pro
               -30                               -25                    -20
cat ccg cac ccg gcc ctc acc tgc tgt cac ctc ggc ctc cca cac ccg      220
His Pro His Pro Ala Leu Thr Cys Cys His Leu Gly Leu Pro His Pro
               -15                               -10                    -5
gtc cgc gct ccc cgc cct ctt cct cgc gta gaa ccg tgg gat cct agg      268
Val Arg Ala Pro Arg Pro Leu Pro Arg Val Glu Pro Trp Asp Pro Arg
               1                               5                      10
tgg cag gac tca gag cta agg tat cca cag gcc atg aat tcc ttc cta      316
Trp Gln Asp Ser Glu Leu Arg Tyr Pro Gln Ala Met Asn Ser Phe Leu
               15                               20                    25
aat gag cgg tca tcg ccg tgc agg acc tta agg caa gaa gca tcg gct      364
Asn Glu Arg Ser Ser Pro Cys Arg Thr Leu Arg Gln Glu Ala Ser Ala
               30                               35                    40                    45
gac aga tgt gat ctc tgaacctgat agattgctga ttttatctta ttttatcctt      419
Asp Arg Cys Asp Leu
               50
gacttggtac aagttttggg atttctgaaa agaccatgca gataaccaca aatatcaaga      479
aagtcgtctt cagtattaag tagaatttag atttaggttt ccttcctgct tcccacctcc      539
ttcgaataag gaaacgtctt tgggaccaac tttatggaat aaataagctg agctgtattt      599
caagtaatat agttataaat taacaatgta gcagttattg atagagaaat tgagaaaact      659
gaaacgtgac cggagtattg gaaataacgt agtacatcac ctagcacaat gacacatagt      719
aggtgctcaa taaatttatg cttataattt ttgtcaaaaa aaaaaataa      768
<210> 81
<211> 1007
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 37..741
<223> sig_peptide
<222> 37..153
<223> Von Heijne matrix
      score 7.2
      seq SALAKLLLTC CSA/LR
<223> polyA_signal
<222> 969..974
<223> polyA_site
<222> 994..1007
<400> 81
cgcaggtccc gaggagcgca gactgtgtcc ctgaca atg gga aca gcc gac agt      54
               Met Gly Thr Ala Asp Ser
               -35

```

gat gag atg gcc ccg gag gcc cca cag cac acc cac atc gat gtg cac	102
Asp Glu Met Ala Pro Glu Ala Pro Gln His Thr His Ile Asp Val His	
-30 -25 -20	
atc cac cag gag tct gcc ctg gcc aag ctc ctg ctc acc tgc tgc tct	150
Ile His Gln Glu Ser Ala Leu Ala Lys Leu Leu Leu Thr Cys Cys Ser	
-15 -10 -5	
gcg ctg cgg ccc cgg gcc acc cag gcc agg ggc agc agc cgg ctg ctg	198
Ala Leu Arg Pro Arg Ala Thr Gln Ala Arg Gly Ser Ser Arg Leu Leu	
1 5 10 15	
gtg gcc tcg tgg gtg atg cag atc gtg ctg ggg atc ttg agt gca gtc	246
Val Ala Ser Trp Val Met Gln Ile Val Leu Gly Ile Leu Ser Ala Val	
20 25 30	
cta gga gga ttt ttc tac atc cgc gac tac acc ctc ctc gtc acc tcg	294
Leu Gly Gly Phe Phe Tyr Ile Arg Asp Tyr Thr Leu Leu Val Thr Ser	
35 40 45	
ggg gct gcc atc tgg aca ggg gct gtg gct gtg ctg gct gga gct gct	342
Gly Ala Ala Ile Trp Thr Gly Ala Val Ala Val Leu Ala Gly Ala Ala	
50 55 60	
gcc ttc att tac gag aaa cgg ggt ggt aca tac tgg gcc ctg ctg agg	390
Ala Phe Ile Tyr Glu Lys Arg Gly Gly Thr Tyr Trp Ala Leu Leu Arg	
65 70 75	
act ctg cta gcg ctg gca gct ttc tcc aca gcc atc gct gcc ctc aaa	438
Thr Leu Leu Ala Leu Ala Ala Phe Ser Thr Ala Ile Ala Ala Leu Lys	
80 85 90 95	
ctt tgg aat gaa gat ttc cga tat ggc tac tct tat tac aac agt gcc	486
Leu Trp Asn Glu Asp Phe Arg Tyr Gly Tyr Ser Tyr Tyr Asn Ser Ala	
100 105 110	
tgc cgc atc tcc agc tcg agt gac tgg aac act cca gcc ccc act cag	534
Cys Arg Ile Ser Ser Ser Asp Trp Asn Thr Pro Ala Pro Thr Gln	
115 120 125	
agt cca gaa gaa gtc aga agg cta cac cta tgt acc tcc ttc atg gac	582
Ser Pro Glu Glu Val Arg Arg Leu His Leu Cys Thr Ser Phe Met Asp	
130 135 140	
atg ctg aag gcc ttg ttc aga acc ctt cag gcc atg ctc ttg ggt gtc	630
Met Leu Lys Ala Leu Phe Arg Thr Leu Gln Ala Met Leu Leu Gly Val	
145 150 155	
tgg att ctg ctg ctt ctg gca tct ctg gcc cct ctg tgg ctg tac tgc	678
Trp Ile Leu Leu Leu Leu Ala Ser Leu Ala Pro Leu Trp Leu Tyr Cys	
160 165 170 175	
tgg aga atg ttc cca acc aaa ggg aaa aga gac cag aag gaa atg ttg	726
Trp Arg Met Phe Pro Thr Lys Gly Lys Arg Asp Gln Lys Glu Met Leu	
180 185 190	
gaa gtg agt gga atc tagccatgcc tctcctgatt attagtgcct ggtgcttctg	781
Glu Val Ser Gly Ile	
195	
caccgggcgt cctgcatct gactgctgga agaagaacca gactgaggaa aagaggctct	841
tcaacagccc cagttatcct ggccccatga ccgtggccac agccctgctc cagcagcact	901
tgccattcc ttacaccct tccccatcct gctccgcttc atgtcccctc ctgagtagtc	961
atgtgataat aaactctcat gttattgttc ccaaaaaaaaa aaaaaa	1007
<210> 82	
<211> 527	
<212> DNA	
<213> Homo sapiens	
<220>	
<223> CDS	
<222> 80..265	
<223> sig_peptide	
<222> 80..142	
<223> Von Heijne matrix	
score 5.4	
seq TFCLIFGLGAVWG/LG	

<223> polyA_signal	
<222> 491..496	
<223> polyA_site	
<222> 517..527	
<400> 82	
cccgccttgat tccaagaacc tcttcgattt ttatTTTTat ttttaaagag ggagacgatg	60
gactgagctg atccgcacc atg gag tct cgg gtc tta ctg aga aca ttc tgt	112
Met Glu Ser Arg Val Leu Leu Arg Thr Phe Cys	
-20 -15	
ttg atc ttc ggt ctc gga gca gtt tgg ggg ctt ggt gtg gac cct tcc	160
Leu Ile Phe Gly Leu Gly Ala Val Trp Gly Leu Gly Val Asp Pro Ser	
-10 -5 1 5	
cta cag att gac gtc tta aca gag tta gaa ctt ggg gag tcc acg acc	208
Leu Gln Ile Asp Val Leu Thr Glu Leu Glu Leu Gly Glu Ser Thr Thr	
10 15 20	
gga gtg cgt cag gtc ccg ggg ctg cat aat ggg acg aaa gcc ttt ctc	256
Gly Val Arg Gln Val Pro Gly Leu His Asn Gly Thr Lys Ala Phe Leu	
25 30 35	
ttt caa gcg tgactgaagc agcagcctgc acatgtggat ggtcatcagt	305
Phe Gln Ala	
40	
gcctcgccca gagatacctg gccttcatcc aaagggaccc tgctgccaca agtccctccag	365
gcagcacccg cactgtggct ccttcgcact gactatgttg gactctgcc a tagactgacc	425
ctcttgtctg gctgctgcag tttgtctgta atgccctgac atgttgcatc ctccccattt	485
ggataaataa aaacaacaaa atgcttctgt caaaaaaaaa aa	527
<210> 83	
<211> 861	
<212> DNA	
<213> Homo sapiens	
<220>	
<223> CDS	
<222> 612..644	
<223> polyA_signal	
<222> 829..834	
<223> polyA_site	
<222> 850..861	
<400> 83	
agctctgggtg gttctggctg ctctggactg tcttcacctt ctttagctgc tgttgcgctt	60
tccgccaccg acgagctaaa ctcaggctgc aacaacagca gcggcagcgt gaaatcaact	120
tgttgcccta tcatggggca tgccatgggg ctggtccttt ccctaccggt tcaactgcttg	180
accttcgcct cctcagcacc ttcaagcccc cagcctacga ggatgtggtt caccgccag	240
gcacaccacc ccccccttat actgtggccc caggccgccc cttgactgct tccagtgaac	300
aaacctgctg ttctctctca tccagctgcc ctgcccactt tgaaggaaca aatgtggaag	360
gtgtttcctc ccaccagagt gccccccctc atcaggaggg tgagccggg gcaggggtga	420
cccttgccctc cacacccccc tctgcccgtt atcgccgttt aactggcgac tccggtattg	480
agctctgccc ttgtctgcc tccggtgagg gtgagccagt caaggagggtg agggttagt	540
ccacctgccc agatctggag gactactccc cgtgtgcaat acccccagag tctgtaccgc	600
agatctttcc c atg ggg ctg tct tcc	644
Met Gly Leu Ser Ser Ser Glu Gly Asp Ile Pro	
1 5 10	
taagtagttt tgagagggtg gatgggttac ttgccacca gaaacagccc tagtcccaac	704
tccttgcggt cctttggccc ctccctgcct acctagaatc tgctgaagg ggctggagag	764
ggacagtatt gggggactgt gctagcttta cccccgcagg acatacacag gagcctttga	824
tctcattaaa gagatgtaaa ccagcaaaaa aaaaaaa	861
<210> 84	
<211> 239	
<212> DNA	
<213> Homo sapiens	
<220>	
<223> CDS	
<222> 61..228	


```

<223> sig_peptide
<222> 61..162
<223> Von Heijne matrix
      score 4
      seq IAVLYLHLYDVFG/DP
<223> polyA_signal
<222> 208..213
<400> 84
aatctgactc ctgagttctc acaacgcttg accaataaga ttcggaagct tcttcagcaa      60
atg gag aga ggc ctg aaa tca gca gac cct cgg gat ggc acc ggt tac      108
Met Glu Arg Gly Leu Lys Ser Ala Asp Pro Arg Asp Gly Thr Gly Tyr
      -30      -25      -20
act ggc tgg gca ggt att gct gtg ctt tac tta cat ctt tat gat gta      156
Thr Gly Trp Ala Gly Ile Ala Val Leu Tyr Leu His Leu Tyr Asp Val
      -15      -10      -5
ttt ggg gac cct gcc tct atg ttc tgt aaa gta ttt gac tta cta gtt      204
Phe Gly Asp Pro Ala Ser Met Phe Cys Lys Val Phe Asp Leu Leu Val
      1      5      10
ctc aat aaa att tta tta gga cta taaaaaaaa a      239
Leu Asn Lys Ile Leu Leu Gly Leu
      15      20
<210> 85
<211> 178
<212> PRT
<213> Homo sapiens
<220>
<223> SIGNAL
<222> -22..-1
<400> 85
Met His Arg Pro Glu Ala Met Leu Leu Leu Leu Thr Leu Ala Leu Leu
      -20      -15      -10
Gly Gly Pro Thr Trp Ala Gly Lys Met Tyr Gly Pro Gly Gly Gly Lys
      -5      1      5      10
Tyr Phe Ser Thr Thr Glu Asp Tyr Asp His Glu Ile Thr Gly Leu Arg
      15      20      25
Val Ser Val Gly Leu Leu Leu Val Lys Ser Val Gln Val Lys Leu Gly
      30      35      40
Asp Ser Trp Asp Val Lys Leu Gly Ala Leu Gly Gly Asn Thr Gln Glu
      45      50      55
Val Thr Leu Gln Pro Gly Glu Tyr Ile Thr Lys Val Phe Val Ala Phe
      60      65      70
Gln Thr Phe Leu Arg Gly Met Val Met Tyr Thr Ser Lys Asp Arg Tyr
      75      80      85      90
Phe Tyr Phe Gly Lys Leu Asp Gly Gln Ile Ser Ser Ala Tyr Pro Ser
      95      100      105
Gln Glu Gly Gln Val Leu Val Gly Ile Tyr Gly Gln Tyr Gln Leu Leu
      110      115      120
Gly Ile Lys Ser Ile Gly Phe Glu Trp Asn Tyr Pro Leu Glu Glu Pro
      125      130      135
Thr Thr Glu Pro Pro Val Asn Leu Thr Tyr Ser Ala Asn Ser Pro Val
      140      145      150
Gly Arg
155
<210> 86
<211> 90
<212> PRT
<213> Homo sapiens
<220>
<223> SIGNAL
<222> -19..-1
<400> 86

```

Met Lys Phe Leu Ala Val Leu Val Leu Leu Gly Val Ser Ile Phe Leu
 -15 -10 -5
 Val Ser Ala Gln Asn Pro Thr Thr Ala Ala Pro Ala Asp Thr Tyr Pro
 1 5 10
 Ala Thr Gly Pro Ala Asp Asp Glu Ala Pro Asp Ala Glu Thr Thr Ala
 15 20 25
 Ala Ala Thr Thr Ala Thr Thr Ala Ala Pro Thr Thr Ala Thr Thr Ala
 30 35 40 45
 Ala Ser Thr Thr Ala Arg Lys Asp Ile Pro Val Leu Pro Lys Trp Val
 50 55 60
 Gly Asp Leu Pro Asn Gly Arg Val Cys Pro
 65 70

<210> 87
 <211> 125
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -15...-1
 <400> 87

Met Lys Leu Leu Thr His Asn Leu Leu Ser Ser His Val Arg Gly Val
 -15 -10 -5 1
 Gly Ser Arg Gly Phe Pro Leu Arg Leu Gln Ala Thr Glu Val Arg Ile
 5 10 15
 Cys Pro Val Glu Phe Asn Pro Asn Phe Val Ala Arg Met Ile Pro Lys
 20 25 30
 Val Glu Trp Ser Ala Phe Leu Glu Ala Ala Asp Asn Leu Arg Leu Ile
 35 40 45
 Gln Val Pro Lys Gly Pro Val Glu Gly Tyr Glu Glu Asn Glu Glu Phe
 50 55 60 65
 Leu Arg Thr Met His His Leu Leu Leu Glu Val Glu Val Ile Glu Gly
 70 75 80
 Thr Leu Gln Cys Pro Glu Ser Gly Arg Met Phe Pro Ile Ser Arg Gly
 85 90 95
 Ile Pro Asn Met Leu Leu Ser Glu Glu Thr Glu Ser
 100 105 110

<210> 88
 <211> 136
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -34...-1
 <400> 88

Met Leu Phe Ser Leu Arg Glu Leu Val Gln Trp Leu Gly Phe Ala Thr
 -30 -25 -20
 Phe Glu Ile Phe Val His Leu Leu Ala Leu Leu Val Phe Ser Val Leu
 -15 -10 -5
 Leu Ala Leu Arg Val Asp Gly Leu Val Pro Gly Leu Ser Trp Trp Asn
 1 5 10
 Val Phe Val Pro Phe Phe Ala Ala Asp Gly Leu Ser Thr Tyr Phe Thr
 15 20 25 30
 Thr Ile Val Ser Val Arg Leu Phe Gln Asp Gly Glu Lys Arg Leu Ala
 35 40 45
 Val Leu Arg Leu Phe Trp Val Leu Thr Val Leu Ser Leu Lys Phe Val
 50 55 60
 Phe Glu Met Leu Leu Cys Gln Lys Leu Ala Glu Gln Thr Arg Glu Leu
 65 70 75
 Trp Phe Gly Leu Ile Thr Ser Pro Leu Phe Ile Leu Leu Gln Leu Leu
 80 85 90
 Met Ile Arg Ala Cys Arg Val Asn

95
 <210> 89
 <211> 238
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -53...-1
 <400> 89
 Met Ala Asp Pro Asp Pro Arg Tyr Pro Arg Ser Ser Ile Glu Asp Asp
 -50 -45 -40
 Phe Asn Tyr Gly Ser Ser Val Ala Ser Ala Thr Val His Ile Arg Met
 -35 -30 -25
 Ala Phe Leu Arg Lys Val Tyr Ser Ile Leu Ser Leu Gln Val Leu Leu
 -20 -15 -10
 Thr Thr Val Thr Ser Thr Val Phe Leu Tyr Phe Glu Ser Val Arg Thr
 1 5 10
 Phe Val His Glu Ser Pro Ala Leu Ile Leu Leu Phe Ala Leu Gly Ser
 15 20 25
 Leu Gly Leu Ile Phe Ala Leu Ile Leu Asn Arg His Lys Tyr Pro Leu
 30 35 40
 Asn Leu Tyr Leu Leu Phe Gly Phe Thr Leu Leu Glu Ala Leu Thr Val
 45 50 55
 Ala Val Val Val Thr Phe Tyr Asp Val Tyr Ile Ile Leu Gln Ala Phe
 60 65 70 75
 Ile Leu Thr Thr Thr Val Phe Phe Gly Leu Thr Val Tyr Thr Leu Gln
 80 85 90
 Ser Lys Lys Asp Phe Ser Lys Phe Gly Ala Gly Leu Phe Ala Leu Leu
 95 100 105
 Trp Ile Leu Cys Leu Ser Gly Phe Leu Lys Phe Phe Leu Tyr Ser Glu
 110 115 120
 Ile Met Glu Leu Val Leu Ala Ala Ala Gly Ala Leu Leu Phe Cys Gly
 125 130 135
 Phe Ile Ile Tyr Asp Thr His Ser Leu Met His Lys Leu Ser Pro Glu
 140 145 150 155
 Glu Tyr Val Leu Ala Ile Ser Leu Tyr Leu Asp Ile Ile Asn Leu
 160 165 170
 Phe Leu His Leu Leu Arg Phe Leu Glu Ala Val Asn Lys Lys
 175 180 185
 <210> 90
 <211> 106
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -71...-1
 <400> 90
 Met Ser Thr Asn Asn Met Ser Asp Pro Arg Arg Pro Asn Lys Val Leu
 -70 -65 -60
 Arg Tyr Lys Pro Pro Pro Ser Glu Cys Asn Pro Ala Leu Asp Asp Pro
 -55 -50 -45 -40
 Thr Pro Asp Tyr Met Asn Leu Leu Gly Met Ile Phe Ser Met Cys Gly
 -35 -30 -25
 Leu Met Leu Lys Leu Lys Trp Cys Ala Trp Val Ala Val Tyr Cys Ser
 -20 -15 -10
 Phe Ile Ser Phe Ala Asn Ser Arg Ser Ser Glu Asp Thr Lys Gln Met
 -5 1 5
 Met Ser Ser Phe Met Leu Ser Ile Ser Ala Val Val Met Ser Tyr Leu
 10 15 20 25
 Gln Asn Pro Gln Pro Met Thr Pro Pro Trp
 30 35

<210> 91
<211> 123
<212> PRT
<213> Homo sapiens
<220>
<223> SIGNAL
<222> -84...-1
<400> 91

Met	Ser	Gly	Gly	Pro	Glu	Ala	Arg	Pro	Pro	Met	Leu	Val	Glu	Gly	Gly
			-80						-75					-70	
Gly	Pro	Glu	Ser	Leu	Gln	Lys	Ala	Pro	Cys	Thr	Arg	Gly	Pro	Pro	Ser
		-65					-60						-55		
His	Pro	Val	Pro	Pro	Ala	Leu	Ala	Phe	Thr	Val	Gly	Asn	Gly	Ser	Gly
	-50					-45						-40			
Pro	Gly	Val	Arg	Cys	Pro	Arg	Asn	Met	Ala	Glu	Gly	His	Pro	Gly	Pro
	-35				-30						-25				
Glu	Arg	Arg	Gln	Ser	Gln	Gln	Gly	Leu	Phe	Arg	Ala	Ala	Trp	Leu	Pro
	-20				-15					-10					-5
Gly	Ser	Arg	Pro	Ser	Pro	Leu	Phe	Cys	Val	Cys	Ser	Val	Thr	Ser	Pro
			1				5						10		
Gly	Trp	Asp	Val	Pro	Gln	Val	His	Arg	Val	Glu	Val	Gly	His	Gly	Arg
	15					20						25			
Arg	Gln	Glu	Thr	His	Pro	Val	Arg	Arg	Arg	Ala					
	30					35									

<210> 92
<211> 75
<212> PRT
<213> Homo sapiens
<220>
<223> SIGNAL
<222> -49...-1
<400> 92

Met	Pro	Arg	Gly	Arg	Arg	Leu	Gly	Met	Val	Phe	Ala	Pro	Pro	Arg	Pro
			-45					-40						-35	
Gly	Gln	Arg	Gln	Ala	Gly	Ala	Pro	Trp	Val	Pro	Glu	Arg	Arg	Lys	Arg
		-30					-25						-20		
Arg	Pro	Asp	Gly	Asp	Thr	Phe	Leu	Leu	Ser	Phe	Leu	Ser	Thr	Thr	Trp
		-15				-10						-5			
Leu	Lys	Thr	Trp	Arg	Ser	Gln	Gln	Tyr	Lys	Glu	Ser	Lys	Ser	Arg	Ser
	1			5						10					15
Cys	Ala	Arg	Glu	Gln	Met	Asn	Ser	Ser	Ser	Cys					
			20						25						

<210> 93
<211> 80
<212> PRT
<213> Homo sapiens
<220>
<223> SIGNAL
<222> -40...-1
<400> 93

Met	Asp	Gly	Ile	Pro	Met	Ser	Met	Lys	Asn	Glu	Met	Pro	Ile	Ser	Gln
	-40				-35					-30					-25
Leu	Leu	Met	Ile	Ile	Ala	Pro	Ser	Leu	Gly	Phe	Val	Leu	Phe	Ala	Leu
			-20						-15					-10	
Phe	Val	Ala	Phe	Leu	Leu	Arg	Gly	Lys	Leu	Met	Glu	Thr	Tyr	Cys	Ser
		-5					1				5				
Gln	Lys	His	Thr	Arg	Leu	Asp	Tyr	Ile	Gly	Asp	Ser	Lys	Asn	Val	Leu
	10				15					20					
Asn	Asp	Val	Gln	His	Gly	Arg	Glu	Asp	Glu	Asp	Gly	Leu	Phe	Thr	Leu
	25				30					35					40

<210> 94

```

<211> 327
<212> PRT
<213> Homo sapiens
<220>
<223> SIGNAL
<222> -49..-1
<400> 94
Met Phe Pro Ser Arg Arg Lys Ala Ala Gln Leu Pro Trp Glu Asp Gly
      -45      -40      -35
Arg Ser Gly Leu Leu Ser Gly Gly Leu Pro Arg Lys Cys Ser Val Phe
      -30      -25      -20
His Leu Phe Val Ala Cys Leu Ser Leu Gly Phe Phe Ser Leu Leu Trp
      -15      -10      -5
Leu Gln Leu Ser Cys Ser Gly Asp Val Ala Arg Ala Val Arg Gly Gln
      1      5      10      15
Gly Gln Glu Thr Ser Gly Pro Pro Arg Ala Cys Pro Pro Glu Pro Pro
      20      25      30
Pro Glu His Trp Glu Glu Asp Ala Ser Trp Gly Pro His Arg Leu Ala
      35      40      45
Val Leu Val Pro Phe Arg Glu Arg Phe Glu Glu Leu Leu Val Phe Val
      50      55      60
Pro His Met Arg Arg Phe Leu Ser Arg Lys Lys Ile Arg His His Ile
      65      70      75
Tyr Val Leu Asn Gln Val Asp His Phe Arg Phe Asn Arg Ala Ala Leu
      80      85      90      95
Ile Asn Val Gly Phe Leu Glu Ser Ser Asn Ser Thr Asp Tyr Ile Ala
      100      105      110
Met His Asp Val Asp Leu Leu Pro Leu Asn Glu Glu Leu Asp Tyr Gly
      115      120      125
Phe Pro Glu Ala Gly Pro Phe His Val Ala Ser Pro Glu Leu His Pro
      130      135      140
Leu Tyr His Tyr Lys Thr Tyr Val Gly Gly Ile Leu Leu Leu Ser Lys
      145      150      155
Gln His Tyr Arg Leu Cys Asn Gly Met Ser Asn Arg Phe Trp Gly Trp
      160      165      170      175
Gly Arg Glu Asp Asp Glu Phe Tyr Arg Arg Ile Lys Gly Ala Gly Leu
      180      185      190
Gln Leu Phe Arg Pro Ser Gly Ile Thr Thr Gly Tyr Lys Thr Phe Arg
      195      200      205
His Leu His Asp Pro Ala Trp Arg Lys Arg Asp Gln Lys Arg Ile Ala
      210      215      220
Ala Gln Lys Gln Glu Gln Phe Lys Val Asp Arg Glu Gly Gly Leu Asn
      225      230      235
Thr Val Lys Tyr His Val Ala Ser Arg Thr Ala Leu Ser Val Gly Gly
      240      245      250      255
Ala Pro Cys Thr Val Leu Asn Ile Met Leu Asp Cys Asp Lys Thr Ala
      260      265      270
Thr Pro Trp Cys Thr Phe Ser
      275
<210> 95
<211> 235
<212> PRT
<213> Homo sapiens
<220>
<223> SIGNAL
<222> -20..-1
<400> 95
Met Arg Pro Leu Ala Gly Gly Leu Leu Lys Val Val Phe Val Val Phe
-20      -15      -10      -5
Ala Ser Leu Cys Ala Trp Tyr Ser Gly Tyr Leu Ala Glu Leu Ile
      1      5      10

```

Pro Asp Ala Pro Leu Ser Ser Ala Ala Tyr Ser Ile Arg Ser Ile Gly
15 20 25
Glu Arg Pro Val Leu Lys Ala Pro Val Pro Lys Arg Gln Lys Cys Asp
30 35 40
His Trp Thr Pro Cys Pro Ser Asp Thr Tyr Ala Tyr Arg Leu Leu Ser
45 50 55 60
Gly Gly Gly Arg Ser Lys Tyr Ala Lys Ile Cys Phe Glu Asp Asn Leu
65 70 75
Leu Met Gly Glu Gln Leu Gly Asn Val Ala Arg Gly Ile Asn Ile Ala
80 85 90
Ile Val Asn Tyr Val Thr Gly Asn Val Thr Ala Thr Arg Cys Phe Asp
95 100 105
Met Tyr Glu Gly Asp Asn Ser Gly Pro Met Thr Lys Phe Ile Gln Ser
110 115 120
Ala Ala Pro Lys Ser Leu Leu Phe Met Val Thr Tyr Asp Asp Gly Ser
125 130 135 140
Thr Arg Leu Asn Asn Asp Ala Lys Asn Ala Ile Glu Ala Leu Gly Ser
145 150 155
Lys Glu Ile Arg Asn Met Lys Phe Arg Ser Ser Trp Val Phe Ile Ala
160 165 170
Ala Lys Gly Leu Glu Leu Pro Ser Glu Ile Gln Arg Glu Lys Ile Asn
175 180 185
His Ser Asp Ala Lys Asn Asn Arg Tyr Ser Gly Trp Pro Ala Glu Ile
190 195 200
Gln Ile Glu Gly Cys Ile Pro Lys Glu Arg Ser
205 210 215
<210> 96
<211> 52
<212> PRT
<213> Homo sapiens
<220>
<223> SIGNAL
<222> -31...-1
<400> 96
Met Arg Val Tyr Lys Arg Thr Gln Leu Arg Gln Glu Thr Gly Pro Lys
-30 -25 -20
Ser Tyr Val Leu Phe Ser Ala Ser Ser Phe Pro Ser Ile Ser Gly Asn
-15 -10 -5 1
Ile Arg Ser Arg Asn Tyr Phe Gln Lys Gln Asn Asn His Trp Phe Gln
5 10 15
Thr Ser Asp Tyr
20
<210> 97
<211> 229
<212> PRT
<213> Homo sapiens
<220>
<223> SIGNAL
<222> -47...-1
<400> 97
Met Gln Asp Glu Asp Gly Tyr Ile Thr Leu Asn Ile Lys Thr Arg Lys
-45 -40 -35
Pro Ala Leu Val Ser Val Gly Pro Ala Ser Ser Phe Trp Trp Arg Val
-30 -25 -20
Met Ala Leu Ile Leu Leu Ile Leu Cys Val Gly Met Val Val Gly Leu
-15 -10 -5 1
Val Ala Leu Gly Ile Trp Ser Val Met Gln Arg Asn Tyr Leu Gln Asp
5 10 15
Glu Asn Glu Asn Arg Thr Gly Thr Leu Gln Gln Leu Ala Lys Arg Phe
20 25 30
Cys Gln Tyr Val Val Lys Gln Ser Glu Leu Lys Gly Thr Phe Lys Gly

35 40 45
 His Lys Cys Ser Pro Cys Asp Thr Asn Trp Arg Tyr Tyr Gly Asp Ser
 50 55 60 65
 Cys Tyr Gly Phe Phe Arg His Asn Leu Thr Trp Glu Glu Ser Lys Gln
 70 75 80
 Tyr Cys Thr Asp Met Asn Ala Thr Leu Leu Lys Ile Asp Asn Arg Asn
 85 90 95
 Ile Val Glu Tyr Ile Lys Ala Arg Thr His Leu Ile Arg Trp Val Gly
 100 105 110
 Leu Ser Arg Gln Lys Ser Asn Glu Val Trp Lys Trp Glu Asp Gly Ser
 115 120 125
 Val Ile Ser Glu Asn Met Phe Glu Phe Leu Glu Asp Gly Lys Gly Asn
 130 135 140 145
 Met Asn Cys Ala Tyr Phe His Asn Gly Lys Met His Pro Thr Phe Cys
 150 155 160
 Glu Asn Lys His Tyr Leu Met Cys Glu Arg Lys Ala Gly Met Thr Lys
 165 170 175
 Val Asp Gln Leu Pro
 180
 <210> 98
 <211> 92
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -24...-1
 <400> 98
 Met Thr Lys Leu Ala Gln Trp Leu Trp Gly Leu Ala Ile Leu Gly Ser
 -20 -15 -10
 Thr Trp Val Ala Leu Thr Thr Gly Ala Leu Gly Leu Glu Leu Pro Leu
 -5 1 5
 Ser Cys Gln Glu Val Leu Trp Pro Leu Pro Ala Tyr Leu Leu Val Ser
 10 15 20
 Ala Gly Cys Tyr Ala Leu Gly Thr Val Gly Tyr Arg Val Ala Thr Phe
 25 30 35 40
 His Asp Cys Glu Asp Ala Ala Arg Glu Leu Gln Ser Gln Ile Gln Glu
 45 50 55
 Ala Arg Ala Asp Leu Ala Arg Arg Gly Leu Arg Phe
 60 65
 <210> 99
 <211> 425
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -23...-1
 <400> 99
 Met Ala Ser Ser Ser Pro Asp Ser Pro Cys Ser Cys Asp Cys Phe Val
 -20 -15 -10
 Ser Val Pro Pro Ala Ser Ala Ile Pro Ala Val Ile Phe Ala Lys Asn
 -5 1 5
 Ser Asp Arg Pro Arg Asp Glu Val Gln Glu Val Val Phe Val Pro Ala
 10 15 20 25
 Gly Thr His Thr Pro Gly Ser Arg Leu Gln Cys Thr Tyr Ile Glu Val
 30 35 40
 Glu Gln Val Ser Lys Thr His Ala Val Ile Leu Ser Arg Pro Ser Trp
 45 50 55
 Leu Trp Gly Ala Glu Met Gly Ala Asn Glu His Gly Val Cys Ile Gly
 60 65 70
 Asn Glu Ala Val Trp Thr Lys Glu Pro Val Gly Glu Gly Glu Ala Leu
 75 80 85

Leu Gly Met Asp Leu Leu Arg Leu Ala Leu Glu Arg Ser Ser Ser Ala
 90 95 100 105
 Gln Glu Ala Leu His Val Ile Thr Gly Leu Leu Glu His Tyr Gly Gln
 110 115 120
 Gly Gly Asn Cys Leu Glu Asp Ala Ala Pro Phe Ser Tyr His Ser Thr
 125 130 135
 Phe Leu Leu Ala Asp Arg Thr Glu Ala Trp Val Leu Glu Thr Ala Gly
 140 145 150
 Arg Leu Trp Ala Ala Gln Arg Ile Gln Glu Gly Ala Arg Asn Ile Ser
 155 160 165
 Asn Gln Leu Ser Ile Gly Thr Asp Ile Ser Ala Gln His Pro Glu Leu
 170 175 180 185
 Arg Thr His Ala Gln Ala Lys Gly Trp Trp Asp Gly Gln Gly Ala Phe
 190 195 200
 Asp Phe Ala Gln Ile Phe Ser Leu Thr Gln Gln Pro Val Arg Met Glu
 205 210 215
 Ala Ala Lys Ala Arg Phe Gln Ala Gly Arg Glu Leu Leu Arg Gln Arg
 220 225 230
 Gln Gly Gly Ile Thr Ala Glu Val Met Met Gly Ile Leu Arg Asp Lys
 235 240 245
 Glu Ser Gly Ile Cys Met Asp Ser Gly Gly Phe Arg Thr Thr Ala Ser
 250 255 260 265
 Met Val Ser Val Leu Pro Gln Asp Pro Thr Gln Pro Cys Val His Phe
 270 275 280
 Leu Thr Ala Thr Pro Asp Pro Ser Arg Ser Val Phe Lys Pro Phe Ile
 285 290 295
 Phe Gly Val Gly Val Ala Gln Ala Pro Gln Val Leu Ser Pro Thr Phe
 300 305 310
 Gly Ala Gln Asp Pro Val Arg Thr Leu Pro Arg Phe Gln Thr Gln Val
 315 320 325
 Asp Arg Arg His Thr Leu Tyr Arg Gly His Gln Ala Ala Leu Gly Leu
 330 335 340 345
 Met Glu Arg Asp Gln Asp Arg Gly Gln Gln Leu Gln Gln Lys Gln Gln
 350 355 360
 Asp Leu Glu Gln Glu Gly Leu Glu Ala Thr Gln Gly Leu Leu Ala Gly
 365 370 375
 Glu Trp Ala Pro Pro Leu Trp Glu Leu Gly Ser Leu Phe Gln Ala Phe
 380 385 390
 Val Lys Arg Glu Ser Gln Ala Tyr Ala
 395 400
 <210> 100
 <211> 87
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -62..-1
 <400> 100
 Met Ala Ile Phe Trp Ile Val His Ala His Phe Trp Ser Pro Leu Pro
 -60 -55 -50
 Pro Arg Leu Pro His Gly Arg Cys Cys Cys Leu Lys Ala Pro Leu Pro
 -45 -40 -35
 Pro Asp Val Gly Pro Leu Gln Val Ala Pro His Leu Phe Ser Val Pro
 -30 -25 -20 -15
 Leu His Ile Leu Thr Val Pro Leu Leu Glu Pro Ala Arg Cys Ser Gly
 -10 -5 1
 Ile Leu Val Phe Phe Leu His Gln Pro Val Ser Ser Leu Ser Phe Cys
 5 10 15
 Tyr Phe Ile Gly Gly Trp Cys
 20 25
 <210> 101

<211> 149
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -100...-1
 <400> 101
 Met Glu Thr Leu Tyr Arg Val Pro Phe Leu Val Leu Glu Cys Pro Asn
 -100 -95 -90 -85
 Leu Lys Leu Lys Lys Pro Pro Trp Leu His Met Pro Ser Ala Met Thr
 -80 -75 -70
 Val Tyr Ala Leu Val Val Val Ser Tyr Phe Leu Ile Thr Gly Gly Ile
 -65 -60 -55
 Ile Tyr Asp Val Ile Val Glu Pro Ser Val Gly Ser Met Thr Asp
 -50 -45 -40
 Glu His Gly His Gln Arg Pro Val Ala Phe Leu Ala Tyr Arg Val Asn
 -35 -30 -25
 Gly Gln Tyr Ile Met Glu Gly Leu Ala Ser Ser Phe Leu Phe Thr Met
 -20 -15 -10 -5
 Gly Gly Leu Gly Phe Ile Ile Leu Asp Arg Ser Asn Ala Pro Asn Ile
 1 5 10
 Pro Lys Leu Asn Arg Phe Leu Leu Phe Ile Gly Phe Val Cys Val
 15 20 25
 Leu Leu Ser Phe Phe Met Ala Arg Val Phe Met Arg Met Lys Leu Pro
 30 35 40
 Gly Tyr Leu Met Gly
 45
 <210> 102
 <211> 187
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -35...-1
 <400> 102
 Met Ala Asn Asn Thr Thr Ser Leu Gly Ser Pro Trp Pro Glu Asn Phe
 -35 -30 -25 -20
 Trp Glu Asp Leu Ile Met Ser Phe Thr Val Ser Met Ala Ile Gly Leu
 -15 -10 -5
 Val Leu Gly Gly Phe Ile Trp Ala Val Phe Ile Cys Leu Ser Arg Arg
 1 5 10
 Arg Arg Ala Ser Ala Pro Ile Ser Gln Trp Ser Ser Ser Arg Arg Ser
 15 20 25
 Arg Ser Ser Tyr Thr His Gly Leu Asn Arg Thr Gly Phe Tyr Arg His
 30 35 40 45
 Ser Gly Cys Glu Arg Arg Ser Asn Leu Ser Leu Ala Ser Leu Thr Phe
 50 55 60
 Gln Arg Gln Ala Ser Leu Glu Gln Ala Asn Ser Phe Pro Arg Lys Ser
 65 70 75
 Ser Phe Arg Ala Ser Thr Phe His Pro Phe Leu Gln Cys Pro Pro Leu
 80 85 90
 Pro Val Glu Thr Glu Ser Gln Leu Val Thr Leu Pro Ser Ser Asn Ile
 95 100 105
 Ser Pro Thr Ile Ser Thr Ser His Ser Leu Ser Arg Pro Asp Tyr Trp
 110 115 120 125
 Ser Ser Asn Ser Leu Arg Val Gly Leu Ser Thr Pro Pro Pro Pro Ala
 130 135 140
 Tyr Glu Ser Ile Ile Lys Ala Phe Pro Asp Ser
 145 150
 <210> 103
 <211> 123

<212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -26..-1
 <400> 103
 Met Ala Thr Ala Ala Gly Ala Thr Tyr Phe Gln Arg Gly Ser Leu Phe
 -25 -20 -15
 Trp Phe Thr Val Ile Thr Leu Ser Phe Gly Tyr Tyr Thr Trp Val Val
 -10 -5 1 5
 Phe Trp Pro Gln Ser Ile Pro Tyr Gln Asn Leu Gly Pro Leu Gly Pro
 10 15 20
 Phe Thr Gln Tyr Leu Val Asp His His Thr Leu Leu Cys Asn Gly
 25 30 35
 Tyr Trp Leu Ala Trp Leu Ile His Val Gly Glu Ser Leu Tyr Ala Ile
 40 45 50
 Val Leu Cys Lys His Lys Gly Ile Thr Ser Gly Arg Ala Gln Leu Leu
 55 60 65 70
 Trp Phe Leu Gln Thr Phe Phe Phe Gly Ile Ala Ser Leu Thr Ile Leu
 75 80 85
 Ile Ala Tyr Lys Arg Lys Arg Gln Lys Gln Thr
 90 95

<210> 104
 <211> 153
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -102..-1
 <400> 104
 Met Ala Ala Gly Leu Phe Gly Leu Ser Ala Arg Arg Leu Leu Ala Ala
 -100 -95 -90
 Ala Ala Thr Arg Gly Leu Pro Ala Ala Arg Val Arg Trp Glu Ser Ser
 -85 -80 -75
 Phe Ser Arg Thr Val Val Ala Pro Ser Ala Val Ala Gly Lys Arg Pro
 -70 -65 -60 -55
 Pro Glu Pro Thr Thr Pro Trp Gln Glu Asp Pro Glu Pro Glu Asp Glu
 -50 -45 -40
 Asn Leu Tyr Glu Lys Asn Pro Asp Ser His Gly Tyr Asp Lys Asp Pro
 -35 -30 -25
 Val Leu Asp Val Trp Asn Met Arg Leu Val Phe Phe Phe Gly Val Ser
 -20 -15 -10
 Ile Ile Leu Val Leu Gly Ser Thr Phe Val Ala Tyr Leu Pro Asp Tyr
 -5 1 5 10
 Arg Met Lys Glu Trp Ser Arg Arg Glu Ala Glu Arg Leu Val Lys Tyr
 15 20 25
 Arg Glu Ala Asn Gly Leu Pro Ile Met Glu Ser Asn Cys Phe Asp Pro
 30 35 40
 Ser Lys Ile Gln Leu Pro Glu Asp Glu
 45 50

<210> 105
 <211> 72
 <212> PRT
 <213> Homo sapiens
 <400> 105
 Leu Pro Val Ser Thr Arg Ile Ile Asn His Ile Tyr Ser Phe Pro Ser
 1 5 10 15
 Val Asp Leu Trp Ile Val Cys Ile Phe Thr Val Ser Val Ser His Leu
 20 25 30
 Phe Glu Lys Gly Thr Leu Tyr Gly Tyr Phe Tyr Val Ile Asn Ser Ser
 35 40 45

Ile Asn Leu Cys Val Asn Asp Cys Leu Pro Val Met Asp Ser Ile Ser
 50 55 60
 Leu Ser Pro Leu Phe Leu Ser His
 65 70

<210> 106

<211> 175

<212> PRT

<213> Homo sapiens

<220>

<223> SIGNAL

<222> -20..-1

<400> 106

Met Glu Lys Ile Pro Val Ser Ala Phe Leu Leu Val Ala Leu Ser
 -20 -15 -10 -5
 Tyr Thr Leu Ala Arg Asp Thr Thr Val Lys Pro Gly Ala Lys Lys Asp
 1 5 10
 Thr Lys Asp Ser Arg Pro Lys Leu Pro Gln Thr Leu Ser Arg Gly Trp
 15 20 25
 Gly Asp Gln Leu Ile Trp Thr Gln Thr Tyr Glu Glu Ala Leu Tyr Lys
 30 35 40
 Ser Lys Thr Ser Asn Lys Pro Leu Met Ile Ile His His Leu Asp Glu
 45 50 55 60
 Cys Pro His Ser Gln Ala Leu Lys Lys Val Phe Ala Glu Asn Lys Glu
 65 70 75
 Ile Gln Lys Leu Ala Glu Gln Phe Val Leu Leu Asn Leu Val Tyr Glu
 80 85 90
 Thr Thr Asp Lys His Leu Ser Pro Asp Gly Gln Tyr Val Pro Arg Ile
 95 100 105
 Met Phe Val Asp Pro Ser Leu Thr Val Arg Ala Asp Ile Thr Gly Arg
 110 115 120
 Tyr Ser Asn Arg Leu Tyr Ala Tyr Glu Pro Ala Asp Thr Ala Leu Leu
 125 130 135 140
 Leu Asp Asn Met Lys Lys Ala Leu Lys Leu Leu Lys Thr Glu Leu
 145 150 155

<210> 107

<211> 303

<212> PRT

<213> Homo sapiens

<220>

<223> SIGNAL

<222> -20..-1

<400> 107

Met Ala Asp Ala Ala Ser Gln Val Leu Leu Gly Ser Gly Leu Thr Ile
 -20 -15 -10 -5
 Leu Ser Gln Pro Leu Met Tyr Val Lys Val Leu Ile Gln Val Gly Tyr
 1 5 10
 Glu Pro Leu Pro Pro Thr Ile Gly Arg Asn Ile Phe Gly Arg Gln Val
 15 20 25
 Cys Gln Leu Pro Gly Leu Phe Ser Tyr Ala Gln His Ile Ala Ser Ile
 30 35 40
 Asp Gly Arg Arg Gly Leu Phe Thr Gly Leu Thr Pro Arg Leu Cys Ser
 45 50 55 60
 Gly Val Leu Gly Thr Val Val His Gly Lys Val Leu Gln His Tyr Gln
 65 70 75
 Glu Ser Asp Lys Gly Glu Glu Leu Gly Pro Gly Asn Val Gln Lys Glu
 80 85 90
 Val Ser Ser Ser Phe Asp His Val Ile Lys Glu Thr Thr Arg Glu Met
 95 100 105
 Ile Ala Arg Ser Ala Ala Thr Leu Ile Thr His Pro Phe His Val Ile
 110 115 120
 Thr Leu Arg Ser Met Val Gln Phe Ile Gly Arg Glu Ser Lys Tyr Cys

125 130 135 140
 Gly Leu Cys Asp Ser Ile Ile Thr Ile Tyr Arg Glu Glu Gly Ile Leu
 145 150 155
 Gly Phe Phe Ala Gly Leu Val Pro Arg Leu Leu Gly Asp Ile Leu Ser
 160 165 170
 Leu Trp Leu Cys Asn Ser Leu Ala Tyr Leu Val Asn Thr Tyr Ala Leu
 175 180 185
 Asp Ser Gly Val Ser Thr Met Asn Glu Met Lys Ser Tyr Ser Gln Ala
 190 195 200
 Val Thr Gly Phe Phe Ala Ser Met Leu Thr Tyr Pro Phe Val Leu Val
 205 210 215 220
 Ser Asn Leu Met Ala Val Asn Asn Cys Gly Leu Ala Gly Gly Cys Pro
 225 230 235
 Pro Tyr Ser Pro Ile Tyr Thr Ser Trp Ile Asp Cys Trp Cys Met Leu
 240 245 250
 Gln Lys Glu Gly Asn Met Ser Arg Gly Asn Ser Leu Phe Phe Arg Lys
 255 260 265
 Val Pro Phe Gly Lys Thr Tyr Cys Cys Asp Leu Lys Met Leu Ile
 270 275 280
 <210> 108
 <211> 65
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -39..-1
 <400> 108
 Met Ser Thr Gly Ile Met Glu Tyr Lys Lys Thr Thr Lys Ala Met Lys
 -35 -30 -25
 Lys Lys Lys Asp Val Leu Phe Thr Ser Tyr Phe Lys Thr Ile Ala Phe
 -20 -15 -10
 Leu Leu Leu Tyr Val Ser Ala Gly Pro Ile Ser Arg Ile Phe Ile Arg
 -5 1 5
 Ser Leu Glu Leu Phe Leu Met Phe Pro Ser Asn Lys His Trp Tyr Ile
 10 15 20 25
 Ser
 <210> 109
 <211> 137
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -17..-1
 <400> 109
 Met Gly Phe Gly Ala Thr Leu Ala Val Gly Leu Thr Ile Phe Val Leu
 -15 -10 -5
 Ser Val Val Thr Ile Ile Ile Cys Phe Thr Cys Ser Cys Cys Cys Leu
 1 5 10 15
 Tyr Lys Thr Cys Arg Arg Pro Arg Pro Val Val Thr Thr Thr Ser
 20 25 30
 Thr Thr Val Val His Ala Pro Tyr Pro Gln Pro Pro Ser Val Pro Pro
 35 40 45
 Ser Tyr Pro Gly Pro Ser Tyr Gln Gly Tyr His Thr Met Pro Pro Gln
 50 55 60
 Pro Gly Met Pro Ala Ala Pro Tyr Pro Met Gln Tyr Pro Pro Pro Tyr
 65 70 75
 Pro Ala Gln Pro Met Gly Pro Pro Ala Tyr His Glu Thr Leu Ala Gly
 80 85 90 95
 Gly Ala Ala Ala Pro Tyr Pro Ala Ser Gln Pro Pro Tyr Asn Pro Ala
 100 105 110
 Tyr Met Asp Ala Pro Lys Ala Ala Leu

115 120
 <210> 110
 <211> 154
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -13..-1
 <400> 110
 Met Ala Leu Leu Leu Ser Val Leu Arg Val Leu Leu Gly Gly Phe Phe
 -10 -5 1
 Ala Leu Val Gly Leu Ala Lys Leu Ser Glu Glu Ile Ser Ala Pro Val
 5 10 15
 Ser Glu Arg Met Asn Ala Leu Phe Val Gln Phe Ala Glu Val Phe Pro
 20 25 30 35
 Leu Lys Val Phe Gly Tyr Gln Pro Asp Pro Leu Asn Tyr Gln Ile Ala
 40 45 50
 Val Gly Phe Leu Glu Leu Leu Ala Gly Leu Leu Leu Val Met Gly Pro
 55 60 65
 Pro Met Leu Gln Glu Ile Ser Asn Leu Phe Leu Ile Leu Leu Met Met
 70 75 80
 Gly Ala Ile Phe Thr Leu Ala Ala Leu Lys Glu Ser Leu Ser Thr Cys
 85 90 95
 Ile Pro Ala Ile Val Cys Leu Gly Phe Leu Leu Leu Asn Val Gly
 100 105 110 115
 Gln Leu Leu Ala Gln Thr Lys Lys Val Val Arg Pro Thr Arg Lys Lys
 120 125 130
 Thr Leu Ser Thr Phe Lys Glu Ser Trp Lys
 135 140
 <210> 111
 <211> 103
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -36..-1
 <400> 111
 Met Ala Asn Leu Phe Ile Arg Lys Met Val Asn Pro Leu Leu Tyr Leu
 -35 -30 -25
 Ser Arg His Thr Val Lys Pro Arg Ala Leu Ser Thr Phe Leu Phe Gly
 -20 -15 -10 -5
 Ser Ile Arg Gly Ala Ala Pro Val Ala Val Glu Pro Gly Ala Ala Val
 1 5 10
 Arg Ser Leu Leu Ser Pro Gly Leu Leu Pro His Leu Leu Pro Ala Leu
 15 20 25
 Gly Phe Lys Asn Lys Thr Val Leu Asn Lys Arg Cys Lys Asp Cys Tyr
 30 35 40
 Leu Val Lys Arg Arg Gly Arg Trp Tyr Val Tyr Cys Lys Thr His Pro
 45 50 55 60
 Arg His Lys Gln Arg Gln Met
 65
 <210> 112
 <211> 86
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -74..-1
 <400> 112
 Met Pro Tyr Ala Phe Thr Ser Pro Cys Pro Cys Ser Phe Val Ser Leu
 -70 -65 -60

Pro Glu Ile Ser Phe Tyr Phe Thr Lys Leu Leu Leu Ile Leu Lys Ala
 -55 -50 -45
 Leu Pro Glu Ser Pro Phe Leu Leu Ala Ser Ser Pro Leu Pro Pro Leu
 -40 -35 -30
 Pro Thr Thr Leu Arg Lys Phe Ile Pro Pro Pro Ser Leu Ile Ser Cys
 -25 -20 -15
 Thr Cys Leu Leu Leu Tyr Leu Thr His Cys Ile Leu Gly Ile Cys Phe
 -10 -5 1 5
 Ala Tyr Pro Phe Ile Leu
 10
 <210> 113
 <211> 395
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -310..-1
 <400> 113
 Met Asp Leu Gly Ile Pro Asp Leu Leu Asp Ala Trp Leu Glu Pro Pro
 -310 -305 -300 -295
 Glu Asp Ile Phe Ser Thr Gly Ser Val Leu Glu Leu Gly Leu His Cys
 -290 -285 -280
 Pro Pro Pro Glu Val Pro Val Thr Arg Leu Gln Glu Gln Gly Leu Gln
 -275 -270 -265
 Gly Trp Lys Ser Gly Gly Asp Arg Gly Cys Gly Leu Gln Glu Ser Glu
 -260 -255 -250
 Pro Glu Asp Phe Leu Lys Leu Phe Ile Asp Pro Asn Glu Val Tyr Cys
 -245 -240 -235
 Ser Glu Ala Ser Pro Gly Ser Asp Ser Gly Ile Ser Glu Asp Ser Cys
 -230 -225 -220 -215
 His Pro Asp Ser Pro Pro Ala Pro Arg Ala Thr Ser Ser Pro Met Leu
 -210 -205 -200
 Tyr Glu Val Val Tyr Glu Ala Gly Ala Leu Glu Arg Met Gln Gly Glu
 -195 -190 -185
 Thr Gly Pro Asn Val Gly Leu Ile Ser Ile Gln Leu Asp Gln Trp Ser
 -180 -175 -170
 Pro Ala Phe Met Val Pro Asp Ser Cys Met Val Ser Glu Leu Pro Phe
 -165 -160 -155
 Asp Ala His Ala His Ile Leu Pro Arg Ala Gly Thr Val Ala Pro Val
 -150 -145 -140 -135
 Pro Cys Thr Thr Leu Leu Pro Cys Gln Thr Leu Phe Leu Thr Asp Glu
 -130 -125 -120
 Glu Lys Arg Leu Leu Gly Gln Glu Gly Val Ser Leu Pro Ser His Leu
 -115 -110 -105
 Pro Leu Thr Lys Ala Glu Glu Arg Val Leu Lys Lys Val Arg Arg Lys
 -100 -95 -90
 Ile Arg Asn Lys Gln Ser Ala Gln Asp Ser Arg Arg Arg Lys Lys Glu
 -85 -80 -75
 Tyr Ile Asp Gly Leu Glu Ser Arg Val Ala Ala Cys Ser Ala Gln Asn
 -70 -65 -60 -55
 Gln Glu Leu Gln Lys Lys Val Gln Glu Leu Glu Arg His Asn Ile Ser
 -50 -45 -40
 Leu Val Ala Gln Leu Arg Gln Leu Gln Thr Leu Ile Ala Gln Thr Ser
 -35 -30 -25
 Asn Lys Ala Ala Gln Thr Ser Thr Cys Val Leu Ile Leu Leu Phe Ser
 -20 -15 -10
 Leu Ala Leu Ile Ile Leu Pro Ser Phe Ser Pro Phe Gln Ser Arg Pro
 -5 1 5 10
 Glu Ala Gly Ser Glu Asp Tyr Gln Pro His Gly Val Thr Ser Arg Asn
 15 20 25
 Ile Leu Thr His Lys Asp Val Thr Glu Asn Leu Glu Thr Gln Val Val

30 35 40
 Glu Ser Arg Leu Arg Glu Pro Pro Gly Ala Lys Asp Ala Asn Gly Ser
 45 50 55
 Thr Arg Thr Leu Leu Glu Lys Met Gly Gly Lys Pro Arg Pro Ser Gly
 60 65 70
 Arg Ile Arg Ser Val Leu His Ala Asp Glu Met
 75 80 85
 <210> 114
 <211> 93
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -18...-1
 <400> 114
 Met Ile His Leu Gly His Ile Leu Phe Leu Leu Leu Leu Pro Val Ala
 -15 -10 -5
 Ala Ala Gln Thr Thr Pro Gly Glu Arg Ser Ser Leu Pro Ala Phe Tyr
 1 5 10
 Pro Gly Thr Ser Gly Ser Cys Ser Gly Cys Gly Ser Leu Ser Leu Pro
 15 20 25 30
 Leu Leu Ala Gly Leu Val Ala Ala Asp Ala Val Ala Ser Leu Leu Ile
 35 40 45
 Val Gly Ala Val Phe Leu Cys Ala Arg Pro Arg Arg Ser Pro Ala Gln
 50 55 60
 Glu Tyr Gly Lys Val Tyr Ile Asn Met Pro Gly Arg Gly
 65 70 75
 <210> 115
 <211> 61
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -21...-1
 <400> 115
 Met Arg Glu Met Pro Val Pro Ser Leu Ile Asn Leu Ala Ala Ser Arg
 -20 -15 -10
 Thr Leu Ser Phe Cys Ile Ser Asp Asn His Val Ser Ser Pro Gly Pro
 -5 1 5 10
 Ala Asn Pro Ser Cys Gly Leu His Pro His Trp Leu Arg Pro Leu Lys
 15 20 25
 Leu Leu Thr Tyr Thr Cys Arg Glu Leu Lys Leu Gln Gly
 30 35 40
 <210> 116
 <211> 331
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -31...-1
 <400> 116
 Met Trp Leu Trp Glu Asp Gln Gly Gly Leu Leu Gly Pro Phe Ser Phe
 -30 -25 -20
 Leu Leu Leu Val Leu Leu Leu Val Thr Arg Ser Pro Val Asn Ala Cys
 -15 -10 -5 1
 Leu Leu Thr Gly Ser Leu Phe Val Leu Leu Arg Val Phe Ser Phe Glu
 5 10 15
 Pro Val Pro Ser Cys Arg Ala Leu Gln Val Leu Lys Pro Arg Asp Arg
 20 25 30
 Ile Ser Ala Ile Ala His Arg Gly Gly Ser His Asp Ala Pro Glu Asn
 35 40 45

Thr Leu Ala Ala Ile Arg Gln Ala Ala Lys Asn Gly Ala Thr Gly Val
 50 55 60 65
 Glu Leu Asp Ile Glu Phe Thr Ser Asp Gly Ile Pro Val Leu Met His
 70 75 80
 Asp Asn Thr Val Asp Arg Thr Thr Asp Gly Thr Gly Arg Leu Cys Asp
 85 90 95
 Leu Thr Phe Glu Gln Ile Arg Lys Leu Asn Pro Ala Ala Asn His Arg
 100 105 110
 Leu Arg Asn Asp Phe Pro Asp Glu Lys Ile Pro Thr Leu Met Glu Ala
 115 120 125
 Val Ala Glu Cys Leu Asn His Asn Leu Thr Ile Phe Phe Asp Val Lys
 130 135 140 145
 Gly His Ala His Lys Ala Thr Glu Ala Leu Lys Lys Met Tyr Met Glu
 150 155 160
 Phe Pro Gln Leu Tyr Asn Asn Ser Val Val Cys Ser Phe Leu Pro Glu
 165 170 175
 Val Ile Tyr Lys Met Arg Gln Thr Asp Arg Asp Val Ile Thr Ala Leu
 180 185 190
 Thr His Arg Pro Trp Ser Leu Ser His Thr Gly Asp Gly Lys Pro Arg
 195 200 205
 Tyr Asp Thr Phe Trp Lys His Phe Ile Phe Val Met Met Asp Ile Leu
 210 215 220 225
 Leu Asp Trp Ser Met His Asn Ile Leu Trp Tyr Leu Cys Gly Ile Ser
 230 235 240
 Ala Phe Leu Met Gln Lys Asp Phe Val Ser Pro Ala Tyr Leu Lys Lys
 245 250 255
 Trp Ser Ala Lys Gly Ile Gln Val Val Gly Trp Thr Val Asn Thr Phe
 260 265 270
 Asp Glu Lys Ser Tyr Tyr Glu Ser His Leu Gly Ser Ser Tyr Ile Thr
 275 280 285
 Asp Ser Met Val Glu Asp Cys Glu Pro His Phe
 290 295 300
 <210> 117
 <211> 210
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -99...-1
 <400> 117
 Met Ala Ala Ser Val Glu Gln Arg Glu Gly Thr Ile Gln Val Gln Gly
 -95 -90 -85
 Gln Ala Leu Phe Arg Glu Ala Leu Pro Gly Ser Gly Gln Ala Arg
 -80 -75 -70
 Phe Ser Val Leu Leu Leu His Gly Ile Arg Phe Ser Ser Glu Thr Trp
 -65 -60 -55
 Gln Asn Leu Gly Thr Leu His Arg Leu Ala Gln Ala Gly Tyr Arg Ala
 -50 -45 -40
 Val Ala Ile Asp Leu Pro Gly Leu Gly His Ser Lys Glu Ala Ala Ala
 -35 -30 -25 -20
 Pro Ala Pro Ile Gly Glu Leu Ala Pro Gly Ser Phe Leu Ala Ala Val
 -15 -10 -5
 Val Asp Ala Leu Glu Leu Gly Pro Pro Val Val Ile Ser Pro Ser Leu
 1 5 10
 Ser Gly Met Tyr Ser Leu Pro Phe Leu Thr Ala Pro Gly Ser Gln Leu
 15 20 25
 Pro Gly Phe Val Pro Val Ala Pro Ile Cys Thr Asp Lys Ile Asn Ala
 30 35 40 45
 Ala Asn Tyr Ala Ser Val Lys Thr Pro Ala Leu Ile Val Tyr Gly Asp
 50 55 60
 Gln Asp Pro Met Gly Gln Thr Ser Phe Glu His Leu Lys Gln Leu Pro

65 70 75
 Asn His Arg Val Leu Ile Met Lys Gly Ala Gly His Pro Cys Tyr Leu
 80 85 90
 Asp Lys Pro Glu Glu Trp His Thr Gly Leu Leu Asp Phe Leu Gln Gly
 95 100 105
 Leu Gln
 110
 <210> 118
 <211> 79
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -67..-1
 <400> 118
 Met Glu Leu Glu Ala Met Ser Arg Tyr Thr Ser Pro Val Asn Pro Ala
 -65 -60 -55
 Val Phe Pro His Leu Thr Val Val Leu Leu Ala Ile Gly Met Phe Phe
 -50 -45 -40
 Thr Ala Trp Phe Phe Val Tyr Glu Val Thr Ser Thr Lys Tyr Thr Arg
 -35 -30 -25 -20
 Asp Ile Tyr Lys Glu Leu Leu Ile Ser Leu Val Ala Ser Leu Phe Met
 -15 -10 -5
 Gly Phe Gly Val Leu Phe Leu Leu Leu Trp Val Gly Ile Tyr Val
 1 5 10
 <210> 119
 <211> 84
 <212> PRT
 <213> Homo sapiens
 <400> 119
 Met Ala Val Trp Pro Glu Val Ser Gln Asn Arg Leu Thr Arg Gly Leu
 1 5 10 15
 Leu Leu Pro Asn Tyr Gln Leu Arg Gly Ser Val Pro Lys Arg Glu Lys
 20 25 30
 Arg Pro Lys Arg Lys His Gln His Leu Phe Thr Pro Ser Glu Arg His
 35 40 45
 Ser Val Cys Leu Asp Cys Leu Leu Glu Ile Ser Leu Ser Gly Lys Gln
 50 55 60
 Trp Arg Asn Val Ile Ser Phe Asn Cys Phe Cys Thr Thr Lys Thr Leu
 65 70 75 80
 Phe Trp Val Asn
 <210> 120
 <211> 92
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -20..-1
 <400> 120
 Met Ala Ser Leu Gly His Ile Leu Val Phe Cys Val Gly Leu Leu Thr
 -20 -15 -10 -5
 Met Ala Lys Ala Glu Ser Pro Lys Glu His Asp Pro Phe Thr Tyr Asp
 1 5 10
 Tyr Gln Ser Leu Gln Ile Gly Gly Leu Val Ile Ala Gly Ile Leu Phe
 15 20 25
 Ile Leu Gly Ile Leu Ile Val Leu Ser Arg Arg Cys Arg Cys Lys Phe
 30 35 40
 Asn Gln Gln Gln Arg Thr Gly Glu Pro Asp Glu Glu Glu Gly Thr Phe
 45 50 55 60
 Arg Ser Ser Ile Arg Arg Leu Ser Thr Arg Arg Arg
 65 70

<210> 121
<211> 210
<212> PRT
<213> Homo sapiens
<220>
<223> SIGNAL
<222> -14..-1
<400> 121

Met Leu Thr Leu Leu Gly Leu Ser Leu Ile Leu Ala Gly Leu Ile Val
-10 -5 1
Gly Gly Ala Cys Ile Tyr Lys His Phe Met Pro Lys Ser Thr Ile Tyr
5 10 15
Arg Gly Glu Met Cys Phe Phe Asp Ser Glu Asp Pro Ala Asn Ser Leu
20 25 30
Arg Gly Gly Glu Pro Asn Phe Leu Pro Val Thr Glu Glu Ala Asp Ile
35 40 45 50
Arg Glu Asp Asp Asn Ile Ala Ile Ile Asp Val Pro Val Pro Ser Phe
55 60 65
Ser Asp Ser Asp Pro Ala Ala Ile Ile His Asp Phe Glu Lys Gly Met
70 75 80
Thr Ala Tyr Leu Asp Leu Leu Leu Gly Asn Cys Tyr Leu Met Pro Leu
85 90 95
Asn Thr Ser Ile Val Met Pro Pro Glu Asn Leu Val Glu Leu Phe Gly
100 105 110
Lys Leu Ala Ser Gly Arg Tyr Leu Pro Gln Thr Tyr Val Val Arg Glu
115 120 125 130
Asp Leu Val Ala Val Glu Glu Ile Arg Asp Val Ser Asn Leu Gly Ile
135 140 145
Phe Ile Tyr Gln Leu Cys Asn Asn Arg Lys Ser Phe Arg Leu Arg Arg
150 155 160
Arg Asp Leu Leu Leu Gly Phe Asn Lys Arg Ala Ile Asp Lys Cys Trp
165 170 175
Lys Ile Arg His Phe Pro Asn Glu Phe Ile Val Glu Thr Lys Ile Cys
180 185 190
Gln Glu
195

<210> 122
<211> 205
<212> PRT
<213> Homo sapiens
<220>
<223> SIGNAL
<222> -139..-1
<400> 122

Met Ala Pro Thr Arg Lys Asp Lys Leu Leu Gln Phe Tyr Pro Ser Leu
-135 -130 -125
Glu Asp Pro Ala Ser Ser Arg Tyr Gln Asn Phe Ser Lys Gly Ser Arg
-120 -115 -110
His Gly Ser Glu Glu Ala Tyr Ile Asp Pro Ile Ala Met Glu Tyr Tyr
-105 -100 -95
Asn Trp Gly Arg Phe Ser Lys Pro Pro Glu Gly Glu Ala Lys Asp Lys
-90 -85 -80
Ala Gly Gly Gly Gly Ser Gly Val Gly Ala Gln Gly Arg Ser His Thr
-75 -70 -65 -60
Ser Arg Gln Glu Arg Arg Leu Gly Leu Gly Ser Asp Asp Ala Asn
-55 -50 -45
Ser Tyr Glu Asn Val Leu Ile Cys Lys Gln Lys Thr Thr Glu Thr Gly
-40 -35 -30
Ala Gln Gln Glu Asp Val Gly Gly Leu Cys Arg Gly Asp Leu Ser Leu
-25 -20 -15
Ser Leu Ala Leu Lys Thr Gly Pro Thr Ser Gly Leu Cys Pro Ser Ala

-10 -5 1 5
 Ser Pro Glu Glu Asp Gly Glu Ser Glu Asp Tyr Gln Asn Ser Ala Ser
 10 15 20
 Ile His Gln Trp Arg Glu Ser Arg Lys Val Met Gly Gln Leu Gln Arg
 25 30 35
 Glu Ala Ser Pro Gly Pro Val Gly Ser Pro Asp Glu Glu Asp Gly Glu
 40 45 50
 Pro Asp Tyr Val Asn Gly Glu Val Ala Ala Thr Glu Ala
 55 60 65
 <210> 123
 <211> 85
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -17..-1
 <400> 123
 Met Lys Lys Val Leu Leu Leu Ile Thr Ala Ile Leu Ala Val Ala Val
 -15 -10 -5
 Gly Phe Pro Val Ser Gln Asp Gln Glu Arg Glu Lys Arg Ser Ile Ser
 1 5 10 15
 Asp Ser Asp Glu Leu Ala Ser Gly Phe Phe Val Phe Pro Tyr Pro Tyr
 20 25 30
 Pro Phe Arg Pro Leu Pro Pro Ile Pro Phe Pro Arg Phe Pro Trp Phe
 35 40 45
 Arg Arg Asn Phe Pro Ile Pro Ile Pro Glu Ser Ala Pro Thr Thr Pro
 50 55 60
 Leu Pro Ser Glu Lys
 65
 <210> 124
 <211> 115
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -51..-1
 <400> 124
 Met Gln Ala Gln Ala Pro Val Val Val Val Thr Gln Pro Gly Val Gly
 -50 -45 -40
 Pro Gly Pro Ala Pro Gln Asn Ser Asn Trp Gln Thr Gly Met Cys Asp
 -35 -30 -25 -20
 Cys Phe Ser Asp Cys Gly Val Cys Leu Cys Gly Thr Phe Cys Phe Pro
 -15 -10 -5
 Cys Leu Gly Cys Gln Val Ala Ala Asp Met Asn Glu Cys Cys Leu Cys
 1 5 10
 Gly Thr Ser Val Ala Met Arg Thr Leu Tyr Arg Thr Arg Tyr Gly Ile
 15 20 25
 Pro Gly Pro Ile Cys Asp Asp Tyr Met Ala Thr Leu Cys Cys Pro His
 30 35 40 45
 Cys Thr Leu Cys Gln Ile Lys Arg Asp Ile Asn Arg Arg Arg Ala Met
 50 55 60
 Arg Thr Phe
 <210> 125
 <211> 81
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -31..-1
 <400> 125
 Met Ser Asn Thr His Thr Val Leu Val Ser Leu Pro His Pro His Pro

-30 -25 -20
Ala Leu Thr Cys Cys His Leu Gly Leu Pro His Pro Val Arg Ala Pro
-15 -10 -5 1
Arg Pro Leu Pro Arg Val Glu Pro Trp Asp Pro Arg Trp Gln Asp Ser
5 10 15
Glu Leu Arg Tyr Pro Gln Ala Met Asn Ser Phe Leu Asn Glu Arg Ser
20 25 30
Ser Pro Cys Arg Thr Leu Arg Gln Glu Ala Ser Ala Asp Arg Cys Asp
35 40 45
Leu
50
<210> 126
<211> 235
<212> PRT
<213> Homo sapiens
<220>
<223> SIGNAL
<222> -39..-1
<400> 126
Met Gly Thr Ala Asp Ser Asp Glu Met Ala Pro Glu Ala Pro Gln His
-35 -30 -25
Thr His Ile Asp Val His Ile His Gln Glu Ser Ala Leu Ala Lys Leu
-20 -15 -10
Leu Leu Thr Cys Cys Ser Ala Leu Arg Pro Arg Ala Thr Gln Ala Arg
-5 1 5
Gly Ser Ser Arg Leu Leu Val Ala Ser Trp Val Met Gln Ile Val Leu
10 15 20 25
Gly Ile Leu Ser Ala Val Leu Gly Gly Phe Phe Tyr Ile Arg Asp Tyr
30 35 40
Thr Leu Leu Val Thr Ser Gly Ala Ala Ile Trp Thr Gly Ala Val Ala
45 50 55
Val Leu Ala Gly Ala Ala Ala Phe Ile Tyr Glu Lys Arg Gly Gly Thr
60 65 70
Tyr Trp Ala Leu Leu Arg Thr Leu Leu Ala Leu Ala Ala Phe Ser Thr
75 80 85
Ala Ile Ala Ala Leu Lys Leu Trp Asn Glu Asp Phe Arg Tyr Gly Tyr
90 95 100 105
Ser Tyr Tyr Asn Ser Ala Cys Arg Ile Ser Ser Ser Asp Trp Asn
110 115 120
Thr Pro Ala Pro Thr Gln Ser Pro Glu Glu Val Arg Arg Leu His Leu
125 130 135
Cys Thr Ser Phe Met Asp Met Leu Lys Ala Leu Phe Arg Thr Leu Gln
140 145 150
Ala Met Leu Leu Gly Val Trp Ile Leu Leu Leu Ala Ser Leu Ala
155 160 165
Pro Leu Trp Leu Tyr Cys Trp Arg Met Phe Pro Thr Lys Gly Lys Arg
170 175 180 185
Asp Gln Lys Glu Met Leu Glu Val Ser Gly Ile
190 195
<210> 127
<211> 62
<212> PRT
<213> Homo sapiens
<220>
<223> SIGNAL
<222> -21..-1
<400> 127
Met Glu Ser Arg Val Leu Leu Arg Thr Phe Cys Leu Ile Phe Gly Leu
-20 -15 -10
Gly Ala Val Trp Gly Leu Gly Val Asp Pro Ser Leu Gln Ile Asp Val
-5 1 5 10

Leu Thr Glu Leu Glu Leu Gly Glu Ser Thr Thr Gly Val Arg Gln Val
 15 20 25
 Pro Gly Leu His Asn Gly Thr Lys Ala Phe Leu Phe Gln Ala
 30 35 40
 <210> 128
 <211> 11
 <212> PRT
 <213> Homo sapiens
 <400> 128
 Met Gly Leu Ser Ser Ser Glu Gly Asp Ile Pro
 1 5 10
 <210> 129
 <211> 56
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -34..-1
 <400> 129
 Met Glu Arg Gly Leu Lys Ser Ala Asp Pro Arg Asp Gly Thr Gly Tyr
 -30 -25 -20
 Thr Gly Trp Ala Gly Ile Ala Val Leu Tyr Leu His Leu Tyr Asp Val
 -15 -10 -5
 Phe Gly Asp Pro Ala Ser Met Phe Cys Lys Val Phe Asp Leu Leu Val
 1 5 10
 Leu Asn Lys Ile Leu Leu Gly Leu
 15 20
 <210> 130
 <211> 542
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 15..311
 <223> sig_peptide
 <222> 15..110
 <223> Von Heijne matrix
 score 3.5
 seq RIHLCQRSXGSQG/VR
 <223> polyA_signal
 <222> 507..512
 <223> polyA_site
 <222> 531..542
 <400> 130
 agatattaac aagg atg gcg gcg gcc gca gca agt cga gga gtc ggg gca 50
 Met Ala Ala Ala Ala Ala Ser Arg Gly Val Gly Ala
 -30 -25
 aag ctg ggc ctg cgt gag att cgc atc cac tta tgt cag cgc tcg scc 98
 Lys Leu Gly Leu Arg Glu Ile Arg Ile His Leu Cys Gln Arg Ser Xaa
 -20 -15 -10 -5
 ggc agc cag ggc gtc agg gac ttc att gag aaa cgc tac gtg gag ctg 146
 Gly Ser Gln Gly Val Arg Asp Phe Ile Glu Lys Arg Tyr Val Glu Leu
 1 5 10
 aag aag gcg aat ccc gac cta ccc atc cta atc cgc gaa tgc tcc gat 194
 Lys Lys Ala Asn Pro Asp Leu Pro Ile Leu Ile Arg Glu Cys Ser Asp
 15 20 25
 gtg cag ccc aag ctc tgg gcc cgc tac gca ttt ggc caa rag acg aat 242
 Val Gln Pro Lys Leu Trp Ala Arg Tyr Ala Phe Gly Gln Xaa Thr Asn
 30 35 40
 gtc cct ttg aac aac ttc agt gct gat cag gta acc aga rcc ctg gag 290
 Val Pro Leu Asn Asn Phe Ser Ala Asp Gln Val Thr Arg Xaa Leu Glu

```

45          50          55          60
aac gtt cta agt ggt aaa gcc tgaagcctcc actgaggatt aagagcaaca      341
Asn Val Leu Ser Gly Lys Ala
          65
gccccagagc ctgggctctg ctggacttar tataatgtga aaaaaatgtg ttctcctatt    401
cctcataaag cttgtgctgt aaaatacttt ctcaggggtgt tcttgcctc atctaccctc    461
taccctttac tgtgcaacca ctgaggcaaa gtagcttaat ataaaaataa aactttattc    521
tgtctcatca aaaaaaaaaa a
<210> 131      542
<211> 909
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 50..529
<223> sig_peptide
<222> 50..130
<223> Von Heijne matrix
      score 7.19999980926514
      seq VLWLSGLSEPGAA/RQ
<223> polyA_signal
<222> 877..882
<223> polyA_site
<222> 899..909
<400> 131
aagacggtgg cgcgattggg acagtcgccca gggatggctg agcgtgaag atg cag cgg      58
                                   Met Gln Arg
                                   -25
gtg tcc ggg ctg ctc tcc tgg acg ctg agc aga gtc ctg tgg ctc tcc      106
Val Ser Gly Leu Leu Ser Trp Thr Leu Ser Arg Val Leu Trp Leu Ser
          -20          -15          -10
ggc ctc tct gag ccg gga gct gcc cgg cag ccc cgg atc atg gaa gag      154
Gly Leu Ser Glu Pro Gly Ala Ala Arg Gln Pro Arg Ile Met Glu Glu
          -5          1          5
aaa gcg cta gag gtt tat gat ttg att aga act atc cgg gac cca gaa      202
Lys Ala Leu Glu Val Tyr Asp Leu Ile Arg Thr Ile Arg Asp Pro Glu
          10          15          20
aag ccc aat act tta gaa gaa ctg gaa gtg gtc tcg gaa agt tgt gtg      250
Lys Pro Asn Thr Leu Glu Glu Leu Glu Val Val Ser Glu Ser Cys Val
          25          30          35          40
gaa gtt cag gag ata aat gaa gaa raa tat ctg gtt att atc agg ttc      298
Glu Val Gln Glu Ile Asn Glu Glu Xaa Tyr Leu Val Ile Ile Arg Phe
          45          50          55
acg cca aca gta cct cat tgc tct ttg gcg act ctt att ggg ctg tgc      346
Thr Pro Thr Val Pro His Cys Ser Leu Ala Thr Leu Ile Gly Leu Cys
          60          65          70
yta arw kta aaa ctt cag cga tgt tta cca ttt aaa cat aag ttg gma      394
Leu Xaa Xaa Lys Leu Gln Arg Cys Leu Pro Phe Lys His Lys Leu Xaa
          75          80          85
atc tac att tct gaa gga acc cac tca rsa gar gaa gac atc aat wwkw      442
Ile Tyr Ile Ser Glu Gly Thr His Ser Xaa Glu Glu Asp Ile Asn Xaa
          90          95          100
cag ata aat gac aaa gag cgw ktg gca kct gca atg gaa aac ccc awc      490
Gln Ile Asn Asp Lys Glu Arg Xaa Ala Xaa Met Glu Asn Pro Xaa
          105          110          115          120
tta cgg gaa att gtg gaa cag tgt gtc ctt gaa cct gac tgawakctgt      539
Leu Arg Glu Ile Val Glu Gln Cys Val Leu Glu Pro Asp
          125          130
tttaaragcc actggcctgt aattgtttga tatatttgtt taaactcttt gtataatgtc    599
agaggactca tgtttaatac ataggtgatt tgtacctcag agcatttttt aaaggattct    659
ttccaagcga gatttaatta taaggtagta cctaatttgt tcaatgtata acattctcag    719

```

gatttgaac acttaaatga tcagacagaa taatattttc tagttattat gtgtaagatg 779
 agttgctatt tttctgatgc tcattctgat acaactattt ttcgtgtcaa atatctactg 839
 tgcccaaatg tactcaattt aaatcattac tctgtaaaat aaataagcag atgattctta 899
 aaaaaaaaaa 909
 <210> 132
 <211> 1149
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 240..416
 <223> sig_peptide
 <222> 240..305
 <223> Von Heijne matrix
 score 3.70000004768372
 seq AVLDCAFYDPTHA/WS
 <223> polyA_signal
 <222> 1117..1122
 <223> polyA_site
 <222> 1139..1149
 <400> 132
 actagcctgc gagtgttctg aggggaagcaa ggaggcggcg gcggccgcag cgagtggcga 60
 gtagtggaac cggtgcttct gaggggtgtc caagatgacc ggttctaacg gatttcaagc 120
 tgaaccagcc acccgaggat ggcattctct cctggaagtt cagccccaac acctcccagt 180
 tctgcttgt ctcctcctgg gacacgtccg tgcgtctcta cgatgtgccg gccaaactcc 239
 atg cgg ctc aag tac cag cac acc ggc gcc gtc ctg gac tgc gcc ttc 287
 Met Arg Leu Lys Tyr Gln His Thr Gly Ala Val Leu Asp Cys Ala Phe
 -20 -15 -10
 tac gat cca acg cat gcc tgg agt gga gga cta gat cat caa ttg aaa 335
 Tyr Asp Pro Thr His Ala Trp Ser Gly Gly Leu Asp His Gln Leu Lys
 -5 1 5 10
 atg cat gat ttg aac act gat caa gaa aat ctt gtt ggg acc atg atg 383
 Met His Asp Leu Asn Thr Asp Gln Glu Asn Leu Val Gly Thr Met Met
 15 20 25
 ccc cta tca gat gtg ttg aat act gtc cac aaa tgaatgtgat ggctcmctgga 436
 Pro Leu Ser Asp Val Leu Asn Thr Val His Lys
 30 35
 akttgggac aaacagttaa actgtgggat cccamaactc cttgtaatgc tgggaccttc 496
 tctcmkctg aaaaggtata taccctctca gtgtctggag accggctgat tgtgggaaca 556
 gcaggccgca gagtgttggg gtgggactta cggaacatgg gttacgtgca gcagcgcagg 616
 gagtccagcc tgaaatacca gactcgtgac atacgagcgt ttccaaacaa gcagggttat 676
 gtattaagct ctattgaagg ccgagtggca gttgagtatt tggaccaag ccctgaggta 736
 cagaagaaga agtatgcctt caaatgtcac agactaaaag aaaataatat tgagcagatt 796
 taccagtcata atgccatttc ttttcacaat atccacaata catttgccac aggtggttct 856
 gatggctttg taaatatttg ggatecattt aacaaaaagc gactgtgcca attccatcgg 916
 taccacacga gcatcgcatc acttgccctt agtaatgatg ggactacgct tgcaatagcg 976
 tcatcatata tgtatgaaat ggatgacaca gaacatcctg aagatgggat cttcattcgc 1036
 caagtgcag atgcagaaac aaaacccaag tcaccatgta cttgacaaga tttcatttac 1096
 ttaagtcca tgttgatgat aataaaacaa ttcgtactcc ccaaaaaaaaaaaa 1149
 <210> 133
 <211> 921
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 111..446
 <223> sig_peptide
 <222> 111..254
 <223> Von Heijne matrix
 score 4.90000009536743
 seq PSLAAGLLFGSLA/GL

<223> polyA_signal
 <222> 890..895
 <223> polyA_site
 <222> 909..921
 <400> 133
 agacacctcg cagtcattcc tgcggcttgc ggcgccttgt agacagccgg ggccttcgtg 60
 agaccggtgc aggcctgggg tagtctccag tctggacaga gaagagaaaa atg cag 116
 Met Gln
 gac act ggc tca gta gtg cct ttg cat tgg ttt ggc ttt ggc tac gca 164
 Asp Thr Gly Ser Val Val Pro Leu His Trp Phe Gly Phe Gly Tyr Ala
 -45 -40 -35
 gca ctg gtt gct tct ggt ggg atc att ggc tat gta aaa gca ggb agc 212
 Ala Leu Val Ala Ser Gly Gly Ile Ile Gly Tyr Val Lys Ala Gly Ser
 -30 -25 -20 -15
 gtg ccg tcc ctg gct gca ggg ctg ctc ttt ggc agt cta gcc ggc ctg 260
 Val Pro Ser Leu Ala Ala Gly Leu Leu Phe Gly Ser Leu Ala Gly Leu
 -10 -5 1
 ggt gct tac cag ctg tct cag gat cca agg aac gtt tgg gtt ttc cta 308
 Gly Ala Tyr Gln Leu Ser Gln Asp Pro Arg Asn Val Trp Val Phe Leu
 5 10 15
 gct aca tct ggt acc ttg gct ggc att atg gga atg agg ttc tac cac 356
 Ala Thr Ser Gly Thr Leu Ala Gly Ile Met Gly Met Arg Phe Tyr His
 20 25 30
 tct gga aaa ttc atg cct gca ggt tta att gca ggt gcc akt ttg ctg 404
 Ser Gly Lys Phe Met Pro Ala Gly Leu Ile Ala Gly Ala Xaa Leu Leu
 35 40 45 50
 atg gtc gcc aaa att gga gtt agt atg ttc aac aga ccc cat 446
 Met Val Ala Lys Ile Gly Val Ser Met Phe Asn Arg Pro His
 55 60
 tagcagaakt catgttccag cttagactga tgaagaatta aaaatctgca tcttccacta 506
 ttttcaatat attaagagaa ataagtgcag catttttgca tctgacattt tacctaaaaa 566
 aaaagacacc aaacttgma raraggtgga aaatcagtca tgattacaaa cctacagagg 626
 tggcgagtat gtaacacaag agcttaataa gaccctcata ragcttgatt cttgtawatt 686
 gatgttgctt tttctttckg tatctgtagg taaatctcaa gggtaaaatg ttaggtgtca 746
 gctttcaggg ctctgaaacc chattccctg ctctgaggaa cagtgtgaaa aaaagtcttt 806
 taggagattt acaatatctg ttcttttgct catcttagac cacagactga ctttgaaatt 866
 atgttaagtg aaatatcaat gaaaataaag ttactataa ataataaaaa aaaaa 921
 <210> 134
 <211> 916
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 123..455
 <223> sig_peptide
 <222> 123..290
 <223> Von Heijne matrix
 score 4.5
 seq FCAGVLLTLLIA/FI
 <223> polyA_signal
 <222> 886..891
 <223> polyA_site
 <222> 904..916
 <400> 134
 aaagtaatct ttatttcgtc atttttgata catagaagcc gtaacggaag caagtgaat 60
 gctcagttct agacgactgc gtcgtgctat gaccggactt tttcttgaaa ggggatgaca 120
 gc atg gga ggc aat ggc tcc aca tgt aaa ccc gac act gaa aga caa 167
 Met Gly Gly Asn Gly Ser Thr Cys Lys Pro Asp Thr Glu Arg Gln
 -55 -50 -45
 ggc act ctc tcc aca gca gcc cca aca act agc cct gca ccc tgt ctc 215
 Gly Thr Leu Ser Thr Ala Ala Pro Thr Thr Ser Pro Ala Pro Cys Leu


```

-40          -35          -30
tct aac cac cac aac aaa aaa cat tta atc ctt gcc ttt tgt gct ggg      263
Ser Asn His His Asn Lys Lys His Leu Ile Leu Ala Phe Cys Ala Gly
-25          -20          -15          -10
gtt cta ctg aca ctg ctg ata gcc ttt atc ttc ctc atc ata aag      311
Val Leu Leu Thr Leu Leu Ile Ala Phe Ile Phe Leu Ile Ile Lys
          -5          1          5
agc tac aga aaa tat cac tcc aag ccc cag gcc cca gat cct cac tca      359
Ser Tyr Arg Lys Tyr His Ser Lys Pro Gln Ala Pro Asp Pro His Ser
          10          15          20
gat cct cca kcc rrg ctt tca tcc atc cca ggg gaa tca ctt acc tat      407
Asp Pro Pro Xaa Xaa Leu Ser Ser Ile Pro Gly Glu Ser Leu Thr Tyr
          25          30          35
gcc agc aca ags ktt caa act ctc aga aka ama gag cam yca ctt ggc      455
Ala Ser Thr Xaa Xaa Gln Thr Leu Arg Xaa Xaa Glu Xaa Xaa Leu Gly
          40          45          50          55
tgagaacccat tctgcagact ttgacccca kgtctatgct caaattaaag taacaaacta      515
actcagcttt tccaatgagg cttgaatcca tttcctcksa tctcagccct atcttcacas      575
atcactttca cttttttaca wattttggac caccacctgt gtgaaactgc agtcggaggt      635
gtttasatgt gatctggcaa tgctatccag catctttgga gaccaatggt cagtcttttc      695
ctggccakag gaaasattga tggccctccc asttgggaact gacagcctgt gagccccttg      755
ggggcataga ctgccttcct tggacccttc caaagtgtgt ggtacrgagc tcagtgcaca      815
gagtattcac ccagcatcat gaatcaactt gggaggagtc aaccaaata acaatctacc      875
aaaaatttca aataaagtca aacccccac aaaaaaaaa a                      916
<210> 135
<211> 520
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 2..433
<223> sig_peptide
<222> 2..232
<223> Von Heijne matrix
      score 4.40000009536743
      seq FEARIALLPLLQA/ET
<223> polyA_signal
<222> 488..493
<223> polyA_site
<222> 510..520
<400> 135
a atg gcg gcg tca aag gtg aag cag gac atg cct ccr mcg ggg ggc tat      49
Met Ala Ala Ser Lys Val Lys Gln Asp Met Pro Pro Xaa Gly Gly Tyr
          -75          -70          -65
ggg ccc atc gac tac aaa cgg aac ttg ccg cgt cga gga ctg tcg ggc      97
Gly Pro Ile Asp Tyr Lys Arg Asn Leu Pro Arg Arg Gly Leu Ser Gly
          -60          -55          -50
tac agc atg ctg gcc ata ggg att gga acc ctg atc tac ggg cac tgg      145
Tyr Ser Met Leu Ala Ile Gly Ile Gly Thr Leu Ile Tyr Gly His Trp
          -45          -40          -35          -30
agc ata atg aag tgg aac cgt gag cgc agg cgc cta caa atc gag gac      193
Ser Ile Met Lys Trp Asn Arg Glu Arg Arg Arg Leu Gln Ile Glu Asp
          -25          -20          -15
ttc gag gct cgc atc gcg ctg ttg cca ctg tta cag gca gaa acc gac      241
Phe Glu Ala Arg Ile Ala Leu Leu Pro Leu Leu Gln Ala Glu Thr Asp
          -10          -5          1
cgg agg acc ttg cag atg ctt cgg gag aac ctg gag gag gag gcc atc      289
Arg Arg Thr Leu Gln Met Leu Arg Glu Asn Leu Glu Glu Glu Ala Ile
          5          10          15
atc atg aag gac gtg ccc gac tgg aag gtg ggg gak tct gtg tyc cac      337
Ile Met Lys Asp Val Pro Asp Trp Lys Val Gly Xaa Ser Val Xaa His

```

20 25 30 35
 aca acc cgc tgg gtg ccc ccc ttg atc ggg gag ctg tac ggg ctg cgc 385
 Thr Thr Arg Trp Val Pro Pro Leu Ile Gly Glu Leu Tyr Gly Leu Arg
 40 45 50
 acc aca aag gag gct ctc cat gcc agc cac ggc ttc atg tgg tac acg 433
 Thr Thr Lys Glu Ala Leu His Ala Ser His Gly Phe Met Trp Tyr Thr
 55 60 65
 taggcctgt gccctccggc cacctggatc cctgcccctc cccactgggg acggaataaa 493
 tgctctgcag acctggaaaa aaaaaaa 520
 <210> 136
 <211> 568
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 34..363
 <223> sig_peptide
 <222> 34..87
 <223> Von Heijne matrix
 score 8.30000019073486
 seq LLSLSSLPLVLLG/WE
 <223> polyA_signal
 <222> 536..541
 <223> polyA_site
 <222> 558..568
 <400> 136
 aaccagactt ctgaccctt gggcaacagc cag atg gag act ggt cgc ctt ttg 54
 Met Glu Thr Gly Arg Leu Leu
 -15
 agc ctc agc tct ctt cct ctt gtt ctc cta ggg tgg gag tac agc agc 102
 Ser Leu Ser Ser Leu Pro Leu Val Leu Leu Gly Trp Glu Tyr Ser Ser
 -10 -5 1 5
 caa acg ctg aac tta gtc cca tcc act tcc atc tta tcc ttt gtg ccc 150
 Gln Thr Leu Asn Leu Val Pro Ser Thr Ser Ile Leu Ser Phe Val Pro
 10 15 20
 ttc atc ccc ctg cat ctt gtc ctt ttt gcc ctc tgg tac ctc cca gtg 198
 Phe Ile Pro Leu His Leu Val Leu Phe Ala Leu Trp Tyr Leu Pro Val
 25 30 35
 ccc cat cat ctc tac ccc cag gga ctc gga rat cat gca gca raa gca 246
 Pro His His Leu Tyr Pro Gln Gly Leu Gly Xaa His Ala Ala Xaa Ala
 40 45 50
 gaa raa ggc aaa cga raa gaa gga gga acc caa kta gct ttg tgg ctt 294
 Glu Xaa Gly Lys Arg Xaa Glu Gly Gly Thr Gln Xaa Ala Leu Trp Leu
 55 60 65
 cgt gtc caa ccc tct tgc cct tog cct gtg tgc ctg gag cca gtc cca 342
 Arg Val Gln Pro Ser Cys Pro Ser Pro Val Cys Leu Glu Pro Val Pro
 70 75 80 85
 cca cgc tcg cgt ttc ctc ctg tagtgctcac aggtcccagc accgatggca 393
 Pro Arg Ser Arg Phe Leu Leu
 90
 ttccctttgc cctgagtctg carcgggtcc cttttgtgct tccttcccct caggtagcct 453
 ctctcccctc gggccactcc cgggggtgag ggggtttacc cttccagcgt gttttttatt 513
 cctgtggggc tcaccccaaa gtattaaaag tagctttgta attcaaaaaa aaaaa 568
 <210> 137
 <211> 419
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 50..286
 <223> sig_peptide

<222>	50..157		
<223>	Von Heijne matrix		
	score 4.80000019073486		
	seq VLLAIGMFFTAWF/FV		
<223>	polyA_signal		
<222>	385..390		
<223>	polyA_site		
<222>	405..416		
<400>	137		
agacgtgttc ttccggtggc ggagggcgga ttagccttcg cggggcaaa atg gag ctc		58	
		Met Glu Leu	
		-35	
gag gcc atg agc aga tat acc agc cca gtg aac cca gct gtc ttc ccc		106	
Glu Ala Met	Ser Arg Tyr Thr Ser Pro Val Asn Pro Ala Val Phe Pro		
	-30 -25 -20		
cat ctg acc gtg gtg ctt ttg gcc att ggc atg ttc ttc acc gcc tgg		154	
His Leu Thr	Val Val Leu Leu Ala Ile Gly Met Phe Phe Thr Ala Trp		
	-15 -10 -5		
ttc ttc gtt tac gag gtc acc tct acc aag tac act cgt gat atc tat		202	
Phe Phe Val	Tyr Glu Val Thr Ser Thr Lys Tyr Thr Arg Asp Ile Tyr		
	1 5 10 15		
aaa gag ctc ctc atc tcc tta gtg gcc tca ctc ttc atg ggc ttt gga		250	
Lys Glu Leu	Leu Ile Ser Leu Val Ala Ser Leu Phe Met Gly Phe Gly		
	20 25 30		
gtc ctc ttc ctg ctg ctc tgg gtt ggc atc tac gtg tgagcacc		296	
Val Leu Phe	Leu Leu Leu Trp Val Gly Ile Tyr Val		
	35 40		
agggtaacaa ccagatggct tcaactgaaac ctgcttttgt aaattacttt tttttactgt		356	
tgctggaagt gtcccacctg ctgctcataa taaatgcaga agtatagcaa aaaaaaaaaa		416	
ccc		419	
<210>	138		
<211>	1289		
<212>	DNA		
<213>	Homo sapiens		
<220>			
<223>	CDS		
<222>	50..637		
<223>	sig_peptide		
<222>	50..151		
<223>	Von Heijne matrix		
	score 5.90000009536743		
	seq LGAAALALLLANT/DV		
<223>	polyA_site		
<222>	1277..1289		
<400>	138		
aatatacttc tttgtcaaga gaagcagagg tgtggacgct gtgtatgaa atg tct ttc		58	
		Met Ser Phe	
ctc cag gac cca agt ttc ttc acc atg ggg atg tgg tcc att ggt gca		106	
Leu Gln Asp	Pro Ser Phe Phe Thr Met Gly Met Trp Ser Ile Gly Ala		
	-30 -25 -20		
gga gcc ctg ggg gct gct gcc ttg gca ttg ctg ctt gcc aac aca gac		154	
Gly Ala Leu	Gly Ala Ala Leu Ala Leu Leu Ala Asn Thr Asp		
	-15 -10 -5 1		
gtg ttt ctg tcc aag ccc cag aaa gcg gcc ctg gag tac ctg gag gat		202	
Val Phe Leu	Ser Lys Pro Gln Lys Ala Ala Leu Glu Tyr Leu Glu Asp		
	5 10 15		
ata gac ctg aaa aca ctg gag aag gaa cca agg act ttc aaa gca aag		250	
Ile Asp Leu	Lys Thr Leu Glu Lys Glu Pro Arg Thr Phe Lys Ala Lys		
	20 25 30		
gag cta tgg gaa aaa aat gga gct gtg att atg gcc gtg cgg agg cca		298	
Glu Leu Trp	Glu Lys Asn Gly Ala Val Ile Met Ala Val Arg Arg Pro		

35	40	45	
ggc tgt ttc ctc tgt cga gag gaa gct gcg gat ctg tcc tcc ctg aaa			346
Gly Cys Phe Leu Cys Arg Glu Glu Ala Ala Asp Leu Ser Ser Leu Lys			
50	55	60	65
agc atg ttg gac cag ctg ggc gtc ccc ctc tat gca gtg gta aag gas			394
Ser Met Leu Asp Gln Leu Gly Val Pro Leu Tyr Ala Val Val Lys Xaa			
70	75	80	
cac atc rgg act gaa ktg aag gat ttc cag cct tat ttc aaa gga gaa			442
His Ile Xaa Thr Glu Xaa Lys Asp Phe Gln Pro Tyr Phe Lys Gly Glu			
85	90	95	
atc ttc ctg gat gaa aar aaa aag ttc tat ggt cca caa agg cgg aag			490
Ile Phe Leu Asp Glu Lys Lys Lys Phe Tyr Gly Pro Gln Arg Arg Lys			
100	105	110	
atg atg ttt atg gga ttt atc cgt ctg gga atg tgg tac aac ttc ttc			538
Met Met Phe Met Gly Phe Ile Arg Leu Gly Met Trp Tyr Asn Phe Phe			
115	120	125	
cga rcc tgg aac gga rgc ttc tct gga aac ctg gaa gga raa ggc ttc			586
Arg Xaa Trp Asn Gly Xaa Phe Ser Gly Asn Leu Glu Gly Xaa Gly Phe			
130	135	140	145
atc ctt ggg gga att ttc gtg gtg gga tca asg aaa gca ggg cat tct			634
Ile Leu Gly Gly Ile Phe Val Val Gly Ser Xaa Lys Ala Gly His Ser			
150	155	160	
tct tgarcgccga gaaaaagaat ttggagacaa agtaaacccta ctttctgttc			687
Ser			
tggaagctgc taagatgac aaaccacaga ctttggcctc agagaaaaaa tgattgtgtg			747
aaactgcccc gctcagggat aaccagggac attcacctgt gtccatggga tgtattgttt			807
ccactcgtgt ccctaaggag tgagaaaccc atttatactc tactctcagt atggattatt			867
aatgtatttt aatattctgt ttaggccac taaggcaaaa tasccecaaa acaagactga			927
caaaaactcg aaaaactaat gaggattatt aagctaaaac ctgggaaata ggaggcttaa			987
aattgactgc caggctgggt gcagtggctc acacctgtaa tcccagcact ttgggaggcc			1047
aaggtgagca agtcacttga ggtcgggagt tccagaccag cctgagcaac atggcgaaac			1107
cccgtctcta ckaaaaatac araaatcacc cgggtgtggt ggcaggcacc tgtagtccca			1167
gctaccgagg aggtcagggc aggagaatca cttgaacctg ggaggtggag gttgcggtga			1227
gctgagatca caccactgta ttccagcctg ggtgactgag actctaacca aaaaaaaaaa			1287
aa			1289
<210> 139			
<211> 715			
<212> DNA			
<213> Homo sapiens			
<220>			
<223> CDS			
<222> 72..602			
<223> sig_peptide			
<222> 72..125			
<223> Von Heijne matrix			
score 5.59999990463257			
seq LTPLFFMFPTGFS/SP			
<223> polyA_site			
<222> 704..715			
<400> 139			
acttcccttc cccctctagc attgctacct tctctcctac acgcacgcag gcatataaac			60
gtagggtttt g atg ctc ctc tgc ctg ttg acc ccg cta ttt ttc atg ttt			110
Met Leu Leu Cys Leu Leu Thr Pro Leu Phe Phe Met Phe			
-15	-10		
cca aca ggt ttt tct tcc ccc agt ccc tca gct gct gct gct cag			158
Pro Thr Gly Phe Ser Ser Pro Ser Pro Ser Ala Ala Ala Ala Gln			
-5	1	5	10
gag gtc aga tct gcc act gat ggt aat acc agc acc act ccg ccc acc			206
Glu Val Arg Ser Ala Thr Asp Gly Asn Thr Ser Thr Thr Pro Pro Thr			
15	20	25	
tct gcc aar aar aka aag tta aac agc agc agc agt agc agc agt aac			254

```

Ser Ala Lys Lys Xaa Lys Leu Asn Ser Ser Ser Ser Ser Ser Ser Asn
  30          35          40
agt agt aac gag aga gaa gac ttt gat tcs acc tct tcc tcc tct tcc      302
Ser Ser Asn Glu Arg Glu Asp Phe Asp Ser Thr Ser Ser Ser Ser Ser
  45          50          55
act cct cct tta caa ccc agg gat tgc gca tcc cct tca acc tgc tcc      350
Thr Pro Pro Leu Gln Pro Arg Asp Ser Ala Ser Pro Ser Thr Ser Ser
  60          65          70          75
ttc tgc ctg ggg gtt tca gtg gct gct tcc agc cac gta ccg ata swg      398
Phe Cys Leu Gly Val Ser Val Ala Ala Ser Ser His Val Pro Ile Xaa
  80          85          90
aar aag ctg cgt ttt gaa rac acc ctg gag ttt gta ggg ttt gat gcg      446
Lys Lys Leu Arg Phe Glu Xaa Thr Leu Glu Phe Val Gly Phe Asp Ala
  95          100          105
aar atg gct gar gaa tcc tcc tcc tcc tcc tcc tca tct tca cca ack      494
Lys Met Ala Glu Glu Ser Ser Ser Ser Ser Ser Ser Ser Ser Pro Thr
  110          115          120
gct gca aca tct cag cag cag caa ctt aaa aat aag agt ata ttg aat      542
Ala Ala Thr Ser Gln Gln Gln Gln Leu Lys Asn Lys Ser Ile Leu Asn
  125          130          135
ctc ttc tgt ggc ttc ggt gca tca tgc aaa cgg cct agc caa atc ttc      590
Leu Phe Cys Gly Phe Gly Ala Ser Cys Lys Arg Pro Ser Gln Ile Phe
  140          145          150          155
tac cac cgt ctc tagctttgct aacagcaaac ctggctctgc taagaagtta      642
Tyr His Arg Leu
gtgatcaaga actttaaaga taagcctaaa ttaccagaaa actacacaga tgaaacctgg      702
caaaaaaaaaaaa aaa      715
<210> 140
<211> 931
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 120..434
<223> sig_peptide
<222> 120..185
<223> Von Heijne matrix
      score 6.30000019073486
      seq FALVWLWLRSTGC/FW
<223> polyA_signal
<222> 899..904
<223> polyA_site
<222> 918..931
<400> 140
aatttcggc gacacctgc agtcattcct gcggcttgcg cgcccttgta gacagccggg      60
gccttcgtga gaccggtgca ggctgggggt agtctcctgt ctggacagag aagagaaaa      119
atg cag gga cac tgg ctc agt agt gcc ttt gca ttg gtt tgg ctt tgg      167
Met Gln Gly His Trp Leu Ser Ser Ala Phe Ala Leu Val Trp Leu Trp
  -20          -15          -10
cta cgc agc act ggt tgc ttc tgg tgg gat cat tgg cta tgt aaa agc      215
Leu Arg Ser Thr Gly Cys Phe Trp Trp Asp His Trp Leu Cys Lys Ser
  -5          1          5          10
agg cag cgt gcc gtc cct ggc tgc agg gct gct ctt tgg cag tct agc      263
Arg Gln Arg Ala Val Pro Gly Cys Arg Ala Ala Leu Trp Gln Ser Ser
  15          20          25
cgg cct ggg tgc tta cca gct gtc tca gga tcc aag gaa cgt ttg ggt      311
Arg Pro Gly Cys Leu Pro Ala Val Ser Gly Ser Lys Glu Arg Leu Gly
  30          35          40
ttt cct agc tac atc tgg tac ctt ggc tgg cat tat ggg aat gag gtt      359
Phe Pro Ser Tyr Ile Trp Tyr Leu Gly Trp His Tyr Gly Asn Glu Val
  45          50          55

```

cta cca ctc tgg aaa att cat gcc tgc agg ttt aat tgc agg tgc cag 407
 Leu Pro Leu Trp Lys Ile His Ala Cys Arg Phe Asn Cys Arg Cys Gln
 60 65 70
 ttt gct gat ggt cgc caa agt tgg agt tagtatgtkc aacagacccc 454
 Phe Ala Asp Gly Arg Gln Ser Trp Ser
 75 80
 attagcagaa gtcattgttcc agcttagatg atgaaraatt aaaaatctgc atcttccact 514
 attttcaata tattaagaga aataagtgc gcatttttgc atctgacatt ttacctaaaa 574
 aaaaaaacmc caaacttggc aaaaagggtgg aaaatcagtc atgattacaa acctacagag 634
 gtggcgagta tgtaacacaa gagcttaata agaccctcat agagcttgat tcttgtatat 694
 tgatgttgc ttttctttct gtatctgtag gtaaatctca agggtaaaat gttaggtgtc 754
 agctttcagg gctctgaaac cchattccct gctctgagga acagtgtgaa aaaaagtctt 814
 ttaggaratt tacaatatct gttcttttgc tcactttara ccacagactg actttgaaat 874
 takgttaagt gaaatatcaa tgaaaataaa gtttactata aataawaaaa aaaaaaa 931
 <210> 141
 <211> 891
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 4..447
 <223> sig_peptide
 <222> 4..147
 <223> Von Heijne matrix
 score 5.69999980926514
 seq LLLFFGKLLVVG/VG
 <223> polyA_signal
 <222> 858..863
 <223> polyA_site
 <222> 880..891
 <400> 141
 atc atg atc gcc atc tac ggg aag aat ttc tgt gtc tca gcc aaa aat 48
 Met Ile Ala Ile Tyr Gly Lys Asn Phe Cys Val Ser Ala Lys Asn
 -45 -40 -35
 gcg ttc atg cta ctc atg cga aac att gtc agg gtg gtc gtc ctg gac 96
 Ala Phe Met Leu Leu Met Arg Asn Ile Val Arg Val Val Val Leu Asp
 -30 -25 -20
 aaa gtc aca gac ctg ctg ctg ttc ttt ggg aag ctg ctg gtg gtc gga 144
 Lys Val Thr Asp Leu Leu Leu Phe Phe Gly Lys Leu Leu Val Val Gly
 -15 -10 -5
 ggc gtg ggg gtc ctg tcc ttc ttt ttt ttc tcc ggt cgc atc ccg ggg 192
 Gly Val Gly Val Leu Ser Phe Phe Phe Phe Ser Gly Arg Ile Pro Gly
 1 5 10 15
 ctg ggt aaa gac ttt aag agc ccc cac ctc aac tat tac tgg ctg ccc 240
 Leu Gly Lys Asp Phe Lys Ser Pro His Leu Asn Tyr Tyr Trp Leu Pro
 20 25 30
 ayc atg acc tcc atc ctg ggg gcc tat gtc atc gcc agy ggc ttc ttc 288
 Xaa Met Thr Ser Ile Leu Gly Ala Tyr Val Ile Ala Ser Gly Phe Phe
 35 40 45
 agc gtt ttc ggc atg tgt gtg gac acg ctc ttc ctc tgc ttc ctg gaa 336
 Ser Val Phe Gly Met Cys Val Asp Thr Leu Phe Leu Cys Phe Leu Glu
 50 55 60
 gac ctg gag cgg aca acg gct ccc tgg acg gcc cta cta cat gtc caa 384
 Asp Leu Glu Arg Thr Thr Ala Pro Trp Thr Ala Leu Leu His Val Gln
 65 70 75
 gag ctt cta aag att ctg ggc aag aag aac gag gcg ccc ccg gac aac 432
 Glu Leu Leu Lys Ile Leu Gly Lys Lys Asn Glu Ala Pro Pro Asp Asn
 80 85 90 95
 aag aaa agg aaa aak tgacagctcc ggccctgatc caggactgca cccaccccc 487
 Lys Lys Arg Lys Xaa
 100

```

accgtccagc catccaacct cacttcgcct tacaggtctc cattttgtgg taaaaaaagg 547
ttttaggcca ggccgcgtgg ctccacgcctg twatccaaca ctttggaragg ctgaggcgagg 607
cggatcacct kaktcaggak tycgagacca kcctggccaa catggtgaaa cctccgtctc 667
tattaaaaat acaaaaatta gccgagagtg gtggcatgca cctgtcatcc cagctactcg 727
ggaggctgag gcaggagaat cgcttgaacc cgggaggcag aggttgacgt gagccgagat 787
cgcgccactg cactccaacc tgggtgacag actctgtctc caaaacaaaa caaacaaca 847
aaaagatttt attaaagata ttttgtaac tcaraaaaaa aaaa 891
<210> 142
<211> 817
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 28..804
<223> sig_peptide
<222> 28..96
<223> Von Heijne matrix
      score 10
      seq PLLGLLLSLPAGA/DV
<223> polyA_site
<222> 806..817
<400> 142
aaccgagctg gatttgtatg ttgcacc atg cct tct tgg atc ggg gct gtg att 54
                        Met Pro Ser Trp Ile Gly Ala Val Ile
                        -20                               -15
ctt ccc ctg ttg ggg ctg ctg ctg tcc ctg ccc gcc ggg gcg gat gtg 102
Leu Pro Leu Leu Gly Leu Leu Leu Ser Leu Pro Ala Gly Ala Asp Val
                        -10                               -5                               1
aag gct cgg agc tgc gga gag gtc cgc cag gcg tac ggt gcc aag gga 150
Lys Ala Arg Ser Cys Gly Glu Val Arg Gln Ala Tyr Gly Ala Lys Gly
                        5                               10                               15
ttc agc ctg gcg gac atc ccc tac cag gag atc gca kgg gaa cac tta 198
Phe Ser Leu Ala Asp Ile Pro Tyr Gln Glu Ile Ala Xaa Glu His Leu
                        20                               25                               30
aga atc tgt cct cag gaa tat aca tgc tgc acc aca gaa atg gar gac 246
Arg Ile Cys Pro Gln Glu Tyr Thr Cys Cys Thr Thr Glu Met Glu Asp
35                               40                               45                               50
aag tta agc caa caa agc aaa ctg gaa ttt gaa aac ctt gtg gaa gag 294
Lys Leu Ser Gln Gln Ser Lys Leu Glu Phe Glu Asn Leu Val Glu Glu
55                               60                               65
aca agc cat ttt gtg cgc acc act ttt gtg tcc agg cat aag aaa ttt 342
Thr Ser His Phe Val Arg Thr Thr Phe Val Ser Arg His Lys Lys Phe
70                               75                               80
gac gaw ttt ttc cga rag ctg ckg gag aat gca raa aag tca cta aat 390
Asp Xaa Phe Phe Arg Xaa Leu Xaa Glu Asn Ala Xaa Lys Ser Leu Asn
85                               90                               95
gat rtg ttt gtm cgg acc tat ggc atg ctg tac wtg car aat kca gaa 438
Asp Xaa Phe Val Arg Thr Tyr Gly Met Leu Tyr Xaa Gln Asn Xaa Glu
100                               105                               110
gtc ttc crg gac ctg ttc aca rag ctg aaa agg tac tac act ggg ggt 486
Val Phe Xaa Asp Leu Phe Thr Xaa Leu Lys Arg Tyr Tyr Thr Gly Gly
115                               120                               125                               130
aat gtg aat ctg gag gaa atg ctg aat gac ttt tgg gct cgg ctg ctg 534
Asn Val Asn Leu Glu Glu Met Leu Asn Asp Phe Trp Ala Arg Leu Leu
135                               140                               145
gaa cgg atg ttt cag cwr awa aac cct cag tat cac ttc agt gaa gac 582
Glu Arg Met Phe Gln Xaa Xaa Asn Pro Gln Tyr His Phe Ser Glu Asp
150                               155                               160
tac ctg gaa tgt gtg agc aaa tac act gac cak ctg aag cca ttt gga 630
Tyr Leu Glu Cys Val Ser Lys Tyr Thr Asp Xaa Leu Lys Pro Phe Gly
165                               170                               175

```

gac gtg ccc cgg aaa ctg aag att cag gtk acc cgc gcc ttc atk gsk 678
 Asp Val Pro Arg Lys Leu Lys Ile Gln Val Thr Arg Ala Phe Xaa Xaa
 180 185 190
 gcc agg acc ttt gtc cag ggg ctg act gtg ggc aga gaa gtt gca aac 726
 Ala Arg Thr Phe Val Gln Gly Leu Thr Val Gly Arg Glu Val Ala Asn
 195 200 205 210
 cga gtt tcc aag gta att gaa aac gtg ctt tct ttc tca ttg gtg ttc 774
 Arg Val Ser Lys Val Ile Glu Asn Val Leu Ser Phe Ser Leu Val Phe
 215 220 225
 ctt gtt tat tct gtt ttt aaa acc aat gtt taaaaaaaaaaa aaa 817
 Leu Val Tyr Ser Val Phe Lys Thr Asn Val
 230 235
 <210> 143
 <211> 1020
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 27..359
 <223> sig_peptide
 <222> 27..212
 <223> Von Heijne matrix
 score 3.59999990463257
 seq SWLSLLAALAHLA/AA
 <223> polyA_signal
 <222> 988..993
 <223> polyA_site
 <222> 1009..1020
 <400> 143
 agtgggtcga kctggggcgc agtcgc atg ggg gag tct atc ccg ctg gcc gcc 53
 Met Gly Glu Ser Ile Pro Leu Ala Ala
 -60 -55
 ccg gtc ccg gtg gaa cag gcg gtg ctg gag acg ttc ttc tct cac ctg 101
 Pro Val Pro Val Glu Gln Ala Val Leu Glu Thr Phe Phe Ser His Leu
 -50 -45 -40
 ggt atc ttc tct tac gac aag gct aag gac aat gtg gag aag gaa cga 149
 Gly Ile Phe Ser Tyr Asp Lys Ala Lys Asp Asn Val Glu Lys Glu Arg
 -35 -30 -25
 gag gcc aac aag agc gcg ggg agc tgg ctg tcg ctg ctg gcg gcc 197
 Glu Ala Asn Lys Ser Ala Gly Gly Ser Trp Leu Ser Leu Leu Ala Ala
 -20 -15 -10
 ttg gcg cac ctg gcc gcg gcc gag aag gtc tat cac agc ctc acc tac 245
 Leu Ala His Leu Ala Ala Ala Glu Lys Val Tyr His Ser Leu Thr Tyr
 -5 1 5 10
 ctg ggg cag aaa cta ggt acc tcc gcc ccg ccc ccc gag ccc ctt gag 293
 Leu Gly Gln Lys Leu Gly Thr Ser Ala Pro Pro Pro Glu Pro Leu Glu
 15 20 25
 gag gaa gta aag ggg gta tat tcc cca dtc ggc agt ggc ttg ggt btc 341
 Glu Glu Val Lys Gly Val Tyr Ser Pro Xaa Gly Ser Gly Leu Gly Xaa
 30 35 40
 ccg tct ctg tgt cac ttc tagtcgcagg ctgcactcgg cattcccaga 389
 Pro Ser Leu Cys His Phe
 45
 tctcctccca ccgttccttt ccttccctgg gcttccacaa gccccgccca ccrgcctgcr 449
 ctgctgatag attggcgaac tgggtagatg ctctttgcaa ggctgtgacc caaaccgaaw 509
 ggtttgccct tttgcctcgt gcatggattg atgccataaa tgagaagtta accaaaaaaa 569
 aaaaacmcwd tyckktttm ccccccccg grmcagaaga gcaaaacttt gcaaaacaac 629
 ctagtcttat tactgaacac tggtgtgtgg cctcttaagg ttaaggcccg agagtcacat 689
 ttagagtctt accccgtctt catagtcccc caatacatat ttaatgacta aagtwataaa 749
 tgaatatgg gcaggaaagg caagaaatat gcctaacact agcaagaaga gacttaaggg 809
 gaaaatggta aacactctta gcacttcatg tacatcttgc ctctgaaata agattcaaga 869

gctgattcaa ctgatttttta ctagtagaag caataagtat aagtagatga gaaggaaata 929
 atagatgtaa aaggcatgga atatgcatac aaaataatat tactgcttaa ttatgacaaa 989
 taaatatatt ttgaatccta aaaaaaaaaa a 1020
 <210> 144
 <211> 1399
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 25..957
 <223> sig_peptide
 <222> 25..93
 <223> Von Heijne matrix
 score 4.09999990463257
 seq LEAFSQAISAIQA/LR
 <223> polyA_signal
 <222> 1368..1373
 <223> polyA_site
 <222> 1388..1399
 <400> 144
 aakagctgct gtggcggcgg caac atg gcg gac gtg ata aat gtc agt gtg 51
 Met Ala Asp Val Ile Asn Val Ser Val
 -20 -15
 aac ctg gag gcc ttt tcc cag gcc att agt gcc atc cag gcg ctg cga 99
 Asn Leu Glu Ala Phe Ser Gln Ala Ile Ser Ala Ile Gln Ala Leu Arg
 -10 -5 1
 tcc agc gtg agc agg gtg ttc gac tgc ctg aag gat ggg atg cgg aac 147
 Ser Ser Val Ser Arg Val Phe Asp Cys Leu Lys Asp Gly Met Arg Asn
 5 10 15
 aag gag acg ctg gag ggc cgg gag aag gcc ttt att gcg cac ttc cag 195
 Lys Glu Thr Leu Glu Gly Arg Glu Lys Ala Phe Ile Ala His Phe Gln
 20 25 30
 gac aac tta cat tcg gtc aac cgg gac ctc aat gag ctg gaa cgt ctg 243
 Asp Asn Leu His Ser Val Asn Arg Asp Leu Asn Glu Leu Glu Arg Leu
 35 40 45 50
 agc aat ctg gta ggc arg cca tct gar aac cat cct ctt cat aac agt 291
 Ser Asn Leu Val Gly Xaa Pro Ser Glu Asn His Pro Leu His Asn Ser
 55 60 65
 ggg ctg tta asc ctg gat cct gtg car gac aaa act cct ctc tat agt 339
 Gly Leu Leu Xaa Leu Asp Pro Val Gln Asp Lys Thr Pro Leu Tyr Ser
 70 75 80
 caa ctc ctt caa gca tat aag tgg tca aac aag ttg cag tac cat gca 387
 Gln Leu Leu Gln Ala Tyr Lys Trp Ser Asn Lys Leu Gln Tyr His Ala
 85 90 95
 gga cta gca tct ggc ctt tta aat cas car tca ktg aag cgt ycc gct 435
 Gly Leu Ala Ser Gly Leu Leu Asn Xaa Gln Ser Xaa Lys Arg Xaa Ala
 100 105 110
 aat cag atg gga gta tct gcc aaa cgt aga cca aag gct cag ccc aca 483
 Asn Gln Met Gly Val Ser Ala Lys Arg Arg Pro Lys Ala Gln Pro Thr
 115 120 125 130
 act ctt gtc cta cca cct caa tat gtt gat gat gtg atc agc cgc att 531
 Thr Leu Val Leu Pro Pro Gln Tyr Val Asp Asp Val Ile Ser Arg Ile
 135 140 145
 gac agg atg ttt cct gaa atg tcc atc cac tta tcc aga ccc aat gga 579
 Asp Arg Met Phe Pro Glu Met Ser Ile His Leu Ser Arg Pro Asn Gly
 150 155 160
 aca tca gca atg ctt ctg gtg acc ttg gga aar gtg ttg aaa gtg awc 627
 Thr Ser Ala Met Leu Leu Val Thr Leu Gly Lys Val Leu Lys Val Xaa
 165 170 175
 gtc gtc rtr cgg arm ctg ttc att gat cga aca ata gtw aag gga tat 675
 Val Val Xaa Arg Xaa Leu Phe Ile Asp Arg Thr Ile Val Lys Gly Tyr

```

      180              185              190
wac gag aat gtc tac rca gaa kat ggc mag ctt gat ata tgg tcc aaa      723
Xaa Glu Asn Val Tyr Xaa Glu Xaa Gly Xaa Leu Asp Ile Trp Ser Lys
195              200              205              210
tcc aac tat caa gta ttc cag aag gtg aca gac cat gcc acc act gcc      771
Ser Asn Tyr Gln Val Phe Gln Lys Val Thr Asp His Ala Thr Thr Ala
      215              220              225
ctg ctc cac taw mag ctg ccc cag atg ccg gat gtc gtg gtc cga tcc      819
Leu Leu His Xaa Xaa Leu Pro Gln Met Pro Asp Val Val Val Arg Ser
      230              235              240
ttc awg acc tgg tta aga agt tac ata aag ctg ttc cag gcc ccg tgc      867
Phe Xaa Thr Trp Leu Arg Ser Tyr Ile Lys Leu Phe Gln Ala Pro Cys
      245              250              255
cag cgc tgc ggg aag ttt ctg cag gac ggc ctt ccc ccg aca tgg agg      915
Gln Arg Cys Gly Lys Phe Leu Gln Asp Gly Leu Pro Pro Thr Trp Arg
      260              265              270
gat ttc cga acc ctc gaa gcc ttc cat gac acc tgc cgg cag      957
Asp Phe Arg Thr Leu Glu Ala Phe His Asp Thr Cys Arg Gln
      275              280              285
tagccccac gctggcccca gcctcagacc ccaccagca ccttcccaga cacgcaggaa      1017
gccacagaa ggctcagctg gttcctcact gccacagatgt gtacagctgc tcctcccttt      1077
cataaagcag cgccatgtgt gcagaggcca ctcttgaaga gcagactccc tctgtggctg      1137
atgggactaa ttattcccac tagccagcgg actgaaggca aagaagacct ttctagaacc      1197
tggtagaagg aagctgtgca gcatgtcctt cgtccatgtg tgtcggcagt gctgggtgtt      1257
gtcgtctccg cgagctgtta ctggaatgag cccttgtgtt catgggtatc gtcatgcggg      1317
gttcttgtgt tttgtggggc ttgggttttg gttaacttat ttttataagc aataaacctt      1377
ttgtatcctg aaaaaaaaaa aa      1399
<210> 145
<211> 666
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 47..319
<223> sig_peptide
<222> 47..226
<223> Von Heijne matrix
score 3.90000009536743
seq SSLVPFFLFTCFG/HF
<223> polyA_site
<222> 656..666
<400> 145
acttttgccct agcatttgac tttggtgttt taagttctgt agttcc atg aca tca      55
                                Met Thr Ser
                                -60
ttg ttt gct gtt gtg tta cag aga gag aag gaa cct cac ctg tgg ctc      103
Leu Phe Ala Val Val Leu Gln Arg Glu Lys Glu Pro His Leu Trp Leu
      -55              -50              -45
agc tca ccc cac atc cgt ttc tca tta cgt gta aat aaa ctg tca gag      151
Ser Ser Pro His Ile Arg Phe Ser Leu Arg Val Asn Lys Leu Ser Glu
      -40              -35              -30
ctg atg tta cag ctt tta cag ttt aaa gca ttc ccc tcg tct cta gtt      199
Leu Met Leu Gln Leu Leu Gln Phe Lys Ala Phe Pro Ser Ser Leu Val
      -25              -20              -15              -10
cct ttt ttc ttg ttt aca tgt ttt ggg cac ttt ccc tca ttc acc acc      247
Pro Phe Phe Leu Phe Thr Cys Phe Gly His Phe Pro Ser Phe Thr Thr
      -5              1              5
ttc cag ggc ttc ata gaa aat aac ttg tta caa aat cag ttc aat tct      295
Phe Gln Gly Phe Ile Glu Asn Asn Leu Leu Gln Asn Gln Phe Asn Ser
      10              15              20
aat gtg gac ata gtg gca tgt tca taattagacc catatagggg aactgagct      349

```

Asn Val Asp Ile Val Ala Cys Ser
 25 30
 ttaaatacgtt gattctaaac tctatacatt aaaaaaattc agcccaggcc cctcaaagcc 409
 tgaraaaatt taatttgctc ttaatttaaat gttccaaaac tcactcttgg aaaaatgcct 469
 gttggaaaac tacagggtggg tcacatgatk gggctgtctc cgtgacactc aggattccag 529
 tcaraaccta atcctcatat ctattgccta caaaaataga ccaagaatgt tgctgtctctt 589
 ttataatcct ttaaatatatt aacattcaag ttttctttgt cttaaattca gcctcttctt 649
 aaaagcaaaa aaaaaaa 666
 <210> 146
 <211> 1131
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 80..940
 <223> sig_peptide
 <222> 80..130
 <223> Von Heijne matrix
 score 3.70000004768372
 seq RIVSAALLAFVQT/HL
 <223> polyA_signal
 <222> 1101..1106
 <223> polyA_site
 <222> 1119..1130
 <400> 146
 agttggtggg gctgggggat gagagctgca ccgcgcggga yaagtcgccg gcggcgcccg 60
 amggagcaga acagagagc atg gag ctg gag agg atc gtc agt gca gcc ctc 112
 Met Glu Leu Glu Arg Ile Val Ser Ala Ala Leu
 -15 -10
 ctt gcc ttt gtc cag aca cac ctc ccg gag gcc gac ctc agt ggc ttg 160
 Leu Ala Phe Val Gln Thr His Leu Pro Glu Ala Asp Leu Ser Gly Leu
 -5 1 5 10
 gat gag gtc atc ttc tcc tat gtg ctt ggg gtc ctg gag gac ctg ggc 208
 Asp Glu Val Ile Phe Ser Tyr Val Leu Gly Val Leu Glu Asp Leu Gly
 15 20 25
 ccc tcg ggc cca tca gag gag aac ttc gat atg gag gct ttc act gag 256
 Pro Ser Gly Pro Ser Glu Glu Asn Phe Asp Met Glu Ala Phe Thr Glu
 30 35 40
 atg atg gag gcc tat gtg cct ggc ttc gcc cac atc ccc agg ggc aca 304
 Met Met Glu Ala Tyr Val Pro Gly Phe Ala His Ile Pro Arg Gly Thr
 45 50 55
 ata ggg gac atg atg cag aar ctc tca ggg cag ctg agc gat gcc vgg 352
 Ile Gly Asp Met Met Gln Lys Leu Ser Gly Gln Leu Ser Asp Ala Xaa
 60 65 70
 aac aaa gag aac ctg caa ccg cag aac tct ggt gtc caa ggt cag gtg 400
 Asn Lys Glu Asn Leu Gln Pro Gln Asn Ser Gly Val Gln Gly Gln Val
 75 80 85 90
 ccc atc tcc cca gag ccc ctg cag cgg ccc gaa atg ctc aaa gaa gag 448
 Pro Ile Ser Pro Glu Pro Leu Gln Arg Pro Glu Met Leu Lys Glu Glu
 95 100 105
 act agg tct tcg gct gct gct gct gca gac acc caa gat gag gca act 496
 Thr Arg Ser Ser Ala Ala Ala Ala Ala Asp Thr Gln Asp Glu Ala Thr
 110 115 120
 ggc gct gag gag gag ctt ctg cca ggg gtg gat gta ctc ctg gag gtg 544
 Gly Ala Glu Glu Glu Leu Leu Pro Gly Val Asp Val Leu Leu Glu Val
 125 130 135
 ttc cct acc tgt tcg gtg gag cag gcc cag tgg gtg ctg gcc aaa gct 592
 Phe Pro Thr Cys Ser Val Glu Gln Ala Gln Trp Val Leu Ala Lys Ala
 140 145 150
 cgg ggg gac ttg gaa gaa gct gtg cag atg ctg gta gag gga aag gaa 640
 Arg Gly Asp Leu Glu Glu Ala Val Gln Met Leu Val Glu Gly Lys Glu

155 160 165 170
 gag ggg cct gca gcc tgg gag ggc ccc aac cag gac ctg ccc aga cgc 688
 Glu Gly Pro Ala Ala Trp Glu Gly Pro Asn Gln Asp Leu Pro Arg Arg
 175 180 185
 ctc aga ggc ccc caa aag gat gag ctg aag tcc ttc atc ctg cag aag 736
 Leu Arg Gly Pro Gln Lys Asp Glu Leu Lys Ser Phe Ile Leu Gln Lys
 190 195 200
 tac atg atg gtg gat agc gca gag gat cag aag att cac cgg ccc atg 784
 Tyr Met Met Val Asp Ser Ala Glu Asp Gln Lys Ile His Arg Pro Met
 205 210 215
 gct ccc aag gag gcc ccc aag aag ctg atc cga tac atc gac aac cag 832
 Ala Pro Lys Glu Ala Pro Lys Lys Leu Ile Arg Tyr Ile Asp Asn Gln
 220 225 230
 gta gtg agc acc aaa ggg gag cga ttc aaa gat gtg cgg aac cct gag 880
 Val Val Ser Thr Lys Gly Glu Arg Phe Lys Asp Val Arg Asn Pro Glu
 235 240 245 250
 gcc gag gag atg aag gcc aca tac atc aac ctc aag cca gcc aga aag 928
 Ala Glu Glu Met Lys Ala Thr Tyr Ile Asn Leu Lys Pro Ala Arg Lys
 255 260 265
 tac cgc ttc cat tgaggcactc gccggactct gcccagacct tctaggctca 980
 Tyr Arg Phe His
 270
 gatccagag ggatgcagga gccctataacc cctacacagg ggccccctaa ctctgtccc 1040
 ccttctctac tcctttgctc catagtgtta acctactctc ggagctgcct ccatgggcac 1100
 agtaaaagtg gcccaaggaa aaaaaaaaaw t 1131
 <210> 147
 <211> 475
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 146..457
 <223> sig_peptide
 <222> 146..292
 <223> Von Heijne matrix
 score 5.19999980926514
 seq CFLCLYPIPLCTS/HP
 <223> polyA_signal
 <222> 442..447
 <223> polyA_site
 <222> 465..475
 <400> 147
 attgtaacaa acagtaccaa tttattttgg ccgtggggtt ttgctttttt tccagttgat 60
 gactttgtga acattcccag gtattggagc ctctgtggcc ttaaagtgtg ctcaagtggag 120
 ggagaccag catagccagg ccagt atg gag cac ctc acg cac agc tct cag 172
 Met Glu His Leu Thr His Ser Ser Gln
 -45
 aag ctg cag gcg gac gaa cat ctg acc aaa gag gtg tgg tgg agg ctc 220
 Lys Leu Gln Ala Asp Glu His Leu Thr Lys Glu Val Trp Ser Arg Leu
 -40 -35 -30 -25
 ctg aaa gag aaa ggg cct gct ggt ctc atc ctc tgc ttc ctt tgc ctt 268
 Leu Lys Glu Lys Gly Pro Ala Gly Leu Ile Leu Cys Phe Leu Cys Leu
 -20 -15 -10
 tac cct ata cct ctc tgc acg tcc cac ccc gtt tkg ctg tgt gcy cac 316
 Tyr Pro Ile Pro Leu Cys Thr Ser His Pro Val Xaa Leu Cys Ala His
 -5 1 5
 ccc cag gat gtg tac ccg gtt gta gta aga gct gaa atc cat gct gag 364
 Pro Gln Asp Val Tyr Pro Val Val Val Arg Ala Glu Ile His Ala Glu
 10 15 20
 ctg tac cag gaa ctt gca tat cta aaa aca gaa act gag tca ctg gcc 412
 Leu Tyr Gln Glu Leu Ala Tyr Leu Lys Thr Glu Thr Glu Ser Leu Ala

```

25          30          35          40
cat ctc ttt gct ctt gtg ccc cag gcc aaa ata aag aat aga gtg      457
His Leu Phe Ala Leu Val Pro Gln Ala Lys Ile Lys Asn Arg Val
          45          50          55
taragtgaata aaaaaaaaaa      475
<210> 148
<211> 949
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 100..351
<223> sig_peptide
<222> 100..207
<223> Von Heijne matrix
      score 4.19999980926514
      seq CLAVSWEAAGCHG/AG
<223> polyA_site
<222> 940..949
<400> 148
aaaggaatac tgacagataa ggccggaaac aaaactgatg gcttgaaaaa catttttatg      60
gaatgtatatt actatcattt tgttttacta tagaggtag atg gga ctc tta act      114
                               Met Gly Leu Leu Thr
                               -35
ttt ggg tac att gaa amc akg ckg aaa act gaa cac aat cct gat cat      162
Phe Gly Tyr Ile Glu Xaa Xaa Xaa Lys Thr Glu His Asn Pro Asp His
-30          -25          -20
cac tcc tgc ctg gct gtc tcc tgg gag gct gcc ggg tgc cac gga gct      210
His Ser Cys Leu Ala Val Ser Trp Glu Ala Ala Gly Cys His Gly Ala
-15          -10          -5          1
ggg aca cag cag agc ccg cta ggt gtt gca ggg ccc tgg agg cca agg      258
Gly Thr Gln Gln Ser Pro Leu Gly Val Ala Gly Pro Trp Arg Pro Arg
          5          10          15
cca ccc tgt gtg ggg tcc ctg ttg gca gcc agg tcc cta cac aaa caa      306
Pro Pro Cys Val Gly Ser Leu Leu Ala Ala Arg Ser Leu His Lys Gln
          20          25          30
gta atc ctg ttt ggc ctc cta ggt ttt gca tat gac cac gca gcc      351
Val Ile Leu Phe Gly Leu Leu Gly Phe Ala Tyr Asp His Ala Ala
          35          40          45
taatttgggg tgtaggggaa cctctgctgg cccttgctcc tttgtatggt gggtgacttt      411
aatggctggc cacatacccc tttctcccag ctactcattc actgacttgg gtaagttcta      471
gcacaatgcg cacttagaaa cagaatgtga cacatcaaca ttaacttttc ctgaaaagaa      531
cagtttgctt aacatggacc cmaaagaagc ttggaattta taagactttc ctttataaga      591
tatagtgggg gtttttttgg gtggaggggg gttgtttttt gttttttgtt ttcaagacag      651
agtctcgctc agttgtccag gctggartgt aktggcatga tctcggctca ctgcarcctc      711
tgccctccag gttcatgcca ttctcctgcc tcancctccc gagtagctgg gactacaggt      771
gtctgccgcc acgcctggct aatttttttg tatttttagt agagacgggg ttccaccatg      831
ttggtcagga tggctcgcg ttcctgacct cgtgatccgc ctgtctcggc ctcccaaagt      891
gctgggatta caggcgtgag ccaccacgcc tggcctataa gatacgyyaa aaaaaaaa      949
<210> 149
<211> 940
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 177..569
<223> sig_peptide
<222> 177..236
<223> Von Heijne matrix
      score 11.1999998092651
      seq AFLLLVALSYTLA/RD

```

<223> polyA_site
 <222> 931..939
 <400> 149
 agaagataat cacttgggga aaggaaggtt cgtttctgag ttagcaacaa gtaaatgcag 60
 cactagtggg tgggattgag gtatgccctg gtgcataaat agagactcag ctgtgctggc 120
 acactcagaa gcttggaccg catcctagcc gccgactcac acaaggcaga gttgcc atg 179
 Met
 -20
 gaa aaa att cca gtg tca gca ttc ttg ctc ctt gtg gcc ctc tcc tac 227
 Glu Lys Ile Pro Val Ser Ala Phe Leu Leu Leu Val Ala Leu Ser Tyr
 -15 -10 -5
 act ctg gcc aga gat acc aca gtc aaa cct gga gcc aaa aag gac aca 275
 Thr Leu Ala Arg Asp Thr Thr Val Lys Pro Gly Ala Lys Lys Asp Thr
 1 5 10
 aag gac tct cga ccc aaa ctg ccc cag acc ctc tcc aga ggt tgg ggt 323
 Lys Asp Ser Arg Pro Lys Leu Pro Gln Thr Leu Ser Arg Gly Trp Gly
 15 20 25
 gac caa ctc atc tgg aca car aca tat gaa raa rct cta twt aaa tcc 371
 Asp Gln Leu Ile Trp Thr Gln Thr Tyr Glu Xaa Xaa Leu Xaa Lys Ser
 30 35 40 45
 aar aca agc aac aaa ccc ttg atg att att cat cac ttg gat gad tgc 419
 Lys Thr Ser Asn Lys Pro Leu Met Ile Ile His His Leu Asp Xaa Cys
 50 55 60
 cca cac agt caa gct tta aaa aaa ktg ttt gct gaa aat aaa raa atc 467
 Pro His Ser Gln Ala Leu Lys Lys Xaa Phe Ala Glu Asn Lys Xaa Ile
 65 70 75
 cag aaa ttg gca ran cag ttt gtc cyc ctc aat ctg gtt tat gaa aca 515
 Gln Lys Leu Ala Xaa Gln Phe Val Xaa Leu Asn Leu Val Tyr Glu Thr
 80 85 90
 act gac aaa cac ctt tct cct gat ggc caa tat ktc ccc cmg gat tat 563
 Thr Asp Lys His Leu Ser Pro Asp Gly Gln Tyr Xaa Pro Xaa Asp Tyr
 95 100 105
 gtt tgt tgaccatct ctgacagtta gagccgatat cactggaaga tattcaaayc 619
 Val Cys
 110
 gtctctatgc ttacgaacct gcagatacag ctctgttgct tgacaacatg aagaaagctc 679
 tcaagttgct gaagactgaa ttgtaaagaa aaaaaatctc caagcccttc tgtctgtcag 739
 gccttgagac ttgaaaccag aagaagtgtg agaagactgg ctagtgtgga agcatagtga 799
 acacactgat taggttatgg tttaatgtta caacaactat tttttaagaa aaacaagtgt 859
 tagaaaattg gtttcaagtg tacatgtgtg aaaacaatat tgtatactac catagtggagc 919
 catgattttc taataaaaaa a 940
 <210> 150
 <211> 887
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> CDS
 <222> 67..459
 <223> sig_peptide
 <222> 67..135
 <223> Von Heijne matrix
 score 5.19999980926514
 seq IGVGLYLLASAAA/FY
 <223> polyA_signal
 <222> 856..861
 <223> polyA_site
 <222> 875..887
 <400> 150
 agcggcgcca tccgggacgg cgggcgggct ggccaccacg ggacaggaag gcacagagca 60
 tggaga atg atg aac ttc cgt cag cgg atg gga tgg att gga gtg gga 108
 Met Met Asn Phe Arg Gln Arg Met Gly Trp Ile Gly Val Gly

	-20	-15	-10	
ttg tat ctg tta gcc agt gca gca gca ttt tac tat gtt ttt gaa atc				156
Leu Tyr Leu Leu Ala Ser Ala Ala Ala Phe Tyr Tyr Val Phe Glu Ile				
	-5	1	5	
agt gag act tac aac agg ctg gcc ttg gaa cac att caa cag cac cct				204
Ser Glu Thr Tyr Asn Arg Leu Ala Leu Glu His Ile Gln Gln His Pro				
	10	15	20	
ggg gag ccc ctt gaa gga acc aca tgg aca cac tcc ttg aaa gct caa				252
Gly Glu Pro Leu Glu Gly Thr Thr Trp Thr His Ser Leu Lys Ala Gln				
	25	30	35	
tta ctc tcc ttg cct ttt tgg gtg tgg aca gtt att ttt ctg gta cct				300
Leu Leu Ser Leu Pro Phe Trp Val Trp Thr Val Ile Phe Leu Val Pro				
	40	45	50	
tac tta car atk ttt ttg ttc cta tac tct tgt aca aaa vct gat ccc				348
Tyr Leu Gln Xaa Phe Leu Phe Leu Tyr Ser Cys Thr Lys Xaa Asp Pro				
	60	65	70	
aaa aca gtg ggc tac tgt wtc atc cct ata tgc ttg gca rtt att tsc				396
Lys Thr Val Gly Tyr Cys Xaa Ile Pro Ile Cys Leu Ala Xaa Ile Xaa				
	75	80	85	
aat cgc cac cag gat ttt gtc aag gct tct aat caa atc agc aaa cta				444
Asn Arg His Gln Asp Phe Val Lys Ala Ser Asn Gln Ile Ser Lys Leu				
	90	95	100	
caa ctg att gac acg taaaatcagt caccgttttt tccctacgat tacaaaactg				499
Gln Leu Ile Asp Thr				
	105			
ccagtcctat atggagtctg atcacaagac tgcagtttct tcacagatct caggaagtgtg				559
tcgtgggggca gaggcttttt aaaaacatgt gattagggag ctatctttat ctgaataata				619
acgaatttttt aggtaaaacc tgagatagag tactacaaaa tcatgttgat gacttcagat				679
tttggaagtt aaatcatgtc tgttatttgc attctttaga aacttgacta agtacctgaa				739
ttcatatttc tattctactg tgcaacatag tgatgattca gaaatttttc ctttgggggaa				799
aaaaatgaat atgaacattt ccattgtgtt aagtgtaaaa aggtccagka catgatcata				859
aaatttaaat tttatacaaa aaaaaaaaa				887
<210> 151				
<211> 2010				
<212> DNA				
<213> Homo sapiens				
<220>				
<223> CDS				
<222> 65..1069				
<223> sig_peptide				
<222> 65..112				
<223> Von Heijne matrix				
score 12.5				
seq FVLLALVAGVLG/NE				
<223> polyA_signal				
<222> 1978..1983				
<223> polyA_site				
<222> 1999..2010				
<400> 151				
atgtcgcccg tgtcccgccg gcccggttccg tgtcgcccg cagtgytgcg gcccgccgckk				60
cacc atg gct gtg ttt gtc gtg ctc ctg gcg ttg gtg gcg ggt gtt ttg				109
Met Ala Val Phe Val Val Leu Leu Ala Leu Val Ala Gly Val Leu				
	-15	-10	-5	
ggg aac gag ttt agt ata tta aaa tca cca ggg tct gtt gtt ttc cga				157
Gly Asn Glu Phe Ser Ile Leu Lys Ser Pro Gly Ser Val Val Phe Arg				
	1	5	10	
aat gga aat tgg cct ata cca gga gag cgg atc cca gac gtg gct gca				205
Asn Gly Asn Trp Pro Ile Pro Gly Glu Arg Ile Pro Asp Val Ala Ala				
	20	25	30	
ttg tcc atg ggc ttc tct gtg aaa gaa gac ctt tct tgg cca gga ctc				253
Leu Ser Met Gly Phe Ser Val Lys Glu Asp Leu Ser Trp Pro Gly Leu				

gca gtg ggt aac ctg ttt cat cgt cct cgg gct agc gtc atg gtg atg	301
Ala Val Gly Asn Leu Phe His Arg Pro Arg Ala Ser Val Met Val Met	
50 55 60	
gtg aag gga gtt aac aac tmc cct cta ccc cca ggc tgt gtc att tcg	349
Val Lys Gly Val Asn Asn Xaa Pro Leu Pro Pro Gly Cys Val Ile Ser	
65 70 75	
tac cct ttg gag aat gca gtt cct ttt agt ctt gac agt gtt gca aat	397
Tyr Pro Leu Glu Asn Ala Val Pro Phe Ser Leu Asp Ser Val Ala Asn	
80 85 90 95	
tcc att cac tcc tta ttt tct gag gaa act cct gtt gtt ttg cag ttg	445
Ser Ile His Ser Leu Phe Ser Glu Glu Thr Pro Val Val Leu Gln Leu	
100 105 110	
gct ccc agt gag gaa aga gtg tat atg gta ggg aag gcm aac tca gtg	493
Ala Pro Ser Glu Arg Val Tyr Met Val Gly Lys Ala Asn Ser Val	
115 120 125	
tgg aar acc ttt cag tca ctt gcg cca gct ccg kta atc rcc tgt ttc	541
Trp Lys Thr Phe Gln Ser Leu Ala Pro Ala Pro Xaa Ile Xaa Cys Phe	
130 135 140	
aag aaa act ctg ttc tca gtt cac tcc ccc ycc att cma ctg agt agg	589
Lys Lys Thr Leu Phe Ser Val His Ser Pro Xaa Ile Xaa Leu Ser Arg	
145 150 155	
aac aat gaa gtt gac cyg ctc ttt ctt tct gaa ctg caa gtg cta cat	637
Asn Asn Glu Val Asp Xaa Leu Phe Leu Ser Glu Leu Gln Val Leu His	
160 165 170 175	
gat att tca agc ttg ctg tct cgt cat aag cat cta gcc aag gat cat	685
Asp Ile Ser Ser Leu Leu Ser Arg His Lys His Leu Ala Lys Asp His	
180 185 190	
tct cct gat tta tat tca ctg gag ctg gca ggt ttg gat gaa att ggg	733
Ser Pro Asp Leu Tyr Ser Leu Glu Leu Ala Gly Leu Asp Glu Ile Gly	
195 200 205	
aag cgt tat ggg gaa gac tct gaa caa ttc aga gat gct tct aag atc	781
Lys Arg Tyr Gly Glu Asp Ser Glu Gln Phe Arg Asp Ala Ser Lys Ile	
210 215 220	
ctt gtt gac gct ctg caa aag ttt gca gat gac atg tac agt ctt tat	829
Leu Val Asp Ala Leu Gln Lys Phe Ala Asp Asp Met Tyr Ser Leu Tyr	
225 230 235	
ggt ggg aat gca gtg gta gag tta gtc act gtc aag tca ttt gac acc	877
Gly Gly Asn Ala Val Val Glu Leu Val Thr Val Lys Ser Phe Asp Thr	
240 245 250 255	
tcc ctc att agg aag aca agg act atc ctt gag gca aaa caa gcg aag	925
Ser Leu Ile Arg Lys Thr Arg Thr Ile Leu Glu Ala Lys Gln Ala Lys	
260 265 270	
aac cca gca agt ccc tat aac ctt gca tat aag tat aat ttt gaa tat	973
Asn Pro Ala Ser Pro Tyr Asn Leu Ala Tyr Lys Tyr Asn Phe Glu Tyr	
275 280 285	
tcc gtg gtt ttc aac atg gta ctt tgg ata atg atc gcc ttg gcc ttg	1021
Ser Val Val Phe Asn Met Val Leu Trp Ile Met Ile Ala Leu Ala Leu	
290 295 300	
gct gtg att atc acc tct tac aat att tgg aac atg gaa tcc tgg ata	1069
Ala Val Ile Ile Thr Ser Tyr Asn Ile Trp Asn Met Glu Ser Trp Ile	
305 310 315	
tgatagcatc atttatagga tgacaaacca gaagattcgg aatggattga atgttacctg	1129
tgccagaatt akaaaagggg gttggaatt ggctgttttg ttaaaatata tcttttagtg	1189
tgctttaaag tagatagtat actttacatt tataaaaaaa aatcaaattt tgttctttat	1249
tttgtgtgtg cctgtgatgt ttttctagag tgaattatag tattgacgtg aatcccactg	1309
tggtatagat tccataatat gcttgaatat tatgatatag ccatttaata acattgattt	1369
cattctgttt aatgaatttg gaaatatgca ctgaaagaaa tgtaaaacat ttagaatagc	1429
tcgtgttatg gaaaaagtg cactgaattt attagacaaa cttacgaatg cttaacttct	1489
ttacacagca taggtgaaaa tcatatttgg gctattgtat actatgaaca atttgtaaat	1549
gtcttaattt gatgtaaata actctgaaac aagagaaaag gtttttaact tagagtagcc	1609


```

ctaaaatatg gatgtgctta tataatcgct tagtttttga actgtatctg agtaacagag 1669
gacagctgtt ttttaaccct cttctgcaag tttgttgacc tacatgggct aatatggata 1729
ctaaaaatac tacattgac taagaagaaa ctagccttgt ggagtatata gatgcttttc 1789
attatacaca caaaaatccc tgaggacat tttgaggcat gaatataaaa catttttatt 1849
tcagtaactt tccccctgt gtaagtact atggtttgtg gtacaacttc attctataga 1909
atattaagtg gaagtgggtg aattctact tttatgttg agtggaccaa tgtctatcaa 1969
gagtgacaaa taaagttaat gatgattcca aaaaaaaaaa a 2010
<210> 152
<211> 387
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 70..321
<223> sig_peptide
<222> 70..234
<223> Von Heijne matrix
      score 4.09999990463257
      seq AVCAALLASHPTA/EV
<223> polyA_signal
<222> 364..369
<223> polyA_site
<222> 375..387
<400> 152
agaaatcgta ggacttccga aagcagcggc ggcgtttgct tcaactgttg gaagtgtgag 60
tgcgcgaaag atg cga aag gtg gtt ttr att acc ggg gct agc agt ggc att 111
      Met Arg Lys Val Val Leu Ile Thr Gly Ala Ser Ser Gly Ile
      -55 -50 -45
ggc ctg gcc ctc tgc aag cgg ctg ctg gcg gaa gat gat gag ctt cat 159
Gly Leu Ala Leu Cys Lys Arg Leu Leu Ala Glu Asp Asp Glu Leu His
      -40 -35 -30
ctg tgt ttg gcg tgc agg aat atg agc aag gca gaa gct gtc tgt gct 207
Leu Cys Leu Ala Cys Arg Asn Met Ser Lys Ala Glu Ala Val Cys Ala
      -25 -20 -15 -10
gct ctg ctg gcc tct cac ccc act gct gag gtc acc att gtc cag gtg 255
Ala Leu Leu Ala Ser His Pro Thr Ala Glu Val Thr Ile Val Gln Val
      -5 1 5
gat gtc agc aac ctg cag tca ttc ttc cgg gcc tcc aag gaa ctt aag 303
Asp Val Ser Asn Leu Gln Ser Phe Arg Ala Ser Lys Glu Leu Lys
      10 15 20
caa agg atg atc tct tgc tgatggattt tttttctcat gtgattgtgc 351
Gln Arg Met Ile Ser Cys
      25
ascataacac ttaataaaaat aagaaaaaaaa aaaaaa 387
<210> 153
<211> 983
<212> DNA
<213> Homo sapiens
<220>
<223> CDS
<222> 38..877
<223> sig_peptide
<222> 38..91
<223> Von Heijne matrix
      score 7.40000009536743
      seq GWLVLCVLAISLA/SM
<223> polyA_signal
<222> 947..952
<223> polyA_site
<222> 974..983
<400> 153

```

aatccagtyg gasttgacaa caggaggcag aggcattc atg gag ggt ccc cgg gga	55
Met Glu Gly Pro Arg Gly	
-15	
tgg ctg gtg ctc tgt gtg ctg gcc ata tcg ctg gcc tct atg gtg acc	103
Trp Leu Val Leu Cys Val Leu Ala Ile Ser Leu Ala Ser Met Val Thr	
-10 -5 1	
gag gac ttg tgc cga gca cca gac ggg aag aaa ggg gag gca gga aga	151
Glu Asp Leu Cys Arg Ala Pro Asp Gly Lys Lys Gly Glu Ala Gly Arg	
5 10 15 20	
cct ggc aga cgg ggg cgg cca ggc ctc aag ggg gag caa ggg gag ccg	199
Pro Gly Arg Arg Gly Arg Pro Gly Leu Lys Gly Glu Gln Gly Glu Pro	
25 30 35	
ggg gcc cct ggc atc cgg aca ggc atc caa ggc ctt aaa gga gac cag	247
Gly Ala Pro Gly Ile Arg Thr Gly Ile Gln Gly Leu Lys Gly Asp Gln	
40 45 50	
ggg gaa cct ggg ccc tct gga aac ccc ggc aag gtg ggc tac cca ggg	295
Gly Glu Pro Gly Pro Ser Gly Asn Pro Gly Lys Val Gly Tyr Pro Gly	
55 60 65	
ccc agc ggc ccc ctc gga gcc cgt ggc atc ccg gga att aaa ggc acc	343
Pro Ser Gly Pro Leu Gly Ala Arg Gly Ile Pro Gly Ile Lys Gly Thr	
70 75 80	
aag ggc agc cca gga aac atc aag gac cag ccg agg cca gcc ttc tcc	391
Lys Gly Ser Pro Gly Asn Ile Lys Asp Gln Pro Arg Pro Ala Phe Ser	
85 90 95 100	
gcc att cgg cgg aac ccc cca atg ggg ggc aac gtg gtc atc ttc gac	439
Ala Ile Arg Arg Asn Pro Pro Met Gly Gly Asn Val Val Ile Phe Asp	
105 110 115	
acg gtc atc acc aac cag gaa gaa ccg tac cag aac cac tcc ggc cga	487
Thr Val Ile Thr Asn Gln Glu Glu Pro Tyr Gln Asn His Ser Gly Arg	
120 125 130	
ttc gtc tgc act gta ccc gct act act tca cct tcc agg tgc tgt	535
Phe Val Cys Thr Val Pro Ala Thr Thr Thr Ser Pro Ser Arg Cys Cys	
135 140 145	
ccc agt ggg aaa tct gcc tgt cca tcg tct cct cct caa ggg gcc agg	583
Pro Ser Gly Lys Ser Ala Cys Pro Ser Ser Pro Pro Gln Gly Ala Arg	
150 155 160	
tcc gac gct ccc tgg gct tct gtg aca cca cca aca agg ggc tct tcc	631
Ser Asp Ala Pro Trp Ala Ser Val Thr Pro Pro Thr Arg Gly Ser Ser	
165 170 175 180	
agg tgg tgt cag ggg gca tgg tgc ttc agc tgc agc agg gtg acc agg	679
Arg Trp Cys Gln Gly Ala Trp Cys Phe Ser Cys Ser Arg Val Thr Arg	
185 190 195	
tct ggg ttg aaa aag acc cca aaa agg gtc aca ttt acc agg gct ctg	727
Ser Gly Leu Lys Lys Thr Pro Lys Arg Val Thr Phe Thr Arg Ala Leu	
200 205 210	
agg ccg aca gcg tct tca gcg gct tcc tca tct tcc cat ctg cct gag	775
Arg Pro Thr Ala Ser Ser Ala Ala Ser Ser Ser Ser His Leu Pro Glu	
215 220 225	
cca ggg aag gac ccc ctc ccc cac cca cct ctc tgg ctt cca tgc tcc	823
Pro Gly Lys Asp Pro Leu Pro His Pro Pro Leu Trp Leu Pro Cys Ser	
230 235 240	
gcc tgt aaa atg ggg gcg cta ttg ctt cag ctg ctg aag gga ggg ggc	871
Ala Cys Lys Met Gly Ala Leu Leu Leu Gln Leu Leu Lys Gly Gly Gly	
245 250 255 260	
tgg ctc tgagagcccc aggactggct gccccgtgac acatgctcta agaagctcgt	927
Trp Leu	
ttcttagacc tcttctgga ataaacatct gtgtctgtgt ctgctgaaaa aaaaaa	983
<210> 154	
<211> 1614	
<212> DNA	
<213> Homo sapiens	

[illegible]

```

ttgttcttta gcttaataaaa tawgtcttat tttaaaaaaa aaaa
<210> 155
<211> 99
<212> PRT
<213> Homo sapiens
<220>
<223> SIGNAL
<222> -32...-1
<400> 155
Met Ala Ala Ala Ala Ala Ser Arg Gly Val Gly Ala Lys Leu Gly Leu
      -30                -25                -20
Arg Glu Ile Arg Ile His Leu Cys Gln Arg Ser Xaa Gly Ser Gln Gly
      -15                -10                -5
Val Arg Asp Phe Ile Glu Lys Arg Tyr Val Glu Leu Lys Lys Ala Asn
1      5      10      15
Pro Asp Leu Pro Ile Leu Ile Arg Glu Cys Ser Asp Val Gln Pro Lys
      20      25      30
Leu Trp Ala Arg Tyr Ala Phe Gly Gln Xaa Thr Asn Val Pro Leu Asn
      35      40      45
Asn Phe Ser Ala Asp Gln Val Thr Arg Xaa Leu Glu Asn Val Leu Ser
      50      55      60
Gly Lys Ala
65
<210> 156
<211> 160
<212> PRT
<213> Homo sapiens
<220>
<223> SIGNAL
<222> -27...-1
<400> 156
Met Gln Arg Val Ser Gly Leu Leu Ser Trp Thr Leu Ser Arg Val Leu
      -25                -20                -15
Trp Leu Ser Gly Leu Ser Glu Pro Gly Ala Ala Arg Gln Pro Arg Ile
      -10      -5      1      5
Met Glu Glu Lys Ala Leu Glu Val Tyr Asp Leu Ile Arg Thr Ile Arg
      10      15      20
Asp Pro Glu Lys Pro Asn Thr Leu Glu Glu Leu Glu Val Val Ser Glu
      25      30      35
Ser Cys Val Glu Val Gln Glu Ile Asn Glu Glu Xaa Tyr Leu Val Ile
      40      45      50
Ile Arg Phe Thr Pro Thr Val Pro His Cys Ser Leu Ala Thr Leu Ile
      55      60      65
Gly Leu Cys Leu Xaa Xaa Lys Leu Gln Arg Cys Leu Pro Phe Lys His
70      75      80      85
Lys Leu Xaa Ile Tyr Ile Ser Glu Gly Thr His Ser Xaa Glu Glu Asp
      90      95      100
Ile Asn Xaa Gln Ile Asn Asp Lys Glu Arg Xaa Ala Xaa Ala Met Glu
      105      110      115
Asn Pro Xaa Leu Arg Glu Ile Val Glu Gln Cys Val Leu Glu Pro Asp
      120      125      130
<210> 157
<211> 59
<212> PRT
<213> Homo sapiens
<220>
<223> SIGNAL
<222> -22...-1
<400> 157
Met Arg Leu Lys Tyr Gln His Thr Gly Ala Val Leu Asp Cys Ala Phe
      -20                -15                -10

```

Tyr Asp Pro Thr His Ala Trp Ser Gly Gly Leu Asp His Gln Leu Lys
 -5 1 5 10
 Met His Asp Leu Asn Thr Asp Gln Glu Asn Leu Val Gly Thr Met Met
 15 20 25
 Pro Leu Ser Asp Val Leu Asn Thr Val His Lys
 30 35
 <210> 158
 <211> 112
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -48...-1
 <400> 158
 Met Gln Asp Thr Gly Ser Val Val Pro Leu His Trp Phe Gly Phe Gly
 -45 -40 -35
 Tyr Ala Ala Leu Val Ala Ser Gly Gly Ile Ile Gly Tyr Val Lys Ala
 -30 -25 -20
 Gly Ser Val Pro Ser Leu Ala Ala Gly Leu Leu Phe Gly Ser Leu Ala
 -15 -10 -5
 Gly Leu Gly Ala Tyr Gln Leu Ser Gln Asp Pro Arg Asn Val Trp Val
 1 5 10 15
 Phe Leu Ala Thr Ser Gly Thr Leu Ala Gly Ile Met Gly Met Arg Phe
 20 25 30
 Tyr His Ser Gly Lys Phe Met Pro Ala Gly Leu Ile Ala Gly Ala Xaa
 35 40 45
 Leu Leu Met Val Ala Lys Ile Gly Val Ser Met Phe Asn Arg Pro His
 50 55 60
 <210> 159
 <211> 111
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -56...-1
 <400> 159
 Met Gly Gly Asn Gly Ser Thr Cys Lys Pro Asp Thr Glu Arg Gln Gly
 -55 -50 -45
 Thr Leu Ser Thr Ala Ala Pro Thr Thr Ser Pro Ala Pro Cys Leu Ser
 -40 -35 -30 -25
 Asn His His Asn Lys Lys His Leu Ile Leu Ala Phe Cys Ala Gly Val
 -20 -15 -10
 Leu Leu Thr Leu Leu Leu Ile Ala Phe Ile Phe Leu Ile Ile Lys Ser
 -5 1 5
 Tyr Arg Lys Tyr His Ser Lys Pro Gln Ala Pro Asp Pro His Ser Asp
 10 15 20
 Pro Pro Xaa Xaa Leu Ser Ser Ile Pro Gly Glu Ser Leu Thr Tyr Ala
 25 30 35 40
 Ser Thr Xaa Xaa Gln Thr Leu Arg Xaa Xaa Glu Xaa Xaa Leu Gly
 45 50 55
 <210> 160
 <211> 144
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -77...-1
 <400> 160
 Met Ala Ala Ser Lys Val Lys Gln Asp Met Pro Pro Xaa Gly Gly Tyr
 -75 -70 -65
 Gly Pro Ile Asp Tyr Lys Arg Asn Leu Pro Arg Arg Gly Leu Ser Gly

-60 -55 -50
 Tyr Ser Met Leu Ala Ile Gly Ile Gly Thr Leu Ile Tyr Gly His Trp
 -45 -40 -35 -30
 Ser Ile Met Lys Trp Asn Arg Glu Arg Arg Leu Gln Ile Glu Asp
 -25 -20 -15
 Phe Glu Ala Arg Ile Ala Leu Leu Pro Leu Leu Gln Ala Glu Thr Asp
 -10 -5 1
 Arg Arg Thr Leu Gln Met Leu Arg Glu Asn Leu Glu Glu Glu Ala Ile
 5 10 15
 Ile Met Lys Asp Val Pro Asp Trp Lys Val Gly Xaa Ser Val Xaa His
 20 25 30 35
 Thr Thr Arg Trp Val Pro Pro Leu Ile Gly Glu Leu Tyr Gly Leu Arg
 40 45 50
 Thr Thr Lys Glu Ala Leu His Ala Ser His Gly Phe Met Trp Tyr Thr
 55 60 65
 <210> 161
 <211> 110
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -18..-1
 <400> 161
 Met Glu Thr Gly Arg Leu Leu Ser Leu Ser Ser Leu Pro Leu Val Leu
 -15 -10 -5
 Leu Gly Trp Glu Tyr Ser Ser Gln Thr Leu Asn Leu Val Pro Ser Thr
 1 5 10
 Ser Ile Leu Ser Phe Val Pro Phe Ile Pro Leu His Leu Val Leu Phe
 15 20 25 30
 Ala Leu Trp Tyr Leu Pro Val Pro His His Leu Tyr Pro Gln Gly Leu
 35 40 45
 Gly Xaa His Ala Ala Xaa Ala Glu Xaa Gly Lys Arg Xaa Glu Gly Gly
 50 55 60
 Thr Gln Xaa Ala Leu Trp Leu Arg Val Gln Pro Ser Cys Pro Ser Pro
 65 70 75
 Val Cys Leu Glu Pro Val Pro Pro Arg Ser Arg Phe Leu Leu
 80 85 90
 <210> 162
 <211> 79
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -36..-1
 <400> 162
 Met Glu Leu Glu Ala Met Ser Arg Tyr Thr Ser Pro Val Asn Pro Ala
 -35 -30 -25
 Val Phe Pro His Leu Thr Val Val Leu Leu Ala Ile Gly Met Phe Phe
 -20 -15 -10 -5
 Thr Ala Trp Phe Phe Val Tyr Glu Val Thr Ser Thr Lys Tyr Thr Arg
 1 5 10
 Asp Ile Tyr Lys Glu Leu Leu Ile Ser Leu Val Ala Ser Leu Phe Met
 15 20 25
 Gly Phe Gly Val Leu Phe Leu Leu Leu Trp Val Gly Ile Tyr Val
 30 35 40
 <210> 163
 <211> 196
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL

<222> -34..-1

<400> 163

Met Ser Phe Leu Gln Asp Pro Ser Phe Phe Thr Met Gly Met Trp Ser
 -30 -25 -20
 Ile Gly Ala Gly Ala Leu Gly Ala Ala Ala Leu Ala Leu Leu Ala
 -15 -10 -5
 Asn Thr Asp Val Phe Leu Ser Lys Pro Gln Lys Ala Ala Leu Glu Tyr
 1 5 10
 Leu Glu Asp Ile Asp Leu Lys Thr Leu Glu Lys Glu Pro Arg Thr Phe
 15 20 25 30
 Lys Ala Lys Glu Leu Trp Glu Lys Asn Gly Ala Val Ile Met Ala Val
 35 40 45
 Arg Arg Pro Gly Cys Phe Leu Cys Arg Glu Glu Ala Ala Asp Leu Ser
 50 55 60
 Ser Leu Lys Ser Met Leu Asp Gln Leu Gly Val Pro Leu Tyr Ala Val
 65 70 75
 Val Lys Xaa His Ile Xaa Thr Glu Xaa Lys Asp Phe Gln Pro Tyr Phe
 80 85 90
 Lys Gly Glu Ile Phe Leu Asp Glu Lys Lys Lys Phe Tyr Gly Pro Gln
 95 100 105 110
 Arg Arg Lys Met Met Phe Met Gly Phe Ile Arg Leu Gly Met Trp Tyr
 115 120 125
 Asn Phe Phe Arg Xaa Trp Asn Gly Xaa Phe Ser Gly Asn Leu Glu Gly
 130 135 140
 Xaa Gly Phe Ile Leu Gly Gly Ile Phe Val Val Gly Ser Xaa Lys Ala
 145 150 155
 Gly His Ser Ser
 160

<210> 164

<211> 177

<212> PRT

<213> Homo sapiens

<220>

<223> SIGNAL

<222> -18..-1

<400> 164

Met Leu Leu Cys Leu Leu Thr Pro Leu Phe Phe Met Phe Pro Thr Gly
 -15 -10 -5
 Phe Ser Ser Pro Ser Pro Ser Ala Ala Ala Ala Gln Glu Val Arg
 1 5 10
 Ser Ala Thr Asp Gly Asn Thr Ser Thr Thr Pro Pro Thr Ser Ala Lys
 15 20 25 30
 Lys Xaa Lys Leu Asn Ser Ser Ser Ser Ser Ser Ser Asn Ser Ser Asn
 35 40 45
 Glu Arg Glu Asp Phe Asp Ser Thr Ser Ser Ser Ser Ser Thr Pro Pro
 50 55 60
 Leu Gln Pro Arg Asp Ser Ala Ser Pro Ser Thr Ser Ser Phe Cys Leu
 65 70 75
 Gly Val Ser Val Ala Ala Ser Ser His Val Pro Ile Xaa Lys Lys Leu
 80 85 90
 Arg Phe Glu Xaa Thr Leu Glu Phe Val Gly Phe Asp Ala Lys Met Ala
 95 100 105 110
 Glu Glu Ser Ser Ser Ser Ser Ser Ser Ser Pro Thr Ala Ala Thr
 115 120 125
 Ser Gln Gln Gln Gln Leu Lys Asn Lys Ser Ile Leu Asn Leu Phe Cys
 130 135 140
 Gly Phe Gly Ala Ser Cys Lys Arg Pro Ser Gln Ile Phe Tyr His Arg
 145 150 155

Leu

<210> 165

<211> 105

<212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -22...-1
 <400> 165
 Met Gln Gly His Trp Leu Ser Ser Ala Phe Ala Leu Val Trp Leu Trp
 -20 -15 -10
 Leu Arg Ser Thr Gly Cys Phe Trp Trp Asp His Trp Leu Cys Lys Ser
 -5 1 5 10
 Arg Gln Arg Ala Val Pro Gly Cys Arg Ala Ala Leu Trp Gln Ser Ser
 15 20 25
 Arg Pro Gly Cys Leu Pro Ala Val Ser Gly Ser Lys Glu Arg Leu Gly
 30 35 40
 Phe Pro Ser Tyr Ile Trp Tyr Leu Gly Trp His Tyr Gly Asn Glu Val
 45 50 55
 Leu Pro Leu Trp Lys Ile His Ala Cys Arg Phe Asn Cys Arg Cys Gln
 60 65 70
 Phe Ala Asp Gly Arg Gln Ser Trp Ser
 75 80

<210> 166
 <211> 148
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -48...-1
 <400> 166
 Met Ile Ala Ile Tyr Gly Lys Asn Phe Cys Val Ser Ala Lys Asn Ala
 -45 -40 -35
 Phe Met Leu Leu Met Arg Asn Ile Val Arg Val Val Val Leu Asp Lys
 -30 -25 -20
 Val Thr Asp Leu Leu Leu Phe Phe Gly Lys Leu Leu Val Val Gly Gly
 -15 -10 -5
 Val Gly Val Leu Ser Phe Phe Phe Phe Ser Gly Arg Ile Pro Gly Leu
 1 5 10 15
 Gly Lys Asp Phe Lys Ser Pro His Leu Asn Tyr Tyr Trp Leu Pro Xaa
 20 25 30
 Met Thr Ser Ile Leu Gly Ala Tyr Val Ile Ala Ser Gly Phe Phe Ser
 35 40 45
 Val Phe Gly Met Cys Val Asp Thr Leu Phe Leu Cys Phe Leu Glu Asp
 50 55 60
 Leu Glu Arg Thr Thr Ala Pro Trp Thr Ala Leu Leu His Val Gln Glu
 65 70 75 80
 Leu Leu Lys Ile Leu Gly Lys Lys Asn Glu Ala Pro Pro Asp Asn Lys
 85 90 95
 Lys Arg Lys Xaa
 100

<210> 167
 <211> 259
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -23...-1
 <400> 167
 Met Pro Ser Trp Ile Gly Ala Val Ile Leu Pro Leu Leu Gly Leu Leu
 -20 -15 -10
 Leu Ser Leu Pro Ala Gly Ala Asp Val Lys Ala Arg Ser Cys Gly Glu
 -5 1 5
 Val Arg Gln Ala Tyr Gly Ala Lys Gly Phe Ser Leu Ala Asp Ile Pro

10 15 20 25
 Tyr Gln Glu Ile Ala Xaa Glu His Leu Arg Ile Cys Pro Gln Glu Tyr
 30 35 40
 Thr Cys Cys Thr Thr Glu Met Glu Asp Lys Leu Ser Gln Gln Ser Lys
 45 50 55
 Leu Glu Phe Glu Asn Leu Val Glu Glu Thr Ser His Phe Val Arg Thr
 60 65 70
 Thr Phe Val Ser Arg His Lys Lys Phe Asp Xaa Phe Phe Arg Xaa Leu
 75 80 85
 Xaa Glu Asn Ala Xaa Lys Ser Leu Asn Asp Xaa Phe Val Arg Thr Tyr
 90 95 100 105
 Gly Met Leu Tyr Xaa Gln Asn Xaa Glu Val Phe Xaa Asp Leu Phe Thr
 110 115 120
 Xaa Leu Lys Arg Tyr Tyr Thr Gly Gly Asn Val Asn Leu Glu Glu Met
 125 130 135
 Leu Asn Asp Phe Trp Ala Arg Leu Leu Glu Arg Met Phe Gln Xaa Xaa
 140 145 150
 Asn Pro Gln Tyr His Phe Ser Glu Asp Tyr Leu Glu Cys Val Ser Lys
 155 160 165
 Tyr Thr Asp Xaa Leu Lys Pro Phe Gly Asp Val Pro Arg Lys Leu Lys
 170 175 180 185
 Ile Gln Val Thr Arg Ala Phe Xaa Xaa Ala Arg Thr Phe Val Gln Gly
 190 195 200
 Leu Thr Val Gly Arg Glu Val Ala Asn Arg Val Ser Lys Val Ile Glu
 205 210 215
 Asn Val Leu Ser Phe Ser Leu Val Phe Leu Val Tyr Ser Val Phe Lys
 220 225 230
 Thr Asn Val
 235
 <210> 168
 <211> 111
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -62...-1
 <400> 168
 Met Gly Glu Ser Ile Pro Leu Ala Ala Pro Val Pro Val Glu Gln Ala
 -60 -55 -50
 Val Leu Glu Thr Phe Phe Ser His Leu Gly Ile Phe Ser Tyr Asp Lys
 -45 -40 -35
 Ala Lys Asp Asn Val Glu Lys Glu Arg Glu Ala Asn Lys Ser Ala Gly
 -30 -25 -20 -15
 Gly Ser Trp Leu Ser Leu Leu Ala Ala Leu Ala His Leu Ala Ala Ala
 -10 -5 1
 Glu Lys Val Tyr His Ser Leu Thr Tyr Leu Gly Gln Lys Leu Gly Thr
 5 10 15
 Ser Ala Pro Pro Pro Glu Pro Leu Glu Glu Glu Val Lys Gly Val Tyr
 20 25 30
 Ser Pro Xaa Gly Ser Gly Leu Gly Xaa Pro Ser Leu Cys His Phe
 35 40 45
 <210> 169
 <211> 311
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -23...-1
 <400> 169
 Met Ala Asp Val Ile Asn Val Ser Val Asn Leu Glu Ala Phe Ser Gln
 -20 -15 -10

Ala Ile Ser Ala Ile Gln Ala Leu Arg Ser Ser Val Ser Arg Val Phe
 -5 1 5
 Asp Cys Leu Lys Asp Gly Met Arg Asn Lys Glu Thr Leu Glu Gly Arg
 10 15 20 25
 Glu Lys Ala Phe Ile Ala His Phe Gln Asp Asn Leu His Ser Val Asn
 30 35 40
 Arg Asp Leu Asn Glu Leu Glu Arg Leu Ser Asn Leu Val Gly Xaa Pro
 45 50 55
 Ser Glu Asn His Pro Leu His Asn Ser Gly Leu Leu Xaa Leu Asp Pro
 60 65 70
 Val Gln Asp Lys Thr Pro Leu Tyr Ser Gln Leu Leu Gln Ala Tyr Lys
 75 80 85
 Trp Ser Asn Lys Leu Gln Tyr His Ala Gly Leu Ala Ser Gly Leu Leu
 90 95 100 105
 Asn Xaa Gln Ser Xaa Lys Arg Xaa Ala Asn Gln Met Gly Val Ser Ala
 110 115 120
 Lys Arg Arg Pro Lys Ala Gln Pro Thr Thr Leu Val Leu Pro Pro Gln
 125 130 135
 Tyr Val Asp Asp Val Ile Ser Arg Ile Asp Arg Met Phe Pro Glu Met
 140 145 150
 Ser Ile His Leu Ser Arg Pro Asn Gly Thr Ser Ala Met Leu Leu Val
 155 160 165
 Thr Leu Gly Lys Val Leu Lys Val Xaa Val Val Xaa Arg Xaa Leu Phe
 170 175 180 185
 Ile Asp Arg Thr Ile Val Lys Gly Tyr Xaa Glu Asn Val Tyr Xaa Glu
 190 195 200
 Xaa Gly Xaa Leu Asp Ile Trp Ser Lys Ser Asn Tyr Gln Val Phe Gln
 205 210 215
 Lys Val Thr Asp His Ala Thr Thr Ala Leu Leu His Xaa Xaa Leu Pro
 220 225 230
 Gln Met Pro Asp Val Val Val Arg Ser Phe Xaa Thr Trp Leu Arg Ser
 235 240 245
 Tyr Ile Lys Leu Phe Gln Ala Pro Cys Gln Arg Cys Gly Lys Phe Leu
 250 255 260 265
 Gln Asp Gly Leu Pro Pro Thr Trp Arg Asp Phe Arg Thr Leu Glu Ala
 270 275 280
 Phe His Asp Thr Cys Arg Gln
 285

<210> 170

<211> 91

<212> PRT

<213> Homo sapiens

<220>

<223> SIGNAL

<222> -60...-1

<400> 170

Met Thr Ser Leu Phe Ala Val Val Leu Gln Arg Glu Lys Glu Pro His
 -60 -55 -50 -45
 Leu Trp Leu Ser Ser Pro His Ile Arg Phe Ser Leu Arg Val Asn Lys
 -40 -35 -30
 Leu Ser Glu Leu Met Leu Gln Leu Leu Gln Phe Lys Ala Phe Pro Ser
 -25 -20 -15
 Ser Leu Val Pro Phe Phe Leu Phe Thr Cys Phe Gly His Phe Pro Ser
 -10 -5 1
 Phe Thr Thr Phe Gln Gly Phe Ile Glu Asn Asn Leu Leu Gln Asn Gln
 5 10 15 20
 Phe Asn Ser Asn Val Asp Ile Val Ala Cys Ser
 25 30

<210> 171

<211> 287

<212> PRT

<213> Homo sapiens

<220>

<223> SIGNAL

<222> -17..-1

<400> 171

Met Glu Leu Glu Arg Ile Val Ser Ala Ala Leu Leu Ala Phe Val Gln
 -15 -10 -5
 Thr His Leu Pro Glu Ala Asp Leu Ser Gly Leu Asp Glu Val Ile Phe
 1 5 10 15
 Ser Tyr Val Leu Gly Val Leu Glu Asp Leu Gly Pro Ser Gly Pro Ser
 20 25 30
 Glu Glu Asn Phe Asp Met Glu Ala Phe Thr Glu Met Met Glu Ala Tyr
 35 40 45
 Val Pro Gly Phe Ala His Ile Pro Arg Gly Thr Ile Gly Asp Met Met
 50 55 60
 Gln Lys Leu Ser Gly Gln Leu Ser Asp Ala Xaa Asn Lys Glu Asn Leu
 65 70 75
 Gln Pro Gln Asn Ser Gly Val Gln Gly Gln Val Pro Ile Ser Pro Glu
 80 85 90 95
 Pro Leu Gln Arg Pro Glu Met Leu Lys Glu Glu Thr Arg Ser Ser Ala
 100 105 110
 Ala Ala Ala Ala Asp Thr Gln Asp Glu Ala Thr Gly Ala Glu Glu Glu
 115 120 125
 Leu Leu Pro Gly Val Asp Val Leu Glu Val Phe Pro Thr Cys Ser
 130 135 140
 Val Glu Gln Ala Gln Trp Val Leu Ala Lys Ala Arg Gly Asp Leu Glu
 145 150 155
 Glu Ala Val Gln Met Leu Val Glu Gly Lys Glu Glu Gly Pro Ala Ala
 160 165 170 175
 Trp Glu Gly Pro Asn Gln Asp Leu Pro Arg Arg Leu Arg Gly Pro Gln
 180 185 190
 Lys Asp Glu Leu Lys Ser Phe Ile Leu Gln Lys Tyr Met Met Val Asp
 195 200 205
 Ser Ala Glu Asp Gln Lys Ile His Arg Pro Met Ala Pro Lys Glu Ala
 210 215 220
 Pro Lys Lys Leu Ile Arg Tyr Ile Asp Asn Gln Val Val Ser Thr Lys
 225 230 235
 Gly Glu Arg Phe Lys Asp Val Arg Asn Pro Glu Ala Glu Glu Met Lys
 240 245 250 255
 Ala Thr Tyr Ile Asn Leu Lys Pro Ala Arg Lys Tyr Arg Phe His
 260 265 270

<210> 172

<211> 104

<212> PRT

<213> Homo sapiens

<220>

<223> SIGNAL

<222> -49..-1

<400> 172

Met Glu His Leu Thr His Ser Ser Gln Lys Leu Gln Ala Asp Glu His
 -45 -40 -35
 Leu Thr Lys Glu Val Trp Ser Arg Leu Leu Lys Glu Lys Gly Pro Ala
 -30 -25 -20
 Gly Leu Ile Leu Cys Phe Leu Cys Leu Tyr Pro Ile Pro Leu Cys Thr
 -15 -10 -5
 Ser His Pro Val Xaa Leu Cys Ala His Pro Gln Asp Val Tyr Pro Val
 1 5 10 15
 Val Val Arg Ala Glu Ile His Ala Glu Leu Tyr Gln Glu Leu Ala Tyr
 20 25 30
 Leu Lys Thr Glu Thr Glu Ser Leu Ala His Leu Phe Ala Leu Val Pro
 35 40 45

Gln Ala Lys Ile Lys Asn Arg Val
50 55

<210> 173

<211> 84

<212> PRT

<213> Homo sapiens

<220>

<223> SIGNAL

<222> -36..-1

<400> 173

Met Gly Leu Leu Thr Phe Gly Tyr Ile Glu Xaa Xaa Xaa Lys Thr Glu
-35 -30 -25
His Asn Pro Asp His His Ser Cys Leu Ala Val Ser Trp Glu Ala Ala
-20 -15 -10 -5
Gly Cys His Gly Ala Gly Thr Gln Gln Ser Pro Leu Gly Val Ala Gly
1 5 10
Pro Trp Arg Pro Arg Pro Pro Cys Val Gly Ser Leu Leu Ala Ala Arg
15 20 25
Ser Leu His Lys Gln Val Ile Leu Phe Gly Leu Leu Gly Phe Ala Tyr
30 35 40
Asp His Ala Ala
45

<210> 174

<211> 131

<212> PRT

<213> Homo sapiens

<220>

<223> SIGNAL

<222> -20..-1

<400> 174

Met Glu Lys Ile Pro Val Ser Ala Phe Leu Leu Leu Val Ala Leu Ser
-20 -15 -10 -5
Tyr Thr Leu Ala Arg Asp Thr Thr Val Lys Pro Gly Ala Lys Lys Asp
1 5 10
Thr Lys Asp Ser Arg Pro Lys Leu Pro Gln Thr Leu Ser Arg Gly Trp
15 20 25
Gly Asp Gln Leu Ile Trp Thr Gln Thr Tyr Glu Xaa Xaa Leu Xaa Lys
30 35 40
Ser Lys Thr Ser Asn Lys Pro Leu Met Ile Ile His His Leu Asp Xaa
45 50 55 60
Cys Pro His Ser Gln Ala Leu Lys Lys Xaa Phe Ala Glu Asn Lys Xaa
65 70 75
Ile Gln Lys Leu Ala Xaa Gln Phe Val Xaa Leu Asn Leu Val Tyr Glu
80 85 90
Thr Thr Asp Lys His Leu Ser Pro Asp Gly Gln Tyr Xaa Pro Xaa Asp
95 100 105
Tyr Val Cys
110

<210> 175

<211> 131

<212> PRT

<213> Homo sapiens

<220>

<223> SIGNAL

<222> -23..-1

<400> 175

Met Met Asn Phe Arg Gln Arg Met Gly Trp Ile Gly Val Gly Leu Tyr
-20 -15 -10
Leu Leu Ala Ser Ala Ala Ala Phe Tyr Tyr Val Phe Glu Ile Ser Glu
-5 1 5
Thr Tyr Asn Arg Leu Ala Leu Glu His Ile Gln Gln His Pro Gly Glu

10	Pro	Leu	Glu	Gly	Thr	Thr	Trp	Thr	His	Ser	Leu	Lys	Ala	Gln	Leu	Leu	25
					30					35						40	
Ser	Leu	Pro	Phe	Trp	Val	Trp	Thr	Val	Ile	Phe	Leu	Val	Pro	Tyr	Leu		
		45						50					55				
Gln	Xaa	Phe	Leu	Phe	Leu	Tyr	Ser	Cys	Thr	Lys	Xaa	Asp	Pro	Lys	Thr		
		60					65					70					
Val	Gly	Tyr	Cys	Xaa	Ile	Pro	Ile	Cys	Leu	Ala	Xaa	Ile	Xaa	Asn	Arg		
		75				80					85						
His	Gln	Asp	Phe	Val	Lys	Ala	Ser	Asn	Gln	Ile	Ser	Lys	Leu	Gln	Leu		
					95					100						105	
Ile	Asp	Thr															
<210>	176																
<211>	335																
<212>	PRT																
<213>	Homo sapiens																
<220>																	
<223>	SIGNAL																
<222>	-16..-1																
<400>	176																
Met	Ala	Val	Phe	Val	Val	Leu	Leu	Ala	Leu	Val	Ala	Gly	Val	Leu	Gly		
	-15					-10					-5						
Asn	Glu	Phe	Ser	Ile	Leu	Lys	Ser	Pro	Gly	Ser	Val	Val	Phe	Arg	Asn		
1				5					10					15			
Gly	Asn	Trp	Pro	Ile	Pro	Gly	Glu	Arg	Ile	Pro	Asp	Val	Ala	Ala	Leu		
			20					25					30				
Ser	Met	Gly	Phe	Ser	Val	Lys	Glu	Asp	Leu	Ser	Trp	Pro	Gly	Leu	Ala		
		35					40					45					
Val	Gly	Asn	Leu	Phe	His	Arg	Pro	Arg	Ala	Ser	Val	Met	Val	Met	Val		
	50					55					60						
Lys	Gly	Val	Asn	Asn	Xaa	Pro	Leu	Pro	Pro	Gly	Cys	Val	Ile	Ser	Tyr		
65					70					75					80		
Pro	Leu	Glu	Asn	Ala	Val	Pro	Phe	Ser	Leu	Asp	Ser	Val	Ala	Asn	Ser		
			85						90					95			
Ile	His	Ser	Leu	Phe	Ser	Glu	Glu	Thr	Pro	Val	Val	Leu	Gln	Leu	Ala		
			100					105					110				
Pro	Ser	Glu	Arg	Val	Tyr	Met	Val	Gly	Lys	Ala	Asn	Ser	Val	Trp			
		115				120					125						
Lys	Thr	Phe	Gln	Ser	Leu	Ala	Pro	Ala	Pro	Xaa	Ile	Xaa	Cys	Phe	Lys		
	130					135					140						
Lys	Thr	Leu	Phe	Ser	Val	His	Ser	Pro	Xaa	Ile	Xaa	Leu	Ser	Arg	Asn		
145					150					155					160		
Asn	Glu	Val	Asp	Xaa	Leu	Phe	Leu</										

305
 <210> 177
 <211> 84
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -55..-1
 <400> 177
 Met Arg Lys Val Val Leu Ile Thr Gly Ala Ser Ser Gly Ile Gly Leu
 -55 -50 -45 -40
 Ala Leu Cys Lys Arg Leu Leu Ala Glu Asp Asp Glu Leu His Leu Cys
 -35 -30 -25
 Leu Ala Cys Arg Asn Met Ser Lys Ala Glu Ala Val Cys Ala Ala Leu
 -20 -15 -10
 Leu Ala Ser His Pro Thr Ala Glu Val Thr Ile Val Gln Val Asp Val
 -5 1 5
 Ser Asn Leu Gln Ser Phe Phe Arg Ala Ser Lys Glu Leu Lys Gln Arg
 10 15 20 25
 Met Ile Ser Cys
 <210> 178
 <211> 280
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -18..-1
 <400> 178
 Met Glu Gly Pro Arg Gly Trp Leu Val Leu Cys Val Leu Ala Ile Ser
 -15 -10 -5
 Leu Ala Ser Met Val Thr Glu Asp Leu Cys Arg Ala Pro Asp Gly Lys
 1 5 10
 Lys Gly Glu Ala Gly Arg Pro Gly Arg Arg Gly Arg Pro Gly Leu Lys
 15 20 25 30
 Gly Glu Gln Gly Glu Pro Gly Ala Pro Gly Ile Arg Thr Gly Ile Gln
 35 40 45
 Gly Leu Lys Gly Asp Gln Gly Glu Pro Gly Pro Ser Gly Asn Pro Gly
 50 55 60
 Lys Val Gly Tyr Pro Gly Pro Ser Gly Pro Leu Gly Ala Arg Gly Ile
 65 70 75
 Pro Gly Ile Lys Gly Thr Lys Gly Ser Pro Gly Asn Ile Lys Asp Gln
 80 85 90
 Pro Arg Pro Ala Phe Ser Ala Ile Arg Arg Asn Pro Pro Met Gly Gly
 95 100 105 110
 Asn Val Val Ile Phe Asp Thr Val Ile Thr Asn Gln Glu Glu Pro Tyr
 115 120 125
 Gln Asn His Ser Gly Arg Phe Val Cys Thr Val Pro Ala Thr Thr Thr
 130 135 140
 Ser Pro Ser Arg Cys Cys Pro Ser Gly Lys Ser Ala Cys Pro Ser Ser
 145 150 155
 Pro Pro Gln Gly Ala Arg Ser Asp Ala Pro Trp Ala Ser Val Thr Pro
 160 165 170
 Pro Thr Arg Gly Ser Ser Arg Trp Cys Gln Gly Ala Trp Cys Phe Ser
 175 180 185 190
 Cys Ser Arg Val Thr Arg Ser Gly Leu Lys Lys Thr Pro Lys Arg Val
 195 200 205
 Thr Phe Thr Arg Ala Leu Arg Pro Thr Ala Ser Ser Ala Ala Ser Ser
 210 215 220
 Ser Ser His Leu Pro Glu Pro Gly Lys Asp Pro Leu Pro His Pro Pro
 225 230 235
 Leu Trp Leu Pro Cys Ser Ala Cys Lys Met Gly Ala Leu Leu Gln

240 245 250
 Leu Leu Lys Gly Gly Gly Trp Leu
 255 260
 <210> 179
 <211> 140
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> SIGNAL
 <222> -51..-1
 <400> 179
 Met Arg Lys Asp Pro Ser Gly Ala Gly Leu Trp Leu His Ser Gly Gly
 -50 -45 -40
 Pro Val Leu Pro Tyr Val Arg Glu Ser Val Arg Arg Asn Pro Ala Ser
 -35 -30 -25 -20
 Ala Ala Thr Pro Ser Thr Ala Val Gly Leu Phe Pro Ala Pro Thr Glu
 -15 -10 -5
 Cys Phe Ala Arg Val Ser Cys Ser Gly Val Glu Ala Leu Gly Arg Arg
 1 5 10
 Asp Trp Leu Gly Gly Gly Pro Arg Ala His Xaa Xaa Ala Thr Glu Xaa
 15 20 25
 Ser Ala Pro Lys Glu Ser Leu Gly Cys His Asp Cys His Ala Ile Lys
 30 35 40 45
 Lys Cys Arg Lys Trp Glu Val Phe Arg Met Thr His Gln Val Leu Phe
 50 55 60
 Pro Arg Val Trp Ala Leu Ser Trp Asn Pro Leu Ala Cys Thr Pro Ser
 65 70 75
 Cys Leu Gln Arg Cys Thr Cys Ile Pro Xaa Cys Ser
 80 85
 <210> 180
 <211> 92
 <212> PRT
 <213> Homo sapiens
 <400> 180
 Met Ala Pro Leu His His Ile Leu Val Phe Cys Val Gly Leu Leu Thr
 1 5 10 15
 Met Ala Lys Ala Glu Ser Pro Lys Glu His Asp Pro Phe Thr Tyr Asp
 20 25 30
 Tyr Gln Ser Leu Gln Ile Gly Gly Leu Val Ile Ala Gly Ile Leu Phe
 35 40 45
 Ile Leu Gly Ile Leu Ile Val Leu Ser Arg Arg Cys Arg Cys Lys Phe
 50 55 60
 Asn Gln Gln Gln Arg Thr Gly Glu Pro Asp Glu Glu Glu Gly Thr Phe
 65 70 75 80
 Arg Ser Ser Ile Arg Arg Leu Ser Thr Arg Arg Arg
 85 90
 <210> 181
 <211> 240
 <212> PRT
 <213> Homo sapiens
 <400> 181
 Leu Leu Ser Arg Thr Val Arg Thr Gln Ile Leu Thr Gly Lys Glu Leu
 1 5 10 15
 Arg Val Ala Thr Gln Glu Lys Glu Gly Ser Ser Gly Arg Cys Met Leu
 20 25 30
 Thr Leu Leu Gly Leu Ser Phe Ile Leu Ala Gly Leu Ile Val Gly Gly
 35 40 45
 Ala Cys Ile Tyr Lys Tyr Phe Met Pro Lys Ser Thr Ile Tyr Arg Gly
 50 55 60
 Glu Met Cys Phe Phe Asp Ser Glu Asp Pro Ala Asn Ser Leu Arg Gly
 65 70 75 80

Gly Glu Pro Asn Phe Leu Pro Val Thr Glu Glu Ala Asp Ile Arg Glu
 85 90 95
 Asp Asp Asn Ile Ala Ile Ile Asp Val Pro Val Pro Ser Phe Ser Asp
 100 105 110
 Ser Asp Pro Ala Ala Ile Ile His Asp Phe Glu Lys Gly Met Thr Ala
 115 120 125
 Tyr Leu Asp Leu Leu Leu Gly Asn Cys Tyr Leu Met Pro Leu Asn Thr
 130 135 140
 Ser Ile Val Met Pro Pro Lys Asn Leu Val Glu Leu Phe Gly Lys Leu
 145 150 155 160
 Ala Ser Gly Arg Tyr Leu Pro Gln Thr Tyr Val Val Arg Glu Asp Leu
 165 170 175
 Val Ala Val Glu Glu Ile Arg Asp Val Ser Asn Leu Gly Ile Phe Ile
 180 185 190
 Tyr Gln Leu Cys Asn Asn Arg Lys Ser Phe Arg Leu Arg Arg Asp
 195 200 205
 Leu Leu Leu Gly Phe Asn Lys Arg Ala Ile Asp Lys Cys Trp Lys Ile
 210 215 220
 Arg His Phe Pro Asn Glu Phe Ile Val Glu Thr Lys Ile Cys Gln Glu
 225 230 235 240
 <210> 182
 <211> 245
 <212> PRT
 <213> Mus musculus
 <400> 182

Glu Leu Cys Pro Gly Val Asn Thr Gln Pro Tyr Leu Cys Glu Thr Gly
 1 5 10 15
 His Cys Cys Gly Glu Thr Gly Cys Cys Thr Tyr Tyr Tyr Glu Leu Trp
 20 25 30
 Trp Phe Trp Leu Leu Trp Thr Val Leu Ile Leu Phe Ser Cys Cys Cys
 35 40 45
 Ala Phe Arg His Arg Arg Ala Lys Leu Arg Leu Gln Gln Gln Arg
 50 55 60
 Gln Arg Glu Ile Asn Leu Leu Ala Tyr His Gly Ala Cys His Gly Ala
 65 70 75 80
 Gly Pro Val Pro Thr Gly Ser Leu Leu Asp Leu Arg Leu Leu Ser Ala
 85 90 95
 Phe Lys Pro Pro Ala Tyr Glu Asp Val Val His His Pro Gly Thr Pro
 100 105 110
 Pro Pro Pro Tyr Thr Val Gly Pro Gly Tyr Pro Trp Thr Ser Ser
 115 120 125
 Glu Cys Thr Arg Cys Ser Ser Glu Ser Ser Cys Ser Ala His Leu Glu
 130 135 140
 Gly Thr Asn Val Glu Gly Val Ser Ser Gln Gln Ser Ala Leu Pro His
 145 150 155 160
 Gln Glu Gly Glu Pro Arg Ala Gly Leu Ser Pro Val His Ile Pro Pro
 165 170 175
 Ser Cys Arg Tyr Arg Arg Leu Thr Gly Asp Ser Gly Ile Glu Leu Cys
 180 185 190
 Pro Cys Pro Asp Ser Ser Glu Gly Glu Pro Leu Lys Glu Ala Arg Ala
 195 200 205
 Ser Ala Ser Gln Pro Asp Leu Glu Asp His Ser Pro Cys Ala Leu Pro
 210 215 220
 Pro Asp Ser Val Ser Gln Val Pro Pro Met Gly Leu Ala Ser Ser Cys
 225 230 235 240
 Gly Thr Ser His Lys
 245